,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,79,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
30,81,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
31,83,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
32,85,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
33,89,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
34,91,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
35,93,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
36,95,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
37,97,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
38,99,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
39,101,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
40,103,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
41,105,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
42,107,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
43,109,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
44,113,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
45,115,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
46,119,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
47,121,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
48,123,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
49,131,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
50,137,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
51,139,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
52,141,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
53,143,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
54,145,1,1,,487337,3559,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
55,147,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad52 strain,Other,,
56,149,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt1 strain,Other,,
57,151,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50EPP+ strain,Other,,
58,153,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mgt1 strain,Other,,
59,155,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
60,157,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
61,159,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad14 strain,Other,,
62,161,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
63,163,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the CLN2oe strain,Other,,
64,165,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
65,167,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
66,169,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt2 strain,Other,,
67,171,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 strain,Other,,
68,173,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 strain,Other,,
69,175,1,1,,487337,3559,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
70,177,1,1,,487337,3559,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,Other,,
71,179,1,1,,443245,3559,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
72,179,1,1,,487337,3559,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
73,192,1,1,,443245,3559,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
74,248,1,1,,443245,3559,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
75,357,2,1,,855969,3559,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
76,357,2,1,,11111260,3559,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
77,357,2,1,,11112116,3559,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
78,361,1,2,,855969,3559,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
79,364,1,3,,855969,3559,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
80,368,2,3,,855969,3559,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
81,371,1,1,,855969,3559,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
82,373,1,4,,855969,3559,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
83,374,2,3,,855969,3559,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
84,375,2,3,,855969,3559,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
85,377,1,3,,10321347,3559,Inactive,42741659.0,5243.0,,,MDR-1,Other,,
86,410,1,5,,11111260,3559,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
87,410,1,5,,11112116,3559,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
88,410,1,5,,11113356,3559,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
89,411,2,1,,855969,3559,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
90,411,2,1,,11111260,3559,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
91,411,2,1,,11112116,3559,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
92,411,2,1,,11113356,3559,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
93,422,1,5,,855969,3559,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
94,422,1,5,,17405145,3559,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
95,425,3,2,,855969,3559,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
96,429,1,5,,855969,3559,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
97,429,1,5,,855969,3559,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
98,429,1,5,,17405145,3559,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
99,429,1,5,,17405145,3559,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
100,430,2,4,,855969,3559,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
101,431,2,4,,855969,3559,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
102,432,2,4,,855969,3559,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
103,436,2,1,,855969,3559,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
104,436,2,1,,17405145,3559,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
105,438,1,4,,855969,3559,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
106,440,3,3,,855969,3559,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
107,441,3,3,,855969,3559,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
108,444,1,1,,855969,3559,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
109,444,1,1,,11111260,3559,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
110,444,1,1,,11112116,3559,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
111,445,3,1,,11111260,3559,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
112,445,3,1,,11112116,3559,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
113,445,3,1,,11113356,3559,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
114,446,1,1,,855969,3559,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
115,446,1,1,,11111260,3559,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
116,446,1,1,,11112116,3559,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
117,447,1,1,,11111260,3559,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
118,447,1,1,,11112116,3559,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
119,447,1,1,,11113356,3559,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
120,448,1,2,,11111260,3559,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
121,448,1,2,,11112116,3559,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
122,448,1,2,,11113356,3559,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
123,449,1,5,,855969,3559,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
124,450,1,2,,855969,3559,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
125,450,1,2,,11111260,3559,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
126,450,1,2,,11112116,3559,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
127,450,1,2,,11113356,3559,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
128,451,1,2,,11111260,3559,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
129,451,1,2,,11112116,3559,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
130,451,1,2,,11113356,3559,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
131,453,2,2,,855969,3559,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
132,454,1,7,,855969,3559,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
133,455,1,7,,855969,3559,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
134,456,1,7,,855969,3559,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
135,457,1,7,,855969,3559,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
136,460,2,2,,855969,3559,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
137,483,1,6,,855969,3559,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
138,485,1,8,,855969,3559,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
139,487,1,2,,855969,3559,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
140,488,2,1,,855969,3559,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
141,501,2,2,,855969,3559,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
142,518,2,6,,855969,3559,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
143,521,2,5,,855969,3559,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
144,522,1,2,,855969,3559,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
145,524,1,3,,855969,3559,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
146,525,1,3,,855969,3559,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
147,526,1,1,,11111260,3559,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
148,526,1,1,,11112116,3559,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
149,526,1,1,,11113356,3559,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
150,527,3,1,,855969,3559,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
151,528,1,4,,855969,3559,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
152,529,1,4,,855969,3559,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
153,530,1,1,,11111260,3559,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
154,530,1,1,,11112116,3559,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
155,530,1,1,,11113356,3559,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
156,538,2,2,,855969,3559,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
157,539,1,2,,855969,3559,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
158,547,1,4,,17405145,3559,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
159,552,1,3,,855969,3559,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
160,555,1,2,,855969,3559,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
161,556,1,3,,855969,3559,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
162,559,2,2,,855969,3559,Inactive,147728.0,,,,RNA polymerase,Screening,,
163,560,1,2,,855969,3559,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
164,561,1,3,,855969,3559,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
165,565,1,4,,855969,3559,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
166,567,1,4,,855969,3559,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
167,568,1,7,,855969,3559,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
168,568,1,7,,855969,3559,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
169,570,1,4,,855969,3559,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
170,571,1,4,,855969,3559,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
171,572,1,5,,855969,3559,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
172,573,1,4,,855969,3559,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
173,574,1,3,,855969,3559,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
174,575,1,4,,855969,3559,Inconclusive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
175,576,1,2,,855969,3559,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
176,577,1,1,,855969,3559,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
177,580,1,5,,855969,3559,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
178,581,2,2,,855969,3559,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
179,583,2,6,,855969,3559,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
180,584,1,3,,11111260,3559,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
181,584,1,3,,11112116,3559,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
182,584,1,3,,11113356,3559,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
183,585,1,4,,11111260,3559,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
184,585,1,4,,11112116,3559,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
185,585,1,4,,11113356,3559,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
186,587,1,5,,855969,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
187,587,1,5,,11111260,3559,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
188,587,1,5,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
189,588,1,4,,855969,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
190,588,1,4,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
191,588,1,4,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
192,589,1,3,,855969,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
193,589,1,3,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
194,589,1,3,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
195,590,1,3,,855969,3559,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
196,590,1,3,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
197,590,1,3,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
198,591,1,4,,855969,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
199,591,1,4,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
200,591,1,4,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
201,592,1,6,,855969,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
202,592,1,6,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
203,592,1,6,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
204,593,1,4,,855969,3559,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
205,593,1,4,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
206,593,1,4,,11112116,3559,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
207,594,1,4,,855969,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
208,594,1,4,,11111260,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
209,594,1,4,,11112116,3559,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
210,595,1,3,,11111260,3559,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
211,595,1,3,,11112116,3559,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
212,595,1,3,,11113356,3559,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
213,596,1,2,,11111260,3559,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
214,596,1,2,,11112116,3559,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
215,596,1,2,,11113356,3559,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
216,597,1,3,,855969,3559,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
217,597,1,3,,11111260,3559,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
218,597,1,3,,11112116,3559,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
219,597,1,3,,11113356,3559,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
220,598,1,4,,855969,3559,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
221,601,1,4,,855969,3559,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
222,602,1,4,,855969,3559,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
223,603,1,2,,11111260,3559,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
224,603,1,2,,11112116,3559,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
225,603,1,2,,11113356,3559,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
226,604,1,3,,855969,3559,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
227,605,1,2,,11111260,3559,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
228,605,1,2,,11112116,3559,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
229,605,1,2,,11113356,3559,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
230,606,1,3,,855969,3559,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
231,606,1,3,,855969,3559,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
232,607,1,3,,11111260,3559,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
233,607,1,3,,11112116,3559,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
234,607,1,3,,11113356,3559,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
235,609,1,2,,855969,3559,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
236,614,1,6,,855969,3559,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
237,615,1,6,,855969,3559,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
238,618,2,6,,855969,3559,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
239,620,2,5,,855969,3559,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
240,622,1,2,,855969,3559,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
241,623,1,3,,855969,3559,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
242,624,1,2,,855969,3559,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
243,625,1,2,,855969,3559,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
244,626,1,3,,855969,3559,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
245,628,2,4,,855969,3559,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
246,629,1,3,,855969,3559,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
247,630,1,1,,855969,3559,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
248,631,1,4,,855969,3559,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
249,631,1,4,,855969,3559,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
250,633,1,3,,855969,3559,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
251,636,1,4,,855969,3559,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
252,637,1,4,,855969,3559,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
253,639,1,2,,855969,3559,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
254,641,1,4,,855969,3559,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
255,645,1,4,,855969,3559,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
256,648,1,3,,855969,3559,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
257,662,1,1,,11111260,3559,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
258,662,1,1,,11112116,3559,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
259,662,1,1,,11113356,3559,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
260,680,1,10,,855969,3559,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
261,684,1,12,,855969,3559,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
262,687,1,17,,855969,3559,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
263,694,1,1,,17405145,3559,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
264,701,1,17,,855969,3559,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
265,708,1,4,,855969,3559,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
266,709,1,2,,855969,3559,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
267,719,1,3,,855969,3559,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
268,731,1,5,,855969,3559,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
269,731,1,5,,855969,3559,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
270,732,1,2,,17405145,3559,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
271,746,1,1,,855969,3559,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
272,750,1,3,,855969,3559,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
273,751,1,3,,855969,3559,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
274,757,1,4,,855969,3559,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
275,758,1,4,,855969,3559,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
276,759,1,4,,855969,3559,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
277,760,1,4,,855969,3559,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
278,761,1,4,,855969,3559,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
279,764,1,4,,855969,3559,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
280,770,1,1,,855969,3559,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
281,771,1,2,,855969,3559,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
282,772,1,2,,855969,3559,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
283,774,1,2,,855969,3559,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
284,775,1,3,,855969,3559,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
285,781,1,1,,855969,3559,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
286,782,1,2,,855969,3559,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
287,782,1,2,,855969,3559,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
288,793,1,2,,855969,3559,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
289,795,1,1,,855969,3559,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
290,797,1,1,,855969,3559,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
291,798,2,12,,855969,3559,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
292,799,1,5,,855969,3559,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
293,800,2,11,,855969,3559,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
294,803,1,4,,855969,3559,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
295,804,1,3,,855969,3559,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
296,813,1,4,,855969,3559,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
297,817,1,1,,855969,3559,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
298,818,1,2,,855969,3559,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
299,827,1,2,,855969,3559,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
300,828,1,5,,855969,3559,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
301,834,1,3,,855969,3559,Inactive,,,,,C. albicans biofilm killing,Screening,,
302,841,1,1,,855969,3559,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
303,847,1,2,,855969,3559,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
304,861,1,1,,855969,3559,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
305,862,1,2,,855969,3559,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
306,868,1,3,,855969,3559,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
307,871,1,2,,855969,3559,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
308,873,1,13,,855969,3559,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
309,875,1,2,,11112116,3559,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
310,875,1,2,,11113356,3559,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
311,878,1,2,,855969,3559,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
312,879,1,2,,11113356,3559,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
313,879,1,2,,11113356,3559,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
314,880,2,1,,855969,3559,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
315,880,2,1,,855969,3559,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
316,880,2,1,,11112116,3559,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
317,880,2,1,,11112116,3559,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
318,880,2,1,,11113356,3559,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
319,880,2,1,,11113356,3559,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
320,880,2,1,,26747061,3559,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
321,880,2,1,,26747061,3559,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
322,880,2,1,,26751574,3559,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
323,880,2,1,,26751574,3559,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
324,880,2,1,,50104201,3559,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
325,880,2,1,,50104201,3559,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
326,881,2,2,,11112116,3559,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
327,881,2,2,,11113356,3559,Inactive,317373425.0,247.0,15.8489,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
328,883,1,3,,11111260,3559,Inactive,13699818.0,1559.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
329,883,1,3,,11112116,3559,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
330,883,1,3,,11113356,3559,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
331,884,1,2,,11112116,3559,Inactive,13435386.0,1576.0,5.0119,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
332,884,1,2,,11113356,3559,Inactive,13435386.0,1576.0,3.1623,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
333,885,1,2,,11112116,3559,Inconclusive,13435386.0,1576.0,5.0119,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
334,885,1,2,,11113356,3559,Active,13435386.0,1576.0,3.1623,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
335,886,1,2,,11111260,3559,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
336,886,1,2,,11111260,3559,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
337,886,1,2,,11112116,3559,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
338,886,1,2,,11112116,3559,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
339,886,1,2,,11113356,3559,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
340,886,1,2,,11113356,3559,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
341,887,1,2,,11112116,3559,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
342,887,1,2,,11113356,3559,Inconclusive,1832253.0,246.0,25.1189,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
343,889,1,3,,11112116,3559,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
344,889,1,3,,11113356,3559,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
345,891,1,2,,11111260,3559,Active,40805836.0,1565.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
346,891,1,2,,11112116,3559,Active,40805836.0,1565.0,6.3096,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
347,891,1,2,,11113356,3559,Active,40805836.0,1565.0,5.0119,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
348,892,1,2,,11112116,3559,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
349,892,1,2,,11113356,3559,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
350,893,1,2,,11112116,3559,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
351,893,1,2,,11112116,3559,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
352,893,1,2,,11113356,3559,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
353,893,1,2,,11113356,3559,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
354,894,2,1,,855969,3559,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
355,894,2,1,,11112116,3559,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
356,894,2,1,,11113356,3559,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
357,894,2,1,,26747061,3559,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
358,894,2,1,,50104201,3559,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
359,895,1,2,,11113356,3559,Inconclusive,21620132.0,4790.0,0.2818,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
360,898,1,1,,855969,3559,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
361,899,1,2,,11111260,3559,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
362,899,1,2,,11112116,3559,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
363,899,1,2,,11113356,3559,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
364,900,1,3,,11112116,3559,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
365,900,1,3,,11113356,3559,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
366,901,1,2,,11112116,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
367,901,1,2,,11113356,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
368,902,1,2,,11112116,3559,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
369,902,1,2,,11113356,3559,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
370,910,1,2,,11113356,3559,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
371,912,1,2,,11111260,3559,Inconclusive,21392848.0,,10.0,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
372,912,1,2,,11112116,3559,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
373,912,1,2,,11113356,3559,Inconclusive,21392848.0,,31.6228,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
374,914,1,3,,855969,3559,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
375,914,1,3,,11111260,3559,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
376,914,1,3,,11112116,3559,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
377,915,1,3,,855969,3559,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
378,915,1,3,,11111260,3559,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
379,915,1,3,,11112116,3559,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
380,917,1,3,,11113356,3559,Inconclusive,120660324.0,7066.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
381,918,1,3,,11113356,3559,Inconclusive,120660324.0,7066.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
382,920,1,2,,855969,3559,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
383,923,1,2,,11112116,3559,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
384,923,1,2,,11113356,3559,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
385,924,1,2,,11112116,3559,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
386,924,1,2,,11113356,3559,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
387,925,1,2,,11111260,3559,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
388,925,1,2,,11112116,3559,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
389,926,1,2,,11111260,3559,Inactive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
390,926,1,2,,11112116,3559,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
391,926,1,2,,11113356,3559,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
392,927,1,3,,11112116,3559,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
393,927,1,3,,11113356,3559,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
394,928,1,2,,11113356,3559,Inconclusive,21620132.0,4790.0,0.2818,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
395,930,1,2,,11113356,3559,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
396,932,1,4,,855969,3559,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
397,938,1,2,,11111260,3559,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
398,938,1,2,,11112116,3559,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
399,938,1,2,,11113356,3559,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
400,940,1,2,,855969,3559,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
401,940,1,2,,17405145,3559,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
402,940,1,2,,26611764,3559,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
403,943,1,2,,11113356,3559,Active,18249941.0,25229.0,6.3096,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
404,944,1,2,,11113356,3559,Active,18249941.0,25229.0,14.1254,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
405,945,1,4,,11113356,3559,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
406,950,1,1,,855969,3559,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
407,951,1,1,,855969,3559,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
408,952,1,1,,855969,3559,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
409,954,1,2,,11113356,3559,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
410,957,1,2,,11113356,3559,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
411,958,1,2,,11113356,3559,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
412,959,1,4,,11113356,3559,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
413,992,1,3,,11113356,3559,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
414,995,1,2,,11112116,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
415,995,1,2,,11113356,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
416,997,1,2,,11113356,3559,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
417,998,1,2,,11113356,3559,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
418,1001,2,2,,855969,3559,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
419,1006,1,6,,855969,3559,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
420,1007,1,1,,855969,3559,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
421,1008,1,2,,855969,3559,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
422,1009,1,2,,855969,3559,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
423,1012,1,4,,855969,3559,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
424,1016,1,4,,855969,3559,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
425,1018,2,5,,855969,3559,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
426,1019,1,4,,855969,3559,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
427,1020,1,5,,855969,3559,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
428,1021,1,1,,855969,3559,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
429,1022,1,1,,855969,3559,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
430,1027,1,3,,855969,3559,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
431,1030,2,1,,855969,3559,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
432,1030,2,1,,11112116,3559,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
433,1030,2,1,,11113356,3559,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
434,1030,2,1,,26747061,3559,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
435,1030,2,1,,26751574,3559,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
436,1030,2,1,,50104201,3559,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
437,1032,1,2,,855969,3559,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
438,1032,1,2,,855969,3559,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
439,1040,1,2,,855969,3559,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
440,1046,1,6,,855969,3559,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
441,1048,1,1,,855969,3559,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
442,1048,1,1,,855969,3559,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
443,1049,1,1,,855969,3559,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
444,1049,1,1,,855969,3559,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
445,1051,1,1,,855969,3559,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
446,1051,1,1,,855969,3559,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
447,1063,1,1,,855969,3559,Active,,,,,Leishmania major promastigote HTS,Screening,,
448,1066,1,2,,855969,3559,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
449,1085,1,1,,855969,3559,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
450,1135,1,3,,855969,3559,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
451,1136,1,3,,855969,3559,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
452,1203,1,3,,855969,3559,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
453,1209,2,2,,855969,3559,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
454,1214,1,4,,855969,3559,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
455,1216,1,5,,855969,3559,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
456,1217,1,4,,855969,3559,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
457,1220,2,2,,855969,3559,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
458,1222,1,6,,855969,3559,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
459,1229,1,3,,855969,3559,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
460,1235,1,2,,855969,3559,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
461,1236,1,1,,855969,3559,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
462,1239,1,3,,855969,3559,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
463,1239,1,3,,855969,3559,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
464,1242,1,1,,855969,3559,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
465,1251,1,1,,855969,3559,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
466,1273,1,1,,855969,3559,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
467,1274,1,2,,855969,3559,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
468,1276,1,1,,855969,3559,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
469,1285,1,1,,855969,3559,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
470,1296,1,1,,855969,3559,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
471,1304,1,2,,855969,3559,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
472,1321,1,2,,855969,3559,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
473,1325,1,2,,855969,3559,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
474,1326,1,4,,855969,3559,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
475,1332,1,1,,49698706,3559,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
476,1359,1,4,,855969,3559,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
477,1362,1,2,,855969,3559,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
478,1376,1,2,,855969,3559,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
479,1377,1,1,,855969,3559,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
480,1379,1,2,,855969,3559,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
481,1379,1,2,,11112116,3559,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
482,1379,1,2,,11113356,3559,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
483,1379,1,2,,26747061,3559,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
484,1379,1,2,,50104201,3559,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
485,1381,1,1,,855969,3559,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
486,1385,2,2,,855969,3559,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
487,1415,1,2,,855969,3559,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
488,1415,1,2,,855969,3559,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
489,1416,1,2,,855969,3559,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
490,1422,1,1,,855969,3559,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
491,1422,1,1,,17405145,3559,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
492,1422,1,1,,26611764,3559,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
493,1423,1,2,,855969,3559,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
494,1423,1,2,,855969,3559,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
495,1424,1,1,,855969,3559,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
496,1430,1,1,,855969,3559,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
497,1434,2,3,,855969,3559,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
498,1434,2,3,,855969,3559,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
499,1439,1,1,,855969,3559,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
500,1439,1,1,,855969,3559,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
501,1440,1,1,,855969,3559,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
502,1440,1,1,,855969,3559,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
503,1441,1,1,,855969,3559,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
504,1441,1,1,,855969,3559,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
505,1443,1,3,,855969,3559,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
506,1445,1,1,,855969,3559,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
507,1446,1,3,,855969,3559,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
508,1448,1,3,,855969,3559,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
509,1452,1,1,,855969,3559,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
510,1452,1,1,,11112116,3559,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
511,1452,1,1,,11113356,3559,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
512,1454,1,1,,855969,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
513,1454,1,1,,11112116,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
514,1454,1,1,,11113356,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
515,1454,1,1,,26747061,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
516,1454,1,1,,50104201,3559,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
517,1456,1,1,,855969,3559,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
518,1457,1,1,,855969,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
519,1457,1,1,,11112116,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
520,1457,1,1,,11113356,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
521,1457,1,1,,26747061,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
522,1457,1,1,,26751574,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
523,1457,1,1,,50104201,3559,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
524,1458,1,1,,855969,3559,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
525,1458,1,1,,11112116,3559,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
526,1458,1,1,,26747061,3559,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
527,1458,1,1,,26751574,3559,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
528,1458,1,1,,50104201,3559,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
529,1459,1,1,,50104201,3559,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
530,1460,1,3,,855969,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
531,1460,1,3,,11113356,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
532,1460,1,3,,26747061,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
533,1460,1,3,,26751574,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
534,1460,1,3,,50104201,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
535,1461,1,2,,855969,3559,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
536,1461,1,2,,50104201,3559,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
537,1463,1,1,,855969,3559,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
538,1463,1,1,,11113356,3559,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
539,1463,1,1,,26747061,3559,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
540,1463,1,1,,26751574,3559,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
541,1463,1,1,,50104201,3559,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
542,1465,1,1,,855969,3559,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
543,1466,1,2,,855969,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
544,1467,1,3,,11112116,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
545,1467,1,3,,11113356,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
546,1467,1,3,,26747061,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
547,1467,1,3,,50104201,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
548,1468,1,1,,855969,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
549,1468,1,1,,11113356,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
550,1468,1,1,,26747061,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
551,1468,1,1,,26751574,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
552,1468,1,1,,50104201,3559,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
553,1469,1,1,,855969,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
554,1469,1,1,,11112116,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
555,1469,1,1,,11113356,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
556,1469,1,1,,26747061,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
557,1469,1,1,,26751574,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
558,1469,1,1,,26751575,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
559,1469,1,1,,50104201,3559,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
560,1471,2,1,,11111260,3559,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
561,1471,2,1,,11112116,3559,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
562,1471,2,1,,11113356,3559,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
563,1471,2,1,,26747061,3559,Unspecified,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
564,1471,2,1,,26751574,3559,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
565,1476,2,1,,855969,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
566,1476,2,1,,11112116,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
567,1476,2,1,,11113356,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
568,1476,2,1,,26747061,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
569,1476,2,1,,50104201,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
570,1477,1,1,,855969,3559,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
571,1477,1,1,,11112116,3559,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
572,1477,1,1,,11113356,3559,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
573,1477,1,1,,26747061,3559,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
574,1477,1,1,,26751574,3559,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
575,1477,1,1,,50104201,3559,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
576,1478,2,1,,855969,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
577,1478,2,1,,11112116,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
578,1478,2,1,,11113356,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
579,1478,2,1,,26747061,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
580,1478,2,1,,50104201,3559,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
581,1479,1,2,,855969,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
582,1479,1,2,,11112116,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
583,1479,1,2,,11113356,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
584,1479,1,2,,26747061,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
585,1479,1,2,,26751574,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
586,1479,1,2,,26751575,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
587,1479,1,2,,50104201,3559,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
588,1481,1,2,,855969,3559,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
589,1486,1,3,,855969,3559,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
590,1487,1,1,,855969,3559,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
591,1487,1,1,,11112116,3559,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
592,1487,1,1,,26751574,3559,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
593,1487,1,1,,50104201,3559,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
594,1490,2,1,,855969,3559,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
595,1490,2,1,,11112116,3559,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
596,1490,2,1,,11113356,3559,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
597,1490,2,1,,26747061,3559,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
598,1490,2,1,,26751574,3559,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
599,1496,1,4,,855969,3559,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
600,1496,1,4,,855969,3559,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
601,1509,1,2,,855969,3559,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
602,1510,1,3,,855969,3559,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
603,1511,1,3,,855969,3559,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
604,1515,1,2,,855969,3559,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
605,1519,1,3,,11112116,3559,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
606,1519,1,3,,11113356,3559,Inconclusive,,,28.1838,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
607,1519,1,3,,26747061,3559,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
608,1519,1,3,,50104201,3559,Inconclusive,,,39.8107,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
609,1527,1,3,,855969,3559,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
610,1529,1,1,,855969,3559,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
611,1530,1,1,,855969,3559,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
612,1531,1,1,,855969,3559,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
613,1532,1,1,,855969,3559,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
614,1554,1,1,,855969,3559,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
615,1556,1,4,,855969,3559,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
616,1565,2,2,,855969,3559,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
617,1566,2,3,,855969,3559,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
618,1578,3,2,,855969,3559,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
619,1580,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
620,1581,1,1,,8149365,3559,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
621,1582,1,1,,8149365,3559,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
622,1583,1,1,,8149365,3559,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
623,1584,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
624,1585,1,1,,8149365,3559,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
625,1586,1,1,,8149365,3559,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
626,1587,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
627,1588,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
628,1589,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
629,1590,1,1,,8149365,3559,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
630,1593,1,1,,8149365,3559,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
631,1594,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
632,1595,1,1,,8149365,3559,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
633,1596,1,1,,8149365,3559,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
634,1597,1,1,,8149365,3559,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
635,1598,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
636,1599,1,1,,8149365,3559,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
637,1600,1,1,,8149365,3559,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
638,1601,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
639,1602,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
640,1603,1,1,,8149365,3559,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
641,1604,1,1,,8149365,3559,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
642,1605,1,1,,8149365,3559,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
643,1606,1,1,,8149365,3559,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
644,1607,1,1,,8149365,3559,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
645,1608,1,1,,8149365,3559,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
646,1609,1,1,,8149365,3559,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
647,1610,1,1,,8149365,3559,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
648,1612,1,1,,8149365,3559,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
649,1613,1,1,,8149365,3559,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
650,1614,1,1,,8149365,3559,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
651,1616,1,1,,8149365,3559,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
652,1619,1,2,,855969,3559,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
653,1621,1,2,,855969,3559,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
654,1626,1,2,,855969,3559,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
655,1631,3,1,,855969,3559,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
656,1634,3,1,,855969,3559,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
657,1654,2,2,,855969,3559,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
658,1656,2,2,,855969,3559,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
659,1662,1,2,,855969,3559,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
660,1663,1,2,,855969,3559,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
661,1665,2,2,,855969,3559,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
662,1672,1,3,,855969,3559,Active,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
663,1688,1,1,,855969,3559,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
664,1688,1,1,,26751574,3559,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
665,1700,1,2,,855969,3559,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
666,1705,1,2,,50104201,3559,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
667,1706,1,2,,855969,3559,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
668,1707,1,3,,50104201,3559,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
669,1708,1,3,,50104201,3559,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
670,1721,1,2,,855969,3559,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
671,1722,1,2,,855969,3559,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
672,1766,1,1,,855969,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
673,1766,1,1,,855969,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
674,1766,1,1,,11112116,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
675,1766,1,1,,11112116,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
676,1766,1,1,,11113356,3559,Inconclusive,18860839.0,4221.0,35.4813,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
677,1766,1,1,,11113356,3559,Inconclusive,56550039.0,4297.0,35.4813,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
678,1766,1,1,,26747061,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
679,1766,1,1,,26747061,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
680,1766,1,1,,26751574,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
681,1766,1,1,,26751574,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
682,1766,1,1,,50104201,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
683,1766,1,1,,50104201,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
684,1768,1,1,,855969,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
685,1768,1,1,,855969,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
686,1768,1,1,,11112116,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
687,1768,1,1,,11112116,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
688,1768,1,1,,11113356,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
689,1768,1,1,,11113356,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
690,1768,1,1,,26747061,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
691,1768,1,1,,26747061,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
692,1768,1,1,,26751574,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
693,1768,1,1,,26751574,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
694,1768,1,1,,50104201,3559,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
695,1768,1,1,,50104201,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
696,1775,1,2,,855969,3559,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
697,1776,1,2,,855969,3559,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
698,1777,3,2,,855969,3559,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
699,1778,3,3,,855969,3559,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
700,1779,2,2,,855969,3559,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
701,1789,1,2,,855969,3559,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
702,1800,1,2,,855969,3559,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
703,1813,1,2,,855969,3559,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
704,1814,1,2,,855969,3559,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
705,1815,1,1,,50104201,3559,Active,,,5.0119,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
706,1816,1,1,,50104201,3559,Active,,,3.9811,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
707,1817,2,2,,855969,3559,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
708,1822,1,3,,855969,3559,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
709,1825,1,1,,855969,3559,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
710,1828,2,1,,50104201,3559,Active,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
711,1832,2,1,,855969,3559,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
712,1845,1,2,,855969,3559,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
713,1850,2,1,,855969,3559,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
714,1850,2,1,,56422397,3559,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
715,1851,1,2,,11112116,3559,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
716,1851,1,2,,11113356,3559,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
717,1851,1,2,1.0,11112116,3559,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
718,1851,1,2,1.0,11113356,3559,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
719,1851,1,2,2.0,11112116,3559,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
720,1851,1,2,2.0,11113356,3559,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
721,1851,1,2,3.0,11112116,3559,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
722,1851,1,2,3.0,11113356,3559,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
723,1851,1,2,4.0,11112116,3559,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
724,1851,1,2,4.0,11113356,3559,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
725,1851,1,2,5.0,11112116,3559,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
726,1851,1,2,5.0,11113356,3559,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
727,1861,2,1,,855969,3559,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
728,1862,1,4,,855969,3559,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
729,1863,2,1,,855969,3559,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
730,1863,2,1,,56422397,3559,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
731,1865,1,1,,855969,3559,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
732,1865,1,1,,11112116,3559,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
733,1865,1,1,,11113356,3559,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
734,1865,1,1,,26747061,3559,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
735,1865,1,1,,26751574,3559,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
736,1865,1,1,,50104201,3559,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
737,1867,1,4,,855969,3559,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
738,1868,1,4,,855969,3559,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
739,1870,1,4,,855969,3559,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
740,1873,1,4,,855969,3559,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
741,1875,2,1,,855969,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
742,1876,1,1,,50104201,3559,Active,,,3.9811,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
743,1877,1,1,,50104201,3559,Active,,,14.1254,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
744,1882,1,1,,50104201,3559,Active,,,3.5481,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
745,1883,1,1,,50104201,3559,Active,,,2.2387,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
746,1885,2,1,,855969,3559,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
747,1886,1,1,,50104201,3559,Active,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
748,1887,1,4,,855969,3559,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
749,1899,1,3,,56422397,3559,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
750,1903,2,3,,855969,3559,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
751,1903,2,3,,56422397,3559,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
752,1906,1,3,,56422397,3559,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
753,1910,1,2,,855969,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
754,1947,1,2,,56422397,3559,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
755,1948,1,1,,11112116,3559,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
756,1948,1,1,,11113356,3559,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
757,1948,1,1,,26747061,3559,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
758,1948,1,1,,50104201,3559,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
759,1950,1,3,,56422397,3559,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
760,1956,1,1,,855969,3559,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
761,1961,2,2,,855969,3559,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
762,1962,1,2,,56422397,3559,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
763,1967,1,1,,85231072,3559,Inconclusive,4505907.0,5376.0,60.1198,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
764,1974,1,2,,56422397,3559,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
765,1984,1,3,,855969,3559,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
766,1986,1,2,,855969,3559,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
767,1987,1,2,,56422397,3559,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
768,1996,2,2,,855969,3559,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
769,2006,3,2,,855969,3559,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
770,2006,3,2,,855969,3559,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
771,2006,3,2,,855969,3559,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
772,2012,3,2,,855969,3559,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
773,2013,2,2,,855969,3559,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
774,2014,3,2,,855969,3559,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
775,2016,1,3,,56422397,3559,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
776,2023,1,3,,56422397,3559,Inconclusive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
777,2025,1,3,,56422397,3559,Inconclusive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
778,2029,1,3,,56422397,3559,Inconclusive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
779,2052,2,1,,56422397,3559,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
780,2057,1,2,,56422397,3559,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
781,2058,3,2,,855969,3559,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
782,2062,1,2,,85209095,3559,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
783,2066,1,4,,56422397,3559,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
784,2071,2,2,,855969,3559,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
785,2073,2,3,,855969,3559,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
786,2073,2,3,,855969,3559,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
787,2094,1,2,,855969,3559,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
788,2094,1,2,,855969,3559,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
789,2094,1,2,,855969,3559,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
790,2097,1,2,,855969,3559,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
791,2098,1,1,,855969,3559,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
792,2099,1,1,,855969,3559,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
793,2100,1,1,,855969,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
794,2101,1,1,,855969,3559,Inconclusive,496369.0,2629.0,0.7943,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
795,2101,1,1,,11112116,3559,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
796,2101,1,1,,11113356,3559,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
797,2101,1,1,,26747061,3559,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
798,2101,1,1,,26751574,3559,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
799,2101,1,1,,50104201,3559,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
800,2107,1,1,,855969,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
801,2107,1,1,,11112116,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
802,2107,1,1,,11113356,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
803,2107,1,1,,26747061,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
804,2107,1,1,,26751574,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
805,2107,1,1,,50104201,3559,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
806,2112,1,1,,855969,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
807,2112,1,1,,11112116,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
808,2112,1,1,,11113356,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
809,2112,1,1,,26747061,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
810,2112,1,1,,26751574,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
811,2112,1,1,,50104201,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
812,2129,1,2,,56422397,3559,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
813,2130,1,3,,56422397,3559,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
814,2147,1,1,,855969,3559,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
815,2147,1,1,,11112116,3559,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
816,2147,1,1,,11113356,3559,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
817,2147,1,1,,26747061,3559,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
818,2147,1,1,,50104201,3559,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
819,2156,2,2,,855969,3559,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
820,2174,1,3,,56422397,3559,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
821,2177,1,3,,56422397,3559,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
822,2205,1,1,,855969,3559,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
823,2216,1,3,,855969,3559,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
824,2221,1,2,,855969,3559,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
825,2227,1,2,,855969,3559,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
826,2234,1,2,,56422397,3559,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
827,2235,1,2,,56422397,3559,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
828,2237,1,2,,855969,3559,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
829,2239,1,2,,855969,3559,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
830,2240,1,1,,85788356,3559,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
831,2241,1,1,,85788356,3559,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
832,2242,1,1,,855969,3559,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
833,2247,1,2,,855969,3559,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
834,2275,1,1,,85788356,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
835,2280,2,3,,56422397,3559,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
836,2288,1,1,,855969,3559,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
837,2289,1,1,,855969,3559,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
838,2300,1,3,,56422397,3559,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
839,2313,1,1,,85788356,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
840,2314,1,2,,855969,3559,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
841,2314,1,2,,855969,3559,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
842,2315,1,2,,855969,3559,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
843,2315,1,2,,855969,3559,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
844,2322,1,1,,85788356,3559,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
845,2323,1,1,,50104201,3559,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
846,2326,1,1,,855969,3559,Inactive,194352380.0,,1.7783,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
847,2326,1,1,,50104201,3559,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
848,2330,1,1,,85788356,3559,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
849,2353,1,3,,50104201,3559,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
850,2364,1,2,,50104201,3559,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
851,2380,1,2,,855969,3559,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
852,2391,1,1,,56422397,3559,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
853,2417,1,1,,855969,3559,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
854,2435,1,2,,56422397,3559,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
855,2445,1,2,,56422397,3559,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
856,2451,1,2,,855969,3559,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
857,2451,1,2,,11112116,3559,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
858,2451,1,2,,11113356,3559,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
859,2451,1,2,,26747061,3559,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
860,2451,1,2,,50104201,3559,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
861,2462,1,1,,56422397,3559,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
862,2462,1,1,,56422397,3559,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
863,2472,1,2,,855969,3559,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
864,2472,1,2,,11112116,3559,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
865,2472,1,2,,11113356,3559,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
866,2472,1,2,,26747061,3559,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
867,2517,2,1,,855969,3559,Inactive,6980812.0,,0.0126,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
868,2517,2,1,,11112116,3559,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
869,2517,2,1,,11113356,3559,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
870,2517,2,1,,26747061,3559,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
871,2517,2,1,,26751574,3559,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
872,2517,2,1,,50104201,3559,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
873,2520,1,4,,855969,3559,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
874,2521,1,3,,855969,3559,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
875,2523,1,1,,855969,3559,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
876,2524,1,2,,855969,3559,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
877,2528,1,2,,855969,3559,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
878,2528,1,2,,11112116,3559,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
879,2528,1,2,,11113356,3559,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
880,2528,1,2,,26747061,3559,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
881,2528,1,2,,26751574,3559,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
882,2528,1,2,,50104201,3559,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
883,2540,1,2,,855969,3559,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
884,2544,1,2,,855969,3559,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
885,2546,1,1,,855969,3559,Inconclusive,188536040.0,19885.0,35.4813,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
886,2546,1,1,,11112116,3559,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
887,2546,1,1,,11113356,3559,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
888,2546,1,1,,26747061,3559,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
889,2546,1,1,,26751574,3559,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
890,2549,1,1,,855969,3559,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
891,2549,1,1,,11112116,3559,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
892,2549,1,1,,11113356,3559,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
893,2549,1,1,,26747061,3559,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
894,2549,1,1,,26751574,3559,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
895,2549,1,1,,50104201,3559,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
896,2550,1,3,,855969,3559,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
897,2551,1,1,,855969,3559,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
898,2551,1,1,,11112116,3559,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
899,2551,1,1,,11113356,3559,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
900,2551,1,1,,26747061,3559,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
901,2551,1,1,,26751574,3559,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
902,2553,1,2,,855969,3559,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
903,2557,1,3,,56422397,3559,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
904,2563,1,1,,855969,3559,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
905,2599,1,2,,855969,3559,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
906,2606,1,2,,56422397,3559,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
907,2629,1,1,,855969,3559,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
908,2629,1,1,,56422397,3559,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
909,2642,1,2,,855969,3559,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
910,2648,1,2,,855969,3559,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
911,2650,2,1,,56422397,3559,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
912,2660,1,1,,90341418,3559,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
913,2661,1,1,,56422397,3559,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
914,2662,2,1,,855969,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
915,2662,2,1,,85231072,3559,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
916,2666,1,1,,90341418,3559,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
917,2667,1,1,,90341418,3559,Active,4826730.0,2475.0,23.2809,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
918,2668,1,1,,90341418,3559,Inconclusive,4826730.0,2475.0,23.2809,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
919,2674,1,1,,855969,3559,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
920,2675,1,1,,855969,3559,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
921,2675,1,1,,50104201,3559,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
922,2676,1,2,,855969,3559,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
923,2685,1,1,,855969,3559,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
924,2690,1,2,,56422397,3559,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
925,2716,1,1,,855969,3559,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
926,2716,1,1,,56422397,3559,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
927,2717,1,2,,56422397,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
928,2718,1,1,,56422397,3559,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
929,2732,1,1,,855969,3559,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
930,2732,1,1,,17405145,3559,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
931,2751,2,2,,56422397,3559,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
932,2774,1,3,,92303886,3559,Inactive,,,,,LOPAC Circadian Assay,Screening,,
933,2796,1,4,,56422397,3559,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
934,2797,1,2,,56422397,3559,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
935,2805,2,2,,855969,3559,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
936,2806,2,2,,855969,3559,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
937,2825,1,2,,855969,3559,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
938,3460,7,1,,103167216,3559,Active,,,1.5,IC50,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Confirmatory,9622542.0,
939,3656,9,1,,103167216,3559,Active,,,7.079,IC50,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Confirmatory,7914536.0,
940,3669,7,2,,103167216,3559,Unspecified,,,1.0,IC50,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Confirmatory,2869146.0,
941,3688,6,2,,103167216,3559,Active,,,0.4,Ki,Affinity for 5-hydroxytryptamine 1 receptor,Confirmatory,9871525.0,
942,3699,7,1,,103167216,3559,Unspecified,,,1.0,Ki,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Confirmatory,1346653.0,
943,3730,9,1,,103167216,3559,Active,,,7.079,IC50,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Confirmatory,8831770.0,
944,3736,8,5,,103167216,3559,Unspecified,112812.0,24473.0,1.0,IC50,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Confirmatory,1676427.0,
945,3744,7,1,,103167216,3559,Active,,,7.0,IC50,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Confirmatory,8568802.0,
946,3746,11,1,,103167216,3559,Active,,,6.21,IC50,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Confirmatory,1672156.0,
947,3756,7,1,,103167216,3559,Active,,,1.993,IC50,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Confirmatory,12361392.0,
948,3760,7,2,,103167216,3559,Active,,,7.0,IC50,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Confirmatory,7914539.0,
949,3992,7,1,,103167216,3559,Active,,,8.4,Ki,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Confirmatory,9876110.0,
950,4027,8,3,,103167216,3559,Inconclusive,,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Other,9667967.0,
951,4042,7,2,,103167216,3559,Active,,,0.401,Ki,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Confirmatory,7473547.0,
952,4053,9,1,,103167216,3559,Active,,,5.75,Ki,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Confirmatory,1353116.0,
953,4055,9,3,,103167216,3559,Active,,,1.8,Ki,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Confirmatory,,
954,4061,7,1,,103167216,3559,Unspecified,,,1.0,Ki,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,Confirmatory,9622541.0,
955,4067,7,1,,103167216,3559,Active,,,1.9,Ki,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Confirmatory,8709107.0,
956,4128,7,4,,103167216,3559,Unspecified,,,1.0,IC50,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,Confirmatory,10743959.0,
957,4136,7,2,,103167216,3559,Active,,,3.2,IC50,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT.,Confirmatory,7783131.0,
958,4334,7,2,,103167216,3559,Active,,,0.401,Ki,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Confirmatory,7473548.0,
959,4356,8,5,,103167216,3559,Unspecified,112812.0,24473.0,1.0,Ki,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Confirmatory,7909336.0,
960,4357,7,1,,103167216,3559,Unspecified,,,0.5,Ki,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Confirmatory,10464021.0,
961,4363,7,1,,103167216,3559,Active,,,0.401,Ki,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Confirmatory,1346653.0,
962,4442,7,2,,103167216,3559,Active,,,2.8,Ki,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Confirmatory,11527728.0,
963,4670,7,1,,103167216,3559,Unspecified,,,10.0,IC50,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Confirmatory,9622542.0,
964,4782,9,1,,103167216,3559,Active,,,0.129,IC50,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Confirmatory,8831770.0,
965,4786,7,2,,103167216,3559,Active,,,0.061,IC50,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Confirmatory,2869146.0,
966,4793,7,1,,103167216,3559,Active,,,0.055999999999999994,IC50,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Confirmatory,1676427.0,
967,4803,9,1,,103167216,3559,Active,,,0.13,IC50,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Confirmatory,1672156.0,
968,4804,9,2,,103167216,3559,Active,112808.0,29595.0,0.033,IC50,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Confirmatory,2875184.0,
969,4804,9,2,,103167216,3559,Active,112817.0,25187.0,0.033,IC50,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Confirmatory,2875184.0,
970,4804,9,2,,103167216,3559,Active,398970.0,29581.0,0.033,IC50,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Confirmatory,2875184.0,
971,4812,7,5,,103167216,3559,Active,112808.0,29595.0,0.018000000000000002,IC50,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Confirmatory,1348090.0,
972,4812,7,5,,103167216,3559,Active,112817.0,25187.0,0.018000000000000002,IC50,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Confirmatory,1348090.0,
973,4812,7,5,,103167216,3559,Active,398970.0,29581.0,0.018000000000000002,IC50,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Confirmatory,1348090.0,
974,4814,7,1,,103167216,3559,Active,,,0.36,IC50,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Confirmatory,8568802.0,
975,4824,7,2,,103167216,3559,Active,,,0.36,IC50,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Confirmatory,7914539.0,
976,5012,9,1,,103167216,3559,Active,,,0.034,Ki,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Confirmatory,9572883.0,
977,5013,7,2,,103167216,3559,Active,,,0.016,Ki,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Confirmatory,9572880.0,
978,5018,6,3,,103167216,3559,Unspecified,,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Other,8496917.0,
979,5035,11,1,,103167216,3559,Active,,,0.0265,Ki,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,Confirmatory,8496917.0,
980,5042,7,2,,103167216,3559,Active,,,0.02344,Ki,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Confirmatory,7907148.0,
981,5053,7,3,,103167216,3559,Unspecified,,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,Other,1348090.0,
982,5061,7,1,,103167216,3559,Active,,,0.17,IC50,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Confirmatory,7707315.0,
983,5123,9,2,,103167216,3559,Active,,,0.0234,Ki,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Confirmatory,8101877.0,
984,5127,4,1,,103167216,3559,Active,,,0.01995,Ki,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Confirmatory,11392544.0,
985,5155,7,1,,103167216,3559,Active,,,0.03,IC50,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Confirmatory,9622542.0,
986,5171,9,1,,103167216,3559,Active,,,0.28800000000000003,IC50,Inhibitory concentration against human 5-HT2A receptor in BEK cells,Confirmatory,8831770.0,
987,5196,9,1,,103167216,3559,Active,,,0.10800000000000001,Ki,Binding affinity towards human 5-HT2A receptor in BEK cells,Confirmatory,8831770.0,
988,5197,7,2,,103167216,3559,Active,,,0.025,Ki,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,14998318.0,
989,5205,7,2,,103167216,3559,Active,,,0.13,Ki,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Confirmatory,14695828.0,
990,5218,7,5,,103167216,3559,Active,112808.0,29595.0,0.042,Ki,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Confirmatory,2889830.0,
991,5218,7,5,,103167216,3559,Active,112817.0,25187.0,0.042,Ki,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Confirmatory,2889830.0,
992,5218,7,5,,103167216,3559,Active,398970.0,29581.0,0.042,Ki,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Confirmatory,2889830.0,
993,5229,7,2,,103167216,3559,Active,,,0.0106,Ki,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Confirmatory,1346653.0,
994,5233,10,5,,103167216,3559,Active,112808.0,29595.0,0.043,Ki,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Confirmatory,10743959.0,
995,5233,10,5,,103167216,3559,Active,112817.0,25187.0,0.043,Ki,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Confirmatory,10743959.0,
996,5233,10,5,,103167216,3559,Active,398970.0,29581.0,0.043,Ki,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Confirmatory,10743959.0,
997,5241,7,2,,103167216,3559,Active,,,0.0042,Ki,Binding affinity towards 5-hydroxytryptamine 2 receptor,Confirmatory,3039136.0,
998,5246,7,5,,103167216,3559,Active,112808.0,29595.0,0.011000000000000001,Ki,Affinity for 5-hydroxytryptamine 2 receptor,Confirmatory,9871525.0,
999,5246,7,5,,103167216,3559,Active,112817.0,25187.0,0.011000000000000001,Ki,Affinity for 5-hydroxytryptamine 2 receptor,Confirmatory,9871525.0,
1000,5246,7,5,,103167216,3559,Active,398970.0,29581.0,0.011000000000000001,Ki,Affinity for 5-hydroxytryptamine 2 receptor,Confirmatory,9871525.0,
1001,5255,9,1,,103167216,3559,Active,,,0.05,Ki,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Confirmatory,1353116.0,
1002,5258,9,3,,103167216,3559,Active,,,0.043,Ki,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Confirmatory,,
1003,5279,7,1,,103167216,3559,Active,,,0.027000000000000003,Ki,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Confirmatory,2888898.0,
1004,5289,7,1,,103167216,3559,Active,,,0.0265,Ki,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Confirmatory,7901415.0,
1005,5321,7,5,,103167216,3559,Active,112808.0,29595.0,0.05248,Ki,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Confirmatory,12482418.0,
1006,5324,4,1,,103167216,3559,Active,112808.0,29595.0,0.05248,Ki,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,11101359.0,
1007,5326,5,1,,103167216,3559,Active,,,0.16596,Ki,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Confirmatory,11784139.0,
1008,5328,4,1,,103167216,3559,Active,112808.0,29595.0,0.04467,Ki,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Confirmatory,8568801.0,
1009,5329,4,1,,103167216,3559,Active,,,0.01995,Ki,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Confirmatory,,
1010,5330,4,1,,103167216,3559,Active,,,0.01995,Ki,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,Confirmatory,7914540.0,
1011,5331,5,1,,103167216,3559,Active,,,0.05248,Ki,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Confirmatory,11754579.0,
1012,5334,4,1,,103167216,3559,Active,,,0.01995,Ki,Serotonergic activity of the compound.,Confirmatory,10966742.0,
1013,5335,4,1,,103167216,3559,Active,,,0.01995,Ki,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Confirmatory,,
1014,5337,4,1,,103167216,3559,Active,,,0.01995,Ki,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Confirmatory,10425088.0,
1015,5363,5,1,,103167216,3559,Active,,,0.16596,Ki,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,14741248.0,
1016,5381,3,7,,103167216,3559,Unspecified,,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Other,11784139.0,
1017,5479,9,1,,103167216,3559,Active,,,0.129,IC50,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Confirmatory,7914536.0,
1018,5483,7,1,,103167216,3559,Active,,,0.055,IC50,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Confirmatory,10377229.0,
1019,5484,7,1,,103167216,3559,Active,,,0.125,IC50,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Confirmatory,12361392.0,
1020,5485,8,5,,103167216,3559,Active,112808.0,29595.0,0.10400000000000001,IC50,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Confirmatory,9876110.0,
1021,5490,8,5,,103167216,3559,Active,112808.0,29595.0,0.055,IC50,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Confirmatory,9406603.0,
1022,5491,7,2,,103167216,3559,Active,,,0.055,IC50,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin.,Confirmatory,7783131.0,
1023,5522,7,1,,103167216,3559,Active,,,0.075,Ki,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Confirmatory,9876110.0,
1024,5558,7,1,,103167216,3559,Active,,,0.087,Ki,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Confirmatory,8709107.0,
1025,5560,7,1,,103167216,3559,Active,,,0.16399999999999998,Ki,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Confirmatory,11784139.0,
1026,5561,9,1,,103167216,3559,Active,,,0.045,Ki,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Confirmatory,8568801.0,
1027,5567,7,1,,103167216,3559,Active,,,0.049,Ki,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Confirmatory,12408724.0,
1028,5569,7,1,,103167216,3559,Active,,,0.16399999999999998,Ki,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Confirmatory,14695828.0,
1029,5614,7,2,,103167216,3559,Unspecified,,,5.0,Ki,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Confirmatory,14998318.0,
1030,5686,7,1,,103167216,3559,Unspecified,,,10.0,IC50,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Confirmatory,9622542.0,
1031,5703,7,2,,103167216,3559,Unspecified,,,1.0,IC50,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Confirmatory,10377229.0,
1032,5708,8,5,,103167216,3559,Unspecified,112817.0,25187.0,1.0,IC50,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Confirmatory,9406603.0,
1033,5835,5,1,,103167216,3559,Active,,,4.570880000000001,Ki,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Confirmatory,11754579.0,
1034,5836,4,1,,103167216,3559,Active,,,2.51189,Ki,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Confirmatory,10425088.0,
1035,5837,4,1,,103167216,3559,Active,,,4.570880000000001,Ki,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Confirmatory,11101359.0,
1036,5951,5,1,,103167216,3559,Active,,,7.24436,Ki,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Confirmatory,14741248.0,
1037,6022,8,5,,103167216,3559,Unspecified,112809.0,15561.0,10.0,Ki,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Confirmatory,8709107.0,
1038,6437,7,1,,103167216,3559,Active,,,2.39,Ki,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Confirmatory,10649982.0,
1039,6563,7,2,,103167216,3559,Unspecified,,,5.0,Ki,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Confirmatory,12825922.0,
1040,6648,7,2,,103167216,3559,Active,,,0.263,Ki,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Confirmatory,12825922.0,
1041,7783,3,4,,103167216,3559,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
1042,8002,5,2,,103167216,3559,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
1043,19424,3,4,,103167216,3559,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
1044,21263,3,3,,103167216,3559,Unspecified,,,,,Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s),Other,8941388.0,
1045,22293,4,4,,103167216,3559,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
1046,23095,3,9,,103167216,3559,Unspecified,112808.0,29595.0,,,Ratio of pKi of 5-HT2A receptor to that of D2 receptor,Other,11101359.0,
1047,23095,3,9,,103167216,3559,Unspecified,47117674.0,24318.0,,,Ratio of pKi of 5-HT2A receptor to that of D2 receptor,Other,11101359.0,
1048,23695,3,3,,103167216,3559,Unspecified,,,,,Partition coefficient (logP),Other,10377229.0,
1049,24452,4,3,,103167216,3559,Unspecified,,,,,logY value was determined,Other,14695828.0,
1050,26304,4,4,,103167216,3559,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
1051,26362,4,3,,103167216,3559,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
1052,27370,6,2,,103167216,3559,Unspecified,,,,,Lethal dose after peroral administration in mouse,Other,2869146.0,
1053,27922,4,3,,103167216,3559,Unspecified,,,,,Calculated partition coefficient (clogP),Other,11728188.0,
1054,28233,3,3,,103167216,3559,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
1055,28235,3,3,,103167216,3559,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
1056,28236,3,3,,103167216,3559,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
1057,29139,4,3,,103167216,3559,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
1058,29337,3,3,,103167216,3559,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
1059,29359,3,3,,103167216,3559,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
1060,29423,3,4,,103167216,3559,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
1061,29811,4,3,,103167216,3559,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
1062,29925,5,2,,103167216,3559,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
1063,33271,7,5,,103167216,3559,Active,231461.0,25083.0,0.019,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1064,33271,7,5,,103167216,3559,Active,231464.0,24175.0,0.019,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1065,33271,7,5,,103167216,3559,Active,543734.0,24173.0,0.019,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1066,33271,7,5,,103167216,3559,Active,1168244.0,29413.0,0.019,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1067,33271,7,5,,103167216,3559,Active,1168247.0,29412.0,0.019,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1068,33271,7,5,,103167216,3559,Active,47117345.0,24174.0,0.019,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1069,34586,6,4,,103167216,3559,Active,,,0.55,IC50,Inhibitory concentration against rat striatal dopamine (D1) sensitive adenylate cyclase activity,Confirmatory,2888899.0,
1070,35191,7,5,,103167216,3559,Unspecified,231461.0,25083.0,1.0,Ki,Binding affinity towards alpha-2 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1071,35191,7,5,,103167216,3559,Unspecified,231464.0,24175.0,1.0,Ki,Binding affinity towards alpha-2 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1072,35191,7,5,,103167216,3559,Unspecified,47117345.0,24174.0,1.0,Ki,Binding affinity towards alpha-2 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1073,35270,7,2,,103167216,3559,Active,,,0.009000000000000001,Ki,Compound was tested for the binding affinity against rat cortical Alpha-1 adrenergic receptor by radioligand [3H]prazosin binding assay.,Confirmatory,8709107.0,
1074,35274,7,2,,103167216,3559,Active,,,0.001,Ki,Evaluated for binding affinity against alpha-1 adrenergic receptor,Confirmatory,10893315.0,
1075,35276,7,5,,103167216,3559,Active,543734.0,24173.0,0.012,Ki,Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1076,35276,7,5,,103167216,3559,Active,1168244.0,29413.0,0.012,Ki,Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1077,35276,7,5,,103167216,3559,Active,1168247.0,29412.0,0.012,Ki,Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1078,35277,7,5,,103167216,3559,Active,543734.0,24173.0,0.0063,Ki,Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain,Confirmatory,8568801.0,
1079,35277,7,5,,103167216,3559,Active,1168244.0,29413.0,0.0063,Ki,Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain,Confirmatory,8568801.0,
1080,35277,7,5,,103167216,3559,Active,1168247.0,29412.0,0.0063,Ki,Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain,Confirmatory,8568801.0,
1081,35285,11,1,,103167216,3559,Active,,,0.013000000000000001,Ki,In vitro binding affinity at Alpha-1 adrenergic receptor in rat cortical tissues,Confirmatory,12408724.0,
1082,35289,7,1,,103167216,3559,Active,,,0.012,Ki,In vitro binding affinity towards alpha-1 adrenergic receptor in rat frontal cortex homogenate using of [3H]prazosin as radioligand,Confirmatory,14695828.0,
1083,35428,7,5,,103167216,3559,Active,543734.0,24173.0,0.001,Ki,Binding affinity towards alpha-1 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1084,35428,7,5,,103167216,3559,Active,1168244.0,29413.0,0.001,Ki,Binding affinity towards alpha-1 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1085,35428,7,5,,103167216,3559,Active,1168247.0,29412.0,0.001,Ki,Binding affinity towards alpha-1 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1086,35436,7,1,,103167216,3559,Active,,,0.0235,Ki,The compound was tested for its binding affinity towards alpha-1 adrenergic receptor by displacing [3H]WB-4101 radioligand in rat cerebral cortexc,Confirmatory,1346653.0,
1087,35638,8,3,,103167216,3559,Inconclusive,,,,,Binding affinity measured at the Alpha-2 adrenergic receptor by the inhibition of [3H]clonidine binding to rat cortex using unlabeled NAbitartrate for nonspecific binding; ND = 'Not determined',Other,9876110.0,
1088,36016,4,1,,103167216,3559,Active,543734.0,24173.0,0.0063100000000000005,Ki,Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor,Confirmatory,8568801.0,
1089,36016,4,1,,103167216,3559,Active,1168244.0,29413.0,0.0063100000000000005,Ki,Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor,Confirmatory,8568801.0,
1090,36016,4,1,,103167216,3559,Active,1168247.0,29412.0,0.0063100000000000005,Ki,Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor,Confirmatory,8568801.0,
1091,36026,9,2,,103167216,3559,Active,543734.0,24173.0,0.054000000000000006,IC50,Binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]- WB-4101,Confirmatory,2875184.0,
1092,36026,9,2,,103167216,3559,Active,1168244.0,29413.0,0.054000000000000006,IC50,Binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]- WB-4101,Confirmatory,2875184.0,
1093,36026,9,2,,103167216,3559,Active,1168247.0,29412.0,0.054000000000000006,IC50,Binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]- WB-4101,Confirmatory,2875184.0,
1094,36113,7,2,,103167216,3559,Active,,,0.019,Ki,Binding affinity towards human alpha-1 adrenergic receptor,Confirmatory,14998318.0,
1095,36122,7,2,,103167216,3559,Active,,,0.0057,Ki,The compound was tested against Alpha-1 adrenergic receptor for percent displacement of radioligand at 10e-6 M,Confirmatory,10464021.0,
1096,36137,7,1,,103167216,3559,Active,,,0.146,Ki,In vitro binding affinity towards alpha-1 adrenergic receptor by using [3H]-prazosin in rat brain cortex membranes.,Confirmatory,10649982.0,
1097,36199,7,2,,103167216,3559,Unspecified,,,5.0,Ki,Binding affinity towards human alpha-2 adrenergic receptor,Confirmatory,14998318.0,
1098,36454,7,1,,103167216,3559,Active,,,0.02,IC50,Affinity towards Alpha-1A adrenergic receptor in membranes from bovine frontal cortex using [3H]prazosin,Confirmatory,9622542.0,
1099,36583,6,3,,103167216,3559,Unspecified,,,,,Induction of ptosis after subcutaneous administration at alpha-1 adrenergic receptor in rat,Other,7562940.0,
1100,36713,7,1,,103167216,3559,Active,,,0.006999999999999999,IC50,"Binding affinity to alpha-1 adrenergic receptor from rat brain homogenate, using [3H]- prazosin as the competitive ligand",Confirmatory,11052797.0,
1101,36730,9,2,,103167216,3559,Active,,,0.0825,IC50,Its affinity towards alpha-1 receptor using [3H]WB-4101 as radioligand in whole brain minus cerebellum,Confirmatory,7914536.0,
1102,36798,9,2,,103167216,3559,Active,231461.0,25083.0,6.0,IC50,Binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- clonidine,Confirmatory,2875184.0,
1103,36798,9,2,,103167216,3559,Active,231464.0,24175.0,6.0,IC50,Binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- clonidine,Confirmatory,2875184.0,
1104,36798,9,2,,103167216,3559,Active,47117345.0,24174.0,6.0,IC50,Binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- clonidine,Confirmatory,2875184.0,
1105,36847,7,2,,103167216,3559,Active,,,0.13,IC50,In vitro affinity for cortical alpha-1 adrenergic receptor labelled with [3H]WB-4101,Confirmatory,2869146.0,
1106,36849,7,1,,103167216,3559,Active,,,0.018000000000000002,IC50,Binding affinity towards alpha-1 adrenergic receptor from rat brain membranes using [3H]prazosin as radioligand,Confirmatory,10377229.0,
1107,36865,7,2,,103167216,3559,Active,,,0.13,IC50,In vitro inhibitory concentration against radioligand [3H]WB-4101 binding to rat cortical alpha-1 adrenergic receptor,Confirmatory,1361578.0,
1108,36891,8,3,,103167216,3559,Inconclusive,,,,,Binding affinity measured at the Alpha-1A adrenergic receptor by the inhibition of [3H]prazosin binding to rat cortex using unlabeled WB-4101 for nonspecific binding; ND = ''Not determined''.,Other,9876110.0,
1109,36912,7,5,,103167216,3559,Active,1168247.0,29412.0,0.01738,Kd,Binding affinity towards Alpha-1A adrenergic receptor in rat denuded thoracic aorta,Confirmatory,12482418.0,
1110,37001,7,5,,103167216,3559,Active,543734.0,24173.0,0.018000000000000002,IC50,Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat brain membranes,Confirmatory,9406603.0,
1111,37001,7,5,,103167216,3559,Active,1168244.0,29413.0,0.018000000000000002,IC50,Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat brain membranes,Confirmatory,9406603.0,
1112,37001,7,5,,103167216,3559,Active,1168247.0,29412.0,0.018000000000000002,IC50,Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat brain membranes,Confirmatory,9406603.0,
1113,37007,7,2,,103167216,3559,Active,,,0.018000000000000002,IC50,Binding affinity towards Alpha-1 adrenergic receptor binding site using [3H]prazosin.,Confirmatory,7783131.0,
1114,37170,7,5,,103167216,3559,Active,543734.0,24173.0,0.031,Ki,Ability to inhibit [3H]WB-4101 binding to alpha-1 adrenergic receptor was determined in rat,Confirmatory,2889830.0,
1115,37170,7,5,,103167216,3559,Active,1168244.0,29413.0,0.031,Ki,Ability to inhibit [3H]WB-4101 binding to alpha-1 adrenergic receptor was determined in rat,Confirmatory,2889830.0,
1116,37170,7,5,,103167216,3559,Active,1168247.0,29412.0,0.031,Ki,Ability to inhibit [3H]WB-4101 binding to alpha-1 adrenergic receptor was determined in rat,Confirmatory,2889830.0,
1117,37306,7,2,,103167216,3559,Active,,,0.01,Ki,Binding affinity was tested on Alpha-1 adrenergic receptor using radioligand [3H](+)-pentazocine binding assay.,Confirmatory,8863803.0,
1118,37361,7,2,,103167216,3559,Active,,,9.6,Ki,Compound was tested for the binding affinity against rat cortical Alpha-2 adrenergic receptor by Radio ligand ([3H]Rx-821002) binding assay,Confirmatory,8709107.0,
1119,37370,7,5,,103167216,3559,Active,231461.0,25083.0,2.7,Ki,Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1120,37370,7,5,,103167216,3559,Active,231464.0,24175.0,2.7,Ki,Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1121,37370,7,5,,103167216,3559,Active,47117345.0,24174.0,2.7,Ki,Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1122,37376,7,1,,103167216,3559,Active,,,2.7,Ki,In vitro binding affinity towards alpha-2 adrenergic receptor in rat frontal cortex homogenate using of [3H]clonidine as radioligand,Confirmatory,14695828.0,
1123,37441,8,3,,103167216,3559,Inconclusive,,,,,Binding affinity was evaluated against Alpha-1 adrenergic receptor on rat cortex using [3H]prazosin as radioligand; ND = Not determined,Other,9667967.0,
1124,37449,7,2,,103167216,3559,Active,,,0.0235,Ki,Binding affinity towards alpha-1 adrenergic receptor using [3H]prazosin as radioligand.,Confirmatory,7473548.0,
1125,37455,7,5,,103167216,3559,Active,543734.0,24173.0,0.023,Ki,Affinity for alpha-1 adrenergic receptor,Confirmatory,9871525.0,
1126,37455,7,5,,103167216,3559,Active,1168244.0,29413.0,0.023,Ki,Affinity for alpha-1 adrenergic receptor,Confirmatory,9871525.0,
1127,37455,7,5,,103167216,3559,Active,1168247.0,29412.0,0.023,Ki,Affinity for alpha-1 adrenergic receptor,Confirmatory,9871525.0,
1128,37475,7,1,,103167216,3559,Active,,,0.001,Ki,Compound was evaluated for its binding affinity with Alpha-1 adrenergic receptor using membranes prepared from rat cerebral cortex,Confirmatory,9622541.0,
1129,40403,4,10,,103167216,3559,Unspecified,114754.0,24925.0,10.0,IC50,Binding affinity against beta-1 adrenergic receptor in rat brain using [3H]DHA,Confirmatory,2875184.0,
1130,40407,8,3,,103167216,3559,Inconclusive,,,,,Binding affinity measured at the Beta-1 adrenergic receptor by the inhibition of [3H]DHA binding to rat cortex using unlabeled isoprenalin for nonspecific binding; ND = 'Not determined',Other,9876110.0,
1131,41473,4,10,,103167216,3559,Unspecified,114768.0,24176.0,10.0,IC50,Binding affinity against beta-2 adrenergic receptor in rat brain using [3H]DHA,Confirmatory,2875184.0,
1132,41748,4,7,,103167216,3559,Unspecified,,,10.0,Ki,Compound was tested for the binding affinity against rat cortical Beta adrenergic receptor by Radio ligand [3H]dihydroalprenolol binding assay.,Confirmatory,8709107.0,
1133,45419,8,5,,103167216,3559,Active,118206.0,1813.0,0.00044,Ki,Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2,Confirmatory,7902870.0,
1134,45420,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0009599999999999999,Ki,Displacement of [3H]-spiperone from CHO-K1 cell membranes expressing human dopamine 3 receptors,Confirmatory,7902870.0,
1135,45592,4,4,,103167216,3559,Active,,,0.0088,IC50,Compound was tested for stimulation of mitogenesis in CHO.hD3 cells in a dose dependent manner,Confirmatory,9873609.0,
1136,45980,6,3,,103167216,3559,Active,,,0.0014,Ki,Compound was evaluated for the inhibition of [3H]haloperidol binding in calf brain homogenates,Confirmatory,7252977.0,
1137,49738,3,4,,103167216,3559,Active,,,,,Compound at a dose of 100 ug/kg was evaluated for the reversal of the inhibition of nerve stimulation using the cat cardioaccelerator nerve preparation; Reversed inhibition,Other,3783613.0,
1138,49739,3,4,,103167216,3559,Active,,,,,Compound at a dose of 50 ug/kg was evaluated for the reversal of the inhibition of nerve stimulation using the cat cardioaccelerator nerve preparation; Reversed inhibition,Other,3783613.0,
1139,50074,5,3,,103167216,3559,Unspecified,,,,,Ability to lower arterial blood pressure in cat at 100 ug/kg; reversed,Other,6854584.0,
1140,51566,3,3,,103167216,3559,Unspecified,,,,,Minimal effective dose required for signs of EPS in cebus monkeys,Other,2866248.0,
1141,61032,7,1,,103167216,3559,Active,,,0.337,IC50,Binding affinity towards Dopamine receptor D1 in rat membranes using [3H]SCH-23390 as radioligand,Confirmatory,1662725.0,
1142,61046,7,3,,103167216,3559,Unspecified,,,,,Compound was tested in vivo for methyl phenidate-induced gnawing behavior antagonistic activity against dopamine receptor D2 in mice,Other,1348090.0,
1143,61079,7,2,,103167216,3559,Active,,,0.0008710000000000001,Ki,Binding affinity against dopamine D2 receptor,Confirmatory,7907148.0,
1144,61151,7,3,,103167216,3559,Active,,,0.036000000000000004,IC50,Binding affinity towards D1 CNS receptor of rat corpus striatum using [3H]SCH-23390 as radioligand,Confirmatory,10377229.0,
1145,61158,4,1,,103167216,3559,Active,,,0.15849000000000002,Ki,In vitro ability to displace [3H]SCH-23390 binding from Dopamine 1 (D1) receptor in rat striatal membrane.,Confirmatory,10425088.0,
1146,61193,8,5,,103167216,3559,Active,118229.0,24316.0,0.036000000000000004,IC50,Inhibitory binding of [3H]SCH-23390 to Dopamine receptor D1 in membranes from rat corpus striatum,Confirmatory,9406603.0,
1147,61236,7,3,,103167216,3559,Unspecified,,,,,Compound was tested in vivo for induction of catalepsy against dopamine receptor D2 in rats,Other,1348090.0,
1148,61316,7,1,,103167216,3559,Active,,,0.00084,Ki,In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.,Confirmatory,9871530.0,
1149,61317,9,5,,103167216,3559,Active,118206.0,1813.0,0.0036,Ki,Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor,Confirmatory,,
1150,61322,4,1,,103167216,3559,Active,,,0.001,Ki,Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone,Confirmatory,,
1151,61326,7,2,,103167216,3559,Active,,,0.006999999999999999,IC50,Compound was tested in vitro for its affinity towards rat striatal Dopamine receptor D2 labeled with [3H]- spiperone,Confirmatory,2869146.0,
1152,61337,9,3,,103167216,3559,Active,,,0.0015,Ki,Ability to displace [3H]spiperone from D2 dopamine receptor isolated from the striata of male Wistar rats,Confirmatory,,
1153,61358,7,2,,103167216,3559,Active,,,0.028999999999999998,Ki,Ability to displace [3H]-SCH- 23390 (0.2 nM) from corpus striatum of rat Dopamine receptor D1,Confirmatory,12519065.0,
1154,61375,7,3,,103167216,3559,Active,,,0.145,Ki,Binding affinity measured at the Dopamine receptor D1 by the inhibition of [3H]SCH-23390 binding to rat striatum using unlabeled apomorphine for nonspecific binding.,Confirmatory,9876110.0,
1155,61387,8,5,,103167216,3559,Active,47117674.0,24318.0,0.00424,IC50,Ability to inhibit the specific binding of [3H]- spiroperidol to Dopamine receptor D2 in rat striatal membrane preparation by 50%,Confirmatory,2888899.0,
1156,61388,7,2,,103167216,3559,Active,,,0.018000000000000002,IC50,Affinity for dopamine receptor D2 binding sites by its ability to displace [3H]spiperone from rat striatum.,Confirmatory,7707315.0,
1157,61399,9,1,,103167216,3559,Active,,,0.0048,IC50,Affinity towards Dopamine receptor D2 was evaluated in rat striatal membrane using [3H]spiperone as radioligand,Confirmatory,8960552.0,
1158,61415,9,1,,103167216,3559,Active,,,0.033,IC50,Binding affinity towards Dopamine receptor D2 was determined in rat striatal homogenate using [3H]- spiperone as radioligand,Confirmatory,8831770.0,
1159,61495,9,1,,103167216,3559,Active,,,0.047,Ki,Binding affinity was measured against dopamine receptor D1 in rat using [3H]SCH-23390 as radioligand,Confirmatory,8027978.0,
1160,61498,7,2,,103167216,3559,Active,,,0.024,Ki,Binding affinity towards Dopamine receptor D1,Confirmatory,3039136.0,
1161,61499,8,5,,103167216,3559,Active,118229.0,24316.0,0.02,Ki,Affinity for Dopamine receptor D1,Confirmatory,9871525.0,
1162,61517,7,1,,103167216,3559,Active,,,0.318,Ki,Half-maximal inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 in rat striatal homogenate,Confirmatory,11784139.0,
1163,61521,9,1,,103167216,3559,Active,,,0.076,Ki,In vitro binding affinity against Dopamine receptor D1 in rat striatal tissue,Confirmatory,8101877.0,
1164,61527,8,1,,103167216,3559,Active,,,0.318,Ki,In vitro binding affinity towards Dopamine receptor D1 in rat tissue homogenate using [3H]-SCH- 23390 as radioligand,Confirmatory,14695828.0,
1165,61531,9,1,,103167216,3559,Active,,,0.467,Ki,Tested for binding affinity towards rat striatal dopamine receptor D1 using [3H]-SCH- 23390 as radioligand,Confirmatory,7932581.0,
1166,61533,7,1,,103167216,3559,Active,,,0.0048,IC50,Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand,Confirmatory,8759642.0,
1167,61547,7,1,,103167216,3559,Active,,,0.0031,IC50,Compound was evaluated In vitro for its activity by binding to Dopamine receptor D2 in the rat brain using [3H]NPA as radioligand.,Confirmatory,1676427.0,
1168,61562,9,3,,103167216,3559,Active,,,0.02,IC50,Compound was measured for affinity at dopamine receptor D2 labeled with [3H]spiroperidol radioligand in striatum tissue,Confirmatory,1672156.0,
1169,61566,7,2,,103167216,3559,Active,,,0.0055,IC50,Compound was tested for its binding affinity towards Dopamine receptor D2 by using [3H]domperidone as radioligand,Confirmatory,1662725.0,
1170,61612,8,5,,103167216,3559,Active,118206.0,1813.0,0.00016,Ki,Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells,Confirmatory,10465538.0,
1171,61613,8,5,,103167216,3559,Active,118206.0,1813.0,0.00044,Ki,Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells,Confirmatory,10465538.0,
1172,61615,3,7,,103167216,3559,Unspecified,,,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptor at 1 uM",Other,10465538.0,
1173,61616,3,7,,103167216,3559,Unspecified,,,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptor at 1 uM dopamine",Other,10465538.0,
1174,61617,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptors at 10 uM",Other,10465538.0,
1175,61618,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptors at 10 uM",Other,10465538.0,
1176,61619,4,5,,103167216,3559,Unspecified,,,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptors at 100 uM",Other,10465538.0,
1177,61620,4,5,,103167216,3559,Unspecified,,,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptor at 100 uM dopamine",Other,10465538.0,
1178,61623,7,2,,103167216,3559,Active,,,0.0022,Ki,Binding affinity to the dopamine receptor D2L in rat brain membranes,Confirmatory,10464021.0,
1179,61637,4,1,,103167216,3559,Active,,,0.007940000000000001,Ki,Binding affinity towards Chinese hamster ovary cells transfected with human D3 receptor using [3H]spiperone,Confirmatory,,
1180,61669,4,1,,103167216,3559,Active,,,0.07078999999999999,Ki,Binding Affinity was determined against Dopamine receptor D1 in rat striatal membranes using [3H]- SCH 23390 radioligand.,Confirmatory,10691686.0,
1181,61670,5,1,,103167216,3559,Active,,,0.09772,Ki,Compound was evaluated for its affinity (pKi) to inhibit [3H]SCH-23390 binding to the Dopamine receptor D1,Confirmatory,1676759.0,
1182,61675,5,1,,103167216,3559,Active,,,0.31623,Ki,Half-maximal inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 in rat striatal homogenate,Confirmatory,11784139.0,
1183,61677,4,1,,103167216,3559,Active,,,0.09772,Ki,Inhibition of [3H]-SCH- 23390 binding to dopamine receptor D1 rat striatal membrane,Confirmatory,7914540.0,
1184,61680,4,1,,103167216,3559,Active,,,0.09772,Ki,Inhibition constant for in vitro inhibition of [3H]-SCH- 23390 binding to striatal membranes Dopamine receptor D1,Confirmatory,,
1185,61788,7,1,,103167216,3559,Active,,,0.0033,Ki,In vitro binding affinity at human D4 dopamine receptor in CHO cells by [3H]spiperone displacement.,Confirmatory,9871530.0,
1186,61789,9,3,,103167216,3559,Active,,,0.0038,Ki,Potency was measured by the displacement of [3H]-spiperone binding to human D4 dopaminergic receptor,Confirmatory,,
1187,61804,7,2,,103167216,3559,Active,,,0.0065,IC50,Binding affinity towards human D4.2 receptor,Confirmatory,10377229.0,
1188,61808,7,2,,103167216,3559,Active,,,0.011000000000000001,Ki,Binding affinity towards human dopamine-4.2 receptor,Confirmatory,14998318.0,
1189,61845,3,7,,103167216,3559,Unspecified,,,,,Selectivity ratio for Dopamine receptor D1 to Dopamine receptor D2,Other,11784139.0,
1190,62007,8,5,,103167216,3559,Active,1706283.0,,0.005,Ki,Displacement of [3H]-YM 09151 from african green monkey Dopamine receptor D2,Confirmatory,8523409.0,
1191,62009,8,1,,103167216,3559,Active,1706283.0,,0.0048,Ki,Displacement of [3H]YM-09151 from recombinant African green monkey Dopamine receptor D2,Confirmatory,7783157.0,
1192,62164,9,1,,103167216,3559,Active,,,0.03,IC50,"Competition in vitro with the dopamine receptor D2 antagonist [3H]spiperone, for binding sites on calf caudate membranes.",Confirmatory,8096548.0,
1193,62168,7,1,,103167216,3559,Active,,,0.0012,IC50,Affinity towards Dopamine receptor D2 in membranes from bovine striatum using [3H]raclopride,Confirmatory,9622542.0,
1194,62337,8,5,,103167216,3559,Active,118205.0,281126.0,0.0007,Ki,Binding towards Dopamine receptor D2 expressed in CHO-K1 cells using [3H]U-86170,Confirmatory,8230107.0,
1195,62338,7,1,,103167216,3559,Active,,,0.0003,Ki,"Evaluated for binding towards Dopamine receptor D2 using [3H]-spiperone as radioligand, in cloned mammalian receptors expressed in CHO-K1 cells",Confirmatory,8230107.0,
1196,62443,8,2,,103167216,3559,Active,,,0.0018,IC50,Inhibition of binding of 1.6 nM [3H]haloperidol to dopamine receptor by 50%,Confirmatory,7288826.0,
1197,62444,8,2,,103167216,3559,Active,,,0.5,IC50,Inhibition of binding of 5 nM [3H]dopamine to dopamine receptor by 50%,Confirmatory,7288826.0,
1198,62445,9,2,,103167216,3559,Active,,,0.5,IC50,Inhibition of [3H]dopamine binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
1199,62446,9,2,,103167216,3559,Active,,,0.0018,IC50,Inhibition of [3H]haloperidol binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
1200,62465,3,8,,103167216,3559,Unspecified,,,,,Ratio of IC50 evaluated by using [3H]DA to [3H]-HP,Other,7288826.0,
1201,62571,3,8,,103167216,3559,Unspecified,,,,,Compound was evaluated for the competitive binding with [3H]NCA binding to Canine striatal membranes.,Other,6737423.0,
1202,62573,6,2,,103167216,3559,Active,,,0.005,IC50,"The IC50 value was reported as apparent, since [3H]NCA was purported to be irreversible. Result indicates the mean of two separate experiments, each performed in triplicate.",Confirmatory,6737423.0,
1203,62581,7,1,,103167216,3559,Active,,,,,Dopamine receptor antagonist activity in the superfused rabbit ear artery preparation,Other,7252977.0,
1204,62590,3,6,,103167216,3559,Unspecified,,,,,"Ability to displace the Dopamine receptor agonist DiPr-5,6-ADTN from rat striatal binding sites in vivo at a dose of 2.7 uM/kg by subcutaneous administration",Other,3560156.0,
1205,62723,7,1,,103167216,3559,Active,,,0.040999999999999995,IC50,Ability to inhibit the binding of [3H]spiroperidol in rat striatal tissue,Confirmatory,2861286.0,
1206,62728,11,1,,103167216,3559,Active,,,0.012,IC50,"Compound was tested for anti-dopamine activity in vitro by its ability to displace [3H]spiperone from rat brain striatal preparations,",Confirmatory,3941414.0,
1207,62736,7,3,,103167216,3559,Active,,,0.009000000000000001,IC50,Affinity for Dopamine receptors in the rat striatum using [3H]spiroperidol displacement.,Confirmatory,2876102.0,
1208,62746,3,7,,103167216,3559,Unspecified,,,,,Intrinsic activity relative to quinpirole in the reversal of forskolin-stimulated cAMP accumulation in cells transfected with the human DA D2 receptor,Other,7932581.0,
1209,62768,7,2,,103167216,3559,Active,,,0.004,IC50,"Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand",Confirmatory,11052797.0,
1210,62769,7,2,,103167216,3559,Active,,,0.0049,IC50,Binding affinity towards human Dopamine receptor D2,Confirmatory,10377229.0,
1211,62771,7,2,,103167216,3559,Active,,,0.0041,IC50,In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.,Confirmatory,9822559.0,
1212,62868,7,2,,103167216,3559,Active,,,0.0066,IC50,Inhibition of [3H]spiperone binding to dopamine receptor from rat corpus striatal membranes,Confirmatory,6131130.0,
1213,62883,7,5,,103167216,3559,Active,118211.0,29238.0,0.009000000000000001,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
1214,62883,7,5,,103167216,3559,Active,118229.0,24316.0,0.009000000000000001,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
1215,62883,7,5,,103167216,3559,Active,118251.0,25195.0,0.009000000000000001,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
1216,62883,7,5,,103167216,3559,Active,6226851.0,25432.0,0.009000000000000001,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
1217,62883,7,5,,103167216,3559,Active,47117674.0,24318.0,0.009000000000000001,IC50,Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate,Confirmatory,6104732.0,
1218,62884,7,5,,103167216,3559,Active,118211.0,29238.0,0.011000000000000001,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1219,62884,7,5,,103167216,3559,Active,118229.0,24316.0,0.011000000000000001,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1220,62884,7,5,,103167216,3559,Active,118251.0,25195.0,0.011000000000000001,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1221,62884,7,5,,103167216,3559,Active,6226851.0,25432.0,0.011000000000000001,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1222,62884,7,5,,103167216,3559,Active,47117674.0,24318.0,0.011000000000000001,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1223,62886,9,1,,103167216,3559,Active,,,0.009000000000000001,IC50,compound was tested for inhibition of 0.5 nM [3H]spiroperidol binding to dopamine receptor from rat striatal membrane.,Confirmatory,3941416.0,
1224,62887,3,6,,103167216,3559,Unspecified,,,,,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate at a dose of 10E-8 M,Other,2866248.0,
1225,62908,7,1,,103167216,3559,Active,,,0.0016,Ki,Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.,Confirmatory,9276014.0,
1226,62909,8,5,,103167216,3559,Active,118206.0,1813.0,0.0014,Ki,Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells,Confirmatory,8642551.0,
1227,62915,8,1,,103167216,3559,Active,,,0.006999999999999999,Ki,Antagonism of dopamine-stimulated [35S]GTP-gamma-S binding against human Dopamine receptor D2 in CHO cells,Confirmatory,11052797.0,
1228,62917,7,1,,103167216,3559,Active,,,0.0016,Ki,Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.,Confirmatory,9406594.0,
1229,63020,7,2,,103167216,3559,Active,,,0.002,Ki,In vitro ability to displace [3H]spiroperidol from rat dopamine receptor,Confirmatory,7154006.0,
1230,63027,9,2,,103167216,3559,Active,118211.0,29238.0,0.0004,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1231,63027,9,2,,103167216,3559,Active,118229.0,24316.0,0.0004,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1232,63027,9,2,,103167216,3559,Active,118251.0,25195.0,0.0004,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1233,63027,9,2,,103167216,3559,Active,6226851.0,25432.0,0.0004,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1234,63027,9,2,,103167216,3559,Active,47117674.0,24318.0,0.0004,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1235,63028,7,5,,103167216,3559,Active,118211.0,29238.0,0.00028,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1236,63028,7,5,,103167216,3559,Active,118229.0,24316.0,0.00028,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1237,63028,7,5,,103167216,3559,Active,118251.0,25195.0,0.00028,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1238,63028,7,5,,103167216,3559,Active,6226851.0,25432.0,0.00028,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1239,63028,7,5,,103167216,3559,Active,47117674.0,24318.0,0.00028,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1240,63055,8,5,,103167216,3559,Active,118206.0,1813.0,0.0014,Ki,Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand,Confirmatory,8642550.0,
1241,63060,7,2,,103167216,3559,Active,,,0.0014,Ki,Binding affinity towards human Dopamine receptor D2,Confirmatory,14998318.0,
1242,63061,7,2,,103167216,3559,Active,,,0.00011999999999999999,Ki,Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand,Confirmatory,12477356.0,
1243,63064,8,5,,103167216,3559,Active,118206.0,1813.0,0.0048,Ki,Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151,Confirmatory,9016321.0,
1244,63074,7,1,,103167216,3559,Active,,,0.018000000000000002,Ki,Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells,Confirmatory,11992769.0,
1245,63075,7,3,,103167216,3559,Active,,,0.00016,Ki,Displacement of [3H]quinpirole from Dopamine receptor D2,Confirmatory,8893836.0,
1246,63076,8,5,,103167216,3559,Active,118206.0,1813.0,0.00066,Ki,Inhibition of [3H]raclopride binding to Dopamine receptor D2,Confirmatory,8893836.0,
1247,63087,7,2,,103167216,3559,Active,,,0.0008900000000000001,Ki,In vitro ability to inhibit the binding of [3H]spiperone to cloned human Dopamine receptor D2 using apomorphine induced climbing test in male Swiss mice,Confirmatory,14552778.0,
1248,63089,11,1,,103167216,3559,Active,,,0.003,Ki,In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.,Confirmatory,12565939.0,
1249,63218,7,2,,103167216,3559,Active,,,0.0037,Ki,In vitro binding affinity towards Dopamine receptor D2 in human using [3H]-spiperone as radioligand,Confirmatory,14695828.0,
1250,63226,7,1,,103167216,3559,Active,,,0.0014,Ki,Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.,Confirmatory,9240352.0,
1251,63233,3,10,,103167216,3559,Unspecified,118206.0,1813.0,,,Ratio of binding affinity for D2 and D4 dopamine receptors,Other,14736232.0,
1252,63233,3,10,,103167216,3559,Unspecified,1345939.0,1815.0,,,Ratio of binding affinity for D2 and D4 dopamine receptors,Other,14736232.0,
1253,63234,3,6,,103167216,3559,Unspecified,,,,,Selectivity is the ratio of binding affinities for human Dopamine receptor D2 to that of Dopamine receptor D3,Other,11992769.0,
1254,63237,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,Inhibition of [35 S] GTP gamma S binding to cell membranes expressing Dopamine receptor D2,Other,8893836.0,
1255,63238,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,Inhibition of [35 S] GTP gamma S binding to cell membranes expressing Dopamine receptor D2 with dopamine,Other,8893836.0,
1256,63251,3,9,,103167216,3559,Active,118206.0,1813.0,,,Displacement of [3H]spiperone from human Dopamine receptor D2,Other,14736232.0,
1257,63347,7,2,,103167216,3559,Active,,,0.27,Ki,Binding affinity towards human Dopamine receptor D1,Confirmatory,14998318.0,
1258,63351,9,1,,103167216,3559,Active,,,0.049,Ki,Compound was tested for the binding affinity against human cloned Dopamine receptor D1 by radioligand ([3H]SCH-23390) binding assay,Confirmatory,8709107.0,
1259,63365,4,1,,103167216,3559,Active,,,0.19952999999999999,Ki,In vitro affinity against Dopamine receptor D1,Confirmatory,11101359.0,
1260,63371,7,2,,103167216,3559,Active,,,0.07586,Ki,Binding affinity against dopamine receptor D1,Confirmatory,7907148.0,
1261,63387,4,1,,103167216,3559,Active,,,0.000891,Ki,Cataleptogenic effect against cloned human Dopamine receptor D2 in male Sprague-Dawley rats in a bar test,Confirmatory,14552778.0,
1262,63412,6,3,,103167216,3559,Unspecified,,,,,Effective dose through peroral route for in vivo inhibition against dopamine receptor D2 in male CF-1 mice by using radioligand [3H]raclopride,Other,8496917.0,
1263,63499,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against apomorphine-induced emesis, after 5 hour of peroral administration in dogs",Other,2571727.0,
1264,63512,8,1,,103167216,3559,Active,,,0.002,Ki,Antagonism of dopamine-stimulated [35S]GTP-gamma-S binding against human Dopamine receptor D4 in CHO cells,Confirmatory,11052797.0,
1265,63513,7,1,,103167216,3559,Active,,,0.0021,Ki,Binding affinity to Human Dopamine receptor D4 expressed in CHO cells was determined using [3H]- nemonapride as radioligand,Confirmatory,8709107.0,
1266,63514,7,1,,103167216,3559,Active,,,0.0022,Ki,Binding affinity to recombinant human dopamine receptor D4 expressed in CHO cells by displacement of [3H]spiperone,Confirmatory,9406594.0,
1267,63524,7,1,,103167216,3559,Active,,,0.0043,Ki,Binding affinity measured at the Dopamine receptor D4 by the inhibition of [3H]spiperone binding to human recombinant CHO cells using unlabeled haloperidol for nonspecific binding.,Confirmatory,9876110.0,
1268,63531,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0023,Ki,Binding affinity towards cloned human Dopamine receptor D4 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand,Confirmatory,8642550.0,
1269,63533,7,2,,103167216,3559,Active,,,0.00074,Ki,Binding affinity towards human Dopamine receptor D4 using [3H]spiroperidol as radioligand,Confirmatory,12477356.0,
1270,63534,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0073,Ki,Binding affinity on human Dopamine receptor D4 expressed in CHO cells using radioligand [3H]-YM 09151,Confirmatory,9016321.0,
1271,63538,8,5,,103167216,3559,Active,1345939.0,1815.0,0.006999999999999999,Ki,Displacement of [3H]-YM 09151 from human Dopamine receptor D4,Confirmatory,8523409.0,
1272,63540,7,1,,103167216,3559,Active,,,0.042,Ki,Displacement of the radioligand [3H]spiperone from the cloned human dopamine receptor D4 expressed in CHO cells,Confirmatory,11992769.0,
1273,63547,7,2,,103167216,3559,Active,,,0.01,Ki,In vitro ability to inhibit the binding of [3H]spiperone to cloned human dopamine receptor D4 using apomorphine induced climbing test in male Swiss mice,Confirmatory,14552778.0,
1274,63549,11,1,,103167216,3559,Active,,,0.0022,Ki,In vitro binding affinity at human cloned Dopamine receptor D4 expressed in Sf9 cell membranes,Confirmatory,12408724.0,
1275,63637,3,7,,103167216,3559,Unspecified,,,,,Ratio of Ki(uM) of D2 receptor to the Ki(uM) of 5-hydroxytryptamine 2 receptor,Other,1353116.0,
1276,63682,7,1,,103167216,3559,Active,,,0.0023,Ki,Ability to displace [3H]spiperone from human dopamine receptor D4 (hD4) receptor stably expressed in HEK293 cells.,Confirmatory,9240352.0,
1277,63692,3,7,,103167216,3559,Unspecified,,,,,Selectivity is the ratio of binding affinities for human Dopamine receptor D4 to that of Dopamine receptor D3,Other,11992769.0,
1278,63699,3,10,,103167216,3559,Active,1345939.0,1815.0,,,Displacement of [3H]spiperone from human Dopamine receptor D4,Other,14736232.0,
1279,63700,4,1,,103167216,3559,Active,,,0.01047,Ki,Cataleptogenic effect against cloned human dopamine receptor D4 in male Sprague-Dawley rats in a bar test,Confirmatory,14552778.0,
1280,63794,4,1,,103167216,3559,Active,,,0.00214,Ki,Binding Affinity was determined against Dopamine receptor D2 in rat striatal membranes using [3H]- spiperone radioligand.,Confirmatory,10691686.0,
1281,63795,7,5,,103167216,3559,Active,47117674.0,24318.0,0.00295,Ki,Binding affinity towards Dopamine receptor D2 in rat frontal striatum using [3H]spiperone,Confirmatory,12482418.0,
1282,63797,4,1,,103167216,3559,Active,,,0.0006309999999999999,Ki,In vitro by displacement of [3H]raclopride from Dopamine receptor D2 on rat striatal membrane,Confirmatory,9046349.0,
1283,63800,5,1,,103167216,3559,Active,,,0.0050100000000000006,Ki,Compound was evaluated for its affinity (pKi) to inhibit [3H]spiperone binding to the Dopamine receptor D2,Confirmatory,1676759.0,
1284,63804,4,1,,103167216,3559,Active,47117674.0,24318.0,0.00331,Ki,Affinity against Dopamine receptor D2,Confirmatory,11101359.0,
1285,63805,4,1,,103167216,3559,Active,,,0.00331,Ki,Compound was measured for the inhibition of [3H]spiperone binding to striatal membrane Dopamine receptor D2,Confirmatory,9934473.0,
1286,63809,5,1,,103167216,3559,Active,,,0.00479,Ki,Half-maximal inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal homogenate,Confirmatory,11784139.0,
1287,63811,4,1,,103167216,3559,Active,47117674.0,24318.0,0.000708,Ki,Displacement of [3H]NPA from rat brain Dopamine receptor D2,Confirmatory,8568801.0,
1288,63818,4,1,,103167216,3559,Active,,,0.0050100000000000006,Ki,Inhibition constant for in vitro inhibition of [3H]spiperone binding to striatal membranes Dopamine receptor D2,Confirmatory,,
1289,63819,4,1,,103167216,3559,Active,,,0.0050100000000000006,Ki,Inhibition of [3H]-spiperone 23390 binding to dopamine receptor D2 rat striatal membrane,Confirmatory,7914540.0,
1290,63820,4,1,,103167216,3559,Active,,,0.0050100000000000006,Ki,Tested in vitro for its ability to inhibit [3H]spiperone binding to Dopamine receptor D2 in rat striatal membrane,Confirmatory,,
1291,63822,4,1,,103167216,3559,Active,,,0.00331,Ki,In vitro ability to displace [3H]spiperone binding from dopamine receptor D2 in rat striatal membrane.,Confirmatory,10425088.0,
1292,63842,4,1,,103167216,3559,Active,,,0.00158,Ki,In vitro binding affinity for Dopamine receptor D4,Confirmatory,11392544.0,
1293,63849,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0022,Ki,Binding towards dopamine receptor D4 expressed in CHO-K1 cells using [3H]spiperone,Confirmatory,8230107.0,
1294,63858,8,1,,103167216,3559,Active,,,0.017,EC50,Agonistic activity against human Dopamine receptor D4.2 using [35S]GTP-gamma-S binding assay,Confirmatory,14611858.0,
1295,63866,9,1,,103167216,3559,Active,,,0.006,IC50,Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells,Confirmatory,8831770.0,
1296,63956,8,5,,103167216,3559,Active,47117674.0,24318.0,0.00059,Ki,Binding affinity was evaluated against Dopamine receptor D2 on rat striatum using [3H]spiperone as radioligand; ND = Not determined,Confirmatory,9667967.0,
1297,63971,7,2,,103167216,3559,Active,,,0.0014,Ki,Binding affinity for dopamine receptor D2 determined using [3H]spiperone,Confirmatory,11527728.0,
1298,63973,10,2,,103167216,3559,Active,,,0.0015,Ki,Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone,Confirmatory,10743959.0,
1299,63997,5,1,,103167216,3559,Active,,,0.000603,Ki,Binding affinity towards dopamine receptor D2,Confirmatory,14741248.0,
1300,64000,4,1,,103167216,3559,Active,,,0.000794,Ki,In vitro binding affinity for Dopamine receptor D2,Confirmatory,11392544.0,
1301,64005,9,1,,103167216,3559,Active,,,0.001,Ki,Binding affinity towards human Dopamine receptor D4.2 in CHO cells,Confirmatory,8831770.0,
1302,64010,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0036,Ki,Displacement of [3H]YM-09151-2 from human Dopamine receptor D4.2 expressed in baculovirus Sf9 cells,Confirmatory,,
1303,64154,9,1,,103167216,3559,Active,,,0.00088,Ki,In vitro binding affinity against Dopamine D2 receptor in rat striatal tissue.,Confirmatory,8101877.0,
1304,64177,7,2,,103167216,3559,Active,,,0.001,Ki,In vitro binding affinity at human Dopamine receptor D4.4 by [3H]YM-09151-2 displacement.,Confirmatory,10649982.0,
1305,64187,7,2,,103167216,3559,Active,,,0.26,Ki,Compound was tested for the Binding affinity against Human cloned Dopamine receptor D5 by Radio ligand ([3H]SCH-23390) binding assay,Confirmatory,8709107.0,
1306,64198,7,2,,103167216,3559,Active,,,0.0005,Ki,Tested for binding affinity towards human D2L receptor using [3H]spiperone as radioligand,Confirmatory,7932581.0,
1307,64264,7,2,,103167216,3559,Active,,,0.0075,IC50,Compound was tested for the inhibition of [3H]spiperone binding to dopamine receptor D2,Confirmatory,1348090.0,
1308,64268,7,2,,103167216,3559,Active,,,0.04,IC50,Inhibition of [3H]raclopride binding at Dopamine receptor D2 from rat striata.,Confirmatory,8568802.0,
1309,64271,7,3,,103167216,3559,Active,,,0.0075,IC50,Binding affinity towards Dopamine receptor D2 of rat corpus striatum using [3H]spiperone as radioligand,Confirmatory,10377229.0,
1310,64285,7,2,,103167216,3559,Active,,,0.012,IC50,In vitro ability to inhibit the binding of [3H]spiperone to dopamine receptor D2 in rat striatal membranes.,Confirmatory,1969484.0,
1311,64295,9,1,,103167216,3559,Active,,,0.012,IC50,In vitro binding affinity at Dopamine receptor D2 in rat by displacing [3H]- spiperone from rat striatal membrane,Confirmatory,4040977.0,
1312,64296,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0137,IC50,Inhibition of [3H]methylspiperone binding to rat striatal membrane Dopamine receptor D2,Confirmatory,9876110.0,
1313,64299,7,2,,103167216,3559,Active,,,0.0175,IC50,In vitro binding affinity for Dopamine D2 receptor of rat using [3H]YM-09151 as radioligand,Confirmatory,12361392.0,
1314,64426,7,2,,103167216,3559,Active,,,0.04,IC50,In vitro binding affinity was measured by displacement of [3H]- raclopride from D2 receptor isolated from the striata of male Dawley rats,Confirmatory,7914539.0,
1315,64434,7,2,,103167216,3559,Active,,,0.006999999999999999,IC50,In vitro inhibitory concentration against radioligand [3H]spiperone binding to rat striatal dopamine receptor D2,Confirmatory,1361578.0,
1316,64435,7,3,,103167216,3559,Active,,,7.5e-05,IC50,In vivo binding affinity against dopamine (D2) receptor in rat caudate-putamen tissue using [3H]nemonapride as radioligand,Confirmatory,14592497.0,
1317,64438,7,1,,103167216,3559,Active,,,0.0012,IC50,Inhibition of 0.1 nM of [125I]- (S)-N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2-methoxy-benzamide binding in striatal homogenates of rat brain,Confirmatory,3172140.0,
1318,64439,7,1,,103167216,3559,Active,,,0.006,IC50,Inhibition of [3H](S)-sulpiride binding in striatal homogenates of rat brain,Confirmatory,3172140.0,
1319,64461,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0075,IC50,Inhibitory binding of [3H]spiperone to Dopamine receptor D2 in membranes from rat corpus striatum,Confirmatory,9406603.0,
1320,64478,11,1,,103167216,3559,Active,,,0.0085,Ki,In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes,Confirmatory,12408724.0,
1321,64479,7,1,,103167216,3559,Active,,,0.0056,Ki,"In vitro binding affinity towards Dopamine receptor D2L, using [3H]spiroperidol radioligand in Sf9 baculovirus expression.",Confirmatory,10649982.0,
1322,64601,9,1,,103167216,3559,Active,,,0.00424,IC50,Neuroleptic activity in terms of [3H]spiroperidol binding in rat striatal membrane to Dopamine receptor D2,Confirmatory,1671414.0,
1323,64612,10,5,,103167216,3559,Active,47117674.0,24318.0,0.0025,IC50,Displacement of [3H]spiroperidol from D2 dopamine receptor,Confirmatory,8176710.0,
1324,64613,7,2,,103167216,3559,Active,,,0.0075,IC50,Binding affinity towards Dopamine receptor D2 binding site using [3H]spiroperidol.,Confirmatory,7783131.0,
1325,64625,6,3,,103167216,3559,Unspecified,,,,,Inhibitory activity against methyl-phenidate-induced gnawing at dopamine receptor D2 in rat,Other,7562940.0,
1326,64645,9,1,,103167216,3559,Active,,,0.0076,Ki,Binding affinity for dopamine receptor D2 long expressed in Sf9 cells using [125I]IABN radioligand,Confirmatory,11356115.0,
1327,64802,8,5,,103167216,3559,Active,1706286.0,,0.003,Ki,Displacement of [3H]-YM 09151 from african monkey Dopamine receptor D3,Confirmatory,8523409.0,
1328,64825,7,2,,103167216,3559,Active,,,0.01,IC50,Binding affinity towards human Dopamine receptor D3,Confirmatory,10377229.0,
1329,64930,7,2,,103167216,3559,Active,,,0.0019,Ki,Displacement of [3H]spiperone (0.5 nM) from rat corpus striatum dopamine D2 receptor,Confirmatory,12519065.0,
1330,64931,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0014,Ki,Ability to inhibit the [3H]spiperone binding to striatum Dopamine receptor D2 was determined in rat,Confirmatory,2889830.0,
1331,64960,7,1,,103167216,3559,Active,,,0.0027,Ki,Ability to displace [3H]spiperone (0.3 nM) from CHO cells of human Dopamine receptor D3,Confirmatory,12519065.0,
1332,64962,7,1,,103167216,3559,Active,,,0.0022,Ki,Ability to displace [3H]spiperone from human cloned Dopamine receptor D3 expressed in CHO K-1 cells in vitro.,Confirmatory,9276014.0,
1333,64963,8,5,,103167216,3559,Active,1169206.0,1814.0,0.002,Ki,Displacement of [3H]spiperone from human Dopamine receptor D3 expressed in CHO cells,Confirmatory,8642551.0,
1334,64974,7,1,,103167216,3559,Active,,,0.0022,Ki,Binding affinity against cloned human dopamine receptor D3 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.,Confirmatory,9406594.0,
1335,64985,8,3,,103167216,3559,Inconclusive,,,,,Binding affinity measured at the Dopamine receptor D3 by the inhibition of [3H]YM-09151-2 binding to human recombinant CCL 1.3 cells using unlabeled 7-OH-DPAT for nonspecific binding; ND = 'Not determined',Other,9876110.0,
1336,64993,8,5,,103167216,3559,Active,1169206.0,1814.0,0.002,Ki,Binding affinity towards cloned human Dopamine receptor D3 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand,Confirmatory,8642550.0,
1337,65078,11,1,,103167216,3559,Active,,,0.00047000000000000004,Ki,Binding affinity against dopamine receptor D2 from rat corpus striatum by using radioligand [3H]sulpiride,Confirmatory,8496917.0,
1338,65087,7,3,,103167216,3559,Active,,,0.0098,Ki,Binding affinity measured at the Dopamine receptor D2 by the inhibition of [3H]methylspiperone binding to rat striatum using unlabeled haloperidol for nonspecific binding.,Confirmatory,9876110.0,
1339,65100,7,1,,103167216,3559,Active,,,0.0011,Ki,Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand,Confirmatory,8709107.0,
1340,65111,9,1,,103167216,3559,Active,,,0.0011,Ki,Binding affinity was measured against dopamine (D2) receptor in rat using [3H]spiperone as radioligand,Confirmatory,8027978.0,
1341,65127,7,1,,103167216,3559,Active,,,0.025,Ki,Displacement of the radioligand [3H]YM-09151-2 from cloned human Dopamine receptor D3 expressed in CHO cells,Confirmatory,11992769.0,
1342,65128,8,5,,103167216,3559,Active,1169206.0,1814.0,0.00274,Ki,Displacement of [3H]raclopride from Dopamine receptor D3,Confirmatory,8893836.0,
1343,65133,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0022,Ki,Displacement of [125I]iodosulpiride from human Dopamine receptor D3 expressed in CHO cells,Confirmatory,14521403.0,
1344,65146,7,2,,103167216,3559,Active,,,0.0046,Ki,In vitro ability to inhibit the binding of [3H]7-OH-DPAT to cloned human Dopamine receptor D3 using apomorphine induced climbing test in male Swiss mice,Confirmatory,14552778.0,
1345,65239,7,2,,103167216,3559,Active,,,0.00075,Ki,Binding affinity towards Dopamine receptor D2,Confirmatory,3039136.0,
1346,65243,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0002,Ki,Affinity for Dopamine receptor D2,Confirmatory,9871525.0,
1347,65245,7,1,,103167216,3559,Active,,,0.0008,Ki,Binding affinity towards dopamine receptor D2 in rat striatal membranes,Confirmatory,11728188.0,
1348,65247,7,2,,103167216,3559,Active,,,0.0002,Ki,Binding affinity was determined against Dopamine receptor D2 using [3H]spiperone,Confirmatory,7473547.0,
1349,65271,9,2,,103167216,3559,Active,,,0.01,Ki,Compound was evaluated for in vitro binding affinity towards Dopamine receptor D2 in rat striatum using [3H]- spiperone as radioligand,Confirmatory,1353116.0,
1350,65280,7,2,,103167216,3559,Active,,,0.0006900000000000001,Ki,Tested for binding affinity towards human D3 receptor using [3H]spiperone as radioligand,Confirmatory,7932581.0,
1351,65288,7,1,,103167216,3559,Active,,,0.002,Ki,Ability to displace [3H]spiperone from human dopamine receptor D3 (hD3) receptor stably expressed in HEK293 cells.,Confirmatory,9240352.0,
1352,65300,3,9,,103167216,3559,Unspecified,1169206.0,1814.0,,,Inhibition of [35 S] GTP gamma S binding to cell membranes expressing Dopamine receptor D3,Other,8893836.0,
1353,65301,3,9,,103167216,3559,Unspecified,1169206.0,1814.0,,,Inhibition of [35 S] GTP gamma S binding to cell membranes expressing Dopamine receptor D3 with dopamine,Other,8893836.0,
1354,65402,7,1,,103167216,3559,Active,,,0.00037,Ki,Compound was evaluated for its binding affinity with Dopamine receptor D2 using membranes prepared from rat striatum,Confirmatory,9622541.0,
1355,65425,10,2,,103167216,3559,Active,47117674.0,24318.0,0.00195,Ki,Inhibition of [3H]spiroperidol binding to Dopamine receptor D2 of rat striatal membranes,Confirmatory,9572883.0,
1356,65426,7,2,,103167216,3559,Active,,,0.0048,Ki,Compound was tested for its binding affinity towards Dopamine receptor D2 using [3H]spiperone from rat striatum,Confirmatory,9572880.0,
1357,65437,3,9,,103167216,3559,Active,1169206.0,1814.0,,,Displacement of [3H]7-OH-DPAT from human Dopamine receptor D3,Other,14736232.0,
1358,65443,4,1,,103167216,3559,Active,,,0.00457,Ki,Cataleptogenic effect against cloned human Dopamine receptor D3 in male Sprague-Dawley rats in a bar test,Confirmatory,14552778.0,
1359,65494,8,2,,103167216,3559,Unspecified,,,1.0,Ki,Inhibitory constant towards reuptake of [125I]-12 from dopamine transporter in rat striatal membranes,Confirmatory,8182712.0,
1360,65559,7,1,,103167216,3559,Active,,,0.0007,Ki,Evaluated for binding towards Dopamine receptor D2 using [3H]N-0437 as radioligand from rat striatal membrane,Confirmatory,8230107.0,
1361,65560,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0002,Ki,Binding towards Dopamine receptor D2 using [3H]spiperone from rat striatal membrane,Confirmatory,8230107.0,
1362,65562,8,5,,103167216,3559,Active,47117674.0,24318.0,0.00033,Ki,Inhibition of [3H]spiperone binding to rat striatal membrane Dopamine receptor D2,Confirmatory,1969484.0,
1363,65563,7,1,,103167216,3559,Active,,,0.0048,Ki,Half-maximal inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal homogenate,Confirmatory,11784139.0,
1364,65564,7,2,,103167216,3559,Active,,,0.004,Ki,In vitro Dopamine receptor D2 affinity by using [3H]-Spiperone as the radioligand in rat limbic system at 1 uM concentration of compound,Confirmatory,2888898.0,
1365,65565,9,2,,103167216,3559,Active,,,0.0018,Ki,In vitro Dopamine receptor D2 affinity by using [3H]spiperone as the radioligand in rat limbic system at 1 uM concentration of compound; value may range from 0.7 to 3.5,Confirmatory,2888898.0,
1366,65602,7,1,,103167216,3559,Active,,,0.047,Ki,Binding affinity for dopamine receptor D3 expressed in Sf9 cells using [125I]IABN the radioligand.,Confirmatory,11356115.0,
1367,65609,7,1,,103167216,3559,Active,,,0.0064,Ki,Binding affinity to rat Dopamine receptor D3 expressed in CHO cells was determined using [125 I] iodosulpride as radioligand,Confirmatory,8709107.0,
1368,65610,7,2,,103167216,3559,Active,,,0.027999999999999997,Ki,Binding affinity towards Dopamine receptor D3 of rat using [3H]spiroperidol as radioligand,Confirmatory,12477356.0,
1369,65619,7,1,,103167216,3559,Active,,,0.018000000000000002,Ki,Half-maximal inhibition of [3H]-7-OH-DPAT binding to Dopamine receptor D3 in rat tissue homogenate,Confirmatory,11784139.0,
1370,65622,7,2,,103167216,3559,Active,,,0.018000000000000002,Ki,In vitro binding affinity towards Dopamine receptor D3 in Sf9 cell membranes using [3H]7-OH-DPAT as radioligand,Confirmatory,14695828.0,
1371,65625,7,1,,103167216,3559,Active,,,0.0143,Ki,Tested for binding affinity against dopamine receptor D3 expressed in Sf9 cells.,Confirmatory,8098771.0,
1372,65713,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0007099999999999999,Ki,Displacement of [3H]NPA from rat brain Dopamine receptor D2,Confirmatory,8568801.0,
1373,65726,11,1,,103167216,3559,Active,,,0.004,Ki,In vitro binding affinity for dopamine receptor D2 of rat nucleus accumbens labeled with [3H]spiperone,Confirmatory,2884314.0,
1374,65733,7,1,,103167216,3559,Active,,,0.0048,Ki,In vitro binding affinity towards Dopamine receptor D2 in rat tissue homogenate using [3H]-spiperone as radioligand,Confirmatory,14695828.0,
1375,65740,7,1,,103167216,3559,Active,,,0.00047000000000000004,Ki,In vitro binding affinity towards dopamine receptor D2 in rat striatal membranes by [3H]sulpiride displacement.,Confirmatory,7901415.0,
1376,65753,8,5,,103167216,3559,Active,118211.0,29238.0,0.003,Ki,Binding affinity towards baculovirus expressed rat dopamine D3 receptors,Confirmatory,7909336.0,
1377,65767,5,1,,103167216,3559,Active,,,0.0182,Ki,Half-maximal inhibition of [3H]7-OH-DPAT binding to Dopamine receptor D3 in rat tissue homogenate,Confirmatory,11784139.0,
1378,65781,9,1,,103167216,3559,Active,,,0.115,Ki,Binding affinity of compound towards Dopamine receptor D3 using [3H]spiperone (1.2 nM) ligand in cortex was determined,Confirmatory,9083484.0,
1379,65785,7,2,,103167216,3559,Active,,,0.021,Ki,Binding affinity towards human Dopamine receptor D3,Confirmatory,14998318.0,
1380,65786,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0064,Ki,Binding towards Dopamine receptor D3 expressed in CHO-K1 cells using [3H]spiperone,Confirmatory,8230107.0,
1381,65790,3,5,,103167216,3559,Unspecified,,,,,Selectivity ratio against Dopamine receptor D3 to Dopamine receptor D1,Other,11784139.0,
1382,65814,10,2,,103167216,3559,Active,,,0.001,Ki,Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand,Confirmatory,12372513.0,
1383,65817,10,2,,103167216,3559,Active,,,0.005,Ki,Binding affinity towards Dopamine type 4 receptor was determined by competitive displacement assays using [3H]-YM 09151 as the competitive ligand,Confirmatory,12372513.0,
1384,65884,7,1,,103167216,3559,Active,,,0.0014,Ki,Displacement of [3H]-Spiperone from Dopamine receptor D2 in rat striatum,Confirmatory,2902226.0,
1385,65885,7,2,,103167216,3559,Active,,,0.0014,Ki,Affinity against the dopamine receptor D2 using [3H]spiperinone.,Confirmatory,7473548.0,
1386,65888,4,6,,103167216,3559,Unspecified,,,0.217,Ki,Tested for affinity against cloned mammalian dopamine autoreceptor (DA) D2 receptors expressed in CHO-K1 cells using [3H]spiperone as radioligand,Confirmatory,8064801.0,
1387,65894,7,2,,103167216,3559,Active,,,0.00186,Ki,Tested for binding affinity towards rat striatal D2 receptor using [3H]spiperone as radioligand,Confirmatory,7932581.0,
1388,65899,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0017,Ki,Displacement of [3H]spiperone from Dopamine receptor D2 of rat corpora striata synaptic membranes,Confirmatory,,
1389,65905,8,5,,103167216,3559,Active,47117674.0,24318.0,0.00037,Ki,Binding affinity towards dopamine D2 receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1390,65908,7,2,,103167216,3559,Active,,,0.0002,Ki,Binding affinity towards dopamine receptor D2 by displacing [3H]spiperone radioligand in rat striatum,Confirmatory,1346653.0,
1391,65919,4,1,,103167216,3559,Active,,,0.0063100000000000005,Ki,In vitro affinity against Dopamine receptor D4,Confirmatory,11101359.0,
1392,65934,7,2,,103167216,3559,Active,,,0.005,IC50,"Binding affinity to dopamine receptor D4 cloned from human, using [3H]- YM09151 as competitive ligand",Confirmatory,11052797.0,
1393,65935,7,2,,103167216,3559,Active,,,0.0013,IC50,In vitro binding affinity at human cloned Dopamine receptor D4.2 by [3H]YM-09151-2 displacement.,Confirmatory,9822559.0,
1394,65950,7,1,,103167216,3559,Active,,,0.0022,Ki,Ability to displace [3H]spiperone from cloned human Dopamine receptor D4 expressed in CHO K-1 cells in vitro,Confirmatory,9276014.0,
1395,65951,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0023,Ki,Displacement of [3H]spiperone from human Dopamine receptor D4 expressed in HEK293 cells,Confirmatory,8642551.0,
1396,82355,5,6,,103167216,3559,Active,7531135.0,3757.0,0.0281,IC50,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Confirmatory,12190308.0,
1397,87242,7,2,,103167216,3559,Active,,,0.73,Ki,Binding affinity towards human histamine H1 receptor,Confirmatory,14998318.0,
1398,87514,7,1,,103167216,3559,Unspecified,,,1.0,IC50,Binding affinity towards histamine H1 receptor from rat brain membranes using [3H]mepyramine as radioligand,Confirmatory,10377229.0,
1399,87516,7,2,,103167216,3559,Unspecified,,,1.0,IC50,Inhibitory binding of [3H]mepyramine to histamine H1 receptors in rat brain membranes,Confirmatory,9406603.0,
1400,87527,9,1,,103167216,3559,Active,,,2.1,Ki,Compound was tested for the binding affinity against rat cortical H1 receptor by Radio ligand [3H]pyrilamine binding assay.,Confirmatory,8709107.0,
1401,87530,8,5,,103167216,3559,Active,399890.0,24448.0,0.384,Ki,Half-maximal inhibition of [3H]pyrilamine binding to Histamine H1 receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1402,87531,7,1,,103167216,3559,Active,,,0.384,Ki,In vitro binding affinity towards Histamine H1 receptor of rat frontal cortex homogenate by using radioligand [3H]pyrilamine,Confirmatory,14695828.0,
1403,88009,4,11,,103167216,3559,Active,1346291.0,100729734.0,,,Displacement of [3H](-)-trans-H2-PAT from histamine H2 PAT binding site by competition binding assay.,Other,10447948.0,
1404,108860,3,3,,103167216,3559,Active,,,,,Relative CNS activity of compound was measured in mice (+++ =for activity in > 6 assays),Other,6106063.0,
1405,109881,3,3,,103167216,3559,Unspecified,,,,,Effect at an intraperitoneal dose of 10 mg/kg against methamphetamine-induced hyperlocomotion in mice,Other,10090790.0,
1406,109889,3,3,,103167216,3559,Unspecified,,,,,"Tail suspension test in mice, dose(mg/Kg ip) = 4;duration of immobility(% vs controls)",Other,9622542.0,
1407,110208,6,2,,103167216,3559,Unspecified,,,,,Ability to inhibit apomorphine (APO) induced climbing behavior in mice by intraperitoneal administration of compound.; value may range from 0.17 to 0.15,Other,2888898.0,
1408,110211,6,2,,103167216,3559,Unspecified,,,,,Ability to inhibit apomorphine (APO) induced stereotyped behavior in mice by intraperitoneal administration of compound.; value may range from 0.09 to 0.10,Other,2888898.0,
1409,110213,6,2,,103167216,3559,Unspecified,,,,,Ability to inhibit apomorphine-induced climbing behavior in mice.,Other,7707315.0,
1410,111333,4,2,,103167216,3559,Unspecified,,,,,Relative central nervous system(CNS) activity was measured in mice; Activity in >=6 assays,Other,7288826.0,
1411,112271,7,2,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine induced climbing affects in mice by administering the compound perorally in mice,Other,10377229.0,
1412,112272,6,2,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine induced climbing affects in mice by administering the compound subcutaneously in mice,Other,10377229.0,
1413,112392,5,2,,103167216,3559,Inconclusive,,,,,Tremor after subcutaneous administration in mice was determined; nt=Not tested,Other,9784113.0,
1414,112508,6,2,,103167216,3559,Unspecified,,,,,In vivo Antipsychotic activity was quantified by induction of catalepsy in mice,Other,10425088.0,
1415,112509,6,2,,103167216,3559,Unspecified,,,,,In vivo Antipsychotic activity was quantified by inhibition of apomorphine-induced climbing(CL 95%) by mice,Other,10425088.0,
1416,112526,6,2,,103167216,3559,Unspecified,,,,,In vivo analgesic activity in mice after subcutaneous administration by hot plate assay method.,Other,2888899.0,
1417,112671,6,2,,103167216,3559,Unspecified,,,,,In vivo inhibition of apomorphine-induced climbing response in mice.,Other,8568802.0,
1418,112708,4,3,,103167216,3559,Unspecified,,,,,Hypothermia in mice after perorla administration,Other,6105217.0,
1419,112713,3,3,,103167216,3559,Unspecified,,,,,Tested for the apomorphine climbing behavior in mice after oral administration,Other,8096548.0,
1420,112818,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for inhibition of Apomorphine induced climbing in Mice,Other,8709107.0,
1421,112952,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for inhibition of norepinephrine lethality in mouse when administered perorally,Other,2869146.0,
1422,112953,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for inhibition of physostigmine lethality in mouse when administered perorally,Other,2869146.0,
1423,112955,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for inhibition of spontaneous motor activity in mouse when administered perorally,Other,2869146.0,
1424,113114,6,2,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine-induced climbing in mice when administered intraperitoneally 60 min prior to apomorphine (1 mg/kg),Other,2889830.0,
1425,113115,6,2,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine-induced climbing in mice when administered perorally 60 min prior to apomorphine (1 mg/kg),Other,2889830.0,
1426,113139,6,2,,103167216,3559,Unspecified,,,,,Compound was tested in vivo for its ability to antagonize apomorphine-induced climbing response in mice upon intraperitoneal administration,Other,9464359.0,
1427,113154,6,2,,103167216,3559,Unspecified,,,,,Dopaminergic antagonistic activity was determined in vivo by antagonising apomorphine induced climbing behavior (APO) in mice by oral administration,Other,12565939.0,
1428,113189,6,2,,103167216,3559,Unspecified,,,,,In vivo antipsychotic activity measured by the inhibition of apomorphine-induced climbing behavior in mice after 30 min po administration.,Other,9876110.0,
1429,113351,6,2,,103167216,3559,Unspecified,,,,,In vivo effective dose for inhibition of apomorphine-induced climbing in mice after intraperitoneal administration at a dose 20 mg/kg,Other,7914536.0,
1430,113543,7,2,,103167216,3559,Unspecified,,,,,Induction of catalepsy in mice,Other,9513593.0,
1431,113544,7,2,,103167216,3559,Unspecified,,,,,Induction of catalepsy in mice.,Other,9513593.0,
1432,113681,6,2,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine-induced climbing following s.c. administration in mice.,Other,9784113.0,
1433,113686,6,2,,103167216,3559,Unspecified,,,,,Inhibition of grooming-induced by SKF 38393 in mice.,Other,9876110.0,
1434,113687,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of head twitches-induced by 2,5-dimethoxy-4-iodoamphetamine in mice.",Other,9876110.0,
1435,113690,6,2,,103167216,3559,Unspecified,,,,,Inhibition of p-chloroamphetamine-induced hyperactivity in mice.,Other,9876110.0,
1436,113713,7,2,,103167216,3559,Unspecified,,,,,Inhibition of the APO-induced stereotyped behavior in mice,Other,9513593.0,
1437,113716,5,2,,103167216,3559,Inactive,,,,,Inhibition of the GBL-induced increase in DOPA accumulation in mice(DA auto receptor agonist activity); IA = inactive,Other,9513593.0,
1438,113718,5,2,,103167216,3559,Inactive,,,,,Inhibition of the GBL-induced increase in DOPA synthesis in mice; IA = inactive,Other,9513593.0,
1439,113719,7,8,,103167216,3559,Unspecified,3023234.0,11548.0,,,Inhibition of noradrenaline lethal effects in mice as alpha-1 induced adrenoceptor antagonist activity,Other,9513593.0,
1440,113719,7,8,,103167216,3559,Unspecified,3121722.0,11550.0,,,Inhibition of noradrenaline lethal effects in mice as alpha-1 induced adrenoceptor antagonist activity,Other,9513593.0,
1441,113719,7,8,,103167216,3559,Unspecified,341940608.0,11549.0,,,Inhibition of noradrenaline lethal effects in mice as alpha-1 induced adrenoceptor antagonist activity,Other,9513593.0,
1442,113872,6,2,,103167216,3559,Unspecified,,,,,Intraperitoneal effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1443,114064,8,7,,103167216,3559,Unspecified,543728.0,15558.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1444,114064,8,7,,103167216,3559,Unspecified,341940154.0,15560.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1445,114064,8,7,,103167216,3559,Unspecified,341940463.0,13489.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1446,114064,8,7,,103167216,3559,Unspecified,550544258.0,15559.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1447,114076,7,3,,103167216,3559,Unspecified,,,,,post-synaptic dopamine autoreceptor antagonist activity evaluated by inhibition of the apomorphine-induced stereotyped behavior in mice.,Other,9513593.0,
1448,114233,5,2,,103167216,3559,Inconclusive,,,,,Salivation after subcutaneous administration in mice; nt=Not tested,Other,9784113.0,
1449,114430,3,3,,103167216,3559,Unspecified,,,,,Antagonism of SKF 10047 -induced hypermotility (% vs controls) dose(mg/Kg po) = 1,Other,9622542.0,
1450,115764,3,3,,103167216,3559,Unspecified,,,,,Antipsychotic activity using locomotor activity (LMA)-inverted screen test in mice (i.p. admin.),Other,2866248.0,
1451,116898,7,2,,103167216,3559,Unspecified,,,,,Lethal dose in mice after perorla administration,Other,6105217.0,
1452,128162,6,2,,103167216,3559,Unspecified,,,,,"Activity of inclined screen in mouse, after 1 hour of peroral administration in mouse",Other,2571727.0,
1453,128163,6,2,,103167216,3559,Unspecified,,,,,"Activity of inclined screen in mouse, after 5 hour of peroral administration in mouse",Other,2571727.0,
1454,128670,6,2,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine-induced climbing behavior in mice after ip administration,Other,2902226.0,
1455,128671,6,4,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine-induced climbing behavior in mice after peroral administration,Other,2902226.0,
1456,128818,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against amphetamine-induced hypermotility, after 1 hour of peroral administration in mouse",Other,2571727.0,
1457,128819,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against amphetamine-induced hypermotility, after 5 hour of peroral administration in mouse",Other,2571727.0,
1458,128984,6,2,,103167216,3559,Unspecified,,,,,"Anticonvulsant activity against electroshock-induced convulsions, after 1 hour of peroral administration in mouse",Other,2571727.0,
1459,128985,6,2,,103167216,3559,Unspecified,,,,,"Anticonvulsant activity against electroshock-induced convulsions, after 5 hours of peroral administration in mouse",Other,2571727.0,
1460,128987,6,2,,103167216,3559,Unspecified,,,,,"Anticonvulsant activity against tryptamine-induced convulsions, after 1 hour of peroral administration in mouse",Other,2571727.0,
1461,129967,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for inhibition of apomorphine-induced climbing in mouse after intraperitoneal administration.,Other,1353116.0,
1462,129968,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for inhibition of apomorphine-induced climbing in mouse after peroral administration.,Other,1353116.0,
1463,130133,6,2,,103167216,3559,Unspecified,,,,,Neuroleptic activity in vivo by ability to antagonise climbing in apomorphine dosed mice after intraperitoneal administration.,Other,2861286.0,
1464,130391,4,3,,103167216,3559,Unspecified,,,,,Hypothermia in mice after peroral administration,Other,6105216.0,
1465,130711,6,2,,103167216,3559,Unspecified,,,,,In vivo inhibition of the apomorphine-induced climbing behavior in mice,Other,11527728.0,
1466,130864,7,2,,103167216,3559,Unspecified,,,,,In vivo the ability to antagonize the apomorphine induced climbing response in mice,Other,7914539.0,
1467,130873,6,2,,103167216,3559,Unspecified,,,,,"Inhibition against apomorphine-induced climbing, after 1 hour of peroral administration in mouse",Other,2571727.0,
1468,130874,6,2,,103167216,3559,Unspecified,,,,,"Inhibition against apomorphine-induced climbing, after 5 hour of peroral administration in mouse",Other,2571727.0,
1469,130877,6,2,,103167216,3559,Unspecified,,,,,"Inhibition against apomorphine-induced turning, after 1 hr of peroral administration in mouse",Other,2571727.0,
1470,130881,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of apomorphine induced mouse climbing, administered intraperitoneally",Other,1672156.0,
1471,130893,7,2,,103167216,3559,Unspecified,,,,,Inhibition of induction of ataxia in mouse after intraperitoneal administration,Other,2892936.0,
1472,130897,7,2,,103167216,3559,Unspecified,,,,,Inhibition of locomotor activity in mouse after intraperitoneal administration,Other,2892936.0,
1473,131045,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of spontaneous motor activity, after 1 hour of peroral administration in mouse",Other,2571727.0,
1474,131046,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of spontaneous motor activity, after 5 hour of peroral administration in mouse",Other,2571727.0,
1475,131051,6,2,,103167216,3559,Unspecified,,,,,"Inhibitory activity against tremorine-induced salivation, after 1 hour of peroral administration in mouse",Other,2571727.0,
1476,131052,7,2,,103167216,3559,Unspecified,,,,,"Inhibitory activity against tremorine-induced salivation, after 5 hour of peroral administration in mouse",Other,2571727.0,
1477,131054,6,2,,103167216,3559,Unspecified,,,,,"Inhibitory activity against tremorine-induced tremors, after 5 hour of peroral administration in mouse",Other,2571727.0,
1478,131206,6,3,,103167216,3559,Unspecified,,,,,"Contractile activity in skeletal muscles, after 5 hour of peroral administration in mouse",Other,2571727.0,
1479,131214,6,2,,103167216,3559,Unspecified,,,,,Lethal dose in mice by administered the compound intraperitoneally,Other,2571727.0,
1480,131247,6,2,,103167216,3559,Unspecified,,,,,Neuroleptic activity determined by its inhibitory effect on apomorphine-induced climbing behavior in mice by intraperitoneal administration in experiment 1 Range is 0.04-0.09,Other,2883318.0,
1481,131248,6,2,,103167216,3559,Unspecified,,,,,Neuroleptic activity determined by its inhibitory effect on apomorphine-induced climbing behavior in mice by intraperitoneal administration in experiment 2 Range is 0.05-0.17,Other,2883318.0,
1482,131362,7,2,,103167216,3559,Unspecified,,,,,Effect on Ataxia in mouse following i.p. administration.,Other,2888894.0,
1483,131363,7,2,,103167216,3559,Unspecified,,,,,Effect on Motor activity in mouse following i.p. administration.,Other,2888894.0,
1484,131364,6,3,,103167216,3559,Unspecified,,,,,"Effect on skeletal muscle tone, after 1 hour of peroral administration in mouse",Other,2571727.0,
1485,131366,6,3,,103167216,3559,Unspecified,,,,,"Effect on skeletal muscle tone, after 5 hour of peroral administration in mouse at dose 20 mg/kg",Other,2571727.0,
1486,131419,6,2,,103167216,3559,Unspecified,,,,,"Potentiation against pentobarbital-induced sleeping, after 1 hour of peroral administration in mouse",Other,2571727.0,
1487,131420,6,2,,103167216,3559,Unspecified,,,,,"Potentiation against pentobarbital-induced sleeping, after 5 hour of peroral administration in mouse",Other,2571727.0,
1488,131589,6,2,,103167216,3559,Unspecified,,,,,"Suppression of aggressive behavior, after 5 hour of peroral administration in mouse",Other,2571727.0,
1489,131722,6,2,,103167216,3559,Unspecified,,,,,Effective dose for inhibition of norepinephrine induced lethality in mouse,Other,1361578.0,
1490,131723,6,2,,103167216,3559,Unspecified,,,,,Effective dose for inhibition of physostigmine induced lethality in mouse,Other,1361578.0,
1491,131872,7,2,,103167216,3559,Unspecified,,,,,Effective dose required for inhibition of DOI-induced head-twitches in mice on ip administration,Other,11392544.0,
1492,131873,7,2,,103167216,3559,Unspecified,,,,,"Effective dose required for inhibition of apomorphine(sc, 2.5 mg/kg ) induced climbing in mice on ip administration",Other,11392544.0,
1493,131875,7,2,,103167216,3559,Unspecified,,,,,"Effective dose required for inhibition of apomorphine(sc, 2.5 mg/kg ) induced stereotypy in mice on ip administration",Other,11392544.0,
1494,132101,6,2,,103167216,3559,Unspecified,,,,,Tested for the inhibition of locomotor activity in mice intraperitoneally; value ranges from 0.2-0.5 mg/Kg,Other,7932581.0,
1495,132128,6,2,,103167216,3559,Unspecified,,,,,Tested in vivo for their ability to antagonize the apomorphine induced stereotypy response in mice,Other,7914539.0,
1496,132130,6,2,,103167216,3559,Unspecified,,,,,Tested in vivo for their ability to induction of catalepsy in mice,Other,7914539.0,
1497,132469,6,2,,103167216,3559,Unspecified,,,,,"The compound was tested for antagonistic activity against apomorphine induced climbing in the mouse, percentages are for reduction in climbing after peroral administration",Other,10464021.0,
1498,133191,3,3,,103167216,3559,Unspecified,,,,,Tested for physostigmine lethality at a dose of 5 mg/kg after oral administration in mice,Other,6128416.0,
1499,133854,3,3,,103167216,3559,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 20 mg/kg",Other,2571727.0,
1500,133857,3,3,,103167216,3559,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 9.4 mg/kg",Other,2571727.0,
1501,134417,7,2,,103167216,3559,Unspecified,,,,,Lethal dose in mice after perorla administration,Other,6105216.0,
1502,134514,3,4,,103167216,3559,Unspecified,,,,,"Contractile activity in skeletal muscles, after 1 hour of peroral administration in mouse at dose 30 mg/kg",Other,2571727.0,
1503,135326,5,2,,103167216,3559,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
1504,135365,3,3,,103167216,3559,Unspecified,,,,,"Inhibitory activity against tremorine-induced tremors, after 1 hour of peroral administration in mouse at dose 20 mg/kg",Other,2571727.0,
1505,138756,3,3,,103167216,3559,Unspecified,,,,,Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1506,138757,3,3,,103167216,3559,Unspecified,,,,,Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1507,138760,3,3,,103167216,3559,Unspecified,,,,,Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1508,138761,3,3,,103167216,3559,Unspecified,,,,,Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1509,138781,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1510,138782,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1511,138785,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1512,138786,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1513,138925,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1514,138926,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1515,138928,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1516,138929,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1517,139070,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1518,139071,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1519,139074,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097537.0,
1520,139075,3,3,,103167216,3559,Unspecified,,,,,Antagonism of apomorphine in reserpinized mice when a dose of 2.7 micro mol/kg is administered intraperitoneally,Other,8097538.0,
1521,140974,10,1,,103167216,3559,Active,,,7.466,Ki,In vitro binding affinity against Muscarinic acetylcholine receptors in rat brain.,Confirmatory,8101877.0,
1522,141053,7,1,,103167216,3559,Active,,,5.5,IC50,Inhibition of binding of 1.0 nM [3H]pirenzepine to cloned human Muscarinic acetylcholine receptor M1 expressed in membranes from CHO-K1 cells,Confirmatory,10377229.0,
1523,141055,8,5,,103167216,3559,Active,113118.0,1128.0,5.5,IC50,Inhibitory binding of [3H]pirenzepine to human Muscarinic acetylcholine receptor M1 in membranes from CHO-K1 cells,Confirmatory,9406603.0,
1524,141100,7,2,,103167216,3559,Active,,,4.67,Ki,Binding affinity towards human muscarinic receptor,Confirmatory,14998318.0,
1525,141155,8,5,,103167216,3559,Inconclusive,,,,,Binding affinity measured at the Muscarinic acetylcholine receptor by the inhibition of [3H]pyrilamine binding to guinea pig cerebellum using unlabeled Triprolidine for nonspecific binding; Not determined; ND = 'Not determined',Other,9876110.0,
1526,141538,9,2,,103167216,3559,Active,113121.0,25229.0,6.6,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1527,141538,9,2,,103167216,3559,Active,113127.0,24260.0,6.6,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1528,141538,9,2,,103167216,3559,Active,113130.0,25111.0,6.6,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1529,141538,9,2,,103167216,3559,Active,113132.0,53949.0,6.6,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1530,141538,9,2,,103167216,3559,Active,12643977.0,81645.0,6.6,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1531,141682,7,2,,103167216,3559,Active,,,0.054000000000000006,IC50,The compound was tested for inhibition of [3H]QNB binding to Muscarinic acetylcholine receptor,Confirmatory,2866248.0,
1532,141832,9,1,,103167216,3559,Active,,,1.8,Ki,Compound was tested for the binding affinity against rat cortical Muscarinic acetylcholine receptor M1 by Radio ligand [3H]pirenzepine binding assay.,Confirmatory,8709107.0,
1533,141837,7,1,,103167216,3559,Unspecified,,,10.0,Ki,Half-maximal inhibition of [3H]QNB binding to Muscarinic acetylcholine receptor M1 in rat frontal cortex homogenate,Confirmatory,11784139.0,
1534,141838,7,1,,103167216,3559,Unspecified,,,10.0,Ki,In vitro binding affinity towards M1 receptor of rat frontal cortex homogenate by using radioligand [3H]QNB,Confirmatory,14695828.0,
1535,142225,4,6,,103167216,3559,Unspecified,,,10.0,Ki,Binding affinity towards Muscarinic acetylcholine receptor in rat was determined,Confirmatory,3039136.0,
1536,142500,8,2,,103167216,3559,Inconclusive,,,,,In vitro inhibition of [3H]-Oxo-Mas binding to M1 and M4 receptors in rat brain homogenate; Not tested.,Other,9784113.0,
1537,142504,4,8,,103167216,3559,Unspecified,,,10.0,IC50,The ability to displace [3H]QNB from Muscarinic acetylcholine receptor in rat brain membrane was determined,Confirmatory,6128416.0,
1538,142687,7,2,,103167216,3559,Active,,,7.4131,Ki,Binding affinity against muscarinic (M) receptor,Confirmatory,7907148.0,
1539,142719,7,1,,103167216,3559,Active,,,2.14,Ki,Binding affinity was measured against muscarinic (M1) receptor in rat using [3H]pirenzepine as radioligand,Confirmatory,8027978.0,
1540,142870,7,1,,103167216,3559,Active,,,6.12,Ki,Binding affinity was measured against muscarinic (M2) receptor at 10 uM in rat using [3H]QN as radioligand,Confirmatory,8027978.0,
1541,142943,8,5,,103167216,3559,Active,12643977.0,81645.0,0.23800000000000002,Ki,Inhibition of [3H]N-methylscopolamine binding to Muscarinic acetylcholine receptor M2 of rat heart membranes,Confirmatory,9572883.0,
1542,142954,9,1,,103167216,3559,Active,,,2.5,Ki,Compound was tested for the binding affinity against rat heart Muscarinic acetylcholine receptor M2 by quinuclidinyl binding assay.,Confirmatory,8709107.0,
1543,145105,3,6,,103167216,3559,Unspecified,,,,,"Binding affinity was measured against N-methyl-D-aspartate (NMDA) receptor in rat using [3H]CGS-19,755 as radioligand at 10 uM",Other,8027978.0,
1544,148465,7,5,,103167216,3559,Active,464311.0,24613.0,5.687,IC50,Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%,Confirmatory,2888899.0,
1545,148465,7,5,,103167216,3559,Active,464313.0,29335.0,5.687,IC50,Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%,Confirmatory,2888899.0,
1546,148465,7,5,,103167216,3559,Active,464314.0,25601.0,5.687,IC50,Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%,Confirmatory,2888899.0,
1547,148465,7,5,,103167216,3559,Active,81882051.0,29336.0,5.687,IC50,Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%,Confirmatory,2888899.0,
1548,149044,7,1,,103167216,3559,Active,,,1.21,Ki,Binding affinity was measured against opioid receptor in rat using [3H]naloxone as radioligand,Confirmatory,8027978.0,
1549,150405,7,1,,103167216,3559,Unspecified,,,10.0,Ki,Compound was tested for its binding affinity towards Opioid receptors in rat membranes in the presence of [3H]naloxone,Confirmatory,9572883.0,
1550,150618,9,2,,103167216,3559,Active,,,5.3,IC50,Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model,Confirmatory,12477351.0,
1551,150735,9,2,,103167216,3559,Active,,,0.2,Ki,High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
1552,150736,3,8,,103167216,3559,Unspecified,,,,,Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Other,12477351.0,
1553,152392,9,1,,103167216,3559,Active,,,0.01,Ki,Inhibitory activity against Opioid receptor sigma 1 isolated from whole rat membranes using [3H](+)-pentazocine as radioligand,Confirmatory,8568804.0,
1554,156831,6,2,,103167216,3559,Inconclusive,,,,Ki,"Compound was tested for its binding affinity towards PCP receptor in rat membranes in the presence of [3H]-(+)-SKF- 10,047",Confirmatory,9572883.0,
1555,156976,8,2,,103167216,3559,Inconclusive,,,,,Compound was tested for its affinity towards PCP receptor in rat brain membrane [3H]MK-801 as radioligand; ND = not determined,Other,1662725.0,
1556,157456,7,1,,103167216,3559,Unspecified,,,10.0,Ki,Binding affinity was measured against phencyclidine (PCP) receptor in rat using [3H]TCP as radioligand,Confirmatory,8027978.0,
1557,160616,8,5,,103167216,3559,Active,75593047.0,,0.1,Ki,Binding affinity for HIV-1 protease,Confirmatory,1875332.0,
1558,160632,5,4,,103167216,3559,Inactive,,,,,The irreversibility of the inactivation reaction of HIV-1 PR was assessed; NI =No detectable reversible reaction,Other,8126707.0,
1559,160777,5,1,,103167216,3559,Unspecified,,,10000000000.0,Ki,Binding affinity to HIV-1 protease,Confirmatory,8021917.0,
1560,160788,9,1,,103167216,3559,Unspecified,,,140.0,IC50,In vitro inhibition of recombinant HIV-2 protease expressed in Escherichia coli strain X90,Confirmatory,8126707.0,
1561,160798,5,4,,103167216,3559,Inactive,,,,,The irreversibility of the inactivation reaction of HIV-2 PR was assessed; NI =No detectable reversible reaction,Other,8126707.0,
1562,161281,10,5,,103167216,3559,Active,7531135.0,3757.0,0.0302,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
1563,161283,8,5,,103167216,3559,Active,7531135.0,3757.0,0.032,IC50,Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1,Confirmatory,12729675.0,
1564,161627,9,2,,103167216,3559,Unspecified,,,10.0,EC50,Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells,Confirmatory,12904059.0,
1565,162182,9,1,,103167216,3559,Unspecified,,,125.0,IC50,In vitro inhibition of recombinant HIV-1 protease expressed in Escherichia coli strain D1210,Confirmatory,8126707.0,
1566,163467,7,2,,103167216,3559,Active,,,0.1,Ki,The compound was tested for its affinity against HIV-2 protease,Confirmatory,1875332.0,
1567,167992,3,3,,103167216,3559,Inactive,,,,,Effective dose for reversal of trifluoperazine-induced catalepsy in rats; I=Inactive (ED50 mg/Kg),Other,1361578.0,
1568,168344,3,3,,103167216,3559,Unspecified,,,,,Social interaction of rats was determined after 1 hr of intraperitoneal administration at 0.25 mg/kg,Other,7707315.0,
1569,168895,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for inhibition of ethanol potentiation in rat when administered perorally,Other,2869146.0,
1570,169189,3,3,,103167216,3559,Inactive,,,,,Conditioned avoidance responding in rat after subcutaneous administration (0.3 mg/kg); expressed as avoidance response/response failure; 9/55,Other,9784113.0,
1571,169242,3,3,,103167216,3559,Unspecified,,,,,Induced locomotor stimulation in non pre-treated rats by 13 umol/kg s.c. administration.,Other,3560156.0,
1572,169289,3,3,,103167216,3559,Unspecified,,,,,Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon ip administration; value ranges from 0.12-0.33,Other,2884314.0,
1573,169395,3,3,,103167216,3559,Unspecified,,,,,Locomotory activity was determined in non pretreated rats at a dose of 2.7 umol/kg by subcutaneous administration,Other,3560156.0,
1574,169423,3,3,,103167216,3559,Unspecified,,,,,Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon po administration; value ranges from 0.1-3.5,Other,2884314.0,
1575,169437,3,3,,103167216,3559,Unspecified,,,,,Potential antipsychotic activity was assessed by measuring the ability to block the conditioned avoidance response(CAR) in rats on oral administration.,Other,2888898.0,
1576,169571,3,3,,103167216,3559,Unspecified,,,,,Dose required for producing 50% block of avoidance responding in rats after peroral administration,Other,6116805.0,
1577,169616,3,4,,103167216,3559,Unspecified,,,,,Compound is evaluated DOPA accumulation in nonhabituated rats for (1.3 micro mol/kg) subcuteneous dose in rat striatum,Other,8064801.0,
1578,169630,4,4,,103167216,3559,Unspecified,,,,,Evaluated for biochemical levels of DOPAC in nonpretreated habituated rats for subcuteneous dose of 100 micro mol/kg in rat striatum,Other,8064801.0,
1579,169650,3,4,,103167216,3559,Unspecified,,,,,"Compound is tested for its ability to displace Di-Pr-5,6-ADTN at 0.25 umol/kg subcutaneous dose from rat striatal binding sites in vivo",Other,8064801.0,
1580,169806,3,3,,103167216,3559,Unspecified,,,,,Compound was assessed for its ability to block a conditioned avoidance response; Dose administered perorally is 1.25 mg/kg; 51-75%block,Other,6105216.0,
1581,169953,3,3,,103167216,3559,Unspecified,,,,,Compound was assessed for its ability to produce catalepsy in rats; Dose administered perorally is 1.25 mg/kg; Group score is 16-30,Other,6105216.0,
1582,170115,3,3,,103167216,3559,Unspecified,,,,,Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 1.25 mg/kg; 51-75% block,Other,6105217.0,
1583,170155,3,3,,103167216,3559,Unspecified,,,,,"Effect of locomotor activity in reserpine pretreated rats at the dose of 25.0uM/Kg, sc ip after count of 30 minute",Other,2120444.0,
1584,170161,3,3,,103167216,3559,Unspecified,,,,,Effect (60 min after administration of 200 (5.3 umol/kg) subcuteneous dose on DA release in brain dialysis model of rat,Other,8064801.0,
1585,170279,3,3,,103167216,3559,Inactive,,,,,Locomotor activity after reserpine pretreatment in rat; Not Tested,Other,3927002.0,
1586,170877,3,3,,103167216,3559,Unspecified,,,,,Percentage change in Social interaction when compound administered at a doe of 0.05 mg/kg ip in rats,Other,8831770.0,
1587,170878,3,3,,103167216,3559,Unspecified,,,,,Percentage change in Social interaction when compound administered at a doe of 0.125 mg/kg ip in rats,Other,8831770.0,
1588,170883,3,3,,103167216,3559,Unspecified,,,,,Percentage change in Total activity (anti psychotic) when compound administered at a doe of 0.05 mg/kg ip in rats,Other,8831770.0,
1589,170884,3,3,,103167216,3559,Unspecified,,,,,Percentage change in Total activity (anti psychotic) when compound administered at a doe of 0.125 mg/kg ip in rats,Other,8831770.0,
1590,170895,3,3,,103167216,3559,Unspecified,,,,,Percentage change in chronic single unit sampling when compound given at a dose of 0.5 mg/kg ip in rats,Other,8831770.0,
1591,170896,3,3,,103167216,3559,Unspecified,,,,,Percentage change in chronic single unit sampling when compound given at a dose of 0.5 mg/kg ip in rats (Expt-2),Other,8831770.0,
1592,171010,3,4,,103167216,3559,Unspecified,,,,,"Change in rectal temperature induced by DiPr-5,6-ADTN at a dose of 2.7 umol/kg of compound by subcutaneous administration",Other,3560156.0,
1593,171230,3,3,,103167216,3559,Unspecified,,,,,Side effect liability of compound at intraperitoneal dose of 0.5 mg/kg on 6.2 (A9 units)dopamine neurons in the nigrostriatal in rat,Other,7707315.0,
1594,171689,3,3,,103167216,3559,Unspecified,,,,,Catalytic action on male Wistar rats after subcutaneous administration of 0.003 mg/kg dose of compound,Other,9406603.0,
1595,171690,3,3,,103167216,3559,Unspecified,,,,,Catalytic action on male Wistar rats after subcutaneous administration of 0.03 mg/kg dose of compound,Other,9406603.0,
1596,171691,3,3,,103167216,3559,Unspecified,,,,,Catalytic action on male Wistar rats after subcutaneous administration of 0.3 mg/kg dose of compound,Other,9406603.0,
1597,171875,3,3,,103167216,3559,Unspecified,,,,,Antipsychotic efficacy of compound at intraperitoneal dose of 0.5 mg/kg on 6.8 (A10 units) dopamine neurons in the mesolimbic region of rat,Other,7707315.0,
1598,171952,3,3,,103167216,3559,Unspecified,,,,,compound was evaluated for its ability to produce catalepsy activity in rats,Other,6105217.0,
1599,173003,3,3,,103167216,3559,Unspecified,,,,,Blockade of uptake of the radiotracer in posterior cortex of rat,Other,9171875.0,
1600,173070,3,3,,103167216,3559,Unspecified,,,,,Percent change in serum prolactin in adult male Dawley rats after intraperitoneal administration.,Other,8096548.0,
1601,173680,3,3,,103167216,3559,Unspecified,,,,,Locomotor activity after no pretreatment in rat at high-dose region expressed as percent of saline control,Other,3927002.0,
1602,173682,3,3,,103167216,3559,Unspecified,,,,,Locomotor activity after no pretreatment in rat at low-dose region expressed as percent of saline control,Other,3927002.0,
1603,173704,3,3,,103167216,3559,Unspecified,,,,,Percent decrease on dopamine agonist-induced rotation in unilaterally 6-OH-DA-lesioned rat at 0.1 mg/kg,Other,6429333.0,
1604,173705,3,3,,103167216,3559,Unspecified,,,,,Percent decrease on dopamine agonist-induced rotation in unilaterally 6-OH-DA-lesioned rat at 0.25 mg/kg,Other,6429333.0,
1605,173706,3,3,,103167216,3559,Unspecified,,,,,Percent decrease on dopamine agonist-induced rotation in unilaterally 6-OH-DA-lesioned rat at 0.5 mg/kg,Other,6429333.0,
1606,173824,2,4,,103167216,3559,Unspecified,,,,,"Locomotor activity, measured for 30 min after injection of drug, administered subcutaneously at 100 umol/kg",Other,,
1607,174834,2,4,,103167216,3559,Unspecified,,,,,"Accumulation of Dihydroxyphenylalanine in limbic region in rat after injecting drug compound 65 min and NSD 1015 at a dose of 0.07 mg/kg administered subcutaneously, 30 min before death, tested in vivo",Other,,
1608,174836,2,4,,103167216,3559,Unspecified,,,,,"Accumulation of Dihydroxyphenylalanine in striatal region in rat after injecting drug compound 65 min and NSD 1015 at a dose of 0.07 mg/kg administered subcutaneously, 30 min before death, tested in vivo",Other,,
1609,175146,3,3,,103167216,3559,Unspecified,,,,,Dose required for producing 20% block of escape responding in rats after peroral administration,Other,6116805.0,
1610,175170,3,4,,103167216,3559,Unspecified,,,,,Compound was tested for its affect on the accumulation of the dopamine metabolite homovanillic acid (HAV) in the rat striatum at 1 mg/kg dose after peroral administration,Other,2875184.0,
1611,175174,3,3,,103167216,3559,Unspecified,,,,,Compound was tested for serum prolactin assay method in rats at 1 mg/kg dose after peroral administration,Other,2875184.0,
1612,175752,3,3,,103167216,3559,Unspecified,,,,,Effect on DOPA accumulation level at an intraperitoneal dose of 0.5 mg/kg in rat,Other,1671416.0,
1613,176062,3,3,,103167216,3559,Unspecified,,,,,Effect on the synthesis rates of dopamine in the rat ventral limbic brain region at 2.7 micro mol/kg,Other,8097537.0,
1614,176063,3,3,,103167216,3559,Unspecified,,,,,Effect on the synthesis rates of dopamine in the rat ventral limbic brain region at 2.7 micro mol/kg.,Other,8097538.0,
1615,176087,3,3,,103167216,3559,Unspecified,,,,,Effect on the synthesis rates of serotonin in the rat ventral limbic brain region 2.7 micro mol/kg.,Other,8097538.0,
1616,176093,3,3,,103167216,3559,Unspecified,,,,,Effect on the synthesis rates of serotonin in the rat ventral limbic brain region at 2.7 micro mol/kg,Other,8097537.0,
1617,176178,6,2,,103167216,3559,Unspecified,,,,,Compound was tested in vivo for its ability to antagonize extrapolatory behavior impairment induced by DOPA in rats upon intraperitoneal administration,Other,9464359.0,
1618,176195,6,2,,103167216,3559,Unspecified,,,,,Effective dose to induce catalepsy in 50% of the rats,Other,6120234.0,
1619,176222,7,2,,103167216,3559,Unspecified,,,,,Effective in vivo peroral dose against induction of catalepsy in rats,Other,1361578.0,
1620,176225,7,2,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine-induced stereotypy in rats via peroral route,Other,1361578.0,
1621,176231,6,2,,103167216,3559,Unspecified,,,,,Effective peroral dose for inhibition of conditioned avoidance response in rats,Other,1361578.0,
1622,176235,6,2,,103167216,3559,Unspecified,,,,,"Inhibitory activity in apomorphine antagonism test at a dose of 20 mg/kg, sc",Other,7907148.0,
1623,176251,6,2,,103167216,3559,Unspecified,,,,,Intracranial self stimulation in rat was determined after 1 hr of intraperitoneal administration of the compound,Other,7707315.0,
1624,176254,6,2,,103167216,3559,Unspecified,,,,,Intraperitoneal effective dose required for inhibition of apomorphine-induced stereotypy in rat,Other,8831770.0,
1625,176323,7,2,,103167216,3559,Unspecified,,,,,In vivo blocking of apomorphine induced hyperactivity following 1 mg/kg i.p. in rats after 60 min.,Other,6128419.0,
1626,176324,7,2,,103167216,3559,Unspecified,,,,,In vivo blocking of apomorphine induced stereotypies following 1 mg/kg i.p. in rats after 60 min.,Other,6128419.0,
1627,176327,6,2,,103167216,3559,Unspecified,,,,,"Body weight gain, after 2 hour period of conditioned feeding in rats",Other,2571727.0,
1628,176331,6,2,,103167216,3559,Unspecified,,,,,Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 1 hr before amphetamine.,Other,2876102.0,
1629,176333,6,2,,103167216,3559,Unspecified,,,,,Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 24 hr before amphetamine.,Other,2876102.0,
1630,176335,6,2,,103167216,3559,Unspecified,,,,,Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 5 hr before amphetamine.,Other,2876102.0,
1631,176339,6,2,,103167216,3559,Unspecified,,,,,Compound was tested in vivo for its ability to induce catalepsy in rats upon intraperitoneal administration,Other,9464359.0,
1632,176370,6,2,,103167216,3559,Unspecified,,,,,Conditioned avoidance response activity was determined by the ability to block the conditioned avoidance of a foot shock (ip),Other,7473547.0,
1633,176371,6,2,,103167216,3559,Unspecified,,,,,Conditioned avoidance response activity was determined by the ability to block the conditioned avoidance of a foot shock (ip),Other,7473548.0,
1634,176413,7,2,,103167216,3559,Unspecified,,,,,Evaluated in vitro for antipsychotic activity (hyperactivity) for the block of apomorphine induced response after ip administration 60 min prior to apomorphine (1 mg/kg sc),Other,1969484.0,
1635,176414,7,2,,103167216,3559,Unspecified,,,,,Evaluated in vitro for antipsychotic activity (stereotypies) for the block of apomorphine induced response after ip administration 60 min prior to apomorphine (1 mg/kg sc),Other,1969484.0,
1636,176457,6,2,,103167216,3559,Unspecified,,,,,Pole climb avoiding activity in rats was determined after 1 hr of intraperitoneal administration of the compound,Other,7707315.0,
1637,176458,6,2,,103167216,3559,Unspecified,,,,,Pole climb escape failures of rats was determined after 1 hr of intraperitoneal administration of the compound,Other,7707315.0,
1638,176476,7,2,,103167216,3559,Unspecified,,,,,Catalepsy interval defined as the time required for both fore limbs to be removed from the bar when administered intraperitoneally,Other,1969484.0,
1639,176499,6,2,,103167216,3559,Unspecified,,,,,Compound is measured for inhibition of catalepsy in rat by peroral administration of compound,Other,10377229.0,
1640,176500,6,2,,103167216,3559,Unspecified,,,,,Inhibition of catalepsy in rat by subcutaneous administration of compound,Other,10377229.0,
1641,176655,7,2,,103167216,3559,Unspecified,,,,,Subcutaneous dose to inhibit apomorphine-induced stereotyped behavior in 50% of rats,Other,6120234.0,
1642,176662,6,2,,103167216,3559,Unspecified,,,,,Suppression of conditioned avoidance behavior in rats after ip administration,Other,2902226.0,
1643,176663,6,2,,103167216,3559,Unspecified,,,,,Suppression of conditioned avoidance behavior in rats following p.o. administration.,Other,2902226.0,
1644,176733,6,2,,103167216,3559,Unspecified,,,,,Dose (administered orally) inhibiting amphetamine-induced locomotor behavior in rats,Other,8568801.0,
1645,176734,6,2,,103167216,3559,Unspecified,,,,,Dose (administered orally) inhibiting apomorphine-induced stereotypy in rats,Other,8568801.0,
1646,176735,6,2,,103167216,3559,Unspecified,,,,,Dose (administered orally) inhibiting spontaneous locomotor behavior in rats,Other,8568801.0,
1647,176743,6,2,,103167216,3559,Unspecified,,,,,Dose inducing catalepsy in rats after oral administration,Other,8568801.0,
1648,176744,6,2,,103167216,3559,Unspecified,,,,,Dose inhibiting conditioned avoidance response in rats after oral administration,Other,8568801.0,
1649,176749,6,2,,103167216,3559,Unspecified,,,,,Dose required to induce 50% maximum catalepsy in rat,Other,8709130.0,
1650,176762,7,2,,103167216,3559,Unspecified,,,,,In vivo DOPA accumulation in non pre-treated rat limbic system following s.c. administration.,Other,3560156.0,
1651,176767,7,2,,103167216,3559,Unspecified,,,,,In vivo DOPA accumulation in non pre-treated rat striatal system following s.c. administration.,Other,3560156.0,
1652,176775,5,3,,103167216,3559,Inactive,,,,,In vivo DOPA accumulation in reserpine pretreated rat limbic system after 1.4 umol/kg ip; I denotes inactive,Other,3560156.0,
1653,176780,5,3,,103167216,3559,Inactive,,,,,In vivo DOPA accumulation in reserpine pretreated rat striatum system after 1.4 umol/kg ip; I denotes inactive,Other,3560156.0,
1654,176802,6,2,,103167216,3559,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by induction of catalepsy in rat,Other,1672156.0,
1655,176804,6,2,,103167216,3559,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by pole climb avoidance in rat,Other,1672156.0,
1656,176805,6,2,,103167216,3559,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by pole climb escape failures in rat,Other,1672156.0,
1657,176807,6,2,,103167216,3559,Unspecified,,,,,Suppression of conditioned avoidance behavior in rats when administered intraperitoneally 60 min before measurement,Other,2889830.0,
1658,176808,6,2,,103167216,3559,Unspecified,,,,,Suppression of conditioned avoidance behavior in rats when administered perorally 60 min before measurement,Other,2889830.0,
1659,176943,7,2,,103167216,3559,Unspecified,,,,,Dose which blocks the hypothermic effect of apomorphine by 50% against Sprague-Dawley rats when administered intraperitoneally,Other,1969484.0,
1660,176965,6,2,,103167216,3559,Unspecified,,,,,In vivo activity was measured by the intracranial self stimulation in rat,Other,1672156.0,
1661,177081,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for inhibition of apomorphine-induced stereotypy behavior in rats after intraperitoneal administration.,Other,1353116.0,
1662,177108,6,2,,103167216,3559,Unspecified,,,,,ED50 value for catalepsy indicates the dose required to produce a 50% of maximum catalepsy score. parentheses value indicate 95% confidence limit.,Other,1346653.0,
1663,177133,6,2,,103167216,3559,Unspecified,,,,,In vivo antipsychotic activity measured by the induction of catalepsy in rats after po administration.,Other,9876110.0,
1664,177227,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for intracranial self-stimulation in rat after intraperitoneal administration.,Other,1353116.0,
1665,177251,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for pole-climb avoidance in rat after peroral administration.,Other,1353116.0,
1666,177252,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for pole-climb avoidance (escape failures) in rat after peroral administration.,Other,1353116.0,
1667,177479,6,2,,103167216,3559,Unspecified,,,,,Effect on Ataxia(ATX) in rat was measured as ED50 by perorally administration of compound.,Other,2888894.0,
1668,177487,6,2,,103167216,3559,Unspecified,,,,,Effect on Motor activity(MA) in rat was measured as ED50 by perorally administration of compound.,Other,2888894.0,
1669,177488,6,2,,103167216,3559,Unspecified,,,,,Effect on Sidman conditioned avoidance in rat.,Other,2888894.0,
1670,177489,7,2,,103167216,3559,Unspecified,,,,,Effect on half-maximal decrease of DOPA formation in rat limbic regions,Other,3656358.0,
1671,177491,7,2,,103167216,3559,Inactive,,,,,Effect on half-maximal decrease of DOPA formation in rat limbic regions; In active (no significant effect at 1.4 pmol/kg ip),Other,3656358.0,
1672,177492,7,2,,103167216,3559,Unspecified,,,,,Effect on half-maximal decrease of DOPA formation in rat striatal regions,Other,3656358.0,
1673,177493,6,2,,103167216,3559,Inactive,,,,,Effect on half-maximal decrease of DOPA formation in rat striatal regions; In active (no significant effect at 1.4 pmol/kg ip),Other,3656358.0,
1674,177498,6,2,,103167216,3559,Unspecified,,,,,In vivo inhibition of amphetamine induced stereotypy in rat by the compound administered intraperitoneally,Other,1672156.0,
1675,177506,6,2,,103167216,3559,Unspecified,,,,,In vivo inhibition of apomorphine induced stereotypy in rat by the compound administered intraperitoneally,Other,1672156.0,
1676,177507,6,2,,103167216,3559,Unspecified,,,,,In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 20 mg/kg expressed as ED50 (mg/kg),Other,8101877.0,
1677,177555,6,2,,103167216,3559,Unspecified,,,,,Ability to block apomorphine-induced stereotypy in rats.,Other,7707315.0,
1678,177621,5,3,,103167216,3559,Unspecified,,,,,Selectivity for mesolimbic over nigrostriatal dopamine system in rat brain as substania nigra zona reticulata infusion of muscimol-induced locomotor activity (LMA) by sc dose,Other,,
1679,177633,7,2,,103167216,3559,Unspecified,,,,,Compound was evaluated in vivo for antagonist activity against apomorphine induced behavioral syndrome such as Hyperactivity in rat after intraperitoneal administration; activity value ranges from 0.27-0.35,Other,4040977.0,
1680,177689,6,2,,103167216,3559,Unspecified,,,,,Effective dose against DOPA accumulation in rat brain limbic region after no pretreatment by subcutaneous administration,Other,3927002.0,
1681,177715,6,2,,103167216,3559,Unspecified,,,,,In vivo suppression of the conditioned avoidance response (CAR) in rats after po administration of the compound,Other,11527728.0,
1682,177716,6,4,,103167216,3559,Unspecified,118211.0,29238.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1683,177716,6,4,,103167216,3559,Unspecified,118229.0,24316.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1684,177716,6,4,,103167216,3559,Unspecified,118251.0,25195.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1685,177716,6,4,,103167216,3559,Unspecified,6226851.0,25432.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1686,177716,6,4,,103167216,3559,Unspecified,47117674.0,24318.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1687,177723,6,2,,103167216,3559,Unspecified,,,,,Induction of catalepsy in rats was determined after 2 hr of intraperitoneal administration of the compound,Other,7707315.0,
1688,177725,6,2,,103167216,3559,Unspecified,,,,,Induction of catalepsy in rats when administered intraperitoneally 4 hr prior to measurement to groups of 9 animals. value is based on at least three dose levels(40% of animals showed catalepsy),Other,2889830.0,
1689,177731,6,2,,103167216,3559,Unspecified,,,,,"Inhibition against conditioned avoidance response, after 1 hour of peroral administration in rats",Other,2571727.0,
1690,177732,6,2,,103167216,3559,Unspecified,,,,,"Inhibition against conditioned avoidance response, after 5 hour of peroral administration in rats",Other,2571727.0,
1691,177741,6,2,,103167216,3559,Unspecified,,,,,"Activity to evoke catalepsy, after 1 hour of peroral administration in rats",Other,2571727.0,
1692,177742,7,2,,103167216,3559,Unspecified,,,,,"Activity to evoke catalepsy, after 5 hour of peroral administration in rats",Other,2571727.0,
1693,177809,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated in vivo for its antipsychotic activity for inhibition of apomorphine-induced stereotypy in rat,Other,7914536.0,
1694,177816,7,2,,103167216,3559,Unspecified,,,,,Compound was evaluated in vivo its antagonist activity against apomorphine induced behavioral syndrome such as Stereotypy in rat after intraperitoneal administration,Other,4040977.0,
1695,177821,5,2,,103167216,3559,Inactive,,,,,Effective dose against DOPA accumulation in rat brain limbic region after reserpine pretreatment by subcutaneous administration; No significant effect at 0.5 mg/kg intraperitoneal administration,Other,3927002.0,
1696,177823,6,2,,103167216,3559,Unspecified,,,,,Effective dose against DOPA accumulation in rat brain striatal region after no pretreatment by subcutaneous administration,Other,3927002.0,
1697,177826,5,2,,103167216,3559,Inactive,,,,,Effective dose against DOPA accumulation in rat brain striatal region after reserpine pretreatment by subcutaneous administration; No significant effect at 0.5 mg/kg intraperitoneal administration,Other,3927002.0,
1698,177879,6,2,,103167216,3559,Unspecified,,,,,Inhibition of Sidman avoidance in rats after peroral administration,Other,2892936.0,
1699,177886,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of apomorphine-induced stereotypy in Rat, after peroral administration",Other,8709130.0,
1700,177887,6,2,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine-induced stereotypy in rats.,Other,9876110.0,
1701,177895,6,2,,103167216,3559,Unspecified,,,,,Inhibition of conditioned avoidance response (CAR) in fasted male Sprague-Dawley rats.,Other,6131130.0,
1702,177902,7,2,,103167216,3559,Unspecified,,,,,Inhibition of firing rates of dopaminergic neurons in the substantia nigra pars compacta by intravenous injection in rats,Other,8097537.0,
1703,177903,7,2,,103167216,3559,Unspecified,,,,,Inhibition of firing rates of dopaminergic neurons in the substantia nigra pars compacta by intravenous injection in rats,Other,8097538.0,
1704,177907,7,2,,103167216,3559,Unspecified,,,,,Inhibition of firing rates of serotonergic neurons in the dorsal raphe nucleus by intravenous injection in rats,Other,8097538.0,
1705,177946,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against amphetamine-induced stereotypy, after 1 hour of peroral administration in rats",Other,2571727.0,
1706,177947,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against amphetamine-induced stereotypy, after 5 hour of peroral administration in rats",Other,2571727.0,
1707,177950,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy, after 1 hour of peroral administration in rats",Other,2571727.0,
1708,177951,6,2,,103167216,3559,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy, after 5 hour of peroral administration in rats",Other,2571727.0,
1709,177958,6,2,,103167216,3559,Unspecified,,,,,Antagonistic activity administered intraperitoneally on head twitches induced by 5- HTP,Other,7707315.0,
1710,178179,6,2,,103167216,3559,Unspecified,,,,,Inhibition of conditioned avoidance response in rat following s.c. administration.,Other,9784113.0,
1711,178197,6,2,,103167216,3559,Unspecified,,,,,Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally,Other,2565400.0,
1712,178242,7,2,,103167216,3559,Unspecified,,,,,Inhibition of shelf-jump avoidance in rats after peroral administration.,Other,2892936.0,
1713,178319,7,2,,103167216,3559,Unspecified,,,,,Compound was tested for anti-dopamine activity in vivo by its ability to inhibit apomorphine induced hyperactivity in rat,Other,3941414.0,
1714,178321,7,2,,103167216,3559,Unspecified,,,,,Compound was tested for anti-dopamine activity in vivo by its ability to inhibit apomorphine induced stereotypy in rat,Other,3941414.0,
1715,178385,7,2,,103167216,3559,Unspecified,,,,,Effective dose for apomorphine induced circling behavior was determined in rats after subcutaneous administration of the compound,Other,1671414.0,
1716,178395,6,2,,103167216,3559,Unspecified,,,,,Effective dose for ethanol potentiation in rats,Other,1361578.0,
1717,178397,6,2,,103167216,3559,Unspecified,,,,,Effective dose for inhibition of spontaneous motor activity in rats,Other,1361578.0,
1718,178399,6,2,,103167216,3559,Unspecified,,,,,Effective dose for motor incoordination in rats was determined by rotarod method,Other,1361578.0,
1719,178517,6,2,,103167216,3559,Unspecified,,,,,Inhibition of conditioned avoidance response (CAR),Other,2869146.0,
1720,178537,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for inhibition of spontaneous motor activity in rat when administered perorally,Other,2869146.0,
1721,178541,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for its ability to induce catalepsy in rats.,Other,2869146.0,
1722,178680,6,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity determined in vivo by inhibition of amphetamine induced locomotor behavior in rats by the po administration.,Other,1676427.0,
1723,178704,7,2,,103167216,3559,Unspecified,,,,,Antagonistic activity against amphetamine-induced stereotypy in rats; (5 mg/kg administered ip 1 hr after the test compound).,Other,3941416.0,
1724,178706,7,2,,103167216,3559,Unspecified,,,,,Compound was tested for the antagonistic activity against amphetamine-induced stereotypy in rats; (5 mg/kg administered ip 24 hr after the test compound),Other,3941416.0,
1725,178710,7,2,,103167216,3559,Unspecified,,,,,Compound was tested for the antagonistic activity against amphetamine-induced stereotypy in rats; (5 mg/kg administered ip 5 hr after the test compound),Other,3941416.0,
1726,178868,6,2,,103167216,3559,Unspecified,,,,,Compound was tested for the inhibition of apomorphine-induced stereotype,Other,2869146.0,
1727,178920,6,2,,103167216,3559,Unspecified,,,,,Effective dose required for antipsychotic activity was evaluated by rat CAR assay,Other,9871525.0,
1728,179827,6,2,,103167216,3559,Unspecified,,,,,Tested for the inhibition of locomotor activity in rats intraperitoneally; value ranges from 0.21-0.3 mg/Kg,Other,7932581.0,
1729,180162,6,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity at a dose 10 times the ED50 value for CAR block for production of catalepsy in the rat (following i.p. dosing),Other,1346653.0,
1730,180185,6,2,,103167216,3559,Unspecified,,,,,The compound was evaluated for the conditioned avoidance response data (CAR) in rat intra peritoneally,Other,7909336.0,
1731,180345,6,3,,103167216,3559,Unspecified,,,,,Activity against the suppression of high base line self stimulation with electrodes in the medial forebrain of the posterior hypothalamus of male hooded rats (Peroral admin.),Other,2866248.0,
1732,180347,6,2,,103167216,3559,Unspecified,,,,,The compound was tested (after peroral administration) for its ability to induce catalepsy in rats,Other,2866248.0,
1733,180521,6,2,,103167216,3559,Unspecified,,,,,The compound was tested for inhibition of sidman avoidance in rat,Other,2866248.0,
1734,180526,6,2,,103167216,3559,Unspecified,,,,,The compound was tested for its ability to induced catalepsy in rats,Other,2866248.0,
1735,180551,6,2,,103167216,3559,Unspecified,,,,,The compound was tested in vivo for induction of catalepsy in rat after ip administration,Other,10464021.0,
1736,180891,7,2,,103167216,3559,Unspecified,,,,,The dosage at which 50% of the animals were cataleptic was measured after (ip) administration in male Sprague-Dawley rats,Other,6128419.0,
1737,180901,6,2,,103167216,3559,Unspecified,,,,,The dose required to reduce the number of apomorphine induced rotation by 50% in rats with monolateral lesion of nigrostriatal tracts,Other,2888899.0,
1738,180915,6,2,,103167216,3559,Unspecified,,,,,The inhibitory effect on the continuous avoidance was expressed as the dose to increase the number of electroshocks by 60% of the rats,Other,6120234.0,
1739,181088,6,2,,103167216,3559,Unspecified,,,,,compound was tested for antipsychotic activity by conditioned avoidance response(CAR) assay in rats with a pretreatment period of 60 min upon peroral administration. Values in brackets indicates 95% confidence limits for ED50,Other,9622541.0,
1740,181191,3,3,,103167216,3559,Unspecified,,,,,Antagonism of SKF 10047 -induced hypermotility (% vs controls) dose(mg/Kg po) = 2,Other,9622542.0,
1741,181422,3,3,,103167216,3559,Unspecified,,,,,Conditioned avoidance response in rats after oral administration,Other,8096548.0,
1742,181424,3,3,,103167216,3559,Unspecified,,,,,Tested for the amphetamine induced stereotyped behavior in rats after oral administration,Other,8096548.0,
1743,181425,3,3,,103167216,3559,Unspecified,,,,,Compound was tested for the presence of catalepsy (CAT) in rats after oral administration,Other,8096548.0,
1744,181661,4,3,,103167216,3559,Active,,,0.01,IC50,Binding affinity against rat striatal membranes using [3H]spiroperidol as the radioligand after 2 hours of conditioned feeding,Confirmatory,2571727.0,
1745,182041,3,3,,103167216,3559,Unspecified,,,,,In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 0.6 mg/kg expressed as percent inhibition,Other,8101877.0,
1746,183724,3,4,,103167216,3559,Unspecified,,,,,"Inhibitory activity in apomorphine antagonism test at a dose of 20 mg/kg, sc",Other,7907148.0,
1747,184035,4,2,,103167216,3559,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by social interaction of rat at 5.0 uM,Other,1672156.0,
1748,184626,7,2,,103167216,3559,Unspecified,,,,,Compound was tested for its acute toxicity in rat after ip administration,Other,3941414.0,
1749,184656,4,3,,103167216,3559,Unspecified,,,,,Compound was evaluated for the inhibition of apomorphine induced stereotypy behavior in rats after sc administration.,Other,1676427.0,
1750,184659,3,3,,103167216,3559,Inactive,,,,,Compound was evaluated for the inhibition of haloperidol induced catalepsy behavior in rats after sc administration; Inactive,Other,1676427.0,
1751,184872,3,3,,103167216,3559,Unspecified,,,,,Minimum effective dose observed in rat catalepsy experiments,Other,11052797.0,
1752,184992,3,3,,103167216,3559,Unspecified,,,,,Compound is evaluated for locomotor activity in nonhabituated rats at 1.3 micro mol/kg of subcuteneous dose,Other,8064801.0,
1753,184995,3,3,,103167216,3559,Unspecified,,,,,Compound is evaluated for locomotor activity in nonpretreated habituated rats at 1.6 micro mol/kg of subcuteneous dose,Other,8064801.0,
1754,185004,3,3,,103167216,3559,Unspecified,,,,,"Compound is tested for concomitant ability to antagonize the locomotor activity induced by Di-Pr-5,6-ADTN",Other,8064801.0,
1755,185022,3,3,,103167216,3559,Unspecified,,,,,Minimum effective dose required for significant dose dependent reduction of amphetamine-induced locomotor activity in male Sprague-Dawley rats on subcutaneous administration (30 min prior to receiving amphetamine 0.5 mg/kg),Other,12372513.0,
1756,185023,3,3,,103167216,3559,Unspecified,,,,,Minimum effective dose required in the catalepsy experiment in rats,Other,12372513.0,
1757,185044,3,3,,103167216,3559,Unspecified,,,,,Minimum effective dose that produced a significant effect relative to the amphetamine alone control using a Fisher's LSD post hoc test (P<0.05),Other,11052797.0,
1758,186042,3,3,,103167216,3559,Unspecified,,,,,"Locomotor activity in male Wistar rats after a dose of 0.003 uM/kg, 30 min before 1 mg/kg of apomorphine administration",Other,9406603.0,
1759,186043,3,3,,103167216,3559,Unspecified,,,,,"Locomotor activity in male Wistar rats after a dose of 0.03 uM/kg, 30 min before 1 mg/kg of apomorphine administration",Other,9406603.0,
1760,186044,3,3,,103167216,3559,Unspecified,,,,,"Locomotor activity in male Wistar rats after a dose of 0.3 uM/kg, 30 min before 1 mg/kg of apomorphine administration",Other,9406603.0,
1761,188453,3,3,,103167216,3559,Inactive,,,,,Drug pretreatment vs. vehicle pretreatment; statistical analysis by Student''s t test at 0.1 mg/kg; NS-Not Significant,Other,6429333.0,
1762,188454,3,3,,103167216,3559,Unspecified,,,,,Drug pretreatment vs. vehicle pretreatment; statistical analysis by Student's t test at 0.25 mg/kg,Other,6429333.0,
1763,188455,3,3,,103167216,3559,Unspecified,,,,,Drug pretreatment vs. vehicle pretreatment; statistical analysis by Student's t test at 0.5 mg/kg,Other,6429333.0,
1764,190818,3,3,,103167216,3559,Unspecified,,,,,Total activity (anti psychotic) when compound administered at a doe of 0.05 mg/kg ip in rats,Other,8831770.0,
1765,190819,3,3,,103167216,3559,Unspecified,,,,,Total activity (anti psychotic) when compound administered at a doe of 0.125 mg/kg ip in rats,Other,8831770.0,
1766,190978,3,4,,103167216,3559,Unspecified,,,,,"Effect on dopamine agonist-induced rotation in unilaterally 6-OH-DA-lesioned rat at 0.1 mg/kg, ip; Compound 35 was injected subcutaneously at 75 mg/kg",Other,6429333.0,
1767,190979,3,4,,103167216,3559,Unspecified,,,,,"Effect on dopamine agonist-induced rotation in unilaterally 6-OH-DA-lesioned rat at 0.25 mg/kg, ip; Compound 35 was injected subcutaneously at 75 mg/kg",Other,6429333.0,
1768,190980,3,4,,103167216,3559,Unspecified,,,,,"Effect on dopamine agonist-induced rotation in unilaterally 6-OH-DA-lesioned rat at 0.5 mg/kg, ip; Compound 35 was injected subcutaneously at 75 mg/kg",Other,6429333.0,
1769,191610,3,3,,103167216,3559,Unspecified,,,,,Anti psychotic effect Social interaction when compound administered at a doe of 0.05 mg/kg ip in rats,Other,8831770.0,
1770,191611,3,3,,103167216,3559,Unspecified,,,,,Anti psychotic effect Social interaction when compound administered at a doe of 0.125 mg/kg ip in rats,Other,8831770.0,
1771,194153,3,4,,103167216,3559,Unspecified,,,,,The percent loss of escape responding was determined for the estimated effective dose 50 values for CAR block,Other,2565400.0,
1772,194369,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of 5-HIAA in rat striatum,Other,7902870.0,
1773,194370,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of 5-HT in rat striatum,Other,7902870.0,
1774,194371,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DA in rat frontal cortex,Other,7902870.0,
1775,194372,3,3,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DA in rat mesolimbic region,Other,7902870.0,
1776,194373,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DA in rat striatum,Other,7902870.0,
1777,194374,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DOPAC in rat frontal cortex,Other,7902870.0,
1778,194375,3,3,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DOPAC in rat mesolimbic region,Other,7902870.0,
1779,194376,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DOPAC in rat striatum,Other,7902870.0,
1780,194377,3,3,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DOPAC/DA in rat mesolimbic region,Other,7902870.0,
1781,194378,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of DOPAC/DA in rat striatum,Other,7902870.0,
1782,194379,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of HVA in rat frontal cortex,Other,7902870.0,
1783,194380,3,3,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of HVA in rat mesolimbic region,Other,7902870.0,
1784,194381,3,4,,103167216,3559,Unspecified,,,,,Effect of compound (0.2 mg/kg ip) on the concentration of HVA in rat striatum,Other,7902870.0,
1785,194522,3,4,,103167216,3559,Unspecified,,,,,Effect of compound on (0.2 mg/kg ip) the concentration of 5-HIAA in rat frontal cortex,Other,7902870.0,
1786,194523,3,3,,103167216,3559,Unspecified,,,,,Effect of compound on (0.2 mg/kg ip) the concentration of 5-HIAA in rat mesolimbic region,Other,7902870.0,
1787,194524,3,4,,103167216,3559,Unspecified,,,,,Effect of compound on (0.2 mg/kg ip) the concentration of 5-HT in rat frontal cortex,Other,7902870.0,
1788,194525,3,3,,103167216,3559,Unspecified,,,,,Effect of compound on (0.2 mg/kg ip) the concentration of 5-HT in rat mesolimbic region,Other,7902870.0,
1789,194526,3,4,,103167216,3559,Unspecified,,,,,Effect of compound on (0.2 mg/kg ip) the concentration of DOPAC/DA in rat frontal cortex,Other,7902870.0,
1790,195772,4,4,,103167216,3559,Unspecified,,,,,Tested for locomotor activity by measuring accumulated counts/30 min in reserpine-non-pretreated rats,Other,3656358.0,
1791,195963,3,3,,103167216,3559,Unspecified,,,,,"effects on sidiman Avoidance performance in rats, number of Avoidance performance(% change from control) p<0.001 dose(mg/Kg po) =1",Other,9622542.0,
1792,195978,3,4,,103167216,3559,Unspecified,,,,,"effects on sidiman Avoidance performance in rats, number of escape failure (absolute change from control), p<0.01, dose(mg/Kg po) =1",Other,9622542.0,
1793,196012,3,3,,103167216,3559,Unspecified,,,,,Compound was evaluated in paw test for the forelimb retraction at effective dose of 20 (mg\\kg),Other,12408724.0,
1794,196014,3,3,,103167216,3559,Unspecified,,,,,Compound was evaluated in paw test for the hindlimb retraction at effective dose of 5 (mg\\kg),Other,12408724.0,
1795,196117,3,3,,103167216,3559,Unspecified,,,,,"effects on sidiman Avoidance performance in rats, number of shocks (absolute change from control), p<0.001, dose(mg/Kg po) =1",Other,9622542.0,
1796,196771,6,3,,103167216,3559,Unspecified,,,,,In vivo accumulation of L-DOPA was measured in striatum of rats,Other,10377229.0,
1797,196821,5,2,,103167216,3559,Active,,,0.039810000000000005,Kd,Compound was evaluated for the pA2 values against Dopamine (DA)-induced contraction of isolated rat vas deferens.,Confirmatory,1676759.0,
1798,196822,5,2,,103167216,3559,Active,,,0.10232999999999999,Kd,Compound was evaluated for the pA2 values against Norepinephrine (NE)-induced contraction of isolated rat vas deferens,Confirmatory,1676759.0,
1799,197732,6,2,,103167216,3559,Unspecified,,,,,Cataleptogenic activity was evaluated for the compound as the 50% effective dose required to induce cataleptic effect in rats,Other,2883318.0,
1800,203686,9,1,,103167216,3559,Active,,,0.00253,Ki,Compound tested for binding affinity towards sigma 1 receptor in quinea pig brain membranes using [3H](+)-pentazocine as the radioligand.,Confirmatory,9632369.0,
1801,203688,7,1,,103167216,3559,Active,,,0.0037,Ki,Compound was evaluated for its in vitro competition binding studies using sigma-ligand (0.05-10000 nM) - [3H](+)-pentazocine (sigma1 receptor) in guinea pig brain membranes,Confirmatory,9651150.0,
1802,203697,7,1,,103167216,3559,Active,,,0.0037,Ki,Binding affinity towards sigma 1 receptor was determined in guinea pig brain membrane using [3H](+)-pentazocine as radioligand,Confirmatory,8295220.0,
1803,203698,7,1,,103167216,3559,Active,,,0.0032,Ki,Compound was tested for its binding affinity towards sigma 1 receptor using [3H](+)-pentazocine from guinea pig brain,Confirmatory,9572880.0,
1804,203699,7,1,,103167216,3559,Active,,,0.0016,Ki,Inhibition of [3H]pentazocine binding to sigma-1 sites in guinea pig brain membranes,Confirmatory,9572883.0,
1805,203702,7,1,,103167216,3559,Active,,,0.0006,Ki,The compound was evaluated for affinity at sigma-1 site by inhibition of [3H](+)-pentazocine (PENT) binding in guinea pig brain.,Confirmatory,8027978.0,
1806,203829,4,4,,103167216,3559,Active,,,0.0117,Ki,Binding affinity towards sigma 2 receptor using [3H]DTG in the presence of 200 nM (+)-NANM from guinea pig brain,Confirmatory,9572880.0,
1807,203830,4,4,,103167216,3559,Active,,,0.0127,Ki,Inhibition of [3H]DTG binding to sigma-2 sites of guinea pig brain membranes,Confirmatory,9572883.0,
1808,203833,4,3,,103167216,3559,Active,,,0.006,Ki,"Affinity at sigma-2 site by inhibition of [3H]1,3-di(2-tolyl)guanidine (DTG) binding in guinea pig brain.",Confirmatory,8027978.0,
1809,203837,3,7,,103167216,3559,Unspecified,,,,,Selectivity for sigma 2 receptor and sigma 1 receptor from guinea pig brain was evaluated,Other,9572880.0,
1810,203842,4,4,,103167216,3559,Active,,,0.012,Ki,Binding affinity towards sigma 2 receptor was determined in rat liver membrane using [3H]DTG as radioligand in presence of dextrallorphan,Confirmatory,8295220.0,
1811,203845,4,4,,103167216,3559,Active,,,0.0285,Ki,Binding affinity towards sigma 2 receptor site in rat liver membranes using [3H]DTG as radioligand in presence of (+)-pentazocine.,Confirmatory,9632369.0,
1812,203846,4,4,,103167216,3559,Active,,,0.012,Ki,Compound was evaluated for its in vitro competition binding studies using sigma-ligand #NAME? in the presence of 1 uM dextrallorphan (sigma2 receptor) in the rat liver membranes.,Confirmatory,9651150.0,
1813,203850,3,8,,103167216,3559,Unspecified,,,,,Selectivity ratio for sigma 2 receptor site in rat liver membranes and sigma 1 receptor site in quinea pig brain membranes,Other,9632369.0,
1814,203851,3,8,,103167216,3559,Unspecified,,,,,"Relative binding to sigma-2 and sigma-1 type receptors, ratio of Ki",Other,8295220.0,
1815,203852,7,1,,103167216,3559,Active,,,0.2138,IC50,The compound was tested for affinity towards sigma-3 receptor,Confirmatory,7990111.0,
1816,203916,3,10,,103167216,3559,Unspecified,112812.0,24473.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
1817,203916,3,10,,103167216,3559,Unspecified,112815.0,25075.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
1818,203916,3,10,,103167216,3559,Unspecified,112820.0,25323.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
1819,203916,3,10,,103167216,3559,Unspecified,398968.0,60448.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
1820,203982,7,1,,103167216,3559,Active,,,0.005,IC50,Displacement of [3H]DTG from sigma opioid receptor of homogenized guinea pig whole brain,Confirmatory,1648140.0,
1821,203984,7,2,,103167216,3559,Active,,,0.00564,IC50,In vitro binding affinity measured on sigma opioid receptor using [3H]DTG as radioligand,Confirmatory,7699710.0,
1822,203998,7,2,,103167216,3559,Active,,,0.005,Ki,Inhibition of [3H]DTG binding to Sigma opioid receptor,Confirmatory,1648139.0,
1823,204001,7,1,,103167216,3559,Active,,,0.0104,Ki,The compound was tested for its binding affinity towards Sigma opioid receptor in guinea pig brain membranes,Confirmatory,1662725.0,
1824,204012,9,1,,103167216,3559,Active,,,0.003,IC50,Inhibitory activity against Sigma opioid receptor,Confirmatory,1648139.0,
1825,204014,9,1,,103167216,3559,Active,,,0.038,Ki,Binding affinity of compound towards sigma receptor using [3H]DTG (4 nM) ligand in hippocampus rat was determined,Confirmatory,9083484.0,
1826,204145,7,1,,103167216,3559,Active,,,0.0022,Ki,Ability to displace [3H](+)-pentazocine from Sigma opioid receptor type 1 of guinea pig brain,Confirmatory,12383018.0,
1827,204147,7,2,,103167216,3559,Active,,,0.0006,Ki,Binding affinity for Sigma opioid receptor type 1 in guinea pig brain homogenate with 0.5 nM [3H](+)-PENT,Confirmatory,,
1828,204149,7,3,,103167216,3559,Active,,,0.00044,Ki,Inhibition of [3H]pentazocine binding to Sigma opioid receptor type 1,Confirmatory,,
1829,204152,9,1,,103167216,3559,Active,,,0.0018,Ki,Inhibition of [3H]- pentazocine binding against alpha-1 from guinea pig brain,Confirmatory,10602703.0,
1830,204153,7,1,,103167216,3559,Active,,,0.0022,Ki,Sigma opioid receptor type 1 affinity in guinea pig brain by employing [3H](+)-pentazocine as radioligand.,Confirmatory,11784148.0,
1831,204290,3,6,,103167216,3559,Unspecified,,,,,Ratio of binding affinity towards Sigma opioid receptor type 1 versus Sigma opioid receptor type 2,Other,12383018.0,
1832,204292,3,8,,103167216,3559,Unspecified,,,,,Selectivity ratio Sigma opioid receptor type 1 to Sigma opioid receptor type 2,Other,11784148.0,
1833,204298,7,2,,103167216,3559,Active,,,0.006,Ki,Binding affinity for Sigma opioid receptor type 2 in guinea pig brain homogenate with 4 nM [3H]-(+)-DTG,Confirmatory,,
1834,204300,4,4,,103167216,3559,Active,,,0.0696,Ki,Inhibition of [3H]-DTG binding to Sigma opioid receptor type 2,Confirmatory,,
1835,204304,8,5,,103167216,3559,Active,81882051.0,29336.0,0.0342,Ki,Ability to displace [3H]ditolylguanidine in the presence of 100 nM (+)-pentazocine from Sigma opioid receptor type 2 of rat liver,Confirmatory,12383018.0,
1836,204313,8,5,,103167216,3559,Active,81882051.0,29336.0,0.0342,Ki,Sigma opioid receptor type 2 affinity in rat liver by employing [3H]ditolylguanidine as radioligand,Confirmatory,11784148.0,
1837,204443,7,1,,103167216,3559,Active,,,0.0037,Ki,Ability to displace [3H](+)-pentazocine at sigma receptor in guinea pig brain membrane was determined,Confirmatory,8360875.0,
1838,204445,7,1,,103167216,3559,Active,,,0.0037,Ki,Binding affinity for sigma receptor using [3H](+)-pentazocine in guinea pig brain homogenates,Confirmatory,1447735.0,
1839,204448,7,1,,103167216,3559,Active,,,0.0042,Ki,Inhibitory activity against sigma receptor isolated from guinea pig brain cortex membrane using [3H]DTG as radioligand,Confirmatory,8568804.0,
1840,204461,7,3,,103167216,3559,Active,,,0.0015,Ki,Binding affinity measured at the sigma receptor by the inhibition of [3H]-3-PPP binding to guinea pig cerebellum using unlabeled 3-PPP for nonspecific binding.,Confirmatory,9876110.0,
1841,204596,8,5,,103167216,3559,Active,74752153.0,10280.0,0.0046,Ki,Binding affinity against sigma receptor of MCF cells,Confirmatory,8021913.0,
1842,204615,8,5,,103167216,3559,Active,81882051.0,29336.0,0.0014,IC50,Compound was tested in vitro for its ability to displace radioligand (+)-[3H]-3-PPP from rat cortical sigma receptor,Confirmatory,1361578.0,
1843,204629,7,1,,103167216,3559,Active,,,0.00295,Ki,Binding affinity was measured on Sigma receptor type 1 with guinea pig membranes and [3H]- pentazocine as ligand.,Confirmatory,11052796.0,
1844,204714,11,2,,103167216,3559,Unspecified,,,1.0,Ki,In vitro binding affinity for serotonin reuptake sites in rat frontal cortex membranes by [3H]paroxetine displacement.,Confirmatory,12565939.0,
1845,204762,7,2,,103167216,3559,Active,,,0.00065,IC50,Compound was evaluated for the binding affinity towards Sigma receptor type 1 using radioligand ([3H]-(+)- Pentazocine) binding assay.,Confirmatory,7783132.0,
1846,204763,7,2,,103167216,3559,Active,,,0.00065,IC50,Binding affinity towards sigma receptor binding site 1 using [3H](+)-pentazocine,Confirmatory,7783131.0,
1847,204764,3,7,,103167216,3559,Unspecified,,,,,Ratio of the binding affinities against Sigma receptor type 1 and Sigma receptor type 2,Other,7783132.0,
1848,204771,8,5,,103167216,3559,Active,81882051.0,29336.0,0.017,IC50,Binding affinity towards Sigma receptor type 2 in whole rat brain homogenates except cerebellum using radioligand ([3H]DTG) binding assay.,Confirmatory,7783132.0,
1849,204772,4,4,,103167216,3559,Active,,,0.017,IC50,Binding affinity towards sigma receptor binding site 2 using [3H]DTG of whole rat brain homogenates except cerebellum,Confirmatory,7783131.0,
1850,204780,8,5,,103167216,3559,Active,81882051.0,29336.0,0.0465,Ki,Binding affinity was measured on Sigma receptor type 2 with rat liver membranes and [3H]- DTG as ligand.,Confirmatory,11052796.0,
1851,204788,9,2,,103167216,3559,Active,,,0.017,IC50,"Binding effinity for sigma receptor using 2 nM of [3H]-DTG as radioligand, in membranes from brain minus cerebellum",Confirmatory,8230107.0,
1852,204791,7,1,,103167216,3559,Active,,,0.0015,Ki,Binding affinity for sigma-1 receptor measured on guinea pig brain membranes using [3H](+)-pentazocine as radioligand,Confirmatory,11356115.0,
1853,204938,4,4,,103167216,3559,Active,,,0.017,Ki,Binding affinity for sigma-2 receptor measured on rat liver membranes using [3H]DTG as radioligand in the presence of (+)-pentazocine,Confirmatory,11356115.0,
1854,205033,9,2,,103167216,3559,Active,112812.0,24473.0,20.0,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1855,205033,9,2,,103167216,3559,Active,112815.0,25075.0,20.0,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1856,205033,9,2,,103167216,3559,Active,112820.0,25323.0,20.0,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1857,205033,9,2,,103167216,3559,Active,398968.0,60448.0,20.0,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1858,205147,6,2,,103167216,3559,Unspecified,,,,,Tested for inhibition of conditioned avoidance in squirrel monkeys; value ranges from 0.4-0.6 mg/Kg,Other,7932581.0,
1859,205150,6,2,,103167216,3559,Unspecified,,,,,The compound was tested for its ability to induced catalepsy in squirrel monkeys,Other,2866248.0,
1860,205174,6,2,,103167216,3559,Unspecified,,,,,The compound was tested for inhibition of sidman avoidance in squirrel monkeys,Other,2866248.0,
1861,205267,9,2,,103167216,3559,Active,,,1.2,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
1862,205268,4,7,,103167216,3559,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
1863,211852,6,2,,103167216,3559,Unspecified,,,,,Acute toxicity on male outbred albino mice upon intraperitoneal administration,Other,9464359.0,
1864,213410,3,8,,103167216,3559,Unspecified,,,,,Compound was tested to block the inhibition of tyrosine hydroxylase by apomorphine at 1 uM,Other,6105221.0,
1865,218670,7,1,,103167216,3559,Active,,,6.0,IC50,The compound was tested for inhibition of [3H]WB-4101 binding to alpha-1 adrenergic receptor of rat frontal cortex,Confirmatory,2866248.0,
1866,218673,7,2,,103167216,3559,Active,,,0.024,Ki,Binding affinity towards alpha-1 adrenergic receptor,Confirmatory,3039136.0,
1867,218788,11,1,,103167216,3559,Active,,,0.02,Ki,Binding affinity towards dopamine receptor D2 was determined by displacement of [3H]spiroperidol from bovine nucleus caudate membranes.,Confirmatory,2883318.0,
1868,218805,3,10,,103167216,3559,Unspecified,231461.0,25083.0,,,Binding affinity towards alpha-2 adrenergic receptor at 1.0 uM concentration,Other,3039136.0,
1869,218805,3,10,,103167216,3559,Unspecified,231464.0,24175.0,,,Binding affinity towards alpha-2 adrenergic receptor at 1.0 uM concentration,Other,3039136.0,
1870,218805,3,10,,103167216,3559,Unspecified,47117345.0,24174.0,,,Binding affinity towards alpha-2 adrenergic receptor at 1.0 uM concentration,Other,3039136.0,
1871,218904,9,3,,103167216,3559,Active,,,0.0327,IC50,In vitro affinity towards D2 receptor using [3H]spiroperidol as radioligand in striatum,Confirmatory,7914536.0,
1872,221060,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of apomorphine-induced climbing behavior in mice, after Intraperitoneal administration",Other,8709130.0,
1873,221062,6,2,,103167216,3559,Unspecified,,,,,"Inhibition of apomorphine-induced climbing behavior in mice, after peroral administration",Other,8709130.0,
1874,223122,6,2,,103167216,3559,Unspecified,,,,,Compound was evaluated for the effective dose that causes lethality in aggregated mice (group toxicity antagonism),Other,1676759.0,
1875,223305,6,2,,103167216,3559,Unspecified,,,,,Effective dose administered in apomorphine induced climbing test in mice (in vivo)value in parentheses represents 95% confidence limit,Other,11101359.0,
1876,223306,6,2,,103167216,3559,Unspecified,,,,,Effective dose administered in catalepsy test in mice(in vivo) value in parentheses represents 95% confidence limit,Other,11101359.0,
1877,224643,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of DOPAC level after first treatment(0.74 umol/kg) in dialysates collected from rat striatum.,Other,11784139.0,
1878,224644,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of Dopamine level after first treatment (0.74 umol/kg) in dialysates collected from rat striatum.,Other,11784139.0,
1879,224645,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of HVA level after first treatment(0.74 umol/kg) in dialysates collected from rat striatum.,Other,11784139.0,
1880,224646,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of DOPAC level after second treatment(7.4 umol/kg) in dialysates collected from rat striatum.,Other,11784139.0,
1881,224647,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of Dopamine level after second treatment(7.4 umol/kg) in dialysates collected from rat striatum,Other,11784139.0,
1882,224648,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of HVA level after second treatment(7.4 umol/kg) in dialysates collected from rat striatum.,Other,11784139.0,
1883,224649,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of DOPAC level after total treatment in dialysates collected from rat striatum.,Other,11784139.0,
1884,224650,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of Dopamine level after total treatment in dialysates collected from rat striatum.,Other,11784139.0,
1885,224651,3,3,,103167216,3559,Unspecified,,,,,Area under curve(AUC) value of HVA level after total treatment in dialysates collected from rat striatum.,Other,11784139.0,
1886,226334,4,4,,103167216,3559,Active,,,0.012,Ki,The Binding affinity was evaluated using [3H]DTG -(+)-Dextrallorphan] in rat liver,Confirmatory,8496936.0,
1887,226336,4,4,,103167216,3559,Active,,,0.026000000000000002,Ki,Tested for [3H]DTG binding to sigma-2 receptor in NG108-15 membrane,Confirmatory,7902870.0,
1888,226337,7,1,,103167216,3559,Active,,,0.00253,Ki,"Binding affinity for sigma 1 opioid receptor, measured on guinea pig brain membranes using [3H]- (+)-pentazocine as radioligand",Confirmatory,11728186.0,
1889,226339,8,1,,103167216,3559,Active,,,0.0022,Ki,"Affinity to sigma-1-receptor, using [3H]pentazocine as radioligand in homogenates of guinea pig brain membranes",Confirmatory,11495592.0,
1890,226340,4,3,,103167216,3559,Active,,,0.02852,Ki,"Binding affinity for sigma 2 opioid receptor, measured on rat liver membranes using [3H]- DTG as radioligand in the presence of (+)-pentazocine",Confirmatory,11728186.0,
1891,226426,3,8,,103167216,3559,Unspecified,,,,,In vitro binding affinity for D2 receptor compared to that of 5-HT2 receptor,Other,11392544.0,
1892,226576,3,8,,103167216,3559,Unspecified,,,,,In vitro binding affinity for D2 receptor compared to that of D4 receptor,Other,11392544.0,
1893,226638,3,3,,103167216,3559,Unspecified,,,,,Hill coefficient value.,Other,8098771.0,
1894,227558,3,7,,103167216,3559,Unspecified,,,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Other,8568801.0,
1895,227559,3,5,,103167216,3559,Unspecified,,,,,Relative binding affinity for dopamine D2 and alpha receptors,Other,8568801.0,
1896,227718,7,1,,103167216,3559,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1897,228343,3,11,,103167216,3559,Unspecified,118206.0,1813.0,,,"Relative binding to dopamine D2 and D4 receptor, ratio of Ki",Other,9276014.0,
1898,228343,3,11,,103167216,3559,Unspecified,1345939.0,1815.0,,,"Relative binding to dopamine D2 and D4 receptor, ratio of Ki",Other,9276014.0,
1899,228503,3,4,,103167216,3559,Unspecified,,,,,"The selectivity was calculated as pKi [3H]spiperone minus pKi [3H]SCH-23,390.",Other,1676759.0,
1900,228677,3,3,,103167216,3559,Unspecified,,,,,Delta ED50 value by Subcutaneous administration (ED50 catalepsy-ED50 Climbing),Other,10377229.0,
1901,228678,3,3,,103167216,3559,Unspecified,,,,,Delta ED50 value by peroral administration (ED50 catalepsy-ED50 Climbing),Other,10377229.0,
1902,229002,4,1,,103167216,3559,Active,,,0.01995,Ki,Compound was measured for the inhibition of [3H]ketanserin binding to rat frontal cortex membrane (5-HT2A receptor),Confirmatory,9934473.0,
1903,229186,7,1,,103167216,3559,Active,,,0.008,IC50,Inhibition of specific binding of [125I]-PIPAG to sigma binding site in Guinea pig brain membranes,Confirmatory,1469697.0,
1904,229188,7,1,,103167216,3559,Active,,,0.017,IC50,Inhibition of specific binding of [3H]3-PPP to sigma binding site in Guinea pig brain membranes,Confirmatory,1469697.0,
1905,229190,7,1,,103167216,3559,Active,,,0.005,IC50,Inhibition of specific binding of [3H]DTG to sigma binding site in Guinea pig brain membranes,Confirmatory,1469697.0,
1906,229192,7,1,,103167216,3559,Active,,,0.004,IC50,Inhibition of specific binding of [3H]NANM of sigma binding site in Guinea pig brain membranes,Confirmatory,1469697.0,
1907,229212,7,2,,103167216,3559,Active,,,0.0037,Ki,"Binding affinity was evaluated against sigma-1 binding site in guinea pig, using [3H]- -(+)- Pentazocine",Confirmatory,8496936.0,
1908,229213,7,1,,103167216,3559,Active,,,0.00033,Ki,Tested for [3H](+)-pentazocine binding to sigma-1 receptor in guinea pig brain membrane,Confirmatory,7902870.0,
1909,229516,3,6,,103167216,3559,Unspecified,,,,,Ratio of IC50 value against dopamine receptor D2 to that of 5-hydroxytryptamine 3 receptor.,Other,7707315.0,
1910,229628,4,7,,103167216,3559,Unspecified,,,,,Selectivity ratio for serotonin 5-HT2A to that of dopamine D2 receptors,Other,14741248.0,
1911,229631,4,6,,103167216,3559,Unspecified,,,,,Selectivity ratio for serotonin 5-HT2C to that of serotonin 5-HT2A receptors,Other,14741248.0,
1912,229637,3,7,,103167216,3559,Unspecified,,,,,Selectivity ratio towards D4 receptor to that of D2 receptor,Other,,
1913,230925,3,10,,103167216,3559,Unspecified,81882051.0,29336.0,,,"Binding affinities for sigma-1 and sigma 2 receptors, ratio of IC50",Other,7783131.0,
1914,230953,3,8,,103167216,3559,Unspecified,,,,,Ratio of binding to dopamine D2A low/D2A high receptors,Other,10465538.0,
1915,231159,3,8,,103167216,3559,Unspecified,,,,,Ratio of the potency for displacement of of [3H]spiperone binding to human D2 dopaminergic receptor/human D4 dopaminergic receptor,Other,,
1916,231161,3,8,,103167216,3559,Unspecified,,,,,Ratio of the sigma-2 receptor versus sigma-1 receptor,Other,8496936.0,
1917,231369,3,3,,103167216,3559,Unspecified,,,,,Ratio representing inhibitory activity against catalepsy to inhibitory activity against amphetamine-induced locomotor behavior in rats,Other,8568801.0,
1918,231370,3,3,,103167216,3559,Unspecified,,,,,Ratio representing inhibitory activity against spontaneous locomotor behavior to inhibitory activity against amphetamine-induced stereotypy in rats,Other,8568801.0,
1919,231459,4,10,,103167216,3559,Unspecified,112808.0,29595.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1920,231459,4,10,,103167216,3559,Unspecified,112817.0,25187.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1921,231459,4,10,,103167216,3559,Unspecified,398970.0,29581.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1922,231459,4,10,,103167216,3559,Unspecified,47117674.0,24318.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1923,231522,3,6,,103167216,3559,Unspecified,,,,,Ratio of binding affinity towards 5-HT2 to D2 receptor was measured,Other,7907148.0,
1924,231526,3,6,,103167216,3559,Unspecified,,,,,Ratio of binding affinity towards D2 to D1 receptor was measured,Other,7907148.0,
1925,231528,3,5,,103167216,3559,Unspecified,,,,,Ratio of binding affinity towards D2 to muscarinic receptor (M) was measured,Other,7907148.0,
1926,231638,3,10,,103167216,3559,Unspecified,47117674.0,24318.0,,,Binding affinity against the D2 dopamine receptor and ratio of IC50(+Na+) / IC50(-Na(+)) [from 2-4 experiments],Other,2889830.0,
1927,231649,3,7,,103167216,3559,Unspecified,,,,,"Binding affinity ratio against human dopamine D2L versus D4.2, calculated using pKi (-logKi) values",Other,12408724.0,
1928,231650,3,5,,103167216,3559,Unspecified,,,,,"Binding affinity ratio against rat cortical tissue 5-HT2 versus human D2, calculated using pKi (-logKi) values",Other,12408724.0,
1929,231653,3,10,,103167216,3559,Unspecified,112808.0,29595.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1930,231653,3,10,,103167216,3559,Unspecified,112817.0,25187.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1931,231653,3,10,,103167216,3559,Unspecified,398970.0,29581.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1932,231653,3,10,,103167216,3559,Unspecified,47117674.0,24318.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1933,231654,3,9,,103167216,3559,Unspecified,118229.0,24316.0,,,Binding ratio of -log Ki between D2 and D1 receptors,Other,8101877.0,
1934,231654,3,9,,103167216,3559,Unspecified,47117674.0,24318.0,,,Binding ratio of -log Ki between D2 and D1 receptors,Other,8101877.0,
1935,231655,3,5,,103167216,3559,Unspecified,,,,,Binding ratio of -log Ki between D2 and M receptors,Other,8101877.0,
1936,231707,3,7,,103167216,3559,Unspecified,,,,,Ratio between binding affinities of dopamine D2 and serotonin 5-HT 2A receptors,Other,9934473.0,
1937,231725,3,8,,103167216,3559,Unspecified,,,,,Ratio between inhibition constants of 5-HT2A receptor and D2 receptor,Other,,
1938,231726,3,8,,103167216,3559,Unspecified,,,,,Ratio between inhibition constants of D1 receptor and D2 receptor,Other,,
1939,232152,3,7,,103167216,3559,Unspecified,,,,,Ratio of 5-HT2A receptor to that of dopamine 2 (D2) receptor in human,Other,14695828.0,
1940,232153,4,6,,103167216,3559,Unspecified,,,,,Ratio of 5-HT2A receptor to that of dopamine 2 (D2) receptor in rat tissue homogenate,Other,14695828.0,
1941,232211,3,9,,103167216,3559,Unspecified,,,,,Selectivity ratio for sigma-1 and sigma 2 receptor binding,Other,,
1942,232307,3,7,,103167216,3559,Unspecified,,,,,Dopamine D2/D3 ratio of the compound,Other,11356115.0,
1943,232327,3,3,,103167216,3559,Unspecified,,,,,Ratio of APO Sterotype ED50 vs catalepsy ED50,Other,2869146.0,
1944,232353,3,3,,103167216,3559,Unspecified,,,,,Ratio of CAR ED50 vs catalepsy ED50,Other,2869146.0,
1945,232372,4,7,,103167216,3559,Unspecified,,,,,Ratio of affinity for D2 and D4 receptors,Other,9871530.0,
1946,232553,3,3,,103167216,3559,Unspecified,,,,,Ratio of ED50 for antagonism of apomorphine induced stereotypy to ED50 for antagonism of apomorphine induced climbing,Other,7914539.0,
1947,232558,3,3,,103167216,3559,Unspecified,,,,,Ratio of ED50 for induction of catalepsy to ED50 for antagonism of apomorphine induced climbing,Other,7914539.0,
1948,232561,3,3,,103167216,3559,Unspecified,,,,,Ratio of ED50 for inhibition of catalepsy induction to stereotypy induction,Other,6120234.0,
1949,233293,3,7,,103167216,3559,Unspecified,,,,,Selectivity ratio is Ki of human dopamine D2 receptor to that of human dopamine D4 receptor.,Other,9406594.0,
1950,233354,5,4,,103167216,3559,Unspecified,,,,,The lipophilicity was measured in an octanol/water system at pH 7.4.,Other,11052796.0,
1951,233472,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,Hill coefficient for [3H]-Raclopride binding for high and low affinity binding to dopamine D2 receptor,Other,10465538.0,
1952,233507,4,1,,103167216,3559,Unspecified,,,8511380.0,Ki,Ratio of inhibition constant of 5-HT2A receptor to that of D2 receptor,Confirmatory,,
1953,233508,3,5,,103167216,3559,Unspecified,,,,,Ratio between pKi values of 5-HT2A and D1 receptors,Other,7914540.0,
1954,233509,3,7,,103167216,3559,Unspecified,,,,,Ratio between pKi values of 5-HT2A and D2 receptors,Other,7914540.0,
1955,233510,3,7,,103167216,3559,Unspecified,,,,,Ratio between pKi values of D1 and D2 receptors,Other,7914540.0,
1956,233807,4,6,,103167216,3559,Unspecified,,,,,The ratio of the IC50 value of Dopamine D2 receptor to that of serotonergic 5-HT2 receptor,Other,7914539.0,
1957,234212,3,3,,103167216,3559,Unspecified,,,,,Therapeutic ratio of ED50 of catalepsy to ED50 of climbing in rat models,Other,2883318.0,
1958,234273,3,8,,103167216,3559,Unspecified,,,,,Selectivity is determined by the ratio of Ki for rat sigma 2 receptor to that of guinea pig sigma-1 receptor,Other,11728186.0,
1959,234393,4,3,,103167216,3559,Unspecified,,,,,ratio between ED50 values of DA receptor antagonist activity and catalepsy.,Other,9513593.0,
1960,235773,3,3,,103167216,3559,Unspecified,,,,,Therapeutic ratio by Peroral dose of administration (quotient ED50 catalepsy/ED50 climbing),Other,10377229.0,
1961,235774,3,3,,103167216,3559,Unspecified,,,,,Therapeutic ratio by Subcutaneous dose of administration (quotient ED50 catalepsy/ED50 climbing),Other,10377229.0,
1962,237685,4,3,,103167216,3559,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
1963,238274,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0073,Ki,Binding affinity for Dopamine receptor D4,Confirmatory,15689154.0,
1964,238350,8,5,,103167216,3559,Active,1169206.0,1814.0,0.01,Ki,Binding affinity for human dopamine receptor D3,Confirmatory,15689154.0,
1965,238489,10,2,,103167216,3559,Active,118206.0,1813.0,0.0022,Ki,Binding affinity for human recombinant dopamine D2 receptor,Confirmatory,15293986.0,
1966,238490,8,5,,103167216,3559,Active,118228.0,1812.0,0.08199999999999999,Ki,Binding affinity for human recombinant dopamine receptor D1,Confirmatory,15293986.0,
1967,238491,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0078,Ki,Binding affinity for human recombinant dopamine receptor D3,Confirmatory,15293986.0,
1968,238492,8,5,,103167216,3559,Active,118214.0,1816.0,0.057999999999999996,Ki,Binding affinity for human recombinant dopamine receptor D5,Confirmatory,15293986.0,
1969,238525,10,2,,103167216,3559,Active,1345939.0,1815.0,0.0073,Ki,Binding affinity for human recombinant dopamine receptor D4.2,Confirmatory,15293986.0,
1970,238699,8,5,,103167216,3559,Active,118206.0,1813.0,0.0013,Ki,Binding affinity for human dopamine receptor D2 long,Confirmatory,15689154.0,
1971,238778,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0019,Ki,In vitro ability to inhibit [3H]6b binding to human Dopamine receptor D4.4,Confirmatory,15380206.0,
1972,238855,8,1,,103167216,3559,Active,118229.0,24316.0,0.359,Ki,Inhibition of [3H]SCH-23390 binding to rat Dopamine receptor D1,Confirmatory,15771415.0,
1973,238882,8,1,,103167216,3559,Active,112808.0,29595.0,0.16399999999999998,Ki,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2A receptor,Confirmatory,15771414.0,
1974,238889,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0014,Ki,In vitro ability to inhibit [3H]spiperone binding to human Dopamine receptor D4.4,Confirmatory,15380206.0,
1975,238940,8,1,,103167216,3559,Active,118229.0,24316.0,0.318,Ki,Inhibition of [3H]-SCH- 23390 binding to rat dopamine D1 receptor,Confirmatory,15771414.0,
1976,238941,8,1,,103167216,3559,Active,47117674.0,24318.0,0.0048,Ki,Inhibition of [3H]spiperone binding to rat dopamine D2 receptor,Confirmatory,15771414.0,
1977,239010,8,5,,103167216,3559,Active,543727.0,3356.0,0.435,Ki,Inhibition of [125I]R91150 binding to human 5-hydroxytryptamine 2A receptor,Confirmatory,15771415.0,
1978,239052,8,5,,103167216,3559,Active,118206.0,1813.0,0.0025,Ki,Inhibition of [3H]-spiperone binding to human Dopamine receptor D2,Confirmatory,15771415.0,
1979,239086,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0026899999999999997,Ki,Inhibitory constant against dopamine D2 receptor using 0.2 nM [3H]-spiperone,Confirmatory,15634021.0,
1980,239105,7,3,,103167216,3559,Active,,,0.0022,Ki,Inhibitory constant against sigma receptor type 1 using 3 nM [3H]pentazocine,Confirmatory,15634021.0,
1981,239150,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0044,Ki,Inhibition of [125I]iodosulpiride binding to human Dopamine receptor D3,Confirmatory,15771415.0,
1982,239151,7,2,,103167216,3559,Active,,,0.018000000000000002,Ki,Inhibition of [3H]7-OH-DPAT binding to Dopamine D3 receptor expressed in Sf9 cells,Confirmatory,15771414.0,
1983,239200,7,3,,103167216,3559,Active,,,0.016,Ki,Inhibitory constant against sigma receptor type 2 using 3 nM [3H]ditolylguanidine,Confirmatory,15634021.0,
1984,239296,7,2,,103167216,3559,Active,,,0.0005,Ki,Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand,Confirmatory,16033255.0,
1985,239347,7,2,,103167216,3559,Active,,,0.0002,Ki,Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand,Confirmatory,16033255.0,
1986,239597,8,5,,103167216,3559,Active,17374795.0,10682.0,0.19,Ki,Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand,Confirmatory,16033255.0,
1987,239905,4,1,,103167216,3559,Active,,,0.000603,Ki,Inhibitory constant towards dopamine D2 receptor was determined,Confirmatory,15878662.0,
1988,239911,4,1,,103167216,3559,Active,,,0.16596,Ki,Inhibitory constant towards 5-hydroxytryptamine 2A receptor (5-HT2A),Confirmatory,15878662.0,
1989,239912,4,1,,103167216,3559,Active,,,7.24436,Ki,Inhibitory constant towards 5-hydroxytryptamine 2C receptor (5-HT2C),Confirmatory,15878662.0,
1990,240820,9,2,,103167216,3559,Active,,,1.4,IC50,Inhibitory concentration against IKr potassium channel,Confirmatory,15324906.0,
1991,242943,3,10,,103167216,3559,Unspecified,1169206.0,1814.0,,,Ratio of dopamine receptor D3 and D4 ki values,Other,15689154.0,
1992,242943,3,10,,103167216,3559,Unspecified,1345939.0,1815.0,,,Ratio of dopamine receptor D3 and D4 ki values,Other,15689154.0,
1993,242944,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,Ratio of dopamine receptor D2 long and D3 ki values,Other,15689154.0,
1994,242944,3,9,,103167216,3559,Unspecified,1169206.0,1814.0,,,Ratio of dopamine receptor D2 long and D3 ki values,Other,15689154.0,
1995,242945,3,10,,103167216,3559,Unspecified,118206.0,1813.0,,,Ratio of dopamine receptor D2 long and D4 ki values,Other,15689154.0,
1996,242945,3,10,,103167216,3559,Unspecified,1345939.0,1815.0,,,Ratio of dopamine receptor D2 long and D4 ki values,Other,15689154.0,
1997,243053,3,5,,103167216,3559,Unspecified,,,,,Ratio of inhibitory constant for 5-hydroxytryptamine 2A receptor to that of dopamine receptor D2,Other,15878662.0,
1998,243151,7,2,,103167216,3559,Active,,,0.0302,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
1999,243188,6,6,,103167216,3559,Active,7531135.0,3757.0,0.02818,IC50,Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state,Confirmatory,15745831.0,
2000,243273,6,2,,103167216,3559,Active,,,0.000891,Ki,Binding affinity towards dopamine receptor D2 was determined,Confirmatory,15808487.0,
2001,243274,6,2,,103167216,3559,Active,,,0.00457,Ki,Binding affinity towards dopamine receptor D3 was determined,Confirmatory,15808487.0,
2002,243275,6,2,,103167216,3559,Active,,,0.01047,Ki,Binding affinity towards dopamine receptor D4 was determined,Confirmatory,15808487.0,
2003,243422,3,10,,103167216,3559,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
2004,246503,5,6,,103167216,3559,Unspecified,1345939.0,1815.0,10.0,EC50,Agonist activity was calculated in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and Galphaqo5,Confirmatory,15380206.0,
2005,251584,3,9,,103167216,3559,Unspecified,112808.0,29595.0,,,Relative binding affinity against 5-hydroxytryptamine 2A and dopamine D2 receptors,Other,15771414.0,
2006,251584,3,9,,103167216,3559,Unspecified,47117674.0,24318.0,,,Relative binding affinity against 5-hydroxytryptamine 2A and dopamine D2 receptors,Other,15771414.0,
2007,254420,8,5,,103167216,3559,Active,118206.0,1813.0,0.002,Ki,In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells,Confirmatory,16250644.0,
2008,254454,8,4,,103167216,3559,Inactive,400629.0,25553.0,,,In vitro inhibitory constant against [3H]paroxetine binding to rat frontal cortex membrane serotonin reuptake site; NA= not active,Other,16250644.0,
2009,255035,4,4,,103167216,3559,Active,,,0.07,IC50,Inhibitory concentration against opioid receptor sigma 2 of rat cerebral cortex using [3H]DTG upon incubation for 120 minutes at 22 degree C,Confirmatory,16140011.0,
2010,255057,7,1,,103167216,3559,Active,,,0.0021,IC50,Inhibitory concentration against opioid receptor sigma 1 of guinea pig cerebral cortex using [3H](+)-pentazocine upon incubation for 150 minutes at 22 degree C,Confirmatory,16140011.0,
2011,255065,7,1,,103167216,3559,Active,,,0.0021,IC50,Inhibitory activity against opioid receptor sigma 1 in guinea pig cerebral cortex using [3H](+)-pentazocine as radio ligand at pH 7.5 for 150 min at 22 degree C,Confirmatory,16140009.0,
2012,255071,4,4,,103167216,3559,Active,,,0.07,IC50,Inhibitory activity against opioid sigma 2 receptor in rat cerebral cortex using [3H]DTG (+300 nM (+)pentazocine) as radio ligand at pH 7.5 for 120 min at 22 degree C,Confirmatory,16140009.0,
2013,255169,3,8,,103167216,3559,Unspecified,81882051.0,29336.0,,,Selectivity against opioid receptor sigma 2 to that of opioid receptor sigma 1,Other,16140009.0,
2014,255170,3,9,,103167216,3559,Unspecified,,,,,Ratio of inhibitory concentration against rat opioid receptor sigma 2 and guinea pig opioid sigma 1,Other,16140011.0,
2015,255689,6,7,,103167216,3559,Unspecified,341940463.0,13489.0,,,Effective dose against apomorphine-induced climbing behavior in mice upon oral administration (Dopaminergic antagonist),Other,16250644.0,
2016,256758,8,5,,103167216,3559,Active,1169206.0,1814.0,0.016,Ki,Displacement of [3H]spiroperidol from cloned human dopamine receptor D3 in CHO cell membrane,Confirmatory,16335915.0,
2017,256759,7,1,,103167216,3559,Unspecified,1169206.0,1814.0,,EC50,Intrinsic activity against dopamine receptor D3 by Eu-GTP binding assay,Confirmatory,16335915.0,
2018,259123,7,3,,103167216,3559,Active,,,0.042,Ki,Displacement of [3H]SCH 23390 from rat caudate putamen dopamine D1-like receptor,Confirmatory,16290142.0,
2019,259124,7,2,,103167216,3559,Active,,,0.0072,Ki,Displacement of [3H]spiperone from rat brain dopamine D2-like receptor,Confirmatory,16290142.0,
2020,259125,8,5,,103167216,3559,Active,118211.0,29238.0,0.024,Ki,Displacement of [3H]PD 128907 from rat ventral striatal membrane dopamine D3-like receptor,Confirmatory,16290142.0,
2021,259126,3,5,,103167216,3559,Unspecified,,,,,Selectivity ratio for dopamine D1-like receptor over dopamine D3 receptor,Other,16290142.0,
2022,259127,3,5,,103167216,3559,Unspecified,,,,,Selectivity ratio for dopamine D2-like receptor over dopamine D3 receptor,Other,16290142.0,
2023,265753,6,2,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine-induced climbing in ip dosed Swiss Webster mouse,Other,16621538.0,
2024,266790,6,1,,103167216,3559,Unspecified,,,,,"Reduction of sc dosed 20 ug/kg 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]-pyridine-induced penile erection in Sprague-Dawley rat at 1 mg/kg, ip",Other,16789750.0,
2025,266791,6,1,,103167216,3559,Unspecified,,,,,"Reduction of icv dosed 1 ug 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]-pyridine-induced penile erection in Sprague-Dawley rat at 1 mg/kg, ip",Other,16789750.0,
2026,269018,3,3,,103167216,3559,Active,,,,,"Inhibition of (E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime-induced erectogenic effect in Wistar rat at 1 umol/kg, ip",Other,16913699.0,
2027,274128,9,5,,103167216,3559,Active,7531135.0,3757.0,0.512,Ki,Displacement of [3H]Astemizole from hERG expressed in HEK293 cells at 10 uM,Confirmatory,16908150.0,
2028,274502,3,3,,103167216,3559,Active,,,,,"Blockade of ABT-670-induced erctogenic activity in rat at 1 umol/kg, ip",Other,17149874.0,
2029,274704,3,3,,103167216,3559,Active,,,,,"Antipsychotic activity in Sprague-Dawley rat assessed as ability to reverse apomorphine effect on prepulse inhibition of the startle response at 1 mg/kg, sc",Other,17149881.0,
2030,277668,3,10,,103167216,3559,Unspecified,118206.0,1813.0,,,Selectivity for dopamine D3 over dopamine D2,Other,17266201.0,
2031,277668,3,10,,103167216,3559,Unspecified,1169206.0,1814.0,,,Selectivity for dopamine D3 over dopamine D2,Other,17266201.0,
2032,277669,3,11,,103167216,3559,Unspecified,1169206.0,1814.0,,,Selectivity for dopamine D3 over dopamine D4,Other,17266201.0,
2033,277669,3,11,,103167216,3559,Unspecified,1345939.0,1815.0,,,Selectivity for dopamine D3 over dopamine D4,Other,17266201.0,
2034,277673,9,1,,103167216,3559,Active,1169206.0,1814.0,0.008320000000000001,Ki,Displacement of [3H]spiperone from human dopamine D3 expressed in CHO cell membrane,Confirmatory,17266201.0,
2035,277674,9,1,,103167216,3559,Active,1345939.0,1815.0,0.00603,Ki,Displacement of [3H]spiperone from human dopamine D4.4 expressed in CHO cell membrane,Confirmatory,17266201.0,
2036,277677,4,1,,103167216,3559,Active,118206.0,1813.0,0.00112,Ki,Binding affinity to dopamine D2,Confirmatory,17266201.0,
2037,277973,4,1,,103167216,3559,Active,112812.0,24473.0,1.6982400000000002,Ki,Displacement of [3H]OH-DPAT from rat cortex 5HT1A receptor,Confirmatory,17300168.0,
2038,277974,4,1,,103167216,3559,Active,112808.0,29595.0,0.08317999999999999,Ki,Displacement of [3H]ketanserin from rat cortex 5HT2A receptor,Confirmatory,17300168.0,
2039,277975,4,1,,103167216,3559,Active,47117674.0,24318.0,0.004370000000000001,Ki,Displacement of [3H]YM-09151-2 from rat striatum D2 receptor,Confirmatory,17300168.0,
2040,277978,6,2,,103167216,3559,Unspecified,,,,,Normalizing effect on methylphenidate-induced behaviours in ip dosed rat after 30 min,Other,17300168.0,
2041,277979,6,2,,103167216,3559,Unspecified,,,,,Induction of catalepsy in ip dosed rat after 60 min by crossed-leg position test,Other,17300168.0,
2042,277984,3,3,,103167216,3559,Unspecified,,,,,Ratio of ED50 for catalepsy induction to ED50 for normalization in ip dosed rat,Other,17300168.0,
2043,277985,3,9,,103167216,3559,Unspecified,47117674.0,24318.0,,,Antagonist activity against rat D2 receptor assessed effect on quinelorane-stimulated [35S]GTP-gamma-S binding,Other,17300168.0,
2044,277986,3,9,,103167216,3559,Unspecified,47117674.0,24318.0,,,Antagonist activity against rat D2 receptor assessed as [35S]GTPgammaS binding relative to quinelorane,Other,17300168.0,
2045,277987,3,9,,103167216,3559,Active,118206.0,1813.0,,,Activity at human D2 receptor expressed in Xenopus oocytes,Other,17300168.0,
2046,280701,3,3,,103167216,3559,Active,,,,,Increase in TG-2 expression in albino Wistar rat primary 14 DIV astroglial cell at 25 uM after 24 hrs by CLSM analysis,Other,17328523.0,
2047,280704,4,3,,103167216,3559,Unspecified,,,,,Increase in apoptosis in albino Wistar rat primary 14 DIV astroglial cells at 25 uM after 24 hrs by TUNEL assay relative to control,Other,17328523.0,
2048,280721,4,3,,103167216,3559,Active,,,,,Activity at sigma 2 receptor in rat astroglial cells,Other,17328523.0,
2049,280722,4,10,,103167216,3559,Active,81882051.0,29336.0,,,Activity at sigma 1 receptor in rat astroglial cells,Other,17328523.0,
2050,294440,8,1,,103167216,3559,Active,118206.0,1813.0,0.0033,Ki,Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cells,Confirmatory,17316913.0,
2051,294441,8,5,,103167216,3559,Active,1345939.0,1815.0,0.10300000000000001,Ki,Displacement of [3H]spiperone from human cloned dopamine D4 receptor expressed in CHO cells,Confirmatory,17316913.0,
2052,294442,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0064,Ki,Displacement of [3H]YM-09151-2 from human cloned dopamine D3 receptor expressed in CHO cells,Confirmatory,17316913.0,
2053,294443,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,Selectivity for human dopamine D3 receptor over human dopamine D2 receptor,Other,17316913.0,
2054,294443,3,9,,103167216,3559,Unspecified,1169206.0,1814.0,,,Selectivity for human dopamine D3 receptor over human dopamine D2 receptor,Other,17316913.0,
2055,294444,3,10,,103167216,3559,Unspecified,1169206.0,1814.0,,,Selectivity for human dopamine D3 receptor over human dopamine D4 receptor,Other,17316913.0,
2056,294444,3,10,,103167216,3559,Unspecified,1345939.0,1815.0,,,Selectivity for human dopamine D3 receptor over human dopamine D4 receptor,Other,17316913.0,
2057,295928,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0022,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane,Confirmatory,17420073.0,
2058,295929,4,3,,103167216,3559,Active,,,0.0342,Ki,Displacement of [3H]ditolylguanidine from sigma 2 receptor in Sprague-Dawley rat liver membrane,Confirmatory,17420073.0,
2059,296886,8,1,,103167216,3559,Active,118206.0,1813.0,0.002,Ki,Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor,Confirmatory,17649988.0,
2060,298031,3,5,,103167216,3559,Unspecified,,,,,"Lipophilicity, log D at pH7.4",Other,17725338.0,
2061,298032,3,3,,103167216,3559,Unspecified,,,,,"Acid dissociation constant, pKa of the compound",Other,17725338.0,
2062,298263,8,5,,103167216,3559,Active,1169206.0,1814.0,0.016,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D3 receptor,Confirmatory,17850060.0,
2063,298264,8,1,,103167216,3559,Active,118206.0,1813.0,0.0026,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor,Confirmatory,17850060.0,
2064,298478,4,1,,103167216,3559,Active,118206.0,1813.0,0.0050100000000000006,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells,Confirmatory,17880057.0,
2065,298479,4,1,,103167216,3559,Active,1169206.0,1814.0,0.00158,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,17880057.0,
2066,298480,4,1,,103167216,3559,Active,1345939.0,1815.0,0.0063100000000000005,Ki,Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells,Confirmatory,17880057.0,
2067,298481,4,1,,103167216,3559,Inactive,231454.0,3350.0,,Ki,Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells,Confirmatory,17880057.0,
2068,298482,4,1,,103167216,3559,Active,543727.0,3356.0,0.1,Ki,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells,Confirmatory,17880057.0,
2069,298483,4,1,,103167216,3559,Inactive,1168220.0,3357.0,,Ki,Displacement of [3H]LSD from 5HT2B receptor expressed in CHO cells,Confirmatory,17880057.0,
2070,298485,4,1,,103167216,3559,Inactive,112816.0,3358.0,,Ki,Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells,Confirmatory,17880057.0,
2071,298486,4,1,,103167216,3559,Inactive,1703010.0,3362.0,,Ki,Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
2072,298487,4,1,,103167216,3559,Active,8488960.0,3363.0,0.31623,Ki,Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells,Confirmatory,17880057.0,
2073,298488,4,1,,103167216,3559,Inactive,1168222.0,3359.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
2074,298488,4,1,,103167216,3559,Inactive,74705987.0,9177.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
2075,298488,4,1,,103167216,3559,Inactive,162416113.0,285242.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
2076,298488,4,1,,103167216,3559,Inactive,166198366.0,170572.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
2077,298488,4,1,,103167216,3559,Inactive,338817899.0,200909.0,,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
2078,298489,4,1,,103167216,3559,Inactive,400630.0,6532.0,,Ki,Displacement of [3H]paraxetine from human 5HT transporter expressed in HEK293 cells,Confirmatory,17880057.0,
2079,298490,4,1,,103167216,3559,Inactive,113118.0,1128.0,,Ki,Displacement of [3H]pirenzepine from human M1 receptor expressed in CHO cells,Confirmatory,17880057.0,
2080,298491,4,1,,103167216,3559,Inactive,23503039.0,1132.0,,Ki,Displacement of [3H]4-DAMP from human M4 receptor expressed in CHO cells,Confirmatory,17880057.0,
2081,298492,4,1,,103167216,3559,Active,543734.0,24173.0,0.01585,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
2082,298492,4,1,,103167216,3559,Active,1168244.0,29413.0,0.01585,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
2083,298492,4,1,,103167216,3559,Active,1168247.0,29412.0,0.01585,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
2084,298493,4,1,,103167216,3559,Inactive,231461.0,25083.0,,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
2085,298493,4,1,,103167216,3559,Inactive,231464.0,24175.0,,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
2086,298493,4,1,,103167216,3559,Inactive,47117345.0,24174.0,,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
2087,298494,4,1,,103167216,3559,Active,399889.0,100730517.0,0.39810999999999996,Ki,Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum,Confirmatory,17880057.0,
2088,301865,4,1,,103167216,3559,Active,118229.0,24316.0,0.05807999999999999,Ki,Displacement of [3H]SCH-23390 from dopamine D1 receptor in rat brain,Confirmatory,17869521.0,
2089,301866,4,1,,103167216,3559,Active,47117674.0,24318.0,0.0005009999999999999,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in rat brain,Confirmatory,17869521.0,
2090,301867,4,1,,103167216,3559,Active,112808.0,29595.0,0.03467,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in rat brain,Confirmatory,17869521.0,
2091,301868,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of pKi for rat brain 5HT2A receptor to pKi for rat brain dopamine D2 receptor,Other,17869521.0,
2092,301871,6,2,,103167216,3559,Unspecified,,,,,Blockade of secondary conditioned avoidance response in ip dosed rat,Other,17869521.0,
2093,301872,6,2,,103167216,3559,Unspecified,,,,,Blockade of conditioned avoidance response in ip dosed rat,Other,17869521.0,
2094,301906,3,3,,103167216,3559,Active,,,,,Induction of catalepsy in Mill Hill hooded rat at 1 mg/kg after 30-180 min,Other,17870534.0,
2095,303620,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0019,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane,Confirmatory,17967001.0,
2096,303621,4,3,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]ditolylguanidine from sigma 2 receptor in rat liver membrane,Confirmatory,17967001.0,
2097,303622,3,3,,103167216,3559,Unspecified,,,,,Selectivity for guinea pig brain sigma 1 receptor to rat liver sigma 2 receptor,Other,17967001.0,
2098,303624,3,4,,103167216,3559,Unspecified,,,,,Growth inhibition of human 5637 cells at 20 uM after 96 hrs relative to control,Other,17967001.0,
2099,303625,3,4,,103167216,3559,Unspecified,,,,,Growth inhibition of human RT4 cells at 20 uM after 96 hrs relative to control,Other,17967001.0,
2100,303626,3,4,,103167216,3559,Unspecified,,,,,Growth inhibition of human A427 cells at 20 uM after 96 hrs relative to control,Other,17967001.0,
2101,303627,3,3,,103167216,3559,Unspecified,,,,,Growth inhibition of human LCLC103H cells at 20 uM after 96 hrs relative to control,Other,17967001.0,
2102,303628,3,4,,103167216,3559,Unspecified,,,,,Growth inhibition of human MCF7 cells at 20 uM after 96 hrs relative to control,Other,17967001.0,
2103,303629,6,2,,103167216,3559,Active,,,10.0,IC50,Growth inhibition of human A427 cells after 96 hrs,Confirmatory,17967001.0,
2104,303630,6,2,,103167216,3559,Active,,,24.9,IC50,Growth inhibition of human MCF7 cells after 96 hrs,Confirmatory,17967001.0,
2105,308685,4,1,,103167216,3559,Active,543727.0,3356.0,0.16596,Ki,Displacement of [3H]ketanserin human cloned serotonin 5HT2A receptor,Confirmatory,17588750.0,
2106,308686,4,1,,103167216,3559,Active,112816.0,3358.0,7.24436,Ki,Displacement of [3H]mesulergine human cloned serotonin 5HT2C receptor,Confirmatory,17588750.0,
2107,308687,4,1,,103167216,3559,Active,118206.0,1813.0,0.000603,Ki,Displacement of [3H]spiperone human cloned dopamine D2 receptor,Confirmatory,17588750.0,
2108,308688,3,3,,103167216,3559,Unspecified,,,,,Ratio of pKi for human 5HT2A receptor to pKi for human D2 receptor,Other,17588750.0,
2109,311524,4,3,,103167216,3559,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
2110,311932,3,10,,103167216,3559,Unspecified,224471897.0,6609.0,,,Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM,Other,18027916.0,
2111,311934,3,3,,103167216,3559,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
2112,311935,3,4,,103167216,3559,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
2113,317390,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0008300000000000001,Ki,Displacement of [3H](+)-PTZ from sigma1 receptor in Hartley guinea pig brain,Confirmatory,18029187.0,
2114,317391,4,3,,103167216,3559,Active,,,0.00958,Ki,Displacement of [3H]DTG from sigma2 receptor in Hartley guinea pig brain,Confirmatory,18029187.0,
2115,317395,3,3,,103167216,3559,Unspecified,,,,,Ratio of Ki for sigma2 receptor in Hartley guinea pig brain to Ki for sigma1 receptor in Hartley guinea pig brain,Other,18029187.0,
2116,318421,3,3,,103167216,3559,Unspecified,,,,,Toxicity in NSA mouse assessed as reduction of locomotor activity,Other,17470817.0,
2117,320558,4,3,,103167216,3559,Active,,,0.007379999999999999,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat liver membrane,Confirmatory,18178434.0,
2118,320561,4,3,,103167216,3559,Active,,,0.00585,Ki,Displacement of [3H]PB28 from sigma 2 receptor in rat liver membrane,Confirmatory,18178434.0,
2119,321564,8,5,,103167216,3559,Active,81882051.0,29336.0,0.00335,Ki,Displacement of [3H](+)-pentazocine from opioid sigma1 receptor in rat brain homogenate,Confirmatory,18278854.0,
2120,321565,4,3,,103167216,3559,Active,,,0.0806,Ki,Displacement of [3H]DTG from opioid sigma2 receptor in rat brain homogenate,Confirmatory,18278854.0,
2121,321566,3,3,,103167216,3559,Unspecified,,,,,Ratio of Ki for rat sigma1 opioid receptor to Ki for rat sigma2 opioid receptor,Other,18278854.0,
2122,323225,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0019,Ki,Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in guinea pig brain membrane,Confirmatory,18221879.0,
2123,323226,4,3,,103167216,3559,Active,,,0.0781,Ki,Displacement of [3H]ditolylguanidine from sigma 2 opioid receptor in rat liver,Confirmatory,18221879.0,
2124,330537,3,4,,103167216,3559,Inactive,,,,,Increase in phospho-AMPK levels in H1RKO mouse hyphalamic slices at 500 nM after 30 mins by Western blotting,Other,17360666.0,
2125,330538,3,3,,103167216,3559,Inactive,,,,,Orexigenic activity in H1RKO mouse,Other,17360666.0,
2126,330561,8,5,,103167216,3559,Unspecified,399890.0,24448.0,2.0,IC50,Displacement of [3H]mepyramine from H1R in rat brain,Confirmatory,17360666.0,
2127,337890,4,4,,103167216,3559,Active,,,0.0115,Ki,Displacement of [3H]DTG from sigma opioid receptor,Confirmatory,8496700.0,
2128,338174,3,4,,103167216,3559,Unspecified,,,,,Displacement of [3H]DTG from sigma opioid receptor assessed as specific binding relative to total binding,Other,8496700.0,
2129,342773,8,5,,103167216,3559,Active,1703010.0,3362.0,6.0,Ki,Binding affinity to human cloned 5HT6 receptor,Confirmatory,18595716.0,
2130,342774,8,5,,103167216,3559,Active,113118.0,1128.0,1.6,Ki,Binding affinity to human cloned muscarinic M1 receptor,Confirmatory,18595716.0,
2131,342775,8,5,,103167216,3559,Active,118228.0,1812.0,0.12,Ki,Binding affinity to human cloned dopamine D1 receptor,Confirmatory,18595716.0,
2132,342777,8,5,,103167216,3559,Active,118206.0,1813.0,0.0014,Ki,Binding affinity to human cloned dopamine D2 receptor,Confirmatory,18595716.0,
2133,342778,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0025,Ki,Binding affinity to human cloned dopamine D3 receptor,Confirmatory,18595716.0,
2134,342779,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0033,Ki,Binding affinity to human cloned dopamine D4 receptor,Confirmatory,18595716.0,
2135,342780,4,3,,103167216,3559,Unspecified,,,,,Ratio of Ki for human cloned dopamine D2 receptor to Ki for human cloned dopamine D4 receptor,Other,18595716.0,
2136,342781,8,5,,103167216,3559,Active,112816.0,3358.0,4.7,Ki,Binding affinity to human cloned 5HT2C receptor,Confirmatory,18595716.0,
2137,342782,8,5,,103167216,3559,Active,547645.0,3269.0,0.44,Ki,Binding affinity to human cloned histamine H1 receptor,Confirmatory,18595716.0,
2138,342783,8,5,,103167216,3559,Active,231454.0,3350.0,3.6,Ki,Binding affinity to human cloned 5HT1A receptor,Confirmatory,18595716.0,
2139,342784,8,5,,103167216,3559,Active,543727.0,3356.0,0.12,Ki,Binding affinity to human cloned 5HT2A receptor,Confirmatory,18595716.0,
2140,342786,8,5,,103167216,3559,Active,81890335.0,,5.5,Ki,Binding affinity to rat NET,Confirmatory,18595716.0,
2141,342787,8,5,,103167216,3559,Active,400630.0,6532.0,1.8,Ki,Binding affinity to human SERT,Confirmatory,18595716.0,
2142,342788,7,2,,103167216,3559,Unspecified,,,,,Blockade of apomorphine-induced climbing stereotypy in Swiss Webster mouse after 30 mins,Other,18595716.0,
2143,342790,3,3,,103167216,3559,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of cataleptogenic behavior at 0.3 mg/kg, ip",Other,18595716.0,
2144,346018,9,5,,103167216,3559,Active,118206.0,1813.0,6.4,Ki,Displacement of [3H]spiroperidol from human cloned dopaminergic D2 receptor expressed in rat C6 cells,Confirmatory,19053888.0,
2145,346264,8,5,,103167216,3559,Active,118206.0,1813.0,0.0042,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting,Confirmatory,19081257.0,
2146,346274,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from opioid sigma1 receptor in guinea pig brain homogenate,Confirmatory,19081725.0,
2147,346275,4,4,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]ditolylguanine from opioid sigma2 receptor in rat liver homogenate in presence of (+)-pentazocine,Confirmatory,19081725.0,
2148,346278,3,4,,103167216,3559,Unspecified,,,,,Displacement of [3H]MK-801 from NMDA receptor in pig brain cortex at 1 uM,Other,19081725.0,
2149,346460,6,2,,103167216,3559,Active,,,0.09699999999999999,IC50,Displacement of radiolabeled haloperidol from sigma opioid receptor,Confirmatory,18983139.0,
2150,351591,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by solid scintillation analysis,Confirmatory,19394833.0,
2151,351592,4,4,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver homogenates by solid scintillation analysis,Confirmatory,19394833.0,
2152,351593,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 1 receptor in guinea pig brain membrane to Ki for sigma 2 receptor in rat liver homogenates,Other,19394833.0,
2153,367545,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.00145,Ki,Displacement of [3H](+)-pentazocine from sigma 1-type opioid receptor in guinea pig brain homogenates,Confirmatory,19119012.0,
2154,367546,4,4,,103167216,3559,Active,,,0.0242,Ki,Displacement of [3H]RHM-1 from sigma 2-type opioid receptor in rat liver homogenates,Confirmatory,19119012.0,
2155,367547,3,4,,103167216,3559,Unspecified,,,,,"Selectivity ratio, Ki for sigma 1 receptor in guinea pig brain homogenates to Ki for sigma 2 receptor in rat liver homogenates",Other,19119012.0,
2156,367548,3,3,,103167216,3559,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,19119012.0,
2157,382243,4,3,,103167216,3559,Active,,,0.001,Ki,Binding affinity to adrenergic alpha1 receptor,Confirmatory,18378462.0,
2158,386623,4,8,,103167216,3559,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
2159,386625,9,5,,103167216,3559,Unspecified,313104181.0,6580.0,141.9,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
2160,387866,8,5,,103167216,3559,Active,118206.0,1813.0,0.00509,Ki,Displacement of [3H]YM-09151-2 from human dopamine D2S receptor in membrane suspensions by liquid scintillation counter,Confirmatory,18793859.0,
2161,387867,4,3,,103167216,3559,Active,,,0.00932,Ki,Displacement of [3H]YM-09151-2 from human dopamine D4.2 receptor in membrane suspensions by liquid scintillation counter,Confirmatory,18793859.0,
2162,387868,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for human dopamine D2S receptor to Ki for human dopamine D4.2 receptor,Other,18793859.0,
2163,391273,8,5,,103167216,3559,Active,118206.0,1813.0,0.000603,Ki,Displacement of [3H]spiperone from human cloned dopamine D2 receptor,Confirmatory,18783204.0,
2164,391274,8,5,,103167216,3559,Active,543727.0,3356.0,0.16596,Ki,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,Confirmatory,18783204.0,
2165,391275,8,5,,103167216,3559,Active,112816.0,3358.0,7.24436,Ki,Displacement of [3H]mesulergine from human cloned 5HT2C receptor,Confirmatory,18783204.0,
2166,391277,3,3,,103167216,3559,Unspecified,,,,,Ratio of pKi for human cloned 5HT2A receptor to pKi for human cloned dopamine D2 receptor,Other,18783204.0,
2167,391475,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane,Confirmatory,18816044.0,
2168,391476,4,3,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver membrane,Confirmatory,18816044.0,
2169,391478,3,3,,103167216,3559,Unspecified,,,,,"Selectivity ratio, Ki for sigma 1 receptor in guinea pig brain membrane to Ki for sigma 2 receptor rat liver membrane",Other,18816044.0,
2170,391747,8,5,,103167216,3559,Active,118206.0,1813.0,0.0042,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells,Confirmatory,18800769.0,
2171,392048,12,1,,103167216,3559,Unspecified,,,,EC50,Cardiotoxicity in iv dosed Dunkin-Hartley guinea pig assessed as drug level required to evoke 50 ms QTc prolongation administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG,Confirmatory,18262683.0,
2172,392049,3,4,,103167216,3559,Unspecified,,,,,"Cardiotoxicity in Dunkin-Hartley guinea pig assessed as maximal QTc prolongation time at 10 mg/kg, iv administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG",Other,18262683.0,
2173,392764,8,5,,103167216,3559,Active,1169206.0,1814.0,0.0055,Ki,Displacement of [3H]N-methylspiperone from human dopamine D3 receptor by liquid scintillation counting,Confirmatory,19155177.0,
2174,392765,8,5,,103167216,3559,Active,118206.0,1813.0,0.0011,Ki,Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting,Confirmatory,19155177.0,
2175,392767,4,3,,103167216,3559,Active,,,0.0001,Ki,Ratio of Ki for human dopamine D2 receptor to Ki for human dopamine D4 receptor,Confirmatory,19155177.0,
2176,393002,8,5,,103167216,3559,Active,1345939.0,1815.0,0.0127,Ki,Displacement of [125I]DOI from human dopamine D4 receptor by liquid scintillation counting,Confirmatory,19155177.0,
2177,393184,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma1 opioid receptor in guinea pig brain by solid scintillation counting,Confirmatory,19196515.0,
2178,393186,4,3,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from sigma2 opioid receptor in rat liver by solid scintillation counting,Confirmatory,19196515.0,
2179,393359,8,5,,103167216,3559,Active,81882051.0,29336.0,0.0057,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in rat liver membrane,Confirmatory,18440098.0,
2180,393360,8,1,,103167216,3559,Active,,,0.235,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat liver membrane,Confirmatory,18440098.0,
2181,393361,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for rat liver sigma 2 receptor to Ki for rat liver sigma 1 receptor,Other,18440098.0,
2182,395324,3,4,,103167216,3559,Unspecified,,,,,"Lipophilicity, log D at pH 7.4 by liquid chromatography",Other,19256501.0,
2183,395325,3,3,,103167216,3559,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
2184,395327,3,3,,103167216,3559,Unspecified,,,,,"Dissociation constant, pKa by capillary electrophoresis",Other,19256501.0,
2185,395328,3,3,,103167216,3559,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
2186,397743,11,2,,103167216,3559,Active,7531135.0,3757.0,0.0268,IC50,Inhibition of human ERG channel,Confirmatory,19534531.0,
2187,404304,3,10,,103167216,3559,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
2188,408340,8,5,,103167216,3559,Active,7531135.0,3757.0,0.0302,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
2189,410137,3,3,,103167216,3559,Active,,,,,"Inhibition of dopamine D2 receptor-mediated apomorphine-induced cage climbing behavior in Swiss albino mouse at 1 mg/kg, ip",Other,18948000.0,
2190,410331,8,5,,103167216,3559,Active,118229.0,24316.0,0.318,Ki,Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry,Confirmatory,19072656.0,
2191,410332,8,5,,103167216,3559,Active,47117674.0,24318.0,0.0026,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry,Confirmatory,19072656.0,
2192,410333,7,1,,103167216,3559,Active,,,0.0009,Ki,Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry,Confirmatory,19072656.0,
2193,410334,8,5,,103167216,3559,Active,112812.0,24473.0,1.8,Ki,Displacement of [3H]8OH-DPAT from 5HT1A receptor in CRL:CD(SD)BR-COBS rat hippocampus by scintillation spectrometry,Confirmatory,19072656.0,
2194,410335,8,5,,103167216,3559,Active,112808.0,29595.0,0.16399999999999998,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry,Confirmatory,19072656.0,
2195,410336,4,3,,103167216,3559,Active,,,4.7,Ki,Displacement of [3H]mesulergine from 5HT2C receptor in CRL:(HA) BR albino guinea pig cortex by scintillation spectrometry,Confirmatory,19072656.0,
2196,410338,9,5,,103167216,3559,Active,7531135.0,3757.0,0.12,Ki,Binding affinity to human ERG expressed in HEK293 cells by whole cell patch clamp method,Confirmatory,19072656.0,
2197,410339,6,2,,103167216,3559,Unspecified,,,,,Sedative activity in NMRI mouse assessed as reduction in spontaneous locomotor activity administered 30 mins prior to testing,Other,19072656.0,
2198,410529,6,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,19072656.0,
2199,410532,6,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in NMRI mouse assessed as reduction in phencyclidine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,19072656.0,
2200,410535,6,2,,103167216,3559,Unspecified,,,,,Toxicity in sc dosed NMRI mouse assessed as cataleptogenic potential administered 30 mins prior to testing measured every 15 mins for 60 mins by horizontal bar test,Other,19072656.0,
2201,414523,3,4,,103167216,3559,Unspecified,,,,,"Hypothermic activity in Sprague-Dawley rat assessed as time duration of maximal body temperature decrease at 5 mg/kg, ip",Other,19290594.0,
2202,414524,3,4,,103167216,3559,Unspecified,,,,,"Hypothermic activity in Sprague-Dawley rat assessed as decrease in core body temperature at 5 mg/kg, ip at time of maximal body temperature decrease",Other,19290594.0,
2203,414525,3,4,,103167216,3559,Active,,,,,"Hypothermic activity in Sprague-Dawley rat assessed as decrease in core body temperature at 5 mg/kg, ip measured up to 150 mins",Other,19290594.0,
2204,415887,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0022,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by liquid scintillation analyzer,Confirmatory,18499305.0,
2205,415888,4,3,,103167216,3559,Active,,,0.034,Ki,Displacement of [3H]ditolylguanidine from sigma 2 receptor in rat liver membrane by liquid scintillation analyzer,Confirmatory,18499305.0,
2206,415889,3,3,,103167216,3559,Unspecified,,,,,Selectivity for sigma 1 receptor in guinea pig brain membrane over sigma 2 receptor in rat liver membrane,Other,18499305.0,
2207,418668,8,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by scintillation analysis,Confirmatory,19243173.0,
2208,418670,4,3,,103167216,3559,Active,,,0.078,Ki,"Displacement of [3H]1,3-ditolylguanine from sigma 2 receptor in rat liver membrane by solid scintillation analysis",Confirmatory,19243173.0,
2209,418674,6,2,,103167216,3559,Unspecified,,,20.0,IC50,Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
2210,418675,6,3,,103167216,3559,Unspecified,,,20.0,IC50,Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
2211,418676,6,2,,103167216,3559,Active,,,10.0,IC50,Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
2212,418677,6,3,,103167216,3559,Unspecified,,,20.0,IC50,Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
2213,418678,6,2,,103167216,3559,Inconclusive,,,,IC50,Cytotoxicity against human DAN-G cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
2214,418679,6,2,,103167216,3559,Unspecified,,,20.0,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
2215,420668,8,5,,103167216,3559,Active,7531135.0,3757.0,0.02818,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
2216,420669,3,4,,103167216,3559,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
2217,420787,3,10,,103167216,3559,Unspecified,1168222.0,3359.0,,,Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM,Other,19144451.0,
2218,425652,7,2,,103167216,3559,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
2219,425653,7,2,,103167216,3559,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
2220,427337,8,5,,103167216,3559,Active,81882051.0,29336.0,0.0057,Ki,Displacement of [3H](+)-pentazocine from sigma1 receptor in rat liver membrane by liquid scintillation counting,Confirmatory,19673530.0,
2221,427338,4,3,,103167216,3559,Active,,,0.235,Ki,Displacement of [3H]DTG from sigma2 receptor in rat liver membrane by liquid scintillation counting,Confirmatory,19673530.0,
2222,427339,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for rat sigma1 receptor to Ki for rat sigma2 receptor,Other,19673530.0,
2223,434955,1,2,,56422397,3559,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
2224,434959,1,1,,85788356,3559,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
2225,434962,1,2,,56422397,3559,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
2226,434973,1,3,,855969,3559,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
2227,434989,1,1,,56422397,3559,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2228,435003,1,3,,855969,3559,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
2229,435005,1,1,,56422397,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
2230,435022,2,2,,855969,3559,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
2231,435030,1,2,,56422397,3559,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2232,435030,1,2,,56422397,3559,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2233,436796,3,4,,103167216,3559,Unspecified,,,,,Selectivity for Wistar rat dopamine D2 receptor over Wistar rat dopamine D1 receptor,Other,19540762.0,
2234,437143,5,1,,103167216,3559,Unspecified,,,,,"Inhibition of haloperidol-induced catalepsy in Swiss albino mouse assessed as time elapsed until release of forepaw from bar at 100 mg/kg, po administered 30 min prior to haloperidol challenge measured after 60 mins by bar test",Other,19447524.0,
2235,437144,5,1,,103167216,3559,Unspecified,,,,,"Inhibition of haloperidol-induced catalepsy in Swiss albino mouse assessed as time elapsed until release of forepaw from bar at 100 mg/kg, po administered 30 min prior to haloperidol challenge measured after 30 mins by bar test",Other,19447524.0,
2236,437145,5,1,,103167216,3559,Unspecified,,,,,"Inhibition of haloperidol-induced catalepsy in Swiss albino mouse assessed as time elapsed until release of forepaw from bar at 100 mg/kg, po administered 30 min prior to haloperidol challenge measured after 90 mins by bar test",Other,19447524.0,
2237,437146,5,1,,103167216,3559,Unspecified,,,,,"Inhibition of haloperidol-induced catalepsy in Swiss albino mouse assessed as time elapsed until release of forepaw from bar at 100 mg/kg, po administered 30 min prior to haloperidol challenge measured after 120 mins by bar test",Other,19447524.0,
2238,437147,5,1,,103167216,3559,Unspecified,,,,,"Inhibition of haloperidol-induced catalepsy in Swiss albino mouse assessed as time elapsed until release of forepaw from bar at 100 mg/kg, po administered 30 min prior to haloperidol challenge measured after 150 mins by bar test",Other,19447524.0,
2239,437148,5,1,,103167216,3559,Unspecified,,,,,"Inhibition of haloperidol-induced catalepsy in Swiss albino mouse assessed as time elapsed until release of forepaw from bar at 100 mg/kg, po administered 30 min prior to haloperidol challenge measured after 180 mins by bar test",Other,19447524.0,
2240,438610,7,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane after 180 mins by scintillation counting,Confirmatory,19791807.0,
2241,438611,3,3,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver membrane after 180 mins by scintillation counting,Confirmatory,19791807.0,
2242,438612,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 2 receptor in rat liver membrane to Ki for sigma 1 receptor in guinea pig brain membrane,Other,19791807.0,
2243,439064,8,5,,103167216,3559,Active,118206.0,1813.0,0.000603,Ki,Displacement of [3H]spiperone from human cloned dopamine D2 receptor,Confirmatory,19796944.0,
2244,439066,8,5,,103167216,3559,Active,543727.0,3356.0,0.16596,Ki,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,Confirmatory,19796944.0,
2245,439067,3,3,,103167216,3559,Unspecified,,,,,Ratio of pKi for human cloned dopamine D2 receptor to pKi for human cloned 5HT2A receptor,Other,19796944.0,
2246,439068,8,5,,103167216,3559,Active,118228.0,1812.0,0.00617,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor,Confirmatory,19796944.0,
2247,439069,8,5,,103167216,3559,Active,1169206.0,1814.0,0.011479999999999999,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor,Confirmatory,19796944.0,
2248,439070,8,5,,103167216,3559,Active,112816.0,3358.0,7.24436,Ki,Displacement of [3H]mesulergine from human 5HT2C receptor,Confirmatory,19796944.0,
2249,444005,8,5,,103167216,3559,Active,74752153.0,10280.0,0.0077599999999999995,Ki,Displacement of [3H](+)-pentazocine from sigma1 receptor in human Jurkat cell membrane,Confirmatory,20067271.0,
2250,444006,5,3,,103167216,3559,Active,,,0.1122,Ki,Displacement of [3H]DTG from sigma2 receptor in rat cerebral cortex cell membrane,Confirmatory,20067271.0,
2251,444007,3,3,,103167216,3559,Unspecified,,,,,Selectivity for human sigma1 receptor over rat sigma2 receptor,Other,20067271.0,
2252,444008,5,2,,103167216,3559,Inconclusive,,,,IC50,Antagonist activity at sigma2 receptor in guinea pig ileum longitudinal muscle assessed as inhibition of 5-HT-induced contractions,Confirmatory,20067271.0,
2253,444050,7,1,,103167216,3559,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
2254,444051,6,2,,103167216,3559,Unspecified,,,,,Total clearance in human,Other,20070106.0,
2255,444052,6,2,,103167216,3559,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
2256,444053,6,2,,103167216,3559,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
2257,444054,6,1,,103167216,3559,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
2258,444055,3,3,,103167216,3559,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
2259,444056,3,3,,103167216,3559,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
2260,444057,3,3,,103167216,3559,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
2261,444058,6,2,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
2262,448410,6,2,,103167216,3559,Active,,,0.003,Ki,Displacement of [3H]spiperone from D2 receptor,Confirmatory,19720528.0,
2263,448641,3,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for guinea pig brain sigma 1 receptor to Ki for rat liver sigma 2 receptor,Other,19709783.0,
2264,448643,3,3,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver after 180 mins by scintillation counting,Confirmatory,19709783.0,
2265,448644,7,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain after 180 mins by scintillation counting,Confirmatory,19709783.0,
2266,449728,1,2,,56422397,3559,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
2267,449739,1,2,,855969,3559,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
2268,449762,1,2,,56422397,3559,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
2269,449763,1,3,,855969,3559,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2270,449768,1,1,,855969,3559,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
2271,451850,3,3,,103167216,3559,Unspecified,,,,,"Dopaminergic activity in apomorphine-induced Wistar rat assessed as licking count at 0.5 mg/kg, iv treated 15 mins before apomorphine challenge measured after 10 mins for 60 mins by behavioral study",Other,19740671.0,
2272,457703,3,3,,103167216,3559,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of catalepsy by measuring time spent on elevated wood bar at 4 mg/kg, po after 30 mins (Rvb = 1.8 +/- 1.1 sec)",Other,20153652.0,
2273,457704,3,3,,103167216,3559,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of catalepsy by measuring time spent on elevated wood bar at 4 mg/kg, po after 60 mins (Rvb = 2.7 +/- 2.9 sec)",Other,20153652.0,
2274,457705,3,3,,103167216,3559,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of catalepsy by measuring time spent on elevated wood bar at 4 mg/kg, po after 90 mins (Rvb = 2.4 +/- 2.6 sec)",Other,20153652.0,
2275,457707,3,3,,103167216,3559,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of motor impairment by measuring permanence time at 4 mg/kg, po by rotarod test (Rvb = 241.4 +/- 18.0 sec)",Other,20153652.0,
2276,458632,7,5,,103167216,3559,Active,118206.0,1813.0,0.0019,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells,Confirmatory,20155917.0,
2277,458633,8,5,,103167216,3559,Active,118206.0,1813.0,0.001,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells,Confirmatory,20155917.0,
2278,458634,3,9,,103167216,3559,Unspecified,118206.0,1813.0,,,Selectivity ratio of Ki for human dopamine D2 receptor at low affinity state to Ki for human dopamine D2 receptor at high affinity state,Other,20155917.0,
2279,458635,3,5,,103167216,3559,Unspecified,,,,,Activity at dopamine D2L receptor expressed in HEK293 cells coexpressing Galphaqi5 assessed as maximal efficacy relative to control,Other,20155917.0,
2280,458639,3,5,,103167216,3559,Unspecified,,,,,"Reduction in 3,4-dihydroxyphenylacetic acid level in Sprague-Dawley rat striatum at 1 umol/kg, sc relative to saline treated control",Other,20155917.0,
2281,458644,3,5,,103167216,3559,Unspecified,,,,,"Reduction in spontaneous locomotor activity in Sprague-Dawley rat striatum at 1 umol/kg, sc relative to control",Other,20155917.0,
2282,458650,3,5,,103167216,3559,Unspecified,,,,,"Reduction in amphetamine-induced locomotor activity in Sprague-Dawley rat striatum at 1 umol/kg, sc relative to control",Other,20155917.0,
2283,463073,1,2,,855969,3559,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
2284,463075,1,1,,855969,3559,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
2285,463079,1,2,,56422397,3559,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
2286,463082,1,1,,56422397,3559,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
2287,463096,1,1,,50104201,3559,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
2288,463097,1,1,,50104201,3559,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
2289,463104,1,2,,855969,3559,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2290,463106,1,2,,90341418,3559,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2291,463111,1,1,,855969,3559,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
2292,463115,1,1,,855969,3559,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
2293,463141,1,2,,56422397,3559,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
2294,463165,1,1,,855969,3559,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
2295,463187,1,1,,855969,3559,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
2296,463189,1,1,,855969,3559,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2297,463189,1,1,,53777689,3559,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2298,463190,1,2,,855969,3559,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
2299,463193,1,1,,855969,3559,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
2300,463195,1,2,,855969,3559,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
2301,463210,1,2,,56422397,3559,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
2302,463212,1,1,,855969,3559,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
2303,463254,1,1,,855969,3559,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2304,467611,3,6,,103167216,3559,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
2305,467612,3,6,,103167216,3559,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
2306,467613,5,3,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
2307,476061,3,4,,103167216,3559,Unspecified,,,,,Selectivity ratio of IC50 for sigma 2 opioid receptor in rat cerebral cortex membrane to IC50 for sigma 1 opioid receptor in human Jurkat cells,Other,19875205.0,
2308,476062,7,5,,103167216,3559,Active,74752153.0,10280.0,0.23,IC50,Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in human Jurkat cells by scintillation counting,Confirmatory,19875205.0,
2309,476063,3,3,,103167216,3559,Active,,,0.023,IC50,Displacement of [3H](+)-pentazocine from sigma 2 receptor in rat cerebral cortex membrane by scintillation counting,Confirmatory,19875205.0,
2310,479242,7,5,,103167216,3559,Active,118206.0,1813.0,0.003,Ki,Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting,Confirmatory,20347298.0,
2311,481104,10,2,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H](+)-pentazocine from sigma1 receptor in guinea pig brain membrane,Confirmatory,20441176.0,
2312,481107,7,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]ditolylguanidine from sigma2 receptor in rat liver membrane,Confirmatory,20441176.0,
2313,485270,1,1,,56422397,3559,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2314,485272,1,1,,56422397,3559,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
2315,485273,2,1,,855969,3559,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
2316,485275,1,3,,56422397,3559,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
2317,485281,1,1,,855969,3559,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2318,485290,1,1,,855969,3559,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2319,485290,1,1,,11112116,3559,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2320,485290,1,1,,11113356,3559,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2321,485290,1,1,,26747061,3559,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2322,485290,1,1,,26751574,3559,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2323,485290,1,1,,50104201,3559,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2324,485294,1,1,,855969,3559,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
2325,485295,1,2,,90341418,3559,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
2326,485297,1,1,,855969,3559,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2327,485297,1,1,,90341418,3559,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2328,485298,1,1,,855969,3559,Inconclusive,,,8.9125,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2329,485298,1,1,,90341418,3559,Active,,,11.5821,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2330,485313,1,2,,855969,3559,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2331,485313,1,2,,90341418,3559,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2332,485314,1,1,,855969,3559,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2333,485314,1,1,,50104201,3559,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2334,485317,1,2,,56422397,3559,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
2335,485341,1,1,,855969,3559,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
2336,485342,1,2,,90341418,3559,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2337,485344,1,1,,855969,3559,Active,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
2338,485345,1,2,,90341418,3559,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2339,485346,1,1,,855969,3559,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2340,485346,1,1,,855969,3559,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2341,485347,1,2,,855969,3559,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
2342,485349,1,1,,855969,3559,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
2343,485350,1,2,,92123987,3559,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2344,485350,1,2,,92125096,3559,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2345,485353,2,1,,855969,3559,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
2346,485358,1,1,,855969,3559,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
2347,485360,1,1,,855969,3559,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
2348,485364,1,1,,855969,3559,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
2349,485366,1,2,,90341418,3559,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2350,485367,1,2,,855969,3559,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2351,485368,1,2,,90341418,3559,Inconclusive,72386991.0,3656265.0,4.2562,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2352,488745,1,4,,85231072,3559,Active,,,7.3753,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2353,488752,1,4,,85231072,3559,Active,,,10.4179,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2354,488772,1,1,,90341418,3559,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2355,488773,1,2,,90341418,3559,Inconclusive,8659577.0,58819.0,2.6679,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2356,488806,1,2,,855969,3559,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
2357,488816,1,1,,90341418,3559,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
2358,488837,1,1,,855969,3559,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2359,488837,1,1,,90341418,3559,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2360,488839,1,1,,56422397,3559,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2361,488839,1,1,,56422397,3559,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2362,488847,1,3,,56422397,3559,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
2363,488862,1,1,,855969,3559,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2364,488862,1,1,,56422397,3559,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2365,488890,1,2,,56422397,3559,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
2366,488895,1,2,,855969,3559,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2367,488895,1,2,,56422397,3559,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2368,488896,1,1,,855969,3559,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2369,488896,1,1,,56422397,3559,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2370,488899,1,1,,56422397,3559,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2371,488922,1,2,,855969,3559,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
2372,488949,1,2,,85231072,3559,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2373,488949,1,2,,90341418,3559,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2374,488953,1,1,,90341418,3559,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2375,488965,1,2,,855969,3559,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2376,488965,1,2,,56422397,3559,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2377,488966,1,1,,56422397,3559,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
2378,488975,1,2,,56422397,3559,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
2379,488977,1,2,,56422397,3559,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
2380,488978,1,1,,90341418,3559,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
2381,488979,1,1,,50104201,3559,Inconclusive,74315350.0,7442.0,11.2202,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
2382,488980,1,1,,85231072,3559,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
2383,488981,1,1,,90341418,3559,Active,4503383.0,1812.0,22.3872,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
2384,488982,1,1,,90341418,3559,Inactive,4503383.0,1812.0,0.08199999999999999,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
2385,488983,1,1,,90341418,3559,Active,4503383.0,1812.0,0.4467,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
2386,489030,2,1,,855969,3559,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
2387,489031,2,1,,855969,3559,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
2388,490176,3,3,,103167216,3559,Unspecified,,,,,"Anticonvulsant activity in rat assessed as protection against maximal electric shock-induced seizures at 0.5 mL, ip",Other,20392546.0,
2389,492182,7,5,,103167216,3559,Active,118206.0,1813.0,0.0011,Ki,Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting,Confirmatory,20542439.0,
2390,492183,7,5,,103167216,3559,Active,1169206.0,1814.0,0.0127,Ki,Displacement of [125I]ABN from human dopamine D3 receptor expressed in HEK293 cells after 60 mins by gamma counting,Confirmatory,20542439.0,
2391,492184,7,5,,103167216,3559,Inconclusive,1345939.0,1815.0,,Ki,Displacement of [125I]ABN from human dopamine D4 receptor expressed in HEK293 cells after 60 mins by gamma counting,Confirmatory,20542439.0,
2392,492185,3,4,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for human dopamine D4 receptor to Ki for human dopamine D2 long receptor,Other,20542439.0,
2393,492186,7,5,,103167216,3559,Active,81862796.0,100135589.0,0.00145,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain homogenates after 1 hr by liquid scintillation counting,Confirmatory,20542439.0,
2394,492187,3,5,,103167216,3559,Active,,,0.0242,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat liver homogenates after 1 hr by liquid scintillation counting,Confirmatory,20542439.0,
2395,492634,6,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in ip dosed NMRI mouse assessed as reduction in spontaneous exploratory locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,20481570.0,
2396,492645,3,3,,103167216,3559,Active,,,,,"Antipsychotic activity in NMRI mouse assessed as increase of PCP-induced locomotor activity at 10 mg/kg, ip administered 30 mins prior to testing measured for 60 mins",Other,20481570.0,
2397,492646,3,3,,103167216,3559,Active,,,,,"Antipsychotic activity in NMRI mouse assessed as increase of PCP-induced locomotor activity at 3 mg/kg, ip administered 30 mins prior to testing measured for 60 mins",Other,20481570.0,
2398,492947,1,1,,855969,3559,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2399,492953,1,1,,56422397,3559,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
2400,492956,1,1,,56422397,3559,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
2401,492967,1,2,,92125096,3559,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2402,492967,1,2,,99301742,3559,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2403,492972,1,1,,56422397,3559,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
2404,493005,1,1,,56422397,3559,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2405,493008,1,1,,56422397,3559,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2406,493008,1,1,,56422397,3559,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2407,493008,1,1,,56422397,3559,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2408,493008,1,1,,56422397,3559,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2409,493011,1,1,,855969,3559,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2410,493012,1,1,,855969,3559,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2411,493014,1,1,,855969,3559,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2412,493017,1,1,,103857205,3559,Unspecified,,3350.0,,,Wombat Data for BeliefDocking,Other,,
2413,493027,1,2,,56422397,3559,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2414,493027,1,2,,56422397,3559,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2415,493033,1,2,,92123987,3559,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2416,493033,1,2,,92125096,3559,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2417,493035,1,2,,56422397,3559,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2418,493035,1,2,,56422397,3559,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2419,493036,1,2,,855969,3559,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
2420,493056,1,1,,855969,3559,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
2421,493084,1,1,,855969,3559,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
2422,493087,1,1,,56422397,3559,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
2423,493091,1,1,,56422397,3559,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
2424,493098,1,1,,56422397,3559,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
2425,493106,1,1,,90341418,3559,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2426,493107,1,1,,90341418,3559,Inconclusive,116283940.0,79915.0,20.5878,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2427,493127,1,1,,50104201,3559,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
2428,493131,1,1,,56422397,3559,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
2429,493140,1,1,,103913830,3559,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
2430,493153,1,1,,90341418,3559,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2431,493153,1,1,,90341418,3559,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2432,493160,1,1,,56422397,3559,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
2433,493162,1,2,,99301742,3559,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2434,493164,1,2,,90341418,3559,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2435,493164,1,2,,90341418,3559,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2436,493164,1,2,,90341418,3559,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2437,493187,1,2,,56422397,3559,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
2438,493189,1,1,,50104201,3559,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
2439,493244,1,1,,56422397,3559,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2440,493244,1,1,,56422397,3559,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2441,493244,1,1,,56422397,3559,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2442,493244,1,1,,56422397,3559,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2443,504326,1,2,,56422397,3559,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2444,504326,1,2,,56422397,3559,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2445,504327,1,1,,855969,3559,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2446,504327,1,1,,90341418,3559,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2447,504329,1,1,,56422397,3559,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
2448,504332,1,1,,855969,3559,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2449,504332,1,1,,50104201,3559,Inactive,168985070.0,,0.0251,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2450,504332,1,1,,90341418,3559,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2451,504333,1,1,,855969,3559,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
2452,504339,1,1,,56422397,3559,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
2453,504357,1,1,,56422397,3559,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2454,504357,1,1,,56422397,3559,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2455,504364,1,1,,85231072,3559,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
2456,504406,1,1,,56422397,3559,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
2457,504408,2,1,,855969,3559,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
2458,504411,1,1,,56422397,3559,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
2459,504414,1,1,,56422397,3559,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2460,504414,1,1,,56422397,3559,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2461,504423,1,1,,56422397,3559,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2462,504441,1,1,,56422397,3559,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2463,504444,1,1,,56422397,3559,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
2464,504454,1,3,,56422397,3559,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
2465,504459,1,3,,855969,3559,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
2466,504462,1,1,,56422397,3559,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
2467,504466,1,1,,855969,3559,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2468,504467,1,1,,855969,3559,Inconclusive,116283940.0,79915.0,25.929000000000002,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2469,504490,1,2,,56422397,3559,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
2470,504523,1,1,,56422397,3559,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2471,504523,1,1,,56422397,3559,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2472,504536,1,1,,90341418,3559,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
2473,504541,1,1,,855969,3559,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
2474,504547,1,1,,90341418,3559,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2475,504548,1,2,,90341418,3559,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
2476,504558,1,1,,56422397,3559,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2477,504577,2,2,,56422397,3559,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2478,504582,2,1,,855969,3559,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2479,504582,2,1,,56422397,3559,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2480,504594,1,1,,855969,3559,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2481,504600,1,2,,855969,3559,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2482,504621,1,1,,56422397,3559,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2483,504634,1,1,,56422397,3559,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2484,504648,1,1,,56422397,3559,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
2485,504651,1,1,,855969,3559,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
2486,504652,1,1,,855969,3559,Active,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
2487,504660,1,1,,855969,3559,Active,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
2488,504690,1,3,,56422397,3559,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
2489,504692,2,2,,56422397,3559,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2490,504700,1,1,,56422397,3559,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2491,504700,1,1,,56422397,3559,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2492,504706,1,1,,855969,3559,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
2493,504707,1,1,,56422397,3559,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2494,504707,1,1,,56422397,3559,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2495,504720,1,1,,56422397,3559,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
2496,504734,1,1,,56422397,3559,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
2497,504749,1,3,,26751574,3559,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2498,504749,1,3,,104171168,3559,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2499,504749,1,3,1.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2500,504749,1,3,2.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2501,504749,1,3,3.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2502,504749,1,3,4.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2503,504749,1,3,5.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2504,504749,1,3,6.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2505,504749,1,3,7.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2506,504749,1,3,8.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2507,504749,1,3,9.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2508,504749,1,3,10.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2509,504749,1,3,11.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2510,504749,1,3,12.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2511,504749,1,3,13.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2512,504749,1,3,14.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2513,504749,1,3,15.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2514,504749,1,3,16.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2515,504749,1,3,17.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2516,504749,1,3,18.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2517,504749,1,3,19.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2518,504749,1,3,20.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2519,504749,1,3,21.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2520,504749,1,3,22.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2521,504749,1,3,23.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2522,504749,1,3,24.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2523,504749,1,3,25.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2524,504749,1,3,26.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2525,504749,1,3,27.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2526,504749,1,3,28.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2527,504749,1,3,29.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2528,504749,1,3,30.0,104171168,3559,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2529,504749,1,3,31.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2530,504749,1,3,32.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2531,504749,1,3,33.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2532,504749,1,3,34.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2533,504749,1,3,35.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2534,504749,1,3,36.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2535,504749,1,3,37.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2536,504749,1,3,38.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2537,504749,1,3,39.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2538,504749,1,3,40.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2539,504749,1,3,41.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2540,504749,1,3,42.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2541,504749,1,3,43.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2542,504749,1,3,44.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2543,504749,1,3,45.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2544,504749,1,3,46.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2545,504749,1,3,47.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2546,504749,1,3,48.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2547,504749,1,3,49.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2548,504749,1,3,50.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2549,504749,1,3,51.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2550,504749,1,3,52.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2551,504749,1,3,53.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2552,504749,1,3,54.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2553,504749,1,3,55.0,104171168,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2554,504749,1,3,56.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2555,504749,1,3,57.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2556,504749,1,3,58.0,26751574,3559,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2557,504749,1,3,59.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2558,504749,1,3,60.0,104171168,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2559,504749,1,3,61.0,26751574,3559,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2560,504766,2,1,,56422397,3559,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2561,504770,1,2,,92123987,3559,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
2562,504775,1,1,,855969,3559,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2563,504775,1,1,,56422397,3559,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2564,504803,1,1,,56422397,3559,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2565,504810,1,2,,855969,3559,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2566,504810,1,2,,90341418,3559,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2567,504812,1,2,,855969,3559,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2568,504812,1,2,,90341418,3559,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2569,504821,1,1,,85231072,3559,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2570,504832,1,1,,855969,3559,Active,,,7.3753,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2571,504832,1,1,,104171168,3559,Active,,,11.9955,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2572,504834,1,1,,855969,3559,Active,,,6.5733,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2573,504834,1,1,,104171168,3559,Inconclusive,,,19.0115,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2574,504836,1,2,,90341418,3559,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2575,504842,1,1,,855969,3559,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2576,504845,1,1,,56422397,3559,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2577,504845,1,1,,90341418,3559,Inactive,86301163.0,5999.0,1.1917,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2578,504845,1,1,,104171168,3559,Inconclusive,86301163.0,5999.0,2.9935,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2579,504847,1,1,,56422397,3559,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2580,504847,1,1,,90341418,3559,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2581,504847,1,1,,104171168,3559,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2582,504865,1,1,,90341418,3559,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2583,504865,1,1,,104171168,3559,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2584,504884,1,2,,56422397,3559,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2585,504891,1,1,,56422397,3559,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2586,504894,1,1,,56422397,3559,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2587,504937,1,2,,56422397,3559,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2588,517706,6,5,,103167216,3559,Active,1706296.0,100144487.0,0.098,Ki,Displacement of [3H]SCH23390 from dopamine D1 receptor in pig striatal membranes,Confirmatory,20839776.0,
2589,517707,6,5,,103167216,3559,Active,118206.0,1813.0,0.0011,Ki,Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells,Confirmatory,20839776.0,
2590,517708,6,5,,103167216,3559,Active,118206.0,1813.0,0.0008699999999999999,Ki,Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells,Confirmatory,20839776.0,
2591,517709,6,5,,103167216,3559,Active,1169206.0,1814.0,0.0075,Ki,Displacement of [3H]Spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,20839776.0,
2592,517710,2,5,,103167216,3559,Active,,,0.006,Ki,Displacement of [3H]Spiperone from human dopamine D4.4 receptor expressed in CHO cells,Confirmatory,20839776.0,
2593,517711,2,6,,103167216,3559,Active,,,0.062,Ki,Displacement of [3H]WAY-100635 from 5-HT1A receptor in pig cerebral cortex homogenates,Confirmatory,20839776.0,
2594,517712,6,5,,103167216,3559,Active,1703009.0,397432.0,0.03,Ki,Displacement of [3H]Ketanserin from 5-HT2 receptor in pig cortex membranes,Confirmatory,20839776.0,
2595,517713,2,6,,103167216,3559,Active,,,0.0068,Ki,Displacement of [3H]Prazosin from adrenergic alpha1 receptor in pig cerebral cortex homogenates,Confirmatory,20839776.0,
2596,521220,3,3,,103167216,3559,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2597,524790,7,2,,103167216,3559,Active,,,3.16228,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2598,524791,7,2,,103167216,3559,Active,,,5.01187,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2599,524792,7,2,,103167216,3559,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2600,524793,7,2,,103167216,3559,Active,,,5.01187,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2601,524794,7,1,,103167216,3559,Active,,,3.16228,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2602,524795,7,2,,103167216,3559,Active,,,7.943280000000001,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2603,524796,7,1,,103167216,3559,Active,,,1.9952599999999998,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2604,538759,9,2,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H](+)-pentazocine from sigma1 receptor guinea pig brain after 180 mins scintillation counting,Confirmatory,20965739.0,
2605,538760,6,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from sigma2 receptor rat liver membranes after 180 mins scintillation counting,Confirmatory,20965739.0,
2606,540209,4,3,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2607,540210,4,3,,103167216,3559,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2608,540211,2,5,,103167216,3559,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2609,540212,4,3,,103167216,3559,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2610,540213,4,3,,103167216,3559,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2611,540222,4,3,,103167216,3559,Unspecified,,,,,Clearance in rat after iv administration,Other,16621936.0,
2612,540223,3,2,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,16621936.0,
2613,540224,4,3,,103167216,3559,Unspecified,,,,,Clearance in dog after iv administration,Other,16621936.0,
2614,540225,4,3,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,16621936.0,
2615,540226,4,3,,103167216,3559,Unspecified,,,,,Clearance in monkey after iv administration,Other,16621936.0,
2616,540227,4,3,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,16621936.0,
2617,540228,4,3,,103167216,3559,Unspecified,,,,,Clearance in human after iv administration,Other,16621936.0,
2618,540229,4,3,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,16621936.0,
2619,540234,2,5,,103167216,3559,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
2620,540253,1,1,,56422397,3559,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2621,540253,1,1,,56422397,3559,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2622,540253,1,1,,56422397,3559,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2623,540256,1,2,,855969,3559,Inconclusive,,,23.1093,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2624,540256,1,2,,50104201,3559,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2625,540256,1,2,,90341418,3559,Inconclusive,,,10.3183,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2626,540263,1,1,,56422397,3559,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2627,540263,1,1,,56422397,3559,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2628,540267,1,1,,56422397,3559,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2629,540275,1,1,,855969,3559,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2630,540276,1,2,,855969,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2631,540276,1,2,,11111260,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2632,540276,1,2,,11112116,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2633,540276,1,2,,11113356,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2634,540276,1,2,,26747061,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2635,540276,1,2,,26747062,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2636,540276,1,2,,26751574,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2637,540276,1,2,,26751575,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2638,540276,1,2,,50100251,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2639,540276,1,2,,50104201,3559,Active,420597.0,,1.0,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2640,540276,1,2,,50104202,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2641,540276,1,2,,56422397,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2642,540276,1,2,,85231072,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2643,540276,1,2,,90341418,3559,Inconclusive,420597.0,,12.99,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2644,540276,1,2,,104171168,3559,Active,420597.0,,10.3225,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2645,540277,1,1,,855969,3559,Inconclusive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2646,540295,1,1,,56422397,3559,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2647,540299,1,2,,92123987,3559,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2648,540299,1,2,,92125096,3559,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2649,540303,1,1,,56422397,3559,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2650,540303,1,1,,56422397,3559,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2651,540303,1,1,,56422397,3559,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2652,540308,1,1,,56422397,3559,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2653,540317,1,1,,56422397,3559,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2654,540336,1,1,,855969,3559,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2655,540336,1,1,,855969,3559,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2656,540336,1,1,,56422397,3559,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2657,540336,1,1,,56422397,3559,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2658,540364,1,2,,56422397,3559,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2659,547621,4,3,,103167216,3559,Active,,,33.0,EC50,Cytotoxicity against BESM cells after 88 hrs by HTS assay,Confirmatory,20547819.0,
2660,547622,4,2,,103167216,3559,Active,,,7.0,EC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Confirmatory,20547819.0,
2661,547804,1,3,,103167216,3559,Unspecified,,,,,"Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells",Other,20547819.0,
2662,549675,1,5,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for guinea pig sigma1 receptor to Ki rat sigma2 receptor,Other,21126878.0,
2663,549676,2,5,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]ditolylguanidine from sigma2 receptor in rat liver membrane by scintillation counting,Confirmatory,21126878.0,
2664,549678,6,5,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane by scintillation counting,Confirmatory,21126878.0,
2665,566274,2,4,,103167216,3559,Active,,,0.185,IC50,Inhibition of rat sigma receptor,Confirmatory,20875743.0,
2666,566430,6,5,,103167216,3559,Active,81862796.0,100135589.0,0.0022,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membrane after 150 mins by liquid scintillation counting,Confirmatory,21055848.0,
2667,566431,2,5,,103167216,3559,Active,,,0.016,Ki,Displacement of [3H]DTG from sigma 2 receptor in guinea pig brain membrane after 120 mins by liquid scintillation counting,Confirmatory,21055848.0,
2668,566432,6,5,,103167216,3559,Active,47117674.0,24318.0,0.0021,Ki,Displacement radioligand form dopamine D2 receptor in rat striatum by liquid scintillation counting,Confirmatory,21055848.0,
2669,566433,6,5,,103167216,3559,Active,118211.0,29238.0,0.0058,Ki,Displacement radioligand form dopamine D3 receptor in rat olfactory tubercle by liquid scintillation counting,Confirmatory,21055848.0,
2670,576612,7,5,,103167216,3559,Active,7531135.0,3757.0,0.02692,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
2671,578855,6,5,,103167216,3559,Active,81862796.0,100135589.0,0.0008300000000000001,Ki,Displacement of [3H]-(+)-pentazocine from Sigma1-receptor in guinea pig brain membrane,Confirmatory,21376604.0,
2672,578856,2,5,,103167216,3559,Active,,,0.00958,Ki,Displacement of [3H]ditolylguanidine from sigma2 receptor in guinea pig brain membrane,Confirmatory,21376604.0,
2673,578857,2,5,,103167216,3559,Unspecified,,,,,"Selectivity ratio, ratio of Ki for pig sigma1 receptor to Ki for pig sigma2 receptor",Other,21376604.0,
2674,586708,6,5,,103167216,3559,Active,81862796.0,100135589.0,0.0015,Ki,Displacement of [3H]-pentazocine from guinea pig sigma1 receptor by liquid scintillation counting,Confirmatory,21348515.0,
2675,586709,6,6,,103167216,3559,Active,51316970.0,65046.0,0.0242,Ki,Displacement of [3H]-DTG from rat sigma2 receptor by liquid scintillation counting,Confirmatory,21348515.0,
2676,586713,2,10,,103167216,3559,Unspecified,1169206.0,1814.0,,,Intrinsic activity at human D3 receptor expressed in human HEK293 cells assessed as inhibition of forskolin-dependent accumulation of [3H]-cyclic AMP at 10 times Ki by spectrophotometric analysis,Other,21348515.0,
2677,586715,2,10,,103167216,3559,Unspecified,118206.0,1813.0,,,Intrinsic activity at human D2 receptor expressed in human HEK293 cells assessed as inhibition of forskolin-dependent accumulation of [3H]-cyclic AMP at 10 times Ki by spectrophotometric analysis,Other,21348515.0,
2678,588208,2,3,,103167216,3559,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
2679,588211,2,3,,103167216,3559,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2680,588212,2,3,,103167216,3559,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2681,588213,2,3,,103167216,3559,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2682,588214,2,3,,103167216,3559,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2683,588215,2,3,,103167216,3559,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2684,588216,2,3,,103167216,3559,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2685,588217,2,3,,103167216,3559,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2686,588218,2,3,,103167216,3559,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2687,588219,2,3,,103167216,3559,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2688,588220,2,3,,103167216,3559,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2689,588334,1,1,,56422397,3559,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2690,588335,1,1,,56422397,3559,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2691,588342,1,1,,855969,3559,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2692,588349,1,1,,90341418,3559,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2693,588352,1,2,,56422397,3559,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2694,588354,1,1,,56422397,3559,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2695,588358,1,2,,56422397,3559,Active,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2696,588368,1,2,,855969,3559,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2697,588378,1,1,,90341418,3559,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2698,588379,1,2,,124880286,3559,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
2699,588391,1,1,,56422397,3559,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2700,588405,1,1,,56422397,3559,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2701,588413,1,2,,56422397,3559,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2702,588436,1,1,,855969,3559,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2703,588436,1,1,,56422397,3559,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2704,588453,1,1,,56422397,3559,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2705,588453,1,1,,85231072,3559,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2706,588453,1,1,,90341418,3559,Inconclusive,8659577.0,58819.0,2.6679,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2707,588456,1,1,,56422397,3559,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2708,588456,1,1,,90341418,3559,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2709,588458,1,1,,56422397,3559,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2710,588459,1,2,,855969,3559,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2711,588459,1,2,,855969,3559,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2712,588459,1,2,,855969,3559,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2713,588460,1,2,,855969,3559,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2714,588460,1,2,,855969,3559,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2715,588460,1,2,,855969,3559,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2716,588461,1,2,,855969,3559,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2717,588461,1,2,,855969,3559,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2718,588461,1,2,,855969,3559,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2719,588466,1,1,,56422397,3559,Inactive,,,,,"HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies, using Cherry Pick 1 compounds",Screening,,
2720,588473,1,1,,56422397,3559,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2721,588473,1,1,,56422397,3559,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2722,588475,1,2,,56422397,3559,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2723,588475,1,2,,56422397,3559,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2724,588478,1,2,,124801028,3559,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2725,588489,1,1,,56422397,3559,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2726,588492,1,1,,56422397,3559,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2727,588493,1,2,,56422397,3559,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2728,588497,1,2,,56422397,3559,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2729,588497,1,2,,56422397,3559,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2730,588497,1,2,,56422397,3559,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2731,588499,1,3,,56422397,3559,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2732,588499,1,3,,56422397,3559,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2733,588499,1,3,,56422397,3559,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2734,588501,1,2,,56422397,3559,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2735,588501,1,2,,56422397,3559,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2736,588501,1,2,,56422397,3559,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2737,588506,1,2,,855969,3559,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2738,588511,1,2,,56422397,3559,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2739,588513,1,1,,26751575,3559,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2740,588514,1,1,,26751575,3559,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2741,588515,1,1,,26751575,3559,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2742,588516,1,1,,26751575,3559,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2743,588519,1,2,,92123987,3559,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2744,588519,1,2,,92125096,3559,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2745,588526,1,1,,26751575,3559,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2746,588527,1,1,,26751575,3559,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2747,588532,1,1,,26751575,3559,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2748,588533,1,1,,26751575,3559,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2749,588534,1,1,,26751575,3559,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2750,588535,1,1,,26751575,3559,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2751,588536,1,1,,26751575,3559,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2752,588537,1,1,,26751575,3559,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2753,588541,1,1,,26751575,3559,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2754,588543,1,1,,26751575,3559,Inconclusive,216409708.0,7421.0,44.6684,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2755,588544,1,1,,26751575,3559,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2756,588545,1,1,,26751575,3559,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2757,588546,1,1,,26751575,3559,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2758,588547,1,1,,26751575,3559,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2759,588549,1,1,,56422397,3559,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2760,588550,1,1,,855969,3559,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2761,588579,1,1,,56422397,3559,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2762,588579,1,1,,90341418,3559,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2763,588579,1,1,,104171168,3559,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2764,588579,1,1,,124880286,3559,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2765,588579,1,1,,124880288,3559,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2766,588579,1,1,,124880292,3559,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2767,588590,1,1,,50104201,3559,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2768,588590,1,1,,56422397,3559,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2769,588591,1,1,,50104201,3559,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2770,588591,1,1,,56422397,3559,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2771,588621,1,1,,56422397,3559,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2772,588627,1,1,,56422397,3559,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2773,588664,1,2,,56422397,3559,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2774,588664,1,2,,56422397,3559,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2775,588674,1,2,,855969,3559,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2776,588674,1,2,,56422397,3559,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2777,588675,1,1,,56422397,3559,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2778,588676,1,1,,56422397,3559,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2779,588685,1,1,,855969,3559,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2780,588689,1,1,,56422397,3559,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2781,588692,2,1,,56422397,3559,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2782,588726,1,2,,56422397,3559,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2783,588727,1,1,,56422397,3559,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2784,588795,1,1,,56422397,3559,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2785,588795,1,1,,90341418,3559,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2786,588814,1,3,,56422397,3559,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2787,588819,1,4,,56422397,3559,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2788,588834,2,1,,26751574,3559,Active,325651834.0,3757.0,0.2239,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2789,588834,2,1,,50104201,3559,Active,325651834.0,3757.0,0.2512,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2790,588850,1,1,,56422397,3559,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2791,588852,1,3,,56422397,3559,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2792,588855,1,1,,56422397,3559,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2793,588856,1,1,,56422397,3559,Inactive,,,12.5893,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2794,589047,1,10,,103167216,3559,Unspecified,84028191.0,1565.0,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
2795,591692,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human HEK293 cells expressing sigma receptor assessed as necrotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.06%),Other,21391684.0,
2796,591693,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human HEK293 cells expressing sigma receptor assessed as late apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 99.76%),Other,21391684.0,
2797,591694,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human HEK293 cells expressing sigma receptor assessed as early apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 99.76%),Other,21391684.0,
2798,592113,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human MCF7 cells expressing sigma receptor assessed as viable cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 97.33%),Other,21391684.0,
2799,592114,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human MCF7 cells expressing sigma receptor assessed as necrotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.27%),Other,21391684.0,
2800,592115,1,5,,103167216,3559,Active,,,,,Cytotoxicity against human MCF7 cells expressing sigma receptor at 0.5 to 50 uM after 48 hrs by MTT assay,Other,21391684.0,
2801,592116,1,5,,103167216,3559,Active,,,,,Cytotoxicity against human MDA-MB-231 cells expressing sigma receptor at 0.5 to 50 uM after 48 hrs by MTT assay,Other,21391684.0,
2802,592124,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human MCF7 cells expressing sigma receptor assessed as late apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 1.48%),Other,21391684.0,
2803,592125,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human MCF7 cells expressing sigma receptor assessed as early apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.92%),Other,21391684.0,
2804,592126,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells expressing sigma receptor assessed as necrotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.25%),Other,21391684.0,
2805,592127,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells expressing sigma receptor assessed as viable cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 98.30%),Other,21391684.0,
2806,592128,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells expressing sigma receptor assessed as late apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 1.21%),Other,21391684.0,
2807,592129,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells expressing sigma receptor assessed as early apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.92%),Other,21391684.0,
2808,592130,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in against african green monkey COS1 cells expressing sigma receptor assessed as necrotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.08%),Other,21391684.0,
2809,592131,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in against african green monkey COS1 cells expressing sigma receptor assessed as viable cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 99.82%),Other,21391684.0,
2810,592132,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in against african green monkey COS1 cells expressing sigma receptor assessed as late apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.04%),Other,21391684.0,
2811,592133,1,6,,103167216,3559,Unspecified,,,,,Induction of apoptosis in against african green monkey COS1 cells expressing sigma receptor assessed as early apoptotic cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 0.06%),Other,21391684.0,
2812,592134,1,5,,103167216,3559,Unspecified,,,,,Induction of apoptosis in human HEK293 cells expressing sigma receptor assessed as viable cells using annexin V/propidium iodide staining at 5 uM after 24 hrs by flow cytometry (Rvb = 99.76%),Other,21391684.0,
2813,592682,1,4,,103167216,3559,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
2814,592683,1,4,,103167216,3559,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
2815,593483,1,10,,103167216,3559,Active,118206.0,1813.0,,,Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells at 4 times IC50 for 5 mins measured after 60 mins by topcount scintillation counting,Other,21421319.0,
2816,595907,5,5,,103167216,3559,Active,81862796.0,100135589.0,0.0022,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membranes after 150 mins,Confirmatory,21476493.0,
2817,595908,1,5,,103167216,3559,Active,,,0.016,Ki,Displacement of [3H]DTG from sigma 2 receptor in guinea pig brain membranes after 120 mins,Confirmatory,21476493.0,
2818,595982,1,5,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 1 receptor in guinea pig brain membranes to Ki for sigma 2 receptor in guinea pig brain membranes,Other,21476493.0,
2819,596432,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse blood at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 1.32 +/- 0.41 %ID/g)",Other,21481592.0,
2820,596433,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse brain at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 3.64 +/- 0.66 %ID/g)",Other,21481592.0,
2821,596434,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse heart at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 1.72 +/- 0.31 %ID/g)",Other,21481592.0,
2822,596435,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse liver at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 5.73 +/- 0.95 %ID/g)",Other,21481592.0,
2823,596436,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse spleen at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 4.35 +/- 0.66 %ID/g)",Other,21481592.0,
2824,596437,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse lung at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 3.84 +/- 0.69 %ID/g)",Other,21481592.0,
2825,596438,5,1,,103167216,3559,Unspecified,,,,,"Biodistribution in haloperidol-pretreated ICR mouse kidney at 1 mg/kg, iv pretreated 5 mins before haloperidol challenge measured after 60 mins postinjection (Rvb = 8.18 +/- 0.13 %ID/g)",Other,21481592.0,
2826,598495,8,2,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain by scintillation analyzer,Confirmatory,21531141.0,
2827,598496,1,5,,103167216,3559,Active,,,0.078,Ki,"Displacement of [3H]-1,3-di(o-tolyl)guanidine from sigma 2 receptor in rat liver by scintillation analyzer",Confirmatory,21531141.0,
2828,598811,5,5,,103167216,3559,Active,81882051.0,29336.0,0.0009,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in rat brain homogenate,Confirmatory,21555222.0,
2829,598812,1,5,,103167216,3559,Active,,,0.00793,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat brain homogenate,Confirmatory,21555222.0,
2830,598813,5,5,,103167216,3559,Active,118228.0,1812.0,,IC50,Displacement of [3H]SCH233930 from human D1 receptor expressed in HEK cells,Confirmatory,21555222.0,
2831,598814,7,2,,103167216,3559,Active,118214.0,1816.0,0.048,Ki,Displacement of [3H]SCH233930 from human D5 receptor expressed in HEK cells,Confirmatory,21555222.0,
2832,598815,6,5,,103167216,3559,Active,118206.0,1813.0,,IC50,Displacement of [3H]N-methylspiperone from human D2 receptor expressed in HEK cells,Confirmatory,21555222.0,
2833,598816,5,5,,103167216,3559,Active,1169206.0,1814.0,0.028999999999999998,Ki,Displacement of [3H]N-methylspiperone from human D3 receptor expressed in HEK cells,Confirmatory,21555222.0,
2834,598817,6,5,,103167216,3559,Active,1345939.0,1815.0,0.005,Ki,Displacement of [3H]N-methylspiperone from human D4 receptor expressed in HEK cells,Confirmatory,21555222.0,
2835,602123,1,1,,56422397,3559,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2836,602141,1,1,,56422397,3559,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2837,602143,1,1,,126496583,3559,Inactive,156564407.0,5338.0,,,Cellular PLD2 isoenzyme activity assays at a set concentration,Screening,,
2838,602143,1,1,,126496583,3559,Inactive,340805823.0,5338.0,,,Cellular PLD2 isoenzyme activity assays at a set concentration,Screening,,
2839,602144,1,1,,126496583,3559,Inactive,4505873.0,5337.0,,,Cellular PLD1 isoenzyme activity assays at set concentration,Screening,,
2840,602144,1,1,,126496583,3559,Inactive,194272176.0,5337.0,,,Cellular PLD1 isoenzyme activity assays at set concentration,Screening,,
2841,602162,1,1,,56422397,3559,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2842,602163,1,1,,56422397,3559,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2843,602179,1,2,,56422397,3559,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2844,602229,1,1,,56422397,3559,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2845,602233,1,1,,56422397,3559,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2846,602244,1,2,,56422397,3559,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2847,602247,1,2,,56422397,3559,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2848,602248,1,2,,56422397,3559,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2849,602250,1,2,,56422397,3559,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2850,602252,1,1,,56422397,3559,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2851,602252,1,1,,56422397,3559,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2852,602261,1,1,,56422397,3559,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2853,602274,1,2,,56422397,3559,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2854,602276,1,1,,855969,3559,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
2855,602277,1,1,,855969,3559,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
2856,602281,1,1,,56422397,3559,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2857,602281,1,1,,56422397,3559,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2858,602289,1,1,,855969,3559,Inactive,,,,,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion: Hit Validation in Malachite Green Assay,Other,,
2859,602310,1,2,,56422397,3559,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2860,602313,1,1,,56422397,3559,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2861,602314,1,2,,92123987,3559,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2862,602314,1,2,,92125096,3559,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2863,602329,1,1,,855969,3559,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2864,602329,1,1,,56422397,3559,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2865,602332,1,1,,56422397,3559,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2866,602332,1,1,,90341418,3559,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2867,602332,1,1,,104171168,3559,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2868,602332,1,1,,124880286,3559,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2869,602332,1,1,,124880288,3559,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2870,602332,1,1,,124880292,3559,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2871,602340,1,2,,56422397,3559,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2872,602342,2,1,,56422397,3559,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2873,602346,1,1,,855969,3559,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2874,602346,1,1,,56422397,3559,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2875,602363,1,1,,855969,3559,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2876,602363,1,1,,56422397,3559,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2877,602393,1,1,,855969,3559,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2878,602393,1,1,,56422397,3559,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2879,602396,1,2,,56422397,3559,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2880,602399,1,2,,56422397,3559,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2881,602405,1,1,,855969,3559,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2882,602405,1,1,,56422397,3559,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2883,602410,1,1,,56422397,3559,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2884,602429,1,1,,56422397,3559,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2885,602438,1,1,,56422397,3559,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2886,602440,1,1,,56422397,3559,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2887,602449,1,2,,56422397,3559,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2888,602481,1,1,,855969,3559,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2889,602481,1,1,,56422397,3559,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2890,603955,1,3,,103167216,3559,Unspecified,,,,,"In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
2891,605696,5,5,,103167216,3559,Active,1706296.0,100144487.0,0.09300000000000001,Ki,Displacement of [3H]SCH23390 from D1 receptor from porcine cerebral cortex homogenates,Confirmatory,21599022.0,
2892,605697,5,5,,103167216,3559,Active,118206.0,1813.0,0.0015,Ki,Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells,Confirmatory,21599022.0,
2893,605698,5,5,,103167216,3559,Active,118206.0,1813.0,0.0011,Ki,Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells,Confirmatory,21599022.0,
2894,605699,5,5,,103167216,3559,Active,1169206.0,1814.0,0.0063,Ki,Displacement of [3H]spiperone from human D3 receptor expressed in CHO cells,Confirmatory,21599022.0,
2895,605700,1,4,,103167216,3559,Active,,,0.0063,Ki,Displacement of [3H]spiperone from human D4.4 receptor expressed in CHO cells,Confirmatory,21599022.0,
2896,619349,5,5,,103167216,3559,Active,81882051.0,29336.0,0.00335,Ki,Displacement of (-)-[3H]pentazocine from sigma 1 receptor in rat brain membrane after 120 mins,Confirmatory,21899931.0,
2897,619350,1,6,,103167216,3559,Active,,,0.0806,Ki,Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat brain membrane after 120 mins,Confirmatory,21899931.0,
2898,619351,1,6,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 1 receptor in rat brain membrane to sigma 2 receptor in rat brain membrane,Other,21899931.0,
2899,619547,8,2,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of (+)-[3H]pentazocine from guinea pig brain sigma 1 receptor after 180 mins by scintillation counting,Confirmatory,21859078.0,
2900,619548,5,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]ditolylguanidine from rat liver sigma 2 receptor by scintillation counting,Confirmatory,21859078.0,
2901,619549,1,5,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for guinea pig brain sigma 1 receptor to Ki for rat liver sigma 2 receptor,Other,21859078.0,
2902,619550,1,5,,103167216,3559,Inactive,,,,,Displacement of (+)-[3H]MK-801 from pig NMDA receptor PCP binding site at 1 uM,Other,21859078.0,
2903,623870,1,1,,855969,3559,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2904,623870,1,1,,855969,3559,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2905,623870,1,1,,56422397,3559,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2906,623870,1,1,,56422397,3559,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2907,623877,1,1,,56422397,3559,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2908,623901,1,1,,56422397,3559,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2909,624030,1,2,,104171168,3559,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2910,624031,1,2,,104171168,3559,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2911,624032,1,2,,104171168,3559,Inconclusive,8393992.0,24660.0,28.6954,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2912,624037,1,3,,56422397,3559,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2913,624038,1,3,,56422397,3559,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2914,624040,1,3,,56422397,3559,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2915,624044,1,2,,104171168,3559,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2916,624101,1,2,,85788356,3559,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2917,624101,1,2,,85789407,3559,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2918,624125,1,4,,56422397,3559,Active,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2919,624126,1,3,,56422397,3559,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2920,624127,1,2,,56422397,3559,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2921,624137,1,1,,85788356,3559,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
2922,624146,1,1,,90341418,3559,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2923,624147,1,1,,90341418,3559,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2924,624148,1,2,,90341418,3559,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2925,624149,1,1,,90341418,3559,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2926,624151,1,1,,85789407,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
2927,624156,1,1,,85788356,3559,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
2928,624168,1,1,,56422397,3559,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2929,624169,1,1,,56422397,3559,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2930,624170,1,1,,56422397,3559,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2931,624170,1,1,,104171168,3559,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2932,624171,1,1,,56422397,3559,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2933,624172,1,1,,56422397,3559,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2934,624172,1,1,,104171168,3559,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2935,624173,1,3,,56422397,3559,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2936,624173,1,3,,104171168,3559,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2937,624178,1,1,,56422397,3559,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2938,624180,1,1,,135650345,3559,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,7908055.0,
2939,624180,1,1,,135650345,3559,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8397408.0,
2940,624180,1,1,,135650345,3559,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8997630.0,
2941,624181,1,1,,135650345,3559,Active,10880131.0,3363.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT7,Other,9298538.0,
2942,624183,1,1,,135650345,3559,Active,113865998.0,15566.0,,,Antagonists at Mouse 5-Hydroxytryptamine receptor 5-HT7,Other,8394987.0,
2943,624202,1,1,,56422397,3559,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2944,624204,1,2,,56422397,3559,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2945,624215,1,1,,135650345,3559,Active,55956923.0,3350.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,8935801.0,
2946,624215,1,1,,135650345,3559,Active,55956923.0,3350.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,9067310.0,
2947,624215,1,1,,135650345,3559,Active,55956923.0,3350.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,9732398.0,
2948,624215,1,1,,135650345,3559,Active,55956923.0,3350.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,9760039.0,
2949,624218,1,1,,135650345,3559,Active,222080049.0,3357.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B,Other,9459568.0,
2950,624222,1,1,,135650345,3559,Active,8393583.0,29595.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A,Other,9655845.0,
2951,624223,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,8935801.0,
2952,624223,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,9732398.0,
2953,624223,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,12629531.0,
2954,624223,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,15102927.0,
2955,624231,1,1,,135650345,3559,Active,4504535.0,3352.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D,Other,8935801.0,
2956,624246,1,1,,56422397,3559,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2957,624256,1,2,,56422397,3559,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2958,624260,1,1,,85788356,3559,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2959,624263,1,1,,56422397,3559,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2960,624263,1,1,,56422397,3559,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2961,624267,1,2,,56422397,3559,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2962,624267,1,2,,56422397,3559,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2963,624268,1,3,,56422397,3559,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2964,624288,1,1,,56422397,3559,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2965,624296,1,1,,855969,3559,Active,7705682.0,51053.0,20.5962,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2966,624296,1,1,,26751574,3559,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2967,624296,1,1,,56422397,3559,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2968,624296,1,1,,104171168,3559,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2969,624297,1,1,,855969,3559,Inconclusive,7705682.0,51053.0,29.0929,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2970,624297,1,1,,26751574,3559,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2971,624297,1,1,,56422397,3559,Inactive,7705682.0,51053.0,1.7783,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2972,624297,1,1,,104171168,3559,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2973,624304,1,2,,56422397,3559,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2974,624330,1,2,,56422397,3559,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2975,624349,1,2,,92123987,3559,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2976,624349,1,2,,92125096,3559,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2977,624349,1,2,,92307379,3559,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2978,624349,1,2,,92308931,3559,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2979,624349,1,2,,121362767,3559,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2980,624352,1,1,,56422397,3559,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2981,624354,1,1,,56422397,3559,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2982,624377,1,1,,855969,3559,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2983,624414,1,1,,56422397,3559,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2984,624415,1,2,,56422397,3559,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2985,624416,1,1,,855969,3559,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2986,624417,1,1,,56422397,3559,Inconclusive,1724069.0,2740.0,28.1838,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2987,624418,1,1,,56422397,3559,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2988,624455,1,1,,90341418,3559,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2989,624463,1,1,,56422397,3559,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2990,624464,1,1,,56422397,3559,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2991,624465,1,1,,855969,3559,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2992,624465,1,1,,56422397,3559,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2993,624466,1,3,,855969,3559,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2994,624467,1,1,,855969,3559,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2995,624483,1,1,,56422397,3559,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2996,625144,5,5,,103167216,3559,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2997,625145,4,7,,103167216,3559,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2998,625146,5,5,,103167216,3559,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2999,625147,4,7,,103167216,3559,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3000,625148,4,7,,103167216,3559,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3001,625149,4,7,,103167216,3559,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3002,625150,5,5,,103167216,3559,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
3003,625151,4,7,,103167216,3559,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3004,625152,4,7,,103167216,3559,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3005,625153,4,7,,103167216,3559,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3006,625154,4,7,,103167216,3559,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3007,625155,4,7,,103167216,3559,Active,543761.0,1133.0,3.89,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3008,625156,1,9,,103167216,3559,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
3009,625157,6,2,,103167216,3559,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
3010,625158,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
3011,625159,5,5,,103167216,3559,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
3012,625160,1,9,,103167216,3559,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
3013,625161,4,7,,103167216,3559,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
3014,625162,4,7,,103167216,3559,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3015,625163,4,7,,103167216,3559,Active,2851402.0,4988.0,2.443,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3016,625164,1,6,,103167216,3559,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
3017,625165,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3018,625166,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3019,625167,5,5,,103167216,3559,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
3020,625168,4,7,,103167216,3559,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
3021,625169,1,6,,103167216,3559,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
3022,625170,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
3023,625171,4,7,,103167216,3559,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
3024,625172,4,7,,103167216,3559,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
3025,625173,5,5,,103167216,3559,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
3026,625174,5,5,,103167216,3559,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
3027,625175,5,5,,103167216,3559,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
3028,625176,1,9,,103167216,3559,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
3029,625177,5,5,,103167216,3559,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3030,625178,5,5,,103167216,3559,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3031,625179,1,9,,103167216,3559,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
3032,625180,5,5,,103167216,3559,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3033,625181,5,5,,103167216,3559,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3034,625182,5,5,,103167216,3559,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3035,625183,5,5,,103167216,3559,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
3036,625184,5,5,,103167216,3559,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3037,625185,5,5,,103167216,3559,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3038,625186,5,5,,103167216,3559,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3039,625187,5,5,,103167216,3559,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3040,625188,1,9,,103167216,3559,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
3041,625189,1,7,,103167216,3559,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
3042,625190,4,5,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
3043,625191,4,7,,103167216,3559,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3044,625192,4,7,,103167216,3559,Active,543727.0,3356.0,0.075,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
3045,625193,5,5,,103167216,3559,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
3046,625194,4,7,,103167216,3559,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
3047,625195,4,7,,103167216,3559,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
3048,625196,5,6,,103167216,3559,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
3049,625197,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
3050,625198,4,7,,103167216,3559,Active,1168247.0,29412.0,0.068,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3051,625199,4,7,,103167216,3559,Active,543734.0,24173.0,0.00894,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3052,625200,4,7,,103167216,3559,Active,1168243.0,146.0,0.084,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3053,625201,4,7,,103167216,3559,Active,1351829.0,150.0,4.973,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
3054,625202,4,7,,103167216,3559,Active,613504690.0,151.0,1.354,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
3055,625203,4,7,,103167216,3559,Active,20141211.0,152.0,1.845,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
3056,625204,4,7,,103167216,3559,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3057,625205,4,7,,103167216,3559,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
3058,625206,4,7,,103167216,3559,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3059,625207,4,7,,103167216,3559,Active,128616.0,6530.0,1.8359999999999999,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3060,625208,5,5,,103167216,3559,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
3061,625209,4,7,,103167216,3559,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
3062,625210,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
3063,625211,1,6,,103167216,3559,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
3064,625212,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
3065,625213,4,7,,103167216,3559,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
3066,625214,1,9,,103167216,3559,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
3067,625215,3,4,,103167216,3559,Active,,,1.7169999999999999,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
3068,625216,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
3069,625217,4,7,,103167216,3559,Active,1168220.0,3357.0,2.05,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3070,625218,4,7,,103167216,3559,Active,112816.0,3358.0,3.347,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
3071,625219,3,4,,103167216,3559,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
3072,625220,4,7,,103167216,3559,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
3073,625221,4,7,,103167216,3559,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3074,625222,4,7,,103167216,3559,Active,400630.0,6532.0,3.386,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
3075,625223,4,7,,103167216,3559,Active,74752153.0,10280.0,0.013000000000000001,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
3076,625224,3,4,,103167216,3559,Active,,,0.057999999999999996,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
3077,625225,3,4,,103167216,3559,Active,,,0.158,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
3078,625226,4,7,,103167216,3559,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
3079,625227,4,7,,103167216,3559,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
3080,625228,4,7,,103167216,3559,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
3081,625229,5,5,,103167216,3559,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
3082,625230,1,6,,103167216,3559,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
3083,625231,4,7,,103167216,3559,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
3084,625232,1,9,,103167216,3559,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
3085,625233,4,7,,103167216,3559,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
3086,625234,3,4,,103167216,3559,Active,,,0.552,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
3087,625235,4,7,,103167216,3559,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
3088,625236,5,5,,103167216,3559,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
3089,625237,4,7,,103167216,3559,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
3090,625238,4,7,,103167216,3559,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
3091,625239,4,7,,103167216,3559,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
3092,625240,1,9,,103167216,3559,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
3093,625241,4,7,,103167216,3559,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
3094,625242,4,7,,103167216,3559,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
3095,625243,5,5,,103167216,3559,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3096,625244,5,5,,103167216,3559,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3097,625245,5,5,,103167216,3559,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3098,625246,1,9,,103167216,3559,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
3099,625247,5,5,,103167216,3559,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3100,625248,5,5,,103167216,3559,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3101,625249,5,5,,103167216,3559,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3102,625250,5,5,,103167216,3559,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3103,625251,5,5,,103167216,3559,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
3104,625252,4,7,,103167216,3559,Active,118228.0,1812.0,0.11,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
3105,625253,4,7,,103167216,3559,Active,118206.0,1813.0,0.00659,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3106,625254,4,7,,103167216,3559,Active,1169206.0,1814.0,0.02,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3107,625255,4,7,,103167216,3559,Active,1345939.0,1815.0,0.563,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3108,625256,4,7,,103167216,3559,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3109,625257,4,7,,103167216,3559,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
3110,625258,4,7,,103167216,3559,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3111,625259,4,7,,103167216,3559,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3112,625260,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
3113,625261,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
3114,625262,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
3115,625263,4,7,,103167216,3559,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
3116,625264,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
3117,625265,1,6,,103167216,3559,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
3118,625266,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
3119,625267,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
3120,625268,4,2,,103167216,3559,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3121,625268,4,2,,103167216,3559,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3122,625268,4,2,,103167216,3559,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3123,625268,4,2,,103167216,3559,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3124,625269,4,7,,103167216,3559,Active,547645.0,3269.0,2.781,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
3125,625270,4,7,,103167216,3559,Active,123120.0,3274.0,1.166,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
3126,625271,5,5,,103167216,3559,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
3127,625272,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
3128,625273,4,6,,103167216,3559,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
3129,625274,1,6,,103167216,3559,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
3130,625275,3,4,,103167216,3559,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
3131,625277,1,3,,103167216,3559,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
3132,625279,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
3133,625280,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
3134,625281,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
3135,625282,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
3136,625283,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
3137,625284,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
3138,625285,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
3139,625286,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
3140,625287,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
3141,625288,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
3142,625289,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
3143,625290,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
3144,625291,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
3145,625292,1,3,,103167216,3559,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
3146,628576,3,2,,103167216,3559,Inconclusive,,,,,Toxicity in albino mouse assessed as induction of catalepsy measured at 30 mins intervals until 240 mins,Other,21824691.0,
3147,629460,4,5,,103167216,3559,Active,1706296.0,100144487.0,0.09300000000000001,Ki,Displacement of [3H]SCH 23390 from pig dopamine D1 receptor in striatal membrane,Confirmatory,21999579.0,
3148,629461,4,5,,103167216,3559,Active,118206.0,1813.0,0.0015,Ki,Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay,Confirmatory,21999579.0,
3149,629462,4,5,,103167216,3559,Active,118206.0,1813.0,0.0011,Ki,Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay,Confirmatory,21999579.0,
3150,629463,4,5,,103167216,3559,Active,1169206.0,1814.0,0.0063,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in chinese hamster CHO cells by radioligand binding assay,Confirmatory,21999579.0,
3151,629464,1,4,,103167216,3559,Active,,,0.0063,Ki,Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in chinese hamster CHO cells by radioligand binding assay,Confirmatory,21999579.0,
3152,635314,1,9,,103167216,3559,Active,74752153.0,10280.0,,,Displacement of [125I]IAF from sigma 1 receptor in human RT4 cells at 10 uM after 30 mins preincubation by photoaffinity labeling experiment,Other,22055714.0,
3153,635315,1,5,,103167216,3559,Active,,,,,Displacement of [125I]IAF from sigma 2 receptor in human RT4 cells at 10 uM after 30 mins preincubation by photoaffinity labeling experiment,Other,22055714.0,
3154,640304,4,5,,103167216,3559,Active,1169206.0,1814.0,0.0046,Ki,Displacement of [3H]N-methylspiperone from human dopamine D3 receptor by liquid scintillation counting,Confirmatory,22245230.0,
3155,640309,4,5,,103167216,3559,Inconclusive,8488960.0,3363.0,,Ki,Displacement of [3H]LSD from human 5HT7 receptor by liquid scintillation counting,Confirmatory,22245230.0,
3156,640310,4,5,,103167216,3559,Active,547645.0,3269.0,0.44,Ki,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Confirmatory,22245230.0,
3157,640311,4,5,,103167216,3559,Inconclusive,20141211.0,152.0,,Ki,Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting,Confirmatory,22245230.0,
3158,640547,4,5,,103167216,3559,Active,113118.0,1128.0,1.6,Ki,Displacement of [3H]QNB from human M1 receptor by liquid scintillation counting,Confirmatory,22245230.0,
3159,642495,4,5,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain homogenates after 180 mins by solid scintillation counting,Confirmatory,22136765.0,
3160,642496,3,4,,103167216,3559,Active,,,,IC50,"Displacement of [3H]-1,3-di(o-tolyl)guanidine from sigma 2 receptor in rat liver homogenates in the presence of (+)-pentazocine",Confirmatory,22136765.0,
3161,642497,1,6,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 2 receptor in rat liver homogenates to sigma 1 receptor in guinea pig brain homogenates,Other,22136765.0,
3162,643383,1,6,,103167216,3559,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
3163,646276,1,3,,103167216,3559,Active,,,,,Antipsychotic activity in CD1 mouse assessed as reduction in spontaneous locomotor activity measuring number of crossings at 0.5 to 1 mg/kg every 5 mins for 1 hr,Other,22277589.0,
3164,646280,1,3,,103167216,3559,Unspecified,,,,,Antipsychotic activity in CD1 mouse assessed as inhibition of MK-801-induced hyperactivity measuring number of crossings measured every 5 mins for 1 hr,Other,22277589.0,
3165,651548,1,1,,85788356,3559,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3166,651550,1,1,,56422397,3559,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
3167,651560,1,1,,56422397,3559,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
3168,651572,1,2,,855969,3559,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
3169,651582,1,1,,56422397,3559,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
3170,651602,1,1,,855969,3559,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3171,651602,1,1,,855969,3559,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3172,651602,1,1,,855969,3559,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3173,651610,2,1,,855969,3559,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3174,651631,4,1,,144203713,3559,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3175,651631,4,1,,144210793,3559,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3176,651632,4,1,,144203713,3559,Inactive,296439460.0,79915.0,18.8336,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3177,651632,4,1,,144210793,3559,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3178,651633,4,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3179,651633,4,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3180,651634,4,1,,144203713,3559,Inactive,,,1.1883,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3181,651634,4,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3182,651635,1,3,,56422397,3559,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3183,651635,1,3,,90341418,3559,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3184,651635,1,3,,124880292,3559,Inconclusive,171543895.0,6311.0,11.2202,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3185,651636,1,1,,56422397,3559,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
3186,651640,1,1,,855969,3559,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
3187,651644,1,1,,56422397,3559,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
3188,651647,1,1,,56422397,3559,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
3189,651654,1,1,,855969,3559,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3190,651654,1,1,,56422397,3559,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3191,651658,1,1,,855969,3559,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3192,651660,1,1,,56422397,3559,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3193,651661,2,1,,855969,3559,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3194,651687,1,1,,56422397,3559,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3195,651699,1,1,,56422397,3559,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3196,651699,1,1,,56422397,3559,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3197,651702,1,2,,56422397,3559,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
3198,651704,2,1,,855969,3559,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3199,651704,2,1,,56422397,3559,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3200,651710,1,1,,855969,3559,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3201,651711,2,1,,855969,3559,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3202,651718,1,2,,855969,3559,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
3203,651719,1,2,,855969,3559,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
3204,651723,1,1,,56422397,3559,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
3205,651724,1,1,,56422397,3559,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
3206,651725,1,1,,56422397,3559,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
3207,651741,1,1,,124880291,3559,Inconclusive,20149576.0,4780.0,43.2771,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3208,651743,1,1,,26751575,3559,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
3209,651749,1,1,,26751575,3559,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
3210,651751,1,1,,26751575,3559,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
3211,651768,1,2,,56422397,3559,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
3212,651777,1,1,,26751575,3559,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3213,651778,1,1,,26751575,3559,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3214,651800,1,1,,855969,3559,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
3215,651819,1,1,,56422397,3559,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
3216,651820,1,1,,855969,3559,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3217,651820,1,1,,56422397,3559,Inconclusive,,,7.9433,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3218,651821,2,4,,855969,3559,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
3219,651828,1,2,,92308931,3559,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3220,651828,1,2,,121361232,3559,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3221,651838,1,1,,26751575,3559,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3222,651838,1,1,1.0,26751575,3559,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3223,651838,1,1,2.0,26751575,3559,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3224,651838,1,1,3.0,26751575,3559,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3225,651838,1,1,4.0,26751575,3559,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3226,651838,1,1,5.0,26751575,3559,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3227,651838,1,1,6.0,26751575,3559,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3228,651838,1,1,7.0,26751575,3559,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3229,651838,1,1,8.0,26751575,3559,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3230,651957,1,1,,855969,3559,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
3231,651958,1,1,,855969,3559,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
3232,651965,1,1,,56422397,3559,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
3233,651999,1,1,,56422397,3559,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
3234,652010,1,1,,855969,3559,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3235,652017,1,1,,855969,3559,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
3236,652025,1,1,,56422397,3559,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
3237,652039,1,1,,855969,3559,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
3238,652048,1,2,,56422397,3559,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3239,652048,1,2,,144203713,3559,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3240,652051,1,1,,56422397,3559,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3241,652051,1,1,,144203713,3559,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3242,652054,1,1,,56422397,3559,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
3243,652067,1,4,,855969,3559,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
3244,652104,1,1,,56422397,3559,Inconclusive,20140568.0,23435.0,0.5623,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
3245,652105,1,1,,56422397,3559,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
3246,652106,1,1,,56422397,3559,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3247,652106,1,1,,90341418,3559,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3248,652115,1,1,,855969,3559,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
3249,652126,1,3,,855969,3559,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
3250,652154,1,1,,855969,3559,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3251,652162,2,1,,855969,3559,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3252,652163,1,1,,855969,3559,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3253,652197,1,1,,855969,3559,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3254,652257,1,1,,855969,3559,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
3255,655088,1,3,,103167216,3559,Unspecified,,,,,"Neurotoxicity in rat assessed as decrease in spontaneous locomotory activity at 1 umol/kg, ip after 30 mins",Other,22370265.0,
3256,655663,4,5,,103167216,3559,Active,81882051.0,29336.0,0.0057,Ki,Displacement of [3H]-pentazocine from sigma 1 opioid receptor in rat liver homogenate by liquid scintillation counting,Confirmatory,24900272.0,
3257,665421,4,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane after 180 mins by solid scintillation counting,Confirmatory,22578786.0,
3258,665422,1,4,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver after 180 mins by solid scintillation counting in the presence of (+)-pentazocine,Confirmatory,22578786.0,
3259,665423,1,4,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for rat sigma 2 receptor to Ki for guinea pig sigma1 receptor,Other,22578786.0,
3260,665430,1,8,,103167216,3559,Inconclusive,7531135.0,3757.0,,,Inhibition of human ERG expressed in CHO cells assessed as remaining activity at 10 uM by fluorescence-based assay,Other,22578786.0,
3261,672150,1,8,,103167216,3559,Inconclusive,113118.0,1128.0,,,Agonist activity at human M1 receptor expressed in CHO-K1 cells assessed as calcium mobilization for 6 mins by Calcium4-based staining relative to acetylcholine,Other,22677319.0,
3262,672151,2,6,,103167216,3559,Inconclusive,113118.0,1128.0,,EC50,Agonist activity at human M1 receptor expressed in CHO-K1 cells assessed as calcium mobilization for 6 mins by Calcium4-based staining,Confirmatory,22677319.0,
3263,672166,2,2,,103167216,3559,Unspecified,,,,,Intrinsic clearance in human liver microsomes at 1 uM after 60 mins,Other,22677319.0,
3264,672167,5,5,,103167216,3559,Active,7531135.0,3757.0,1.1,IC50,Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay,Confirmatory,22677319.0,
3265,672168,4,5,,103167216,3559,Active,118206.0,1813.0,0.003,Ki,Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay,Confirmatory,22677319.0,
3266,674364,5,5,,103167216,3559,Active,7531135.0,3757.0,0.23,IC50,Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay,Confirmatory,22694270.0,
3267,674895,4,5,,103167216,3559,Active,81882051.0,29336.0,0.0035,Ki,Displacement of (+)-[3H]pentazocine from sigma1 receptor in Sprague-Dawley rat cerebral membrane after 90 mins by liquid scintillation counting,Confirmatory,22831799.0,
3268,674896,1,4,,103167216,3559,Active,,,0.0516,Ki,Displacement of [3H]DTG from sigma2 receptor in Sprague-Dawley rat liver membrane after 90 mins by liquid scintillation counting in presence of pentazocine,Confirmatory,22831799.0,
3269,675970,4,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H]-(+)pentazocine from guinea pig brain sigma 1-type opioid receptor after 120 mins by scintillation counting analysis,Confirmatory,22515405.0,
3270,675971,1,4,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]-di-o-tolyguanidine from rat liver sigma 2 receptor after 180 mins by scintillation counting analysis,Confirmatory,22515405.0,
3271,675977,1,4,,103167216,3559,Unspecified,,,,,"Selectivity index, ratio of Ki for guinea pig brain sigma1 receptor to Ki for rat liver sigma2 receptor",Other,22515405.0,
3272,679764,1,8,,103167216,3559,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Haloperidol: 100 uM) in MDR1-expressing MDCKII cells",Other,12438524.0,
3273,680297,1,8,,103167216,3559,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Haloperidol: 80 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
3274,681116,1,8,,103167216,3559,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,12438524.0,
3275,681619,2,7,,103167216,3559,Unspecified,238054374.0,5243.0,33.0,Km,TP_TRANSPORTER: ATP hydrolysis in membranes from MDR1-expressing insect cells,Confirmatory,12031686.0,
3276,686940,1,1,,855969,3559,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3277,686964,1,1,,855969,3559,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3278,686970,1,2,,56422397,3559,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3279,686971,1,2,,56422397,3559,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3280,686977,2,1,,49698706,3559,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
3281,686978,1,1,,56422397,3559,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3282,686978,1,1,,124880286,3559,Active,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3283,686978,1,1,,124880288,3559,Active,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3284,686978,1,1,,144203713,3559,Inconclusive,79154014.0,55775.0,23.715,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3285,686979,1,1,,56422397,3559,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3286,686979,1,1,,124880286,3559,Active,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3287,686979,1,1,,124880288,3559,Inconclusive,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3288,686979,1,1,,144203713,3559,Inconclusive,79154014.0,55775.0,23.715,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3289,686992,2,1,,855969,3559,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3290,686996,1,1,,855969,3559,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3291,687014,1,1,,855969,3559,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3292,687016,1,1,,855969,3559,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3293,687035,1,1,,163564537,3559,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3294,687037,1,3,,163564537,3559,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
3295,701161,1,3,,103167216,3559,Active,,,0.022000000000000002,Ki,Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in guinea pig brain membranes after 120 mins by scintillation counter,Confirmatory,22784008.0,
3296,701162,3,5,,103167216,3559,Active,74752153.0,10280.0,0.0021,Ki,Displacement of [3H](+)pentazocine from human sigma 1 receptor transfected in HEK293 cell membranes after 120 mins by scintillation counter,Confirmatory,22784008.0,
3297,701944,1,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 1 receptor in guinea pig membrane to Ki for sigma 2 receptor in rat liver membrane,Other,22913577.0,
3298,701945,4,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]di-o-tolylguanidine from Sigma 2 receptor in rat liver membrane after 120 mins by scintillation counting,Confirmatory,22913577.0,
3299,701946,3,5,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting,Confirmatory,22913577.0,
3300,702710,1,2,,103167216,3559,Unspecified,,,,,Neurotoxicity in sc dosed C57BL/6 mouse assessed as induction of catalepsy measured at 0.5 to 1 hr,Other,22944118.0,
3301,704016,3,5,,103167216,3559,Active,81862796.0,100135589.0,0.006,Ki,Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain homogenates,Confirmatory,23013229.0,
3302,705396,2,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in sc dosed rat prepulse inhibition model,Other,22834877.0,
3303,705397,2,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in sc dosed rat assessed as decrease in amphetamine-induced spontaneous locomotor activity,Other,22834877.0,
3304,705398,2,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in sc dosed rat assessed as decrease in phencyclidine-induced locomotor activity,Other,22834877.0,
3305,705399,2,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in sc dosed rat assessed as decrease in spontaneous locomotor activity,Other,22834877.0,
3306,705400,2,2,,103167216,3559,Unspecified,,,,,Antipsychotic activity in sc dosed rat by conditioned avoidance response test,Other,22834877.0,
3307,705722,1,4,,103167216,3559,Active,,,0.0572,Ki,Displacement of [3H]di-o-tolylguanidine from Sigma2 receptor in rat liver homogenate,Confirmatory,22853801.0,
3308,705723,3,5,,103167216,3559,Active,81882051.0,29336.0,0.0033,Ki,Displacement of [3H](+)-pentazocine from Sigma1 receptor in rat liver homogenate,Confirmatory,22853801.0,
3309,705725,1,3,,103167216,3559,Active,,,0.08063,Ki,Displacement of [3H]di-o-tolylguanidine from Sigma2 receptor in rat brain homogenate,Confirmatory,22853801.0,
3310,705726,3,5,,103167216,3559,Active,81882051.0,29336.0,0.00335,Ki,Displacement of [3H](+)-pentazocine from Sigma1 receptor in rat brain homogenate,Confirmatory,22853801.0,
3311,711571,2,5,,103167216,3559,Unspecified,,,,,Half life in human liver microsomes,Other,21413808.0,
3312,711572,1,6,,103167216,3559,Active,,,,,Inhibition of CYP3A4,Other,21413808.0,
3313,711573,2,5,,103167216,3559,Unspecified,,,,,Clearance in human liver microsomes,Other,21413808.0,
3314,711574,2,5,,103167216,3559,Unspecified,,,,,Half life in rat liver microsomes,Other,21413808.0,
3315,711575,2,5,,103167216,3559,Unspecified,,,,,Clearance in rat liver microsomes,Other,21413808.0,
3316,711576,1,2,,103167216,3559,Active,,,0.0781,Ki,Inhibition of sigma 2 receptor,Confirmatory,21413808.0,
3317,711577,4,1,,103167216,3559,Active,,,0.0019,Ki,Inhibition of sigma 1 receptor,Confirmatory,21413808.0,
3318,711578,5,2,,103167216,3559,Active,118214.0,1816.0,0.038,Ki,Inhibition of human dopamine D5 receptor,Confirmatory,21413808.0,
3319,711579,5,2,,103167216,3559,Active,1345939.0,1815.0,0.007940000000000001,Ki,Inhibition of human dopamine D4 receptor,Confirmatory,21413808.0,
3320,711580,5,2,,103167216,3559,Active,118206.0,1813.0,0.0028399999999999996,Ki,Inhibition of human dopamine D2 receptor,Confirmatory,21413808.0,
3321,711581,5,2,,103167216,3559,Active,1169206.0,1814.0,0.0104,Ki,Inhibition of human dopamine D3 receptor,Confirmatory,21413808.0,
3322,711582,5,2,,103167216,3559,Active,118228.0,1812.0,0.107,Ki,Inhibition of human dopamine D1 receptor,Confirmatory,21413808.0,
3323,711583,1,2,,103167216,3559,Unspecified,,,,,Apparent permeability across human Caco2 cells,Other,21413808.0,
3324,711584,1,2,,103167216,3559,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21413808.0,
3325,711585,4,1,,103167216,3559,Unspecified,,,,,Solubility of the compound,Other,21413808.0,
3326,711586,1,2,,103167216,3559,Unspecified,,,,,"Partition coefficient, log D of the compound at pH 7.4",Other,21413808.0,
3327,712768,1,4,,103167216,3559,Active,,,0.07400000000000001,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat PC12 cell membrane after 2 hrs by microbeta scintillation counting analysis,Confirmatory,23641311.0,
3328,712770,3,5,,103167216,3559,Active,81882051.0,29336.0,0.006999999999999999,Ki,Displacement of [3H]pentazocine from sigma 1 receptor in rat brain membrane after 2.5 hrs by microbeta scintillation counting analysis,Confirmatory,23641311.0,
3329,715355,1,2,,103167216,3559,Unspecified,,,,,"Toxicity in rat assessed as induction of catalepsy up to 1.5 mg/kg, po",Other,22892116.0,
3330,715356,1,2,,103167216,3559,Unspecified,,,,,"Toxicity in rat assessed as increase in prolactin level up to 1.5 mg/kg, po",Other,22892116.0,
3331,717103,1,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 2 receptor in rat PC12 cell membrane to Ki for sigma 1 receptor in rat brain membrane,Other,23084435.0,
3332,717111,1,3,,103167216,3559,Active,,,0.013000000000000001,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat PC12 cell membrane after 2 hrs by scintillation counting,Confirmatory,23084435.0,
3333,717217,3,5,,103167216,3559,Active,81882051.0,29336.0,0.0017,Ki,Displacement of [3H](+)-pentazocine from sigma 1 receptor in rat brain membrane after 2.5 hrs by scintillation counting,Confirmatory,23084435.0,
3334,720504,1,1,,56422397,3559,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3335,720508,1,1,,855969,3559,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3336,720509,1,1,,855969,3559,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3337,720511,1,1,,855969,3559,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3338,720516,2,1,,144203713,3559,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3339,720516,2,1,,144210793,3559,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3340,720532,1,1,,124880286,3559,Active,420597.0,,12.5893,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3341,720532,1,1,,124880288,3559,Active,420597.0,,15.8489,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3342,720532,1,1,,124880292,3559,Active,420597.0,,12.5893,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3343,720532,1,1,,144203713,3559,Inconclusive,420597.0,,7.0795,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3344,720533,1,1,,124880286,3559,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3345,720533,1,1,,124880288,3559,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3346,720533,1,1,,124880292,3559,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3347,720533,1,1,,144203713,3559,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3348,720538,1,2,,90341418,3559,Inactive,220983390.0,410.0,4.2562,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
3349,720542,1,2,,56422397,3559,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3350,720543,1,1,,855969,3559,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3351,720551,1,2,,56422397,3559,Active,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3352,720552,2,1,,144203713,3559,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3353,720552,2,1,,144210793,3559,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3354,720553,1,2,,56422397,3559,Active,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3355,720559,1,2,,90341418,3559,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
3356,720572,1,2,,90341418,3559,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
3357,720573,1,2,,90341418,3559,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
3358,720579,2,1,,56422397,3559,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3359,720579,2,1,,124880288,3559,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3360,720580,1,1,,56422397,3559,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3361,720580,1,1,,124880288,3559,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3362,720582,1,1,,855969,3559,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3363,720596,1,1,,855969,3559,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3364,720634,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3365,720634,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3366,720635,2,1,,144203713,3559,Inconclusive,,,2.9849,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3367,720635,2,1,,144210793,3559,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3368,720636,1,1,,124880291,3559,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3369,720637,2,1,,144203713,3559,Inconclusive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3370,720637,2,1,,144210793,3559,Inconclusive,,,6.11306,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3371,720641,1,2,,92307379,3559,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3372,720641,1,2,,92308931,3559,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3373,720647,1,2,,855969,3559,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
3374,720648,1,1,,855969,3559,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3375,720653,1,1,,26751575,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3376,720659,1,1,,26751575,3559,Active,325495557.0,8856.0,7.9433,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3377,720674,2,2,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3378,720674,2,2,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3379,720675,2,2,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3380,720675,2,2,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3381,720678,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3382,720678,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3383,720679,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3384,720679,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3385,720680,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3386,720680,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3387,720681,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3388,720681,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3389,720682,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3390,720682,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3391,720683,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3392,720683,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3393,720684,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3394,720684,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3395,720685,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3396,720685,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3397,720686,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3398,720686,2,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3399,720687,2,2,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3400,720687,2,2,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3401,720691,4,1,,144203713,3559,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3402,720691,4,1,,144210793,3559,Inactive,311348376.0,2908.0,43.6412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3403,720692,3,1,,144203713,3559,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3404,720692,3,1,,144210793,3559,Inconclusive,311348376.0,2908.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3405,720693,3,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3406,720693,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3407,720700,1,4,,855969,3559,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3408,720702,1,1,,855969,3559,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3409,720704,1,4,,855969,3559,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3410,720707,1,2,,56422397,3559,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3411,720708,1,2,,56422397,3559,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3412,720709,1,2,,56422397,3559,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3413,720711,1,2,,56422397,3559,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3414,720717,1,3,,92123987,3559,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3415,720717,1,3,,92125096,3559,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3416,720717,1,3,,92307379,3559,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3417,720717,1,3,,92308931,3559,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3418,720719,2,1,,144203713,3559,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3419,720719,2,1,,144210793,3559,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3420,720725,2,1,,144203713,3559,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3421,720725,2,1,,144210793,3559,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3422,724159,1,4,,103167216,3559,Active,,,0.0207,Ki,Displacement of [3H]ditolyguanidine from sigma2 receptor in rat liver membranes,Confirmatory,23199475.0,
3423,724160,1,4,,103167216,3559,Unspecified,,,,,"Selectivity index, ratio of Ki for sigma2 receptor in rat liver membranes to Ki for sigma1 receptor in rat brain membranes",Other,23199475.0,
3424,724161,2,5,,103167216,3559,Active,81882051.0,29336.0,0.00495,Ki,Displacement of (+)-[3H]pentazocine from sigma1 receptor in rat brain membranes,Confirmatory,23199475.0,
3425,729692,3,1,,103167216,3559,Unspecified,118206.0,1813.0,,IC50,Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay,Confirmatory,23332346.0,
3426,729708,5,1,,103167216,3559,Inconclusive,231454.0,3350.0,,EC50,Agonist activity at 5-HT1A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay,Confirmatory,23332346.0,
3427,729709,3,1,,103167216,3559,Inconclusive,118228.0,1812.0,,IC50,Antagonist activity at dopamine D1 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay,Confirmatory,23332346.0,
3428,729710,3,1,,103167216,3559,Inconclusive,118228.0,1812.0,,EC50,Agonist activity at dopamine D1 receptor (unknown origin) expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding by scintillation proximity assay,Confirmatory,23332346.0,
3429,735277,1,3,,103167216,3559,Active,,,1.0,Ki,Displacement of [3H]-Di-o-tolyguanidine from guinea pig sigma2 receptor after 120 mins by liquid scintillation counting analysis,Confirmatory,23560650.0,
3430,735278,2,5,,103167216,3559,Active,74752153.0,10280.0,0.0021,Ki,Displacement of [3H]-(+)-pentazocine from human sigma1 receptor transfected in HEK293 cells after 120 mins by liquid scintillation counting analysis,Confirmatory,23560650.0,
3431,737843,1,4,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 2 receptor in rat liver membranes to Ki for sigma 1 receptor in guinea pig brain membranes,Other,23462714.0,
3432,737844,1,4,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis,Confirmatory,23462714.0,
3433,737845,2,5,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis,Confirmatory,23462714.0,
3434,737904,1,3,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for rat liver sigma2 receptor to rat brain sigma1 receptor,Other,23566245.0,
3435,737905,1,3,,103167216,3559,Active,,,0.0207,Ki,"Displacement of [3H]-1,3-di-o-tolylguanidine from rat liver sigma2 receptor by competitive binding assay",Confirmatory,23566245.0,
3436,737906,2,5,,103167216,3559,Active,81882051.0,29336.0,0.00495,Ki,Displacement of (+)-[3H]pentazocine from rat brain sigma1 receptor by competitive binding assay,Confirmatory,23566245.0,
3437,743012,3,1,,144203713,3559,Active,,,5.9557,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3438,743012,3,1,,144210793,3559,Active,,,7.6959,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3439,743014,3,1,,144203713,3559,Active,,,3.3491,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3440,743014,3,1,,144210793,3559,Active,,,1.7229,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3441,743015,3,1,,144203713,3559,Active,,,5.9557,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3442,743015,3,1,,144210793,3559,Active,,,1.7229,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3443,743033,3,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3444,743033,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3445,743035,2,1,,144203713,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3446,743035,2,1,,144210793,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3447,743036,2,1,,144203713,3559,Inconclusive,124375976.0,367.0,0.5354,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3448,743036,2,1,,144210793,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3449,743040,3,1,,144203713,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3450,743040,3,1,,144210793,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3451,743041,3,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3452,743041,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3453,743042,3,1,,144203713,3559,Inconclusive,124375976.0,367.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3454,743042,3,1,,144210793,3559,Active,124375976.0,367.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3455,743053,2,1,,144203713,3559,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3456,743053,2,1,,144210793,3559,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3457,743054,2,1,,144203713,3559,Active,124375976.0,367.0,29.8493,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3458,743054,2,1,,144210793,3559,Active,124375976.0,367.0,40.8562,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3459,743063,2,1,,144203713,3559,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3460,743063,2,1,,144210793,3559,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3461,743064,3,1,,144203713,3559,Active,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3462,743064,3,1,,144210793,3559,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3463,743065,3,1,,144203713,3559,Active,399498506.0,24831.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3464,743065,3,1,,144210793,3559,Active,399498506.0,24831.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3465,743066,3,1,,144203713,3559,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3466,743066,3,1,,144210793,3559,Inconclusive,399498506.0,24831.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3467,743067,2,1,,144203713,3559,Inconclusive,399498506.0,24831.0,27.644000000000002,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3468,743067,2,1,,144210793,3559,Inconclusive,399498506.0,24831.0,44.9702,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3469,743069,2,1,,144203713,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3470,743069,2,1,,144210793,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3471,743074,2,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3472,743074,2,1,,144210793,3559,Inconclusive,,,27.5357,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3473,743075,2,1,,144203713,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3474,743075,2,1,,144210793,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3475,743077,2,1,,144203713,3559,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3476,743077,2,1,,144210793,3559,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3477,743078,2,1,,144203713,3559,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3478,743078,2,1,,144210793,3559,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3479,743079,3,1,,144203713,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3480,743079,3,1,,144210793,3559,Inconclusive,348019627.0,2099.0,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3481,743080,3,1,,144203713,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3482,743080,3,1,,144210793,3559,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3483,743081,3,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3484,743081,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3485,743083,3,1,,144203713,3559,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3486,743083,3,1,,144210793,3559,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3487,743084,3,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3488,743084,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3489,743085,3,1,,144203713,3559,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3490,743085,3,1,,144210793,3559,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3491,743086,3,1,,144203713,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3492,743086,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3493,743091,2,1,,144203713,3559,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3494,743091,2,1,,144210793,3559,Inconclusive,348019627.0,2099.0,72.6538,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3495,743094,3,1,,144203713,3559,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3496,743094,3,1,,144210793,3559,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3497,743122,2,1,,144203713,3559,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3498,743122,2,1,,144210793,3559,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3499,743126,1,1,,855969,3559,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3500,743139,2,1,,144203713,3559,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3501,743139,2,1,,144210793,3559,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3502,743140,2,1,,144203713,3559,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3503,743140,2,1,,144210793,3559,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3504,743191,3,1,,144210793,3559,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3505,743191,3,1,,170464841,3559,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3506,743194,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3507,743194,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3508,743199,2,1,,144210793,3559,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3509,743199,2,1,,170464841,3559,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3510,743202,4,1,,144210793,3559,Inconclusive,20149576.0,4780.0,19.3312,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3511,743202,4,1,,170464841,3559,Inconclusive,20149576.0,4780.0,29.846999999999998,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3512,743203,3,1,,144210793,3559,Active,,,54.4827,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3513,743203,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3514,743205,1,1,,90341418,3559,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3515,743205,1,1,,90341418,3559,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3516,743206,1,1,,90341418,3559,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3517,743206,1,1,,90341418,3559,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3518,743207,1,1,,90341418,3559,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3519,743207,1,1,,90341418,3559,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3520,743209,3,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3521,743209,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3522,743210,4,1,,144210793,3559,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3523,743210,4,1,,170464841,3559,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3524,743211,3,1,,144210793,3559,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3525,743211,3,1,,170464841,3559,Inconclusive,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3526,743212,3,1,,144210793,3559,Inconclusive,216409690.0,5467.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3527,743212,3,1,,170464841,3559,Inconclusive,216409690.0,5467.0,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3528,743213,3,1,,144210793,3559,Active,,,30.8956,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3529,743213,3,1,,170464841,3559,Active,,,21.13,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3530,743215,3,1,,144210793,3559,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3531,743215,3,1,,170464841,3559,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3532,743217,3,1,,144210793,3559,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3533,743217,3,1,,170464841,3559,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3534,743218,3,1,,144210793,3559,Active,,,30.8956,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3535,743218,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3536,743219,3,1,,144210793,3559,Inconclusive,20149576.0,4780.0,15.3553,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3537,743219,3,1,,170464841,3559,Inconclusive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3538,743220,3,1,,144210793,3559,Inconclusive,325495553.0,9971.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3539,743220,3,1,,170464841,3559,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3540,743221,3,1,,144210793,3559,Inconclusive,,,12.2998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3541,743221,3,1,,170464841,3559,Inconclusive,,,0.2371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3542,743222,3,1,,144210793,3559,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3543,743222,3,1,,170464841,3559,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3544,743223,3,1,,144210793,3559,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3545,743223,3,1,,170464841,3559,Inconclusive,216409708.0,7421.0,15.089,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3546,743224,3,1,,144210793,3559,Inconclusive,,,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3547,743224,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3548,743225,3,1,,144210793,3559,Inconclusive,,,27.5357,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3549,743225,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3550,743226,2,1,,144210793,3559,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3551,743226,2,1,,170464841,3559,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3552,743227,2,1,,144210793,3559,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3553,743227,2,1,,170464841,3559,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3554,743228,3,1,,144210793,3559,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3555,743228,3,1,,170464841,3559,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3556,743238,1,1,,855969,3559,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3557,743239,2,1,,144210793,3559,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3558,743239,2,1,,170464841,3559,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3559,743240,2,1,,144210793,3559,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3560,743240,2,1,,170464841,3559,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3561,743241,2,1,,144210793,3559,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3562,743241,2,1,,170464841,3559,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3563,743242,2,1,,144210793,3559,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3564,743242,2,1,,170464841,3559,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3565,743244,1,1,,90341418,3559,Inconclusive,,,3.1623,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3566,743244,1,1,,144203713,3559,Inconclusive,,,22.3872,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3567,743247,1,2,,855969,3559,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3568,743247,1,2,,56422397,3559,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3569,743255,1,1,,56422397,3559,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3570,743266,1,2,,56422397,3559,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3571,743269,1,1,,855969,3559,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3572,743269,1,1,,855969,3559,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3573,743279,1,2,,56422397,3559,Active,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3574,743287,1,1,,855969,3559,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
3575,743288,1,1,,26751575,3559,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3576,743292,1,1,,26751575,3559,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3577,743344,1,1,,104171168,3559,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3578,743345,1,1,,104171168,3559,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3579,743346,1,1,,104171168,3559,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3580,743347,1,1,,104171168,3559,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3581,743397,1,1,,855969,3559,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3582,743398,1,1,,855969,3559,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3583,743398,1,1,,56422397,3559,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3584,750619,1,1,,103167216,3559,Unspecified,,,,,"Therapeutic Index, ratio of ED50 for catalepsy in mouse to ED50 for antipsychotic activity in po dosed mouse assessed as reduction in MK-801-induced hyperactivity",Other,23675993.0,
3585,750620,1,1,,103167216,3559,Unspecified,,,,,"Therapeutic Index, ratio of ED50 for catalepsy in mouse to ED50 for antipsychotic activity in po dosed mouse assessed as reduction in apomorphine-induced climbing behavior",Other,23675993.0,
3586,750622,1,1,,103167216,3559,Unspecified,,,,,Toxicity in po dosed mouse assessed as induction of catalepsy,Other,23675993.0,
3587,750623,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic activity in po dosed mouse assessed as reduction in MK-801-induced hyperactivity administered for 30 mins prior to MK-801-challenge measured after 90 mins,Other,23675993.0,
3588,750624,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic activity in po dosed mouse assessed as reduction in apomorphine-induced climbing behavior administered for 30 mins prior to apomorphine-challenge measured at 10 to 30 mins post-dose,Other,23675993.0,
3589,751647,3,2,,103167216,3559,Active,74752153.0,10280.0,,IC50,Displacement of [3H]Haloperidol from sigma 1 receptor in human jurkat cells after 4 hrs,Confirmatory,23403082.0,
3590,751711,1,5,,103167216,3559,Unspecified,74752153.0,10280.0,,,Displacement of [3H]Haloperidol from sigma 1 receptor in human jurkat cells at 10 uM after 4 hrs relative to control,Other,23403082.0,
3591,751847,1,1,,103167216,3559,Active,,,0.024,IC50,Binding affinity to human sigma receptor by radioligand displacement assay,Confirmatory,23466604.0,
3592,752209,1,1,,103167216,3559,Active,,,0.043,IC50,Binding affinity to Sigma receptor (unknown origin) by radioligand displacement assay,Confirmatory,23582449.0,
3593,753962,1,2,,103167216,3559,Active,,,0.0435,Ki,Displacement of [3H]DTG from sigma2 receptor in Sprague-Dawley rat liver membrane after 150 mins by liquid scintillation counting analysis,Confirmatory,23680866.0,
3594,753963,2,3,,103167216,3559,Active,81862796.0,100135589.0,0.0028,Ki,Displacement of [3H](+)pentazocine from sigma1 receptor in Dunkin Hartley guinea pig brain membrane after 120 mins by liquid scintillation counting analysis,Confirmatory,23680866.0,
3595,763632,1,1,,103167216,3559,Inactive,,,,,"Antipsychotic activity in CF1 mouse assessed as prevention of ketamine-induced hyperlocomotion at 0.01 mg/kg, po administered 30 mins prior ketamine challenge measured for 20 mins post challenge",Other,23792350.0,
3596,763638,1,1,,103167216,3559,Active,,,,,"Antipsychotic activity in CF1 mouse assessed as prevention of apomorphine-induced climbing behaviour at 0.5 mg/kg, po administered 30 mins prior apomorphine challenge measured 5 to 30 mins post challenge",Other,23792350.0,
3597,776366,1,2,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma-2 receptor in rat liver membrane to Ki for sigma-1 receptor in guinea pig brain cortex membrane,Other,24095744.0,
3598,776367,1,2,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]DTG from sigma-2 receptor in rat liver membrane after 120 mins by scintillation counting,Confirmatory,24095744.0,
3599,776368,2,3,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of (+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membrane after 120 mins by scintillation counting,Confirmatory,24095744.0,
3600,781326,1,2,,103167216,3559,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
3601,781328,1,2,,103167216,3559,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
3602,781329,1,2,,103167216,3559,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
3603,781330,1,2,,103167216,3559,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
3604,835848,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/6,Other,,
3605,835849,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/6,Other,,
3606,835850,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/7,Other,,
3607,835851,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/7,Other,,
3608,835852,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/7,Other,,
3609,835853,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/7,Other,,
3610,835854,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/7,Other,,
3611,835855,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/7,Other,,
3612,835856,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/7,Other,,
3613,835857,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/7,Other,,
3614,835858,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/7,Other,,
3615,835859,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/7,Other,,
3616,835860,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/7,Other,,
3617,835861,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/7,Other,,
3618,835862,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/7,Other,,
3619,835897,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/15,Other,,
3620,835898,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/16,Other,,
3621,835899,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/16,Other,,
3622,835900,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/16,Other,,
3623,835901,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/16,Other,,
3624,835902,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/16,Other,,
3625,835903,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/16,Other,,
3626,835904,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/16,Other,,
3627,835905,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/16,Other,,
3628,835906,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/16,Other,,
3629,835907,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/16,Other,,
3630,835908,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/16,Other,,
3631,835909,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/16,Other,,
3632,835910,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/16,Other,,
3633,835911,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/16,Other,,
3634,835912,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/16,Other,,
3635,835913,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/16,Other,,
3636,835914,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/16,Other,,
3637,836011,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 247/5,Other,,
3638,836012,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 247/5,Other,,
3639,836013,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 247/5,Other,,
3640,836014,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 247/5,Other,,
3641,836015,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 247/6,Other,,
3642,836016,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 247/6,Other,,
3643,836017,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 247/6,Other,,
3644,836018,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 247/6,Other,,
3645,836019,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 247/6,Other,,
3646,836020,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 247/6,Other,,
3647,836021,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 247/6,Other,,
3648,836022,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 247/6,Other,,
3649,836023,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 247/6,Other,,
3650,836024,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 247/6,Other,,
3651,836025,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 247/6,Other,,
3652,836026,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 247/6,Other,,
3653,836702,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 247/6,Other,,
3654,836703,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 247/6,Other,,
3655,836704,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 247/6,Other,,
3656,836705,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 247/6,Other,,
3657,836706,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 247/6,Other,,
3658,836707,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 247/7,Other,,
3659,836708,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 247/7,Other,,
3660,836709,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 247/7,Other,,
3661,836710,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 247/7,Other,,
3662,836711,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 247/7,Other,,
3663,836712,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 247/7,Other,,
3664,836713,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 247/7,Other,,
3665,836714,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 247/7,Other,,
3666,836715,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 247/7,Other,,
3667,836716,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 247/7,Other,,
3668,836717,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 247/7,Other,,
3669,836718,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 247/7,Other,,
3670,836719,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 247/7,Other,,
3671,836720,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 247/7,Other,,
3672,836721,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 247/7,Other,,
3673,836722,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 247/7,Other,,
3674,836723,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 247/7,Other,,
3675,836724,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 247/8,Other,,
3676,836725,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 247/8,Other,,
3677,836726,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 247/8,Other,,
3678,836727,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 247/8,Other,,
3679,836728,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 247/8,Other,,
3680,836729,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 247/8,Other,,
3681,836730,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 247/8,Other,,
3682,836731,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 247/8,Other,,
3683,836732,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 247/8,Other,,
3684,836733,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 247/8,Other,,
3685,838029,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/7,Other,,
3686,838030,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/7,Other,,
3687,838031,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/7,Other,,
3688,838032,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/7,Other,,
3689,838033,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/8,Other,,
3690,838034,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/8,Other,,
3691,838035,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/8,Other,,
3692,838036,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/8,Other,,
3693,838037,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/8,Other,,
3694,838038,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/8,Other,,
3695,838039,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/8,Other,,
3696,838040,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/8,Other,,
3697,838041,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/8,Other,,
3698,838042,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/8,Other,,
3699,838043,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/8,Other,,
3700,838044,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/8,Other,,
3701,838045,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/8,Other,,
3702,838046,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/8,Other,,
3703,838047,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/8,Other,,
3704,838048,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/8,Other,,
3705,838049,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/8,Other,,
3706,838050,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/9,Other,,
3707,838727,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/9,Other,,
3708,838728,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/9,Other,,
3709,838729,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/9,Other,,
3710,838730,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/9,Other,,
3711,838731,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/9,Other,,
3712,838732,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/9,Other,,
3713,838733,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/9,Other,,
3714,838734,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/9,Other,,
3715,838735,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/9,Other,,
3716,838736,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/9,Other,,
3717,838737,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/9,Other,,
3718,838738,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/9,Other,,
3719,838739,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/9,Other,,
3720,838740,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/9,Other,,
3721,838741,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/9,Other,,
3722,838742,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/9,Other,,
3723,838743,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/10,Other,,
3724,838744,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/10,Other,,
3725,838745,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/10,Other,,
3726,838746,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/10,Other,,
3727,838747,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/10,Other,,
3728,838748,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/10,Other,,
3729,838749,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/10,Other,,
3730,838750,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/10,Other,,
3731,838751,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/10,Other,,
3732,840907,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/10,Other,,
3733,840908,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/10,Other,,
3734,840909,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/10,Other,,
3735,840910,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/10,Other,,
3736,840911,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/10,Other,,
3737,840912,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/10,Other,,
3738,840913,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/10,Other,,
3739,840914,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/10,Other,,
3740,840915,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/11,Other,,
3741,840916,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/11,Other,,
3742,840917,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/11,Other,,
3743,840918,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/11,Other,,
3744,841592,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/11,Other,,
3745,841593,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/11,Other,,
3746,841594,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/11,Other,,
3747,841595,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/11,Other,,
3748,841596,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/11,Other,,
3749,841597,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/11,Other,,
3750,841598,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/11,Other,,
3751,841599,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/11,Other,,
3752,841600,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/11,Other,,
3753,841601,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/11,Other,,
3754,841602,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/11,Other,,
3755,841603,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/11,Other,,
3756,841604,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/11,Other,,
3757,841605,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/12,Other,,
3758,841606,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/12,Other,,
3759,841607,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/12,Other,,
3760,841608,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/12,Other,,
3761,841609,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/12,Other,,
3762,841610,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/12,Other,,
3763,841611,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/12,Other,,
3764,841612,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/12,Other,,
3765,841613,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/12,Other,,
3766,841614,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/12,Other,,
3767,841615,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/12,Other,,
3768,841616,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/12,Other,,
3769,841617,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/12,Other,,
3770,841618,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/12,Other,,
3771,841619,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/12,Other,,
3772,841620,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/12,Other,,
3773,841621,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/12,Other,,
3774,841622,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/13,Other,,
3775,841623,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/13,Other,,
3776,841624,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/13,Other,,
3777,841625,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/13,Other,,
3778,843792,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/13,Other,,
3779,843793,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/13,Other,,
3780,843794,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/13,Other,,
3781,843795,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/13,Other,,
3782,844467,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/13,Other,,
3783,844468,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/13,Other,,
3784,844469,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/13,Other,,
3785,844470,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/13,Other,,
3786,844471,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/13,Other,,
3787,844472,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/13,Other,,
3788,844473,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/13,Other,,
3789,844474,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/13,Other,,
3790,844475,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/13,Other,,
3791,844476,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/14,Other,,
3792,844477,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/14,Other,,
3793,844478,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/14,Other,,
3794,844479,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/14,Other,,
3795,844480,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/14,Other,,
3796,844481,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/14,Other,,
3797,844482,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/14,Other,,
3798,844483,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/14,Other,,
3799,844484,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/14,Other,,
3800,844485,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/14,Other,,
3801,844486,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/14,Other,,
3802,844487,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/14,Other,,
3803,844488,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/14,Other,,
3804,844489,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/14,Other,,
3805,844490,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/14,Other,,
3806,844491,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/14,Other,,
3807,844492,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/14,Other,,
3808,844493,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/15,Other,,
3809,844494,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/15,Other,,
3810,844495,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/15,Other,,
3811,844496,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/15,Other,,
3812,844497,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/15,Other,,
3813,844498,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/15,Other,,
3814,844499,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/15,Other,,
3815,844500,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/15,Other,,
3816,844501,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/15,Other,,
3817,844502,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/15,Other,,
3818,844503,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/15,Other,,
3819,844504,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/15,Other,,
3820,844505,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/15,Other,,
3821,844506,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/15,Other,,
3822,844507,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/15,Other,,
3823,844508,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/15,Other,,
3824,845284,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 247/5,Other,,
3825,845285,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 247/5,Other,,
3826,845286,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 247/5,Other,,
3827,845287,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 247/5,Other,,
3828,845288,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 247/5,Other,,
3829,845289,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 247/5,Other,,
3830,845290,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 247/5,Other,,
3831,845291,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 247/5,Other,,
3832,845292,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 247/5,Other,,
3833,845293,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 247/5,Other,,
3834,845294,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 247/5,Other,,
3835,845295,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 247/5,Other,,
3836,845296,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 247/5,Other,,
3837,846584,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/5,Other,,
3838,846585,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/5,Other,,
3839,846586,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/5,Other,,
3840,846587,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/5,Other,,
3841,846588,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/5,Other,,
3842,846589,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/5,Other,,
3843,846590,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/5,Other,,
3844,846591,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/5,Other,,
3845,846592,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/5,Other,,
3846,846593,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/5,Other,,
3847,846594,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/5,Other,,
3848,846595,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/5,Other,,
3849,846596,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/5,Other,,
3850,846597,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/5,Other,,
3851,846598,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/5,Other,,
3852,846599,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 248/5,Other,,
3853,846600,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 248/5,Other,,
3854,846601,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 248/6,Other,,
3855,846602,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 248/6,Other,,
3856,846603,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 248/6,Other,,
3857,846604,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 248/6,Other,,
3858,846605,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 248/6,Other,,
3859,846606,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 248/6,Other,,
3860,846607,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 248/6,Other,,
3861,846608,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 248/6,Other,,
3862,846609,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 248/6,Other,,
3863,846610,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 248/6,Other,,
3864,846611,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 248/6,Other,,
3865,846612,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 248/6,Other,,
3866,846613,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 248/6,Other,,
3867,846614,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 248/6,Other,,
3868,846615,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 248/6,Other,,
3869,860904,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/9,Other,,
3870,860905,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/9,Other,,
3871,860906,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/9,Other,,
3872,860907,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/9,Other,,
3873,860908,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/9,Other,,
3874,860909,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/9,Other,,
3875,860910,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/9,Other,,
3876,860911,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/9,Other,,
3877,860912,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/9,Other,,
3878,860913,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/10,Other,,
3879,860914,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/10,Other,,
3880,860950,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/16,Other,,
3881,862285,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/5,Other,,
3882,862286,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/5,Other,,
3883,862287,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/5,Other,,
3884,862288,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/5,Other,,
3885,862289,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/5,Other,,
3886,862290,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/5,Other,,
3887,862291,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/5,Other,,
3888,862292,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/5,Other,,
3889,862293,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/5,Other,,
3890,862294,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/5,Other,,
3891,862295,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/5,Other,,
3892,862296,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/5,Other,,
3893,862297,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/5,Other,,
3894,862298,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/5,Other,,
3895,862299,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/5,Other,,
3896,862300,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/5,Other,,
3897,862301,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/5,Other,,
3898,862302,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/5,Other,,
3899,862303,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/5,Other,,
3900,862304,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/5,Other,,
3901,862305,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/5,Other,,
3902,862306,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/6,Other,,
3903,862307,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/6,Other,,
3904,862308,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/6,Other,,
3905,862309,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/6,Other,,
3906,862343,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/13,Other,,
3907,862344,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/13,Other,,
3908,862345,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/13,Other,,
3909,862346,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/13,Other,,
3910,862347,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/13,Other,,
3911,862348,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/13,Other,,
3912,862349,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/13,Other,,
3913,862350,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/13,Other,,
3914,862351,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/13,Other,,
3915,862352,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/13,Other,,
3916,862353,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/13,Other,,
3917,862354,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/13,Other,,
3918,862355,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/13,Other,,
3919,862356,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/13,Other,,
3920,863041,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/13,Other,,
3921,863042,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/13,Other,,
3922,863043,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/13,Other,,
3923,863044,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/13,Other,,
3924,863045,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/13,Other,,
3925,863046,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/13,Other,,
3926,863047,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/14,Other,,
3927,863048,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/14,Other,,
3928,863049,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/14,Other,,
3929,863050,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/14,Other,,
3930,863051,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/14,Other,,
3931,863052,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/14,Other,,
3932,863053,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/14,Other,,
3933,863054,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/14,Other,,
3934,863055,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/14,Other,,
3935,863056,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/14,Other,,
3936,863057,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/14,Other,,
3937,863058,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/14,Other,,
3938,863059,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/14,Other,,
3939,863060,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/14,Other,,
3940,863061,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/14,Other,,
3941,863062,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/14,Other,,
3942,863063,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/14,Other,,
3943,863064,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/14,Other,,
3944,863065,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/14,Other,,
3945,863066,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/14,Other,,
3946,863067,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/14,Other,,
3947,863068,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/15,Other,,
3948,863069,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/15,Other,,
3949,863070,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/15,Other,,
3950,863071,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/15,Other,,
3951,863072,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/15,Other,,
3952,863073,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/15,Other,,
3953,863074,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/15,Other,,
3954,863104,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/10,Other,,
3955,863105,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/10,Other,,
3956,863106,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/10,Other,,
3957,863107,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/10,Other,,
3958,863108,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/10,Other,,
3959,863109,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/10,Other,,
3960,863110,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/10,Other,,
3961,863111,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/10,Other,,
3962,863112,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/10,Other,,
3963,863113,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/10,Other,,
3964,863114,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/10,Other,,
3965,863115,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/10,Other,,
3966,863116,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/10,Other,,
3967,863117,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/10,Other,,
3968,863118,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/10,Other,,
3969,863119,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/10,Other,,
3970,863120,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/10,Other,,
3971,863121,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/10,Other,,
3972,863122,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/10,Other,,
3973,863123,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/11,Other,,
3974,863124,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/11,Other,,
3975,863125,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/11,Other,,
3976,863126,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/11,Other,,
3977,863127,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/11,Other,,
3978,863128,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/11,Other,,
3979,863129,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/11,Other,,
3980,863130,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/11,Other,,
3981,863131,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/11,Other,,
3982,863810,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/11,Other,,
3983,863811,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/11,Other,,
3984,863812,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/11,Other,,
3985,863813,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/11,Other,,
3986,863814,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/11,Other,,
3987,863815,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/11,Other,,
3988,863816,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/11,Other,,
3989,863817,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/11,Other,,
3990,863818,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/11,Other,,
3991,863819,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/11,Other,,
3992,863820,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/11,Other,,
3993,863821,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/11,Other,,
3994,863822,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/12,Other,,
3995,863823,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/12,Other,,
3996,863824,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/12,Other,,
3997,863825,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/12,Other,,
3998,863826,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/12,Other,,
3999,863827,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/12,Other,,
4000,863828,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/12,Other,,
4001,865176,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/6,Other,,
4002,865177,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/6,Other,,
4003,865178,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/6,Other,,
4004,865179,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/6,Other,,
4005,865180,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/6,Other,,
4006,865181,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/6,Other,,
4007,865182,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/6,Other,,
4008,865183,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/6,Other,,
4009,865184,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/6,Other,,
4010,865185,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/6,Other,,
4011,865186,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/6,Other,,
4012,865187,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/6,Other,,
4013,865188,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/6,Other,,
4014,865189,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/6,Other,,
4015,865190,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/6,Other,,
4016,865191,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/6,Other,,
4017,865192,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/6,Other,,
4018,865193,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/7,Other,,
4019,865194,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/7,Other,,
4020,865195,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/7,Other,,
4021,865196,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/7,Other,,
4022,865197,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/7,Other,,
4023,865198,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/7,Other,,
4024,865199,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/7,Other,,
4025,865200,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/7,Other,,
4026,865201,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/7,Other,,
4027,865202,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/7,Other,,
4028,865203,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/7,Other,,
4029,865204,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/7,Other,,
4030,865205,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/7,Other,,
4031,865206,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/7,Other,,
4032,865207,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/7,Other,,
4033,865208,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/7,Other,,
4034,865209,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/7,Other,,
4035,865210,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/7,Other,,
4036,865211,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/7,Other,,
4037,865212,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/7,Other,,
4038,865213,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/7,Other,,
4039,865214,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/8,Other,,
4040,865215,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/8,Other,,
4041,865216,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/8,Other,,
4042,865255,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/15,Other,,
4043,865256,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/15,Other,,
4044,865257,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/15,Other,,
4045,865258,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/15,Other,,
4046,865259,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/15,Other,,
4047,865260,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/15,Other,,
4048,865261,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/15,Other,,
4049,865900,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/8,Other,,
4050,865901,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/8,Other,,
4051,865902,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/8,Other,,
4052,865903,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/8,Other,,
4053,865904,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/8,Other,,
4054,865905,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/8,Other,,
4055,865906,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/8,Other,,
4056,865945,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/15,Other,,
4057,865946,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/15,Other,,
4058,865947,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/15,Other,,
4059,865948,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/15,Other,,
4060,865949,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/15,Other,,
4061,865950,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/15,Other,,
4062,865951,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/15,Other,,
4063,865952,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/16,Other,,
4064,865953,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/16,Other,,
4065,865954,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/16,Other,,
4066,865955,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/16,Other,,
4067,865956,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/16,Other,,
4068,865957,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/16,Other,,
4069,865958,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/16,Other,,
4070,865959,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/16,Other,,
4071,865960,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/16,Other,,
4072,865961,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/16,Other,,
4073,865962,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/16,Other,,
4074,865963,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/16,Other,,
4075,865964,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/16,Other,,
4076,865965,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/16,Other,,
4077,865966,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/16,Other,,
4078,865967,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/16,Other,,
4079,865968,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/16,Other,,
4080,865969,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/16,Other,,
4081,865970,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/16,Other,,
4082,865971,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/16,Other,,
4083,865972,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/16,Other,,
4084,865973,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/5,Other,,
4085,865974,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/5,Other,,
4086,865975,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/5,Other,,
4087,865976,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/5,Other,,
4088,865977,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/5,Other,,
4089,865978,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/5,Other,,
4090,865979,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/5,Other,,
4091,865980,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/5,Other,,
4092,865981,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/5,Other,,
4093,865982,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/5,Other,,
4094,865983,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/5,Other,,
4095,865984,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/5,Other,,
4096,865985,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/5,Other,,
4097,866017,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/12,Other,,
4098,866018,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/12,Other,,
4099,866019,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/12,Other,,
4100,866020,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/12,Other,,
4101,866021,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/12,Other,,
4102,866022,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/12,Other,,
4103,866023,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/12,Other,,
4104,866024,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/12,Other,,
4105,866025,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/12,Other,,
4106,866026,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/12,Other,,
4107,866027,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/12,Other,,
4108,866028,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/12,Other,,
4109,866029,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/12,Other,,
4110,866030,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/12,Other,,
4111,866031,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/13,Other,,
4112,866032,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/13,Other,,
4113,866033,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/13,Other,,
4114,866034,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/13,Other,,
4115,866035,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/13,Other,,
4116,866715,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/13,Other,,
4117,866716,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/13,Other,,
4118,866717,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/13,Other,,
4119,866718,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/13,Other,,
4120,866719,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/13,Other,,
4121,866720,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/13,Other,,
4122,866721,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/13,Other,,
4123,866722,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/13,Other,,
4124,866723,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/13,Other,,
4125,866724,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/13,Other,,
4126,866725,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/13,Other,,
4127,866726,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/13,Other,,
4128,866727,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/13,Other,,
4129,866728,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/13,Other,,
4130,866729,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/13,Other,,
4131,866730,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/13,Other,,
4132,866731,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/14,Other,,
4133,866732,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/14,Other,,
4134,866733,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/14,Other,,
4135,866734,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/14,Other,,
4136,866735,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/14,Other,,
4137,866736,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/14,Other,,
4138,866737,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/14,Other,,
4139,866738,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/14,Other,,
4140,866739,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/14,Other,,
4141,866740,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/14,Other,,
4142,866741,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/14,Other,,
4143,866742,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/14,Other,,
4144,868086,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/8,Other,,
4145,868087,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/8,Other,,
4146,868088,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/8,Other,,
4147,868089,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/8,Other,,
4148,868090,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/8,Other,,
4149,868091,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/8,Other,,
4150,868092,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/8,Other,,
4151,868093,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/8,Other,,
4152,868094,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/8,Other,,
4153,868095,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/8,Other,,
4154,868096,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/8,Other,,
4155,868097,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/9,Other,,
4156,868098,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/9,Other,,
4157,868099,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/9,Other,,
4158,868100,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/9,Other,,
4159,868101,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/9,Other,,
4160,868102,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/9,Other,,
4161,868103,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/9,Other,,
4162,868104,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/9,Other,,
4163,868105,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/9,Other,,
4164,868106,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/9,Other,,
4165,868107,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/9,Other,,
4166,868108,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/9,Other,,
4167,868109,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/9,Other,,
4168,868110,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/9,Other,,
4169,868111,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/9,Other,,
4170,868112,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/9,Other,,
4171,868113,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/9,Other,,
4172,868114,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/9,Other,,
4173,868115,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/9,Other,,
4174,868116,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/9,Other,,
4175,868117,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/9,Other,,
4176,868800,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/10,Other,,
4177,868801,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/10,Other,,
4178,868802,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/10,Other,,
4179,868803,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/10,Other,,
4180,868804,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/10,Other,,
4181,868805,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/10,Other,,
4182,868806,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/10,Other,,
4183,868807,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/10,Other,,
4184,868808,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/10,Other,,
4185,868809,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/10,Other,,
4186,868810,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/10,Other,,
4187,868811,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/10,Other,,
4188,868812,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/10,Other,,
4189,868813,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/10,Other,,
4190,868814,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/10,Other,,
4191,868815,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/10,Other,,
4192,868846,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/5,Other,,
4193,868847,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/5,Other,,
4194,868848,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/5,Other,,
4195,868849,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/5,Other,,
4196,868850,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/5,Other,,
4197,868851,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/5,Other,,
4198,868852,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/5,Other,,
4199,868853,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/5,Other,,
4200,868854,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/6,Other,,
4201,868855,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/6,Other,,
4202,868856,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/6,Other,,
4203,868857,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/6,Other,,
4204,868858,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/6,Other,,
4205,868859,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/6,Other,,
4206,868860,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/6,Other,,
4207,868861,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/6,Other,,
4208,868862,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/6,Other,,
4209,868863,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/6,Other,,
4210,868864,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/6,Other,,
4211,868865,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/6,Other,,
4212,868866,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/6,Other,,
4213,868867,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/6,Other,,
4214,868868,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/6,Other,,
4215,868869,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/6,Other,,
4216,868870,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/6,Other,,
4217,868871,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/6,Other,,
4218,868872,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/6,Other,,
4219,868873,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/6,Other,,
4220,868874,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/6,Other,,
4221,868875,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/7,Other,,
4222,868876,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/7,Other,,
4223,868877,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/7,Other,,
4224,868878,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/7,Other,,
4225,868879,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/7,Other,,
4226,868880,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/7,Other,,
4227,868881,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/7,Other,,
4228,868882,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/7,Other,,
4229,868883,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/7,Other,,
4230,868884,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/7,Other,,
4231,868885,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/7,Other,,
4232,868886,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/7,Other,,
4233,868887,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/7,Other,,
4234,868888,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/7,Other,,
4235,868889,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/7,Other,,
4236,868925,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/14,Other,,
4237,868926,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/14,Other,,
4238,868927,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/14,Other,,
4239,868928,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/14,Other,,
4240,868929,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/14,Other,,
4241,868930,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/14,Other,,
4242,868931,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/14,Other,,
4243,868932,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/14,Other,,
4244,868933,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/14,Other,,
4245,868934,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/15,Other,,
4246,868935,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/15,Other,,
4247,869569,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/7,Other,,
4248,869570,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/7,Other,,
4249,869571,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/7,Other,,
4250,869615,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/15,Other,,
4251,869616,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/15,Other,,
4252,869617,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/15,Other,,
4253,869618,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/15,Other,,
4254,869619,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/15,Other,,
4255,869620,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/15,Other,,
4256,869621,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/15,Other,,
4257,869622,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/15,Other,,
4258,869623,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/15,Other,,
4259,869624,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/15,Other,,
4260,869625,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/15,Other,,
4261,869626,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/15,Other,,
4262,869627,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/15,Other,,
4263,869628,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/15,Other,,
4264,869629,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/15,Other,,
4265,869630,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/15,Other,,
4266,869631,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/15,Other,,
4267,869632,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/15,Other,,
4268,869633,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/15,Other,,
4269,869634,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/16,Other,,
4270,869635,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/16,Other,,
4271,869636,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/16,Other,,
4272,869637,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/16,Other,,
4273,869638,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/16,Other,,
4274,869639,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/16,Other,,
4275,869640,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/16,Other,,
4276,869641,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/16,Other,,
4277,869642,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/16,Other,,
4278,869643,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/16,Other,,
4279,869644,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/16,Other,,
4280,869645,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/16,Other,,
4281,869646,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/16,Other,,
4282,869647,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/16,Other,,
4283,869648,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/16,Other,,
4284,869649,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/16,Other,,
4285,869650,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/16,Other,,
4286,870994,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/10,Other,,
4287,870995,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/10,Other,,
4288,870996,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/10,Other,,
4289,870997,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/10,Other,,
4290,870998,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/10,Other,,
4291,870999,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/11,Other,,
4292,871000,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/11,Other,,
4293,871001,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/11,Other,,
4294,871002,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/11,Other,,
4295,871003,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/11,Other,,
4296,871004,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/11,Other,,
4297,871005,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/11,Other,,
4298,871006,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/11,Other,,
4299,871007,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/11,Other,,
4300,871008,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/11,Other,,
4301,871009,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/11,Other,,
4302,871010,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/11,Other,,
4303,871011,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/11,Other,,
4304,871012,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/11,Other,,
4305,871013,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/11,Other,,
4306,871014,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/11,Other,,
4307,871015,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/11,Other,,
4308,871016,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/11,Other,,
4309,871702,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/11,Other,,
4310,871703,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/11,Other,,
4311,871704,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/11,Other,,
4312,871705,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/12,Other,,
4313,871706,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 247/12,Other,,
4314,871707,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 247/12,Other,,
4315,871708,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 247/12,Other,,
4316,871709,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 247/12,Other,,
4317,871710,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 247/12,Other,,
4318,871711,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 247/12,Other,,
4319,871712,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 247/12,Other,,
4320,871713,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 247/12,Other,,
4321,871714,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 247/12,Other,,
4322,871715,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 247/12,Other,,
4323,871716,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 247/12,Other,,
4324,871717,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 247/12,Other,,
4325,871718,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 247/12,Other,,
4326,871719,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 247/12,Other,,
4327,871720,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 247/12,Other,,
4328,871721,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 247/12,Other,,
4329,871722,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 247/12,Other,,
4330,871723,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 247/12,Other,,
4331,871724,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 247/12,Other,,
4332,871725,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 247/12,Other,,
4333,871726,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 247/13,Other,,
4334,871755,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/7,Other,,
4335,871756,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/7,Other,,
4336,871757,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/7,Other,,
4337,871758,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/8,Other,,
4338,871759,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/8,Other,,
4339,871760,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/8,Other,,
4340,871761,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/8,Other,,
4341,871762,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/8,Other,,
4342,871763,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/8,Other,,
4343,871764,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/8,Other,,
4344,871765,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/8,Other,,
4345,871766,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/8,Other,,
4346,871767,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/8,Other,,
4347,871768,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/8,Other,,
4348,871769,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/8,Other,,
4349,871770,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 248/8,Other,,
4350,871771,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 248/8,Other,,
4351,871772,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 248/8,Other,,
4352,871773,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 248/8,Other,,
4353,871774,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 248/8,Other,,
4354,871775,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/8,Other,,
4355,871776,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/8,Other,,
4356,871777,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/8,Other,,
4357,871778,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 248/8,Other,,
4358,871779,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 248/9,Other,,
4359,871780,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 248/9,Other,,
4360,871781,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 248/9,Other,,
4361,871782,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 248/9,Other,,
4362,871783,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 248/9,Other,,
4363,871784,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 248/9,Other,,
4364,871785,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 248/9,Other,,
4365,871786,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 248/9,Other,,
4366,871787,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 248/9,Other,,
4367,871788,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 248/9,Other,,
4368,871789,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 248/9,Other,,
4369,871790,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 248/9,Other,,
4370,871834,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 248/16,Other,,
4371,871835,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 248/16,Other,,
4372,871836,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 248/16,Other,,
4373,932190,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
4374,932191,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
4375,932192,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
4376,932193,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
4377,932194,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
4378,932195,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
4379,932196,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
4380,932197,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
4381,932198,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
4382,932199,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
4383,932200,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
4384,932201,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
4385,932202,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
4386,932203,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
4387,932204,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
4388,932205,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
4389,932206,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
4390,932207,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
4391,932208,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
4392,937389,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
4393,937390,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
4394,937391,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
4395,937392,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
4396,937393,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
4397,937394,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
4398,937395,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
4399,937396,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
4400,937397,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
4401,937398,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
4402,937399,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
4403,937400,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
4404,937401,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
4405,937402,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
4406,937403,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
4407,937404,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
4408,937405,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
4409,937406,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
4410,937407,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
4411,956213,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
4412,956214,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
4413,956215,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
4414,956216,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
4415,956217,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
4416,956218,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
4417,956219,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
4418,956220,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
4419,956221,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
4420,956222,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
4421,956223,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
4422,956224,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
4423,956225,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
4424,958674,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
4425,958675,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
4426,958676,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
4427,958677,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
4428,958678,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
4429,958679,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
4430,972598,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
4431,973230,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
4432,973231,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
4433,973232,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
4434,973233,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
4435,973234,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
4436,973235,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
4437,973236,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
4438,973237,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
4439,973238,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
4440,973239,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
4441,973240,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
4442,973241,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
4443,973242,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
4444,973243,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
4445,973244,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
4446,973245,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
4447,973246,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
4448,973247,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
4449,977599,1,1,,103167216,3559,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4450,977602,1,2,,103167216,3559,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4451,996688,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
4452,996689,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
4453,996690,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
4454,996691,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020318",Other,,
4455,999731,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020318",Other,,
4456,999732,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
4457,999733,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
4458,999734,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020318",Other,,
4459,999735,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
4460,999736,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
4461,999737,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
4462,999738,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
4463,999739,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020318",Other,,
4464,999740,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
4465,999741,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
4466,999742,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020318",Other,,
4467,999743,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
4468,999744,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020318,Other,,
4469,999745,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020318,Other,,
4470,999746,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020318",Other,,
4471,999747,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
4472,999748,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
4473,999749,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020318",Other,,
4474,999750,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020318,Other,,
4475,999751,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
4476,999752,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
4477,999753,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
4478,999754,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020318",Other,,
4479,999755,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020318,Other,,
4480,999756,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
4481,999757,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020318",Other,,
4482,999758,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020318",Other,,
4483,999759,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
4484,999760,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020318",Other,,
4485,999761,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020318",Other,,
4486,999762,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020318",Other,,
4487,999763,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020318,Other,,
4488,999764,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
4489,999765,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020318",Other,,
4490,999766,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020318",Other,,
4491,999767,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020318,Other,,
4492,999768,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020318",Other,,
4493,1000349,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020318",Other,,
4494,1002175,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
4495,1002176,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020318",Other,,
4496,1002177,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020318",Other,,
4497,1002178,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020318",Other,,
4498,1002179,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
4499,1002180,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
4500,1002181,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020318,Other,,
4501,1002182,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020318",Other,,
4502,1002183,1,3,,103167216,3559,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020318,Other,,
4503,1002184,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020318",Other,,
4504,1002185,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
4505,1002186,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020318",Other,,
4506,1002187,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020318",Other,,
4507,1002188,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
4508,1002189,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
4509,1002190,1,3,,103167216,3559,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020318",Other,,
4510,1037148,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/10,Other,,
4511,1037149,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/10,Other,,
4512,1037150,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/11,Other,,
4513,1037151,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/11,Other,,
4514,1037152,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/11,Other,,
4515,1037153,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/11,Other,,
4516,1037154,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/11,Other,,
4517,1037155,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/12,Other,,
4518,1037156,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/12,Other,,
4519,1037157,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/12,Other,,
4520,1037158,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/12,Other,,
4521,1037159,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/12,Other,,
4522,1037160,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/13,Other,,
4523,1037161,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/13,Other,,
4524,1037162,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/13,Other,,
4525,1037163,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/13,Other,,
4526,1037164,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/13,Other,,
4527,1037165,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/14,Other,,
4528,1037830,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/14,Other,,
4529,1037831,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/14,Other,,
4530,1037832,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/14,Other,,
4531,1037833,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/14,Other,,
4532,1037834,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/15,Other,,
4533,1037835,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/15,Other,,
4534,1037836,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/15,Other,,
4535,1037837,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/15,Other,,
4536,1037838,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/15,Other,,
4537,1037839,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/16,Other,,
4538,1037840,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/16,Other,,
4539,1037841,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/16,Other,,
4540,1037842,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/16,Other,,
4541,1037843,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/16,Other,,
4542,1037844,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/5,Other,,
4543,1037845,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/5,Other,,
4544,1037846,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/5,Other,,
4545,1037847,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/5,Other,,
4546,1037848,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/5,Other,,
4547,1037849,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/6,Other,,
4548,1037850,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/6,Other,,
4549,1037851,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/6,Other,,
4550,1037852,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/6,Other,,
4551,1037853,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/6,Other,,
4552,1037854,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/7,Other,,
4553,1037855,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/7,Other,,
4554,1037856,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/7,Other,,
4555,1037857,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/7,Other,,
4556,1037858,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/7,Other,,
4557,1040007,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/8,Other,,
4558,1040008,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/8,Other,,
4559,1040009,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/8,Other,,
4560,1040010,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/8,Other,,
4561,1040011,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/8,Other,,
4562,1040012,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/9,Other,,
4563,1040013,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/9,Other,,
4564,1040014,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/9,Other,,
4565,1040015,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/9,Other,,
4566,1040016,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/9,Other,,
4567,1040682,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/10,Other,,
4568,1040683,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/10,Other,,
4569,1040684,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/10,Other,,
4570,1040685,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/10,Other,,
4571,1040686,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/10,Other,,
4572,1040687,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/11,Other,,
4573,1040688,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/11,Other,,
4574,1040689,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/11,Other,,
4575,1040690,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/11,Other,,
4576,1040691,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/11,Other,,
4577,1040692,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/12,Other,,
4578,1040693,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/12,Other,,
4579,1040694,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/12,Other,,
4580,1040695,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/12,Other,,
4581,1040696,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/12,Other,,
4582,1040697,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/13,Other,,
4583,1040698,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/13,Other,,
4584,1040699,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/13,Other,,
4585,1040700,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/13,Other,,
4586,1040701,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/13,Other,,
4587,1040702,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/14,Other,,
4588,1040703,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/14,Other,,
4589,1040704,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/14,Other,,
4590,1040705,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/14,Other,,
4591,1040706,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/14,Other,,
4592,1040707,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/15,Other,,
4593,1040708,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/15,Other,,
4594,1040709,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/15,Other,,
4595,1040710,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/15,Other,,
4596,1040711,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/15,Other,,
4597,1040712,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 248/16,Other,,
4598,1040713,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 248/16,Other,,
4599,1040714,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 248/16,Other,,
4600,1040715,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 248/16,Other,,
4601,1040716,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 248/16,Other,,
4602,1045661,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/5,Other,,
4603,1045662,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/5,Other,,
4604,1045663,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/5,Other,,
4605,1045664,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/5,Other,,
4606,1045665,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/5,Other,,
4607,1045666,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/6,Other,,
4608,1045667,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/6,Other,,
4609,1046336,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/6,Other,,
4610,1046337,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/6,Other,,
4611,1046338,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/6,Other,,
4612,1046339,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/7,Other,,
4613,1046340,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/7,Other,,
4614,1046341,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/7,Other,,
4615,1046342,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/7,Other,,
4616,1046343,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/7,Other,,
4617,1046344,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/8,Other,,
4618,1046345,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/8,Other,,
4619,1046346,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/8,Other,,
4620,1046347,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/8,Other,,
4621,1046348,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/8,Other,,
4622,1046349,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/9,Other,,
4623,1046350,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/9,Other,,
4624,1046351,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/9,Other,,
4625,1046352,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 247/9,Other,,
4626,1046353,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 247/9,Other,,
4627,1046354,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 247/10,Other,,
4628,1046355,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 247/10,Other,,
4629,1046356,1,2,,103167216,3559,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 247/10,Other,,
4630,1053175,2,1,,178126026,3559,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
4631,1053188,2,1,,56422397,3559,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4632,1053197,1,1,,855969,3559,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
4633,1053286,1,2,,103167216,3559,Unspecified,,,,,Fraction unbound in rat brain homogenate at 5 uM after 4 hrs equilibrium dialysis method,Other,24047231.0,
4634,1054122,3,2,,103167216,3559,Active,7531135.0,3757.0,0.01,IC50,Inhibition of human ERG,Confirmatory,23919353.0,
4635,1060807,1,2,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for guinea pig brain sigma1 receptor to Ki for guinea pig brain sigma2 receptor,Other,24290063.0,
4636,1060808,1,2,,103167216,3559,Active,,,0.013000000000000001,Ki,"Displacement of [3H]DTG from guinea pig brain sigma2 receptor after 120 mins by scintillation counting analysis in presence of SKF10,047",Confirmatory,24290063.0,
4637,1060809,2,3,,103167216,3559,Active,81862796.0,100135589.0,0.0013,Ki,Displacement of [3H]-(+)-pentazocine from guinea pig brain sigma1 receptor after 150 mins by scintillation counting analysis,Confirmatory,24290063.0,
4638,1061889,1,2,,103167216,3559,Unspecified,,,,IC50,Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting,Confirmatory,24332655.0,
4639,1062947,1,1,,103167216,3559,Unspecified,,,,,Selectivity ratio of pKi for human 5-HT2A receptor to pKi for human D2 receptor,Other,24316025.0,
4640,1062948,2,3,,103167216,3559,Active,118206.0,1813.0,0.000603,Ki,Displacement of [3H]spiperone from human D2 receptor,Confirmatory,24316025.0,
4641,1062949,2,3,,103167216,3559,Active,543727.0,3356.0,0.16596,Ki,Displacement of [3H]ketanserin from human 5-HT2A receptor,Confirmatory,24316025.0,
4642,1063780,3,1,,103167216,3559,Active,,,0.01318,Ki,Displacement of [3H]DTG from sigma 2 receptor (unknown origin),Confirmatory,24365159.0,
4643,1063782,4,2,,103167216,3559,Active,74752153.0,10280.0,0.0016600000000000002,Ki,Displacement of [3H](+)Pentazocine from sigma 1 receptor (unknown origin),Confirmatory,24365159.0,
4644,1063796,4,2,,103167216,3559,Active,118206.0,1813.0,0.00355,Ki,Displacement of [3H]N-Methylspiperone from dopamine D2 receptor (unknown origin),Confirmatory,24365159.0,
4645,1071720,1,1,,103167216,3559,Unspecified,,,,,"Therapeutic index, ratio of ED50 for induction of catalepsy to ED50 for antipsychotic activity in po dosed Kunming mouse assessed as reduction in MK801-induced hyperactivity",Other,24487191.0,
4646,1071721,1,1,,103167216,3559,Unspecified,,,,,"Therapeutic index, ratio of ED50 for induction of catalepsy to ED50 for antipsychotic activity in po dosed Kunming mouse assessed as reversal of apomorphine-induced cage climbing response",Other,24487191.0,
4647,1071722,1,1,,103167216,3559,Unspecified,,,,,Toxicity in po dosed Kunming mouse assessed as induction of catalepsy,Other,24487191.0,
4648,1071723,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic activity in po dosed Kunming mouse assessed as reduction in MK801-induced hyperactivity compound administered 30 mins prior to MK801 challenge measured for 90 mins post challenge,Other,24487191.0,
4649,1071724,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic activity in po dosed Kunming mouse assessed as reversal of apomorphine-induced cage climbing response compound administered 30 mins prior to apomorphine challenge measured for 30 mins post challenge,Other,24487191.0,
4650,1079931,1,1,,103167216,3559,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
4651,1079932,1,1,,103167216,3559,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
4652,1079933,1,1,,103167216,3559,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
4653,1079934,1,1,,103167216,3559,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
4654,1079935,1,1,,103167216,3559,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
4655,1079936,1,1,,103167216,3559,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
4656,1079937,1,1,,103167216,3559,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
4657,1079938,1,1,,103167216,3559,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
4658,1079939,1,1,,103167216,3559,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
4659,1079940,1,1,,103167216,3559,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
4660,1079941,1,1,,103167216,3559,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
4661,1079942,1,1,,103167216,3559,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
4662,1079943,1,1,,103167216,3559,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
4663,1079944,1,1,,103167216,3559,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
4664,1079945,1,1,,103167216,3559,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
4665,1079946,1,1,,103167216,3559,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
4666,1079947,1,1,,103167216,3559,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
4667,1079948,1,1,,103167216,3559,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
4668,1079949,1,1,,103167216,3559,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
4669,1083278,1,2,,103167216,3559,Unspecified,,,,,"Bioavailability in Homo sapiens (human) at 2.5 mg, intranasal after 15 min",Other,,
4670,1083279,1,2,,103167216,3559,Unspecified,,,,,"Bioavailability in Homo sapiens (human) at 2.5 mg, intramuscular after 15 min",Other,,
4671,1083280,1,2,,103167216,3559,Unspecified,,,,,Plasma protein binding in Homo sapiens (human),Other,,
4672,1084841,1,2,,103167216,3559,Unspecified,,,,,"Induction of catalepsy in ip dosed Mus musculus albino (mouse) at 1 mg/kg, ip measured at 30 min interval until 120 min and at the end of 240 min",Other,,
4673,1085638,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced oxidative stress in Mus musculus Swiss albino (mouse) assessed reduction in glutathione peroxidase activity in brain by measuring malondialdehyde level at 100 mg/kg, ip administered 30 min prior to haloperidol injection",Other,,
4674,1085639,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced oxidative stress in Mus musculus Swiss albino (mouse) assessed reduction in superoxide dismutase activity in brain by measuring malondialdehyde level at 100 mg/kg, ip administered 30 min prior to haloperidol injection by NBT reduction assay",Other,,
4675,1085640,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced oxidative stress in Mus musculus Swiss albino (mouse) assessed reduction in glutathione level in brain by measuring malondialdehyde level at 100 mg/kg, ip administered 30 min prior to haloperidol injection",Other,,
4676,1085641,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced oxidative stress in Mus musculus Swiss albino (mouse) assessed reduction in lipid peroxidation in brain by measuring malondialdehyde level at 100 mg/kg, ip administered 30 min prior to haloperidol injection by TBARS assay",Other,,
4677,1085643,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 180 min",Other,,
4678,1085644,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 150 min",Other,,
4679,1085645,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 120 min",Other,,
4680,1085646,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 90 min",Other,,
4681,1085647,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 60 min",Other,,
4682,1085648,1,2,,103167216,3559,Unspecified,,,,,"Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 30 min",Other,,
4683,1093077,2,3,,103167216,3559,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4684,1093078,2,3,,103167216,3559,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4685,1093079,1,4,,103167216,3559,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4686,1093079,1,4,,103167216,3559,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4687,1093080,1,4,,103167216,3559,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4688,1093080,1,4,,103167216,3559,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4689,1093081,2,3,,103167216,3559,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4690,1093082,2,3,,103167216,3559,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
4691,1093494,1,2,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma-2 receptor in Cavia porcellus (guinea pig) brain membranes to Ki for sigma-1 receptor in Cavia porcellus (guinea pig) brain membranes,Other,,
4692,1093495,1,2,,103167216,3559,Active,,,0.059000000000000004,Ki,Displacement of [3H]DTG from sigma-1 receptor in Cavia porcellus (guinea pig) brain membranes,Confirmatory,,
4693,1093496,2,3,,103167216,3559,Active,81862796.0,100135589.0,0.0092,Ki,Displacement of [3H](+)pentazocine from sigma-1 receptor in Cavia porcellus (guinea pig) brain membranes,Confirmatory,,
4694,1094467,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as GSH-Px activity per mg protein in brain homogenate at 100 mg/kg, po administered 30 min before haloperidol challenge measured after 4 hr post challenge by spectrophotometry (Rvb = 2.129 +/- 0.06 U/mg protein)",Other,,
4695,1094468,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as Cu-Zn-SOD activity per gram protein in brain homogenate at 100 mg/kg, po administered 30 min before haloperidol challenge measured after 4 hr post challenge by NBT reduction assay (Rvb = 1.794 +/- 0.03 U/g protein)",Other,,
4696,1094469,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as GSH level per gram of brain tissue at 100 mg/kg, po administered 30 min before haloperidol challenge measured after 4 hr post challenge by spectrophotometry (Rvb = 23.45 +/- 0.23 ug/g tissue)",Other,,
4697,1094471,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean cumulative descent time at 100 mg/kg, po administered 30 min before haloperidol challenge (Rvb = 33 +/- 1.34 min)",Other,,
4698,1094472,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean descent time at 100 mg/kg, po administered 30 min before haloperidol challenge measured at 30 min post challenge",Other,,
4699,1094473,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean descent time at 100 mg/kg, po administered 30 min before haloperidol challenge measured at 60 min post challenge",Other,,
4700,1094474,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean descent time at 100 mg/kg, po administered 30 min before haloperidol challenge measured at 90 min post challenge",Other,,
4701,1094475,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean descent time at 100 mg/kg, po administered 30 min before haloperidol challenge measured at 120 min post challenge",Other,,
4702,1094476,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean descent time at 100 mg/kg, po administered 30 min before haloperidol challenge measured at 150 min post challenge",Other,,
4703,1094477,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as mean descent time at 100 mg/kg, po administered 30 min before haloperidol challenge measured at 180 min post challenge",Other,,
4704,1094478,1,2,,103167216,3559,Unspecified,,,,,"Neuroprotective activity in haloperidol-induced catalepsy Mus musculus Swiss albino (mouse) model assessed as inhibition of MDA equivalent TBARS release per mg protein in brain homogenate at 100 mg/kg, po administered 30 min before haloperidol challenge measured after 4 hr post challenge by spectrophotometry (Rvb = 1.157 +/- 0.06 nmol/mg protein)",Other,,
4705,1097336,1,3,,103167216,3559,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
4706,1117298,1,2,,170464841,3559,Inactive,,,2.5119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
4707,1117301,1,2,,170464841,3559,Inactive,,,28.1838,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
4708,1117302,1,2,,170464841,3559,Inactive,,,3.5481,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
4709,1117303,1,2,,170464841,3559,Inactive,,,28.19,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
4710,1117304,1,2,,170464841,3559,Active,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
4711,1117305,1,2,,170464841,3559,Active,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
4712,1117310,1,1,,170464841,3559,Inactive,,,2.51189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
4713,1117311,1,1,,170464841,3559,Inactive,,,28.1838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
4714,1117312,1,1,,170464841,3559,Active,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
4715,1117314,1,1,,170464841,3559,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
4716,1117315,1,1,,170464841,3559,Inactive,,,3.5481300000000005,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
4717,1117318,1,1,,170464841,3559,Inactive,,,28.1838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
4718,1117326,1,1,,170464841,3559,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
4719,1117329,1,1,,170464841,3559,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
4720,1117336,1,1,,170464841,3559,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
4721,1117340,1,1,,170464841,3559,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4722,1117341,1,1,,170464841,3559,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4723,1117342,1,1,,170464841,3559,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4724,1117343,1,1,,170464841,3559,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4725,1117346,1,1,,170464841,3559,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4726,1119145,2,2,,103167216,3559,Active,118206.0,1813.0,0.000603,Ki,Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay,Confirmatory,,
4727,1119146,2,2,,103167216,3559,Active,543727.0,3356.0,0.16596,Ki,Displacement of [3H]ketanserin from human cloned 5-HT2A receptor by in vitro binding assay,Confirmatory,,
4728,1119148,1,1,,103167216,3559,Unspecified,,,,,Ratio of pKi for human cloned 5-HT2A receptor to pKi for human cloned D2 receptor,Other,,
4729,1120202,1,3,,103167216,3559,Active,81862796.0,100135589.0,0.0039,Ki,Displacement of [3H]-(+)-pentazocine from guinea pig brain sigma-1 receptor after 180 mins by scintillation counting analysis,Confirmatory,,
4730,1120203,1,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]-di-o-tolylguanidine from rat liver sigma-2 receptor after 180 mins by scintillation counting analysis,Confirmatory,,
4731,1120204,1,1,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for rat liver sigma-2 receptor to Ki for guinea pig brain sigma-1 receptor,Other,,
4732,1123512,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 1 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
4733,1123526,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 0.1 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
4734,1123527,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 0.2 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
4735,1123528,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in Wistar HLA rat assessed as inhibition of methamphetamine-induced stereotyped behavior at 0.5 mg/kg, ip administered 20 mins before methamphetamine challenge measured every 30 mins for 3 hrs followed by every 1 hr for further 3 hrs",Other,37336.0,
4736,1125902,3,2,,103167216,3559,Active,118206.0,1813.0,0.0014,Ki,Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis,Confirmatory,24666157.0,
4737,1125903,3,2,,103167216,3559,Active,1169206.0,1814.0,0.002,Ki,Displacement of [3H]methylspiperone from human D3 receptor expressed in HEK293 cell membrane after 90 mins by scintillation counting analysis,Confirmatory,24666157.0,
4738,1125905,1,1,,103167216,3559,Unspecified,,,,,Ratio of Ki for human D3 receptor expressed in HEK293 cell membrane to Ki for human D2L receptor expressed in HEK cell membrane,Other,24666157.0,
4739,1127303,1,3,,103167216,3559,Active,81862796.0,100135589.0,0.0026,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Dunkin Hartley guinea pig membrane after 180 mins by liquid scintillation counting analysis,Confirmatory,24735647.0,
4740,1127304,1,2,,103167216,3559,Active,,,0.0364,Ki,Displacement of [3H]-DTG from sigma 2 receptor in Dunkin Hartley guinea pig membrane after 120 mins by liquid scintillation counting analysis in the presence of sigma 1 receptor blocker (-)-SKF-10047,Confirmatory,24735647.0,
4741,1127305,1,2,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 2 receptor in Dunkin Hartley guinea pig membrane to Ki for sigma 1 receptor in Dunkin Hartley guinea pig membrane,Other,24735647.0,
4742,1127647,3,1,,103167216,3559,Active,,,0.02,Ki,Displacement of [3H]progesterone from sigma-1 opioid receptor in porcine liver microsome membranes,Confirmatory,23734634.0,
4743,1128476,1,1,,103167216,3559,Unspecified,,,,,Toxicity in rat step-down latency model assessed as frank catalepsy at 30 mg/kg,Other,24559051.0,
4744,1128477,1,1,,103167216,3559,Active,,,,,"Inhibition of conditioned avoidance response in Sprague-Dawley rat model at 2 mg/kg, po after 2 hrs by electric foot shock test",Other,24559051.0,
4745,1129361,1,1,,103167216,3559,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
4746,1129878,1,3,,103167216,3559,Active,81862796.0,100135589.0,0.0066,Ki,Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting analysis,Confirmatory,24617836.0,
4747,1129880,1,3,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]-DTG from sigma-2 receptor in rat liver homogenates after 120 mins by scintillation counting analysis in presence of (+)-pentazocine,Confirmatory,24617836.0,
4748,1129882,1,3,,103167216,3559,Active,74752153.0,10280.0,0.04,Ki,Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in human RPMI8226 cell membranes after 120 mins by scintillation counting analysis,Confirmatory,24617836.0,
4749,1129883,1,2,,103167216,3559,Active,,,0.2,Ki,Displacement of [3H]-DTG from sigma-2 receptor in human RT4 cell membranes after 120 mins by scintillation counting analysis in presence of (+)-pentazocine,Confirmatory,24617836.0,
4750,1135532,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic activity in po dosed squirrel monkey assessed as inhibition of conditioned avoidance response measured as maximum number of shocks,Other,19627.0,
4751,1135533,1,1,,103167216,3559,Unspecified,,,,,"Blockade of po dosed apomorphine-induced stereotyped behavior in Sprague-Dawley rat assessed as continuous sniffing, licking, gnawing, or biting",Other,19627.0,
4752,1135928,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 1 hr prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
4753,1135930,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 16 hrs prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
4754,1135931,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 2 days prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
4755,1135932,1,1,,103167216,3559,Active,,,,,Neuroleptic activity in ip dosed ICR-DUB mouse assessed as survival administered 3 days prior to d-amphetamine challenge measured after 24 hrs,Other,22753.0,
4756,1136082,3,1,,103167216,3559,Active,,,0.5,IC50,Displacement of [3H]-DA from dopamine receptor in calf caudate membranes after 15 mins by liquid scintillation counting analysis,Confirmatory,25967.0,
4757,1136083,3,1,,103167216,3559,Active,,,0.0018,IC50,Displacement of [3H]-HALO from dopamine receptor in calf caudate membranes after 10 mins by liquid scintillation counting analysis,Confirmatory,25967.0,
4758,1136084,1,1,,103167216,3559,Unspecified,,,,,Ratio of IC50 for displacement of [3H]-DA from dopamine receptor in calf caudate membranes to IC50 for displacement of [3H]-HALO from dopamine receptor in calf caudate membranes,Other,25967.0,
4759,1136138,1,1,,103167216,3559,Unspecified,,,,,Ratio of MED for inhibition of amphetamine-induced stereotyped-behavior in ip dosed Sprague-Dawley rat to ED50 for suppression of conditioned avoidance response in ip dosed Sprague-Dawley rat,Other,27637.0,
4760,1136346,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as inhibition of Sidman avoidance measured for 4 to 6 hrs,Other,31478.0,
4761,1136348,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in Sprague-Dawley rat assessed as inhibition of Sidman avoidance at 1.25 mg/kg, po relative to control",Other,31478.0,
4762,1136350,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in ip dosed Long-Evans rat assessed as inhibition of pole-climb avoidance,Other,31478.0,
4763,1136351,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in ip dosed Long-Evans rat assessed as increase in escape failure,Other,31478.0,
4764,1136359,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in squirrel monkey assessed as inhibition of Sidman avoidance at 1 mg/kg, po measured for 4 hrs",Other,31478.0,
4765,1136360,1,1,,103167216,3559,Unspecified,,,,,"Neuroleptic activity in squirrel monkey assessed as inhibition of Sidman avoidance at 0.75 mg/kg, po measured for 4 hrs",Other,31478.0,
4766,1136362,1,1,,103167216,3559,Unspecified,,,,,Non-specific toxicity in po dosed Beagle dog assessed as inhibition of apomorphine hydrochloride-induced emesis,Other,31478.0,
4767,1136364,1,1,,103167216,3559,Unspecified,,,,,Non-specific toxicity in ip dosed Wistar rat assessed as inhibition of amphetamine-induced circling administered 60 mins prior to amphetamine challenge,Other,31478.0,
4768,1136368,1,1,,103167216,3559,Unspecified,,,,,Non-specific toxicity in sc dosed Wistar rat assessed as inhibition of apomorphine hydrochloride-induced stereotypy administered 1 hr prior to apomorphine hydrochloride challenge measured after 5 to 20 mins,Other,31478.0,
4769,1136369,1,1,,103167216,3559,Unspecified,,,,,Non-specific toxicity in ip dosed Wistar rat assessed as inhibition of d-amphetamine sulfate-induced stereotypy administered 1 hr prior to d-amphetamine sulfate challenge measured after 55 to 65 mins,Other,31478.0,
4770,1136414,1,1,,103167216,3559,Active,,,,,"Antipsychotic activity in mouse assessed as protection against amphetamine-induced lethality at 5 mg/kg, ip treated 30 mins before amphetamine challenge",Other,31487.0,
4771,1136415,1,1,,103167216,3559,Active,,,,,"Antipsychotic activity in mouse assessed as protection against amphetamine-induced lethality at 50 mg/kg, ip treated 30 mins before amphetamine challenge",Other,31487.0,
4772,1136418,1,1,,103167216,3559,Active,,,,,"Antipsychotic activity in mouse assessed as increase in brain dopamine turnover at 25 to 30 mg/kg, ip pretreated with 200 mg/kg, ip alpha-methyl-p-tyrosine tyrosine hydroxylase inhibitor",Other,31487.0,
4773,1136419,3,2,,103167216,3559,Active,117786.0,81636.0,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4774,1136419,3,2,,103167216,3559,Active,117787.0,64508.0,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4775,1136419,3,2,,103167216,3559,Active,117788.0,54223.0,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4776,1136419,3,2,,103167216,3559,Active,416857.0,25289.0,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4777,1136419,3,2,,103167216,3559,Active,729243.0,29241.0,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4778,1136419,3,2,,103167216,3559,Active,2833201.0,64532.0,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4779,1136419,3,2,,103167216,3559,Active,81900271.0,,2.3,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
4780,1142394,1,3,,103167216,3559,Active,118206.0,1813.0,0.00085,Ki,Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells,Confirmatory,24779610.0,
4781,1144195,1,1,,103167216,3559,Unspecified,,,,,Acute toxicity in ip dosed Swiss-Webster mouse administered as single dose after 7 days,Other,1246033.0,
4782,1144197,1,1,,103167216,3559,Unspecified,,,,,Acute toxicity in ip dosed Swiss-Webster mouse assessed as death administered as single dose after 72 hrs,Other,1246033.0,
4783,1144198,1,1,,103167216,3559,Unspecified,,,,,Acute toxicity in ip dosed Swiss-Webster mouse assessed as tremor administered as single dose after 72 hrs,Other,1246033.0,
4784,1144199,1,1,,103167216,3559,Unspecified,,,,,Acute toxicity in ip dosed Swiss-Webster mouse assessed as ataxia administered as single dose after 72 hrs,Other,1246033.0,
4785,1144202,1,1,,103167216,3559,Unspecified,,,,,"Depression of forced motor activity in Swiss-Webster mouse at 10 mg/kg, ip after 30 mins by rotarod test relative to control",Other,1246033.0,
4786,1144205,1,1,,103167216,3559,Unspecified,,,,,"Depression of forced motor activity in Swiss-Webster mouse at 5 mg/kg, ip after 30 mins by rotarod test relative to control",Other,1246033.0,
4787,1144210,1,1,,103167216,3559,Unspecified,,,,,"Depression of forced motor activity in Swiss-Webster mouse at 2.5 mg/kg, ip after 30 mins by rotarod test relative to control",Other,1246033.0,
4788,1144214,1,1,,103167216,3559,Unspecified,,,,,"Depression of spontaneous motor activity in Swiss-Webster mouse at 10 mg/kg, ip by photocell cage test relative to control",Other,1246033.0,
4789,1144217,1,1,,103167216,3559,Unspecified,,,,,"Depression of spontaneous motor activity in Swiss-Webster mouse at 5 mg/kg, ip by photocell cage test relative to control",Other,1246033.0,
4790,1144222,1,1,,103167216,3559,Unspecified,,,,,"Depression of spontaneous motor activity in Swiss-Webster mouse at 2.5 mg/kg, ip by photocell cage test relative to control",Other,1246033.0,
4791,1144230,1,1,,103167216,3559,Active,,,,,"Depression of motor activity in Wistar rat at 1 to 6 mg/kg, ip",Other,1246033.0,
4792,1144248,1,1,,103167216,3559,Unspecified,,,,,"Reduction in body temperature in Wistar rat at 1 to 6 mg/kg, ip relative to control",Other,1246033.0,
4793,1144250,1,1,,103167216,3559,Active,,,,,"Induction of ptosis in Wistar rat at 1 to 6 mg/kg, ip",Other,1246033.0,
4794,1146534,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in po dosed STD-ddY mouse assessed as protection against methamphetamine-induced toxicity administered 1 hr before methamphetamine challenge measured after 24 hrs,Other,31476.0,
4795,1146535,1,1,,103167216,3559,Unspecified,,,,,Neuroleptic activity in po dosed STD-ddY mouse assessed as inhibition of spontaneous motor activity by measuring number of revolution of cage for 5 mins,Other,31476.0,
4796,1146536,1,1,,103167216,3559,Unspecified,,,,,Inhibition of methamphetamine-induced stereotyped behavior in po dosed albino Wistar rat administered 2 hrs before methamphetamine challenge measured up to 3 hrs,Other,31476.0,
4797,1146537,1,1,,103167216,3559,Unspecified,,,,,Inhibition of apomorphine-induced stereotyped behavior in po dosed albino Wistar rat administered 2 hrs before apomorphine challenge measured after 20 mins,Other,31476.0,
4798,1146538,1,1,,103167216,3559,Unspecified,,,,,Toxicity in po dosed albino Wistar rat assessed as induction of catalepsy after 8 hrs,Other,31476.0,
4799,1146539,1,1,,103167216,3559,Unspecified,,,,,Ratio of ED50 for po dosed albino Wistar rat assessed as induction of catalepsy to ED50 for methamphetamine-induced stereotyped behavior in po dosed albino Wistar rat,Other,31476.0,
4800,1146540,1,1,,103167216,3559,Unspecified,,,,,Ratio of ED50 for po dosed albino Wistar rat assessed as induction of catalepsy to ED50 for apomorphine-induced stereotyped behavior in po dosed albino Wistar rat,Other,31476.0,
4801,1146541,1,1,,103167216,3559,Unspecified,,,,,Acute toxicity in po dosed STD-ddY mouse assessed as mortality up to 7 days,Other,31476.0,
4802,1147993,1,1,,103167216,3559,Active,,,,,"Reduction in apomorphine-induced sterotypic climbing in Swiss-Webster mouse at 0.1 mg/kg, ip administered 30 mins prior to apomorphine-challenge measured after 5 mins",Other,569208.0,
4803,1152669,2,2,,103167216,3559,Active,118206.0,1813.0,0.004,Ki,Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis,Confirmatory,24805037.0,
4804,1153309,3,2,,103167216,3559,Active,118206.0,1813.0,0.000708,IC50,Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay,Confirmatory,24831693.0,
4805,1153310,1,3,,103167216,3559,Unspecified,118206.0,1813.0,,,Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay relative to qunipirole,Other,24831693.0,
4806,1159367,1,3,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of (+)-pentazocine from sigma1 receptor in guinea pig brain cortex membrane by scintillation counting analysis,Confirmatory,24996139.0,
4807,1159368,1,2,,103167216,3559,Active,,,0.078,Ki,Displacement of (+)-DTG from sigma2 receptor in rat liver membrane by scintillation counting analysis,Confirmatory,24996139.0,
4808,1159370,1,2,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for guinea pig sigma1 receptor to Ki for rat sigma2 receptor,Other,24996139.0,
4809,1159386,1,2,,103167216,3559,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
4810,1159387,1,2,,103167216,3559,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
4811,1159388,1,2,,103167216,3559,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
4812,1159389,1,2,,103167216,3559,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4813,1159390,1,2,,103167216,3559,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4814,1159394,1,2,,103167216,3559,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
4815,1159395,1,2,,103167216,3559,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
4816,1159509,1,1,,144210793,3559,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4817,1159509,1,1,,170464841,3559,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4818,1159515,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4819,1159515,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4820,1159516,1,1,,144210793,3559,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4821,1159516,1,1,,170464841,3559,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4822,1159517,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4823,1159517,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4824,1159518,1,1,,144210793,3559,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4825,1159518,1,1,,170464841,3559,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4826,1159519,1,1,,144210793,3559,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4827,1159519,1,1,,170464841,3559,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4828,1159520,1,1,,144210793,3559,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4829,1159520,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4830,1159521,1,1,,144210793,3559,Inconclusive,15928672.0,19885.0,15.3553,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4831,1159521,1,1,,170464841,3559,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4832,1159523,1,1,,144210793,3559,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4833,1159523,1,1,,170464841,3559,Inconclusive,15928672.0,19885.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4834,1159524,1,1,,56422397,3559,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4835,1159524,1,1,,124880286,3559,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4836,1159524,1,1,,124880288,3559,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4837,1159525,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4838,1159525,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4839,1159526,1,1,,144210793,3559,Inconclusive,119627033.0,3725.0,17.3739,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4840,1159526,1,1,,170464841,3559,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4841,1159527,1,1,,144210793,3559,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4842,1159527,1,1,,170464841,3559,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4843,1159528,1,1,,144210793,3559,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4844,1159528,1,1,,170464841,3559,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4845,1159529,1,1,,144210793,3559,Active,,,27.5357,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4846,1159529,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4847,1159531,1,1,,144210793,3559,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4848,1159531,1,1,,170464841,3559,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4849,1159550,3,1,,252401944,3559,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
4850,1159551,1,1,,144210793,3559,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4851,1159551,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4852,1159552,1,1,,144210793,3559,Active,325495463.0,5914.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4853,1159552,1,1,,170464841,3559,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4854,1159553,2,1,,144210793,3559,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4855,1159553,2,1,,170464841,3559,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4856,1159555,1,1,,144210793,3559,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4857,1159555,1,1,,170464841,3559,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4858,1159580,2,1,,268734565,3559,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4859,1159580,2,1,,273002834,3559,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4860,1159583,2,1,,178126026,3559,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
4861,1159606,1,1,,56422397,3559,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
4862,1159607,2,1,,312309708,3559,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4863,1159614,1,2,,170464841,3559,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
4864,1159620,1,1,,103167216,3559,Active,,,,,Summary of drug indications.,Other,,
4865,1168795,1,2,,103167216,3559,Unspecified,1169206.0,1814.0,,,Displacement of [3H]Spiperone from D3 receptor (unknown origin) transfected in HEK293T cells at 10 uM after 50 mins by liquid scintillation counting analysis,Other,25308766.0,
4866,1168796,1,2,,103167216,3559,Active,1169206.0,1814.0,0.016040000000000002,Ki,Displacement of [3H]Spiperone from D3 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis,Confirmatory,25308766.0,
4867,1168800,2,1,,103167216,3559,Active,118206.0,1813.0,0.41,IC50,Antagonist activity at D2 receptor (unknown origin) after 40 mins by [35S]GTP-gammaS binding assay in presence of quinpirole,Confirmatory,25308766.0,
4868,1169865,1,1,,103167216,3559,Unspecified,,,,,Effect on spontaneous exploratory locomotor activity in sc dosed NMRI mouse measured for 30 mins with activity counts each 5 mins,Other,25343529.0,
4869,1169867,1,1,,103167216,3559,Inconclusive,,,,,Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in MK801-induced locomotor activity dosed 15 to 30 mins before administration of MK801 measured for 60 mins,Other,25343529.0,
4870,1169869,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity dosed 15 to 30 mins before administration of methamphetamine measured for 60 mins,Other,25343529.0,
4871,1169871,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in PCP-induced locomotor activity dosed 15 to 30 mins before administration of methamphetamine measured for 60 mins,Other,25343529.0,
4872,1174073,1,2,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H](+)-pentazocine from sigma1 receptor in guinea pig brain membranes after 180 mins by scintillation counting method,Confirmatory,25458498.0,
4873,1174074,1,1,,103167216,3559,Active,,,0.0781,Ki,Displacement of [3H]DTG from sigma2 receptor in rat liver membranes after 180 mins by scintillation counting method,Confirmatory,25458498.0,
4874,1174258,1,2,,103167216,3559,Active,74752153.0,10280.0,0.0119,Ki,Displacement of [3H](+)-pentazocine from human sigma 1 receptor in human Jurkat cell membranes incubated for 2 hrs by liquid scintillation counting,Confirmatory,25462240.0,
4875,1174259,1,1,,103167216,3559,Active,,,0.175,Ki,Displacement of [3H]-DTG from human sigma 2 receptor in human Jurkat cell membranes incubated for 1 hr by liquid scintillation counting,Confirmatory,25462240.0,
4876,1174260,1,1,,103167216,3559,Unspecified,,,,,"Selectivity index, ratio of Ki for human sigma 2 receptor in human Jurkat cell membranes to Ki for human sigma 1 receptor in human Jurkat cell membranes",Other,25462240.0,
4877,1177034,1,2,,103167216,3559,Unspecified,118206.0,1813.0,,,Intrinsic agonist activity at human D2 long receptor expressed in HEK293 cells assessed as inhibition of a forskolin-dependent whole cell adenylyl cyclase activity after 20 mins relative to quinpirole,Other,25556097.0,
4878,1177035,1,2,,103167216,3559,Unspecified,1169206.0,1814.0,,,Intrinsic agonist activity at human D3 receptor expressed in HEK293 cells assessed as inhibition of a forskolin-dependent whole cell adenylyl cyclase activity after 20 mins relative to quinpirole,Other,25556097.0,
4879,1179609,1,2,,103167216,3559,Active,81862796.0,100135589.0,0.0063,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain cortex membranes,Confirmatory,24913984.0,
4880,1179610,1,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes in presence of (+)-pentazocine,Confirmatory,24913984.0,
4881,1179611,1,1,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma 2 receptor in rat liver membranes to Ki for sigma 1 receptor in guinea pig brain cortex membranes,Other,24913984.0,
4882,1184607,1,2,,103167216,3559,Active,118206.0,1813.0,0.00081,Ki,Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay,Confirmatory,25047579.0,
4883,1184608,1,2,,103167216,3559,Active,118206.0,1813.0,0.00085,Ki,Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay,Confirmatory,25047579.0,
4884,1184609,1,2,,103167216,3559,Active,1169206.0,1814.0,0.0026,Ki,Displacement of [3H]spiperone from human D3 receptor stably expressed in CHO cell membranes by competitive binding assay,Confirmatory,25047579.0,
4885,1184610,1,2,,103167216,3559,Active,1345939.0,1815.0,0.0059,Ki,Displacement of [3H]spiperone from human D4.4 receptor stably expressed in CHO cell membranes by competitive binding assay,Confirmatory,25047579.0,
4886,1184611,1,2,,103167216,3559,Active,1706296.0,100144487.0,0.0095,Ki,Displacement of [3H]SCH23390 from porcine striatal membranes D1 receptor by competitive binding assay,Confirmatory,25047579.0,
4887,1185661,1,2,,103167216,3559,Active,81862796.0,100135589.0,0.0066,Ki,Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membranes,Confirmatory,25062506.0,
4888,1185663,1,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]-DTG from sigma-2 receptor in rat liver membrane in presence of (+)-pentazocine,Confirmatory,25062506.0,
4889,1185959,1,2,,103167216,3559,Active,231454.0,3350.0,3.6,Ki,Displacement of [3H] 8-OH-DPAT from human 5-HT1A receptor by liquid scintillation counting,Confirmatory,25070422.0,
4890,1185960,1,2,,103167216,3559,Active,543727.0,3356.0,0.12,Ki,Displacement of [3H]Ketanserin from human 5-HT2A receptor by liquid scintillation counting,Confirmatory,25070422.0,
4891,1185961,1,2,,103167216,3559,Inconclusive,8488960.0,3363.0,,Ki,Displacement of [3H]LSD from human 5-HT7 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4892,1185962,1,2,,103167216,3559,Active,118228.0,1812.0,0.12,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4893,1185963,1,2,,103167216,3559,Active,118206.0,1813.0,0.0008900000000000001,Ki,Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4894,1185964,1,2,,103167216,3559,Active,1169206.0,1814.0,0.0025,Ki,Displacement of [3H]N-methylspiperone from human dopamine D3 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4895,1185965,1,2,,103167216,3559,Active,6226851.0,25432.0,0.01,Ki,Displacement of [3H]N-methylspiperone from rat dopamine D4 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4896,1185966,1,2,,103167216,3559,Inconclusive,118214.0,1816.0,,Ki,Displacement of [3H]SCH23390 from human dopamine D5 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4897,1185968,1,2,,103167216,3559,Active,112817.0,25187.0,4.7,Ki,Displacement of [3H]Mesulergine from rat 5-HT2C receptor by liquid scintillation counting,Confirmatory,25070422.0,
4898,1185969,1,2,,103167216,3559,Active,547645.0,3269.0,0.44,Ki,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Confirmatory,25070422.0,
4899,1185970,1,2,,103167216,3559,Inconclusive,113118.0,1128.0,,,Displacement of [3H]QNB from human muscarinic M1 receptor by liquid scintillation counting,Other,25070422.0,
4900,1185971,1,2,,103167216,3559,Inconclusive,113122.0,1129.0,,,Displacement of [3H]QNB from human muscarinic M2 receptor by liquid scintillation counting,Other,25070422.0,
4901,1185972,1,2,,103167216,3559,Inconclusive,113125.0,1131.0,,,Displacement of [3H]QNB from human muscarinic M3 receptor by liquid scintillation counting,Other,25070422.0,
4902,1185973,1,2,,103167216,3559,Inconclusive,266667.0,6531.0,,Ki,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Confirmatory,25070422.0,
4903,1185974,1,2,,103167216,3559,Active,128616.0,6530.0,5.5,Ki,Displacement of [3H]Nisoxetine from human Norepinephrine transporter by liquid scintillation counting,Confirmatory,25070422.0,
4904,1185975,1,2,,103167216,3559,Active,400630.0,6532.0,1.8,Ki,Displacement of [3H]Citalopram from human Serotonin transporter by liquid scintillation counting,Confirmatory,25070422.0,
4905,1185976,1,1,,103167216,3559,Unspecified,,,,,Antipsychotic activity in ip dosed Swiss-Webster mouse assessed as inhibition of APO-induced climbing behavior after 30 mins,Other,25070422.0,
4906,1185977,1,1,,103167216,3559,Unspecified,,,,,Toxicity in ip dosed Sprague-Dawley rat assessed as catalepsy by Bar test,Other,25070422.0,
4907,1185978,1,1,,103167216,3559,Unspecified,,,,,Toxicity in ip dosed Sprague-Dawley rat assessed as catalepsy by crossed-legs position test,Other,25070422.0,
4908,1187744,1,2,,103167216,3559,Active,1169206.0,1814.0,5.9999999999999995e-05,IC50,Antagonist activity against D3R in human U2OS cells assessed as inhibition of (+)-PD128907-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay,Confirmatory,25126833.0,
4909,1187745,1,2,,103167216,3559,Active,118206.0,1813.0,0.00016,IC50,Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay,Confirmatory,25126833.0,
4910,1187746,1,1,,103167216,3559,Unspecified,,,,,"Selectivity index, ratio of IC50 for for human D2LR to IC50 for human D3R by beta-galactosidase based beta-arrestin recruitment assay",Other,25126833.0,
4911,1189645,1,2,,103167216,3559,Active,47117674.0,24318.0,0.0023,Ki,Displacement of [3H]-spiperone from dopamine D2 receptor in rat striatum by scintillation counting method,Confirmatory,25461306.0,
4912,1189657,1,2,,103167216,3559,Active,81862796.0,100135589.0,0.0025,Ki,Displacement of [3H]-(+)-pentazocine from sigma 1 receptor guinea pig brain membranes incubated for 150 mins by scintillation counting method,Confirmatory,25461306.0,
4913,1189658,1,1,,103167216,3559,Active,,,0.018000000000000002,Ki,Displacement of [3H]-DTG from sigma 2 receptor guinea pig brain membranes incubated for 120 mins by scintillation counting method,Confirmatory,25461306.0,
4914,1189659,1,2,,103167216,3559,Active,118211.0,29238.0,0.0088,Ki,Displacement of [3H]-7-OH-DPAT from dopamine D3 receptor in rat olfactory tubercle by scintillation counting method,Confirmatory,25461306.0,
4915,1191388,1,2,,103167216,3559,Active,81862796.0,100135589.0,0.0066,Ki,Displacement of (+)-[3H]pentazocine from guinea pig brain cortex sigma1 receptor by scintillation analyzer,Confirmatory,25528334.0,
4916,1191389,1,1,,103167216,3559,Active,,,0.078,Ki,Displacement of [3H]DTG from rat liver sigma2 receptor by scintillation analyzer,Confirmatory,25528334.0,
4917,1191390,1,1,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for rat liver sigma2 receptor to Ki for guinea pig brain cortex sigma1 receptor,Other,25528334.0,
4918,1191391,1,1,,103167216,3559,Inconclusive,,,,,Displacement of [3H]MK801 from pig brain cortex NMDA receptor PCP binding site at 1 uM by scintillation analyzer,Other,25528334.0,
4919,1196314,1,2,,103167216,3559,Active,118206.0,1813.0,0.004,Ki,Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method,Confirmatory,25557493.0,
4920,1197502,1,2,,103167216,3559,Active,74752153.0,10280.0,0.0119,Ki,Displacement of [3H](+)Pentazocine from sigma 1 receptor in human Jurkat cells after 120 mins by liquid scintillation counting analysis,Confirmatory,25602932.0,
4921,1197503,1,1,,103167216,3559,Active,,,0.175,Ki,Displacement of [3H]DTG from sigma 1 receptor in human Jurkat cells after 60 mins by liquid scintillation counting analysis in presence of pentazocine,Confirmatory,25602932.0,
4922,1197504,1,1,,103167216,3559,Unspecified,,,,,Selectivity ratio of Ki for sigma2 receptor in human Jurkat cells to Ki for sigma1 receptor human Jurkat cells,Other,25602932.0,
4923,1204343,1,2,,103167216,3559,Unspecified,118206.0,1813.0,,,Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells assessed as total radioligand binding at 1 uM incubated for 60 mins by microbeta plate reader based method,Other,25965777.0,
4924,1204344,1,2,,103167216,3559,Unspecified,118206.0,1813.0,,,Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells assessed as total radioligand binding at 1.66 x 10'-7 M incubated for 60 mins by microbeta plate reader based method,Other,25965777.0,
4925,1207158,1,1,,103167216,3559,Active,,,7.0,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
4926,1207187,1,1,,103167216,3559,Active,,,1.7,IC50,Inhibition of voltage-gated L-type Ca channel (species unknown),Confirmatory,21300721.0,
4927,1207217,1,1,,103167216,3559,Active,,,0.027000000000000003,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
4928,1207248,1,2,,103167216,3559,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
4929,1207744,1,1,,103167216,3559,Active,,,1.3,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
4930,1209972,1,2,,103167216,3559,Active,60416369.0,1557.0,2.87,IC50,Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
4931,1209973,1,2,,103167216,3559,Unspecified,84028191.0,1565.0,30.0,IC50,Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
4932,1209974,1,2,,103167216,3559,Active,116241312.0,1576.0,8.2,IC50,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
4933,1210013,1,2,,103167216,3559,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control,Other,22328583.0,
4934,1210014,1,2,,103167216,3559,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
4935,1210015,1,2,,103167216,3559,Unspecified,117144.0,1544.0,30.0,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
4936,1210016,1,2,,103167216,3559,Unspecified,117225.0,1558.0,30.0,IC50,Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
4937,1210017,1,2,,103167216,3559,Unspecified,6686268.0,1559.0,30.0,IC50,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
4938,1210069,1,2,,103167216,3559,Active,21264413.0,1573.0,4.69,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
4939,1210070,1,2,,103167216,3559,Active,84028191.0,1565.0,3.64,IC50,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,Confirmatory,23033255.0,
4940,1210071,1,2,,103167216,3559,Active,116241312.0,1576.0,33.1,IC50,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Confirmatory,23033255.0,
4941,1210072,1,2,,103167216,3559,Unspecified,6686268.0,1559.0,50.0,IC50,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,Confirmatory,23033255.0,
4942,1210073,1,2,,103167216,3559,Unspecified,60416369.0,1557.0,50.0,IC50,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,Confirmatory,23033255.0,
4943,1210074,1,2,,103167216,3559,Unspecified,117144.0,1544.0,50.0,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,Confirmatory,23033255.0,
4944,1211293,1,2,,103167216,3559,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
4945,1211294,1,1,,103167216,3559,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
4946,1211295,1,1,,103167216,3559,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
4947,1211296,1,2,,103167216,3559,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
4948,1211297,1,1,,103167216,3559,Unspecified,,,,,Drug recovery in plasma (unknown origin),Other,21098647.0,
4949,1211298,1,1,,103167216,3559,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21098647.0,
4950,1213024,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Intrinsic clearance in recombinant human UGT2B7 measured per mg of protein at 10 to 400 uM by LC-MS/MS analysis,Other,22028316.0,
4951,1213025,1,2,,103167216,3559,Unspecified,136727.0,7364.0,590.0,Ki,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation measured as inhibition constant at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Confirmatory,22028316.0,
4952,1213026,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured per mg of protein at 25 uM by LC-MS/MS analysis,Other,22028316.0,
4953,1213027,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured per mg of protein at 100 uM by LC-MS/MS analysis,Other,22028316.0,
4954,1213028,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured per mg of protein at 200 uM by LC-MS/MS analysis,Other,22028316.0,
4955,1213032,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM hecogenin relative to control,Other,22028316.0,
4956,1213033,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM hecogenin relative to control,Other,22028316.0,
4957,1213034,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM hecogenin,Other,22028316.0,
4958,1213035,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4959,1213036,1,2,,103167216,3559,Unspecified,136729.0,54658.0,,,Drug metabolism assessed as recombinant human UGT1A1 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4960,1213037,1,2,,103167216,3559,Unspecified,549152.0,54659.0,,,Drug metabolism assessed as recombinant human UGT1A3 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4961,1213038,1,2,,103167216,3559,Unspecified,29840832.0,54578.0,,,Drug metabolism assessed as recombinant human UGT1A6 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4962,1213039,1,2,,103167216,3559,Unspecified,30173486.0,54577.0,,,Drug metabolism assessed as recombinant human UGT1A7 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4963,1213040,1,2,,103167216,3559,Unspecified,29839637.0,54576.0,,,Drug metabolism assessed as recombinant human UGT1A8 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4964,1213041,1,2,,103167216,3559,Unspecified,29839636.0,54575.0,,,Drug metabolism assessed as recombinant human UGT1A10 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4965,1213042,1,2,,103167216,3559,Unspecified,6175083.0,7363.0,,,Drug metabolism assessed as recombinant human UGT2B4 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4966,1213043,1,2,,103167216,3559,Unspecified,332278237.0,7366.0,,,Drug metabolism assessed as recombinant human UGT2B15 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4967,1213044,1,2,,103167216,3559,Unspecified,6136104.0,7367.0,,,Drug metabolism assessed as recombinant human UGT2B17 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4968,1213045,1,1,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as Sprague-Dawley rat liver microsomes assessed as velocity of O-glucuronidation at 100 uM by LC-MS/MS analysis,Other,22028316.0,
4969,1213046,1,2,,103167216,3559,Unspecified,136729.0,54658.0,,,Drug metabolism assessed as recombinant human UGT1A1 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4970,1213047,1,2,,103167216,3559,Unspecified,549152.0,54659.0,,,Drug metabolism assessed as recombinant human UGT1A3 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4971,1213048,1,2,,103167216,3559,Unspecified,29840832.0,54578.0,,,Drug metabolism assessed as recombinant human UGT1A6 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4972,1213049,1,2,,103167216,3559,Unspecified,30173486.0,54577.0,,,Drug metabolism assessed as recombinant human UGT1A7 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4973,1213050,1,2,,103167216,3559,Unspecified,29839637.0,54576.0,,,Drug metabolism assessed as recombinant human UGT1A8 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4974,1213051,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4975,1213052,1,2,,103167216,3559,Unspecified,29839636.0,54575.0,,,Drug metabolism assessed as recombinant human UGT1A10 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4976,1213053,1,2,,103167216,3559,Unspecified,6175083.0,7363.0,,,Drug metabolism assessed as recombinant human UGT2B4 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4977,1213054,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4978,1213055,1,2,,103167216,3559,Unspecified,332278237.0,7366.0,,,Drug metabolism assessed as recombinant human UGT2B15 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4979,1213056,1,2,,103167216,3559,Unspecified,6136104.0,7367.0,,,Drug metabolism assessed as recombinant human UGT2B17 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4980,1213057,1,1,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide retention time at 100 uM by LC-MS/MS analysis,Other,22028316.0,
4981,1213058,1,1,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as retention time at 100 uM by LC-MS/MS analysis,Other,22028316.0,
4982,1213059,1,1,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as N-glucuronide retention time at 100 uM by LC-MS/MS analysis,Other,22028316.0,
4983,1213060,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as velocity of O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4984,1213061,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as velocity of O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4985,1213062,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as velocity of O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4986,1213063,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as velocity of N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4987,1213064,1,1,,103167216,3559,Unspecified,,,85.0,Km,Drug metabolism assessed as human liver microsomes assessed as O-glucuronidation at 10 to 400 uM by LC-MS/MS analysis,Confirmatory,22028316.0,
4988,1213065,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronidation measured per mg of protein at 10 to 400 uM by LC-MS/MS analysis,Other,22028316.0,
4989,1213066,1,2,,103167216,3559,Unspecified,,,,,Intrinsic clearance in human liver microsomes measured per mg of protein at 10 to 400 uM by LC-MS/MS analysis,Other,22028316.0,
4990,1213067,1,2,,103167216,3559,Unspecified,136731.0,54657.0,64.0,Km,Drug metabolism assessed as recombinant human UGT1A4 assessed as O-glucuronidation at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Confirmatory,22028316.0,
4991,1213068,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as O-glucuronidation measured per mg of protein at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4992,1213069,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Intrinsic clearance in recombinant human UGT1A4 measured per mg of protein at 10 to 400 uM by LC-MS/MS analysis,Other,22028316.0,
4993,1213070,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,174.0,Km,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Confirmatory,22028316.0,
4994,1213071,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation measured per mg of protein at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4995,1213072,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Intrinsic clearance in recombinant human UGT1A9 measured per mg of protein at 10 to 400 uM by LC-MS/MS analysis,Other,22028316.0,
4996,1213073,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,344.0,Ki,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation measured as inhibition constant at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Confirmatory,22028316.0,
4997,1213074,1,2,,103167216,3559,Active,136727.0,7364.0,45.0,Km,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Confirmatory,22028316.0,
4998,1213075,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation measured per mg of protein at 10 to 400 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4999,1213076,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM niflumic acid relative to control,Other,22028316.0,
5000,1213077,1,2,,103167216,3559,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human UGT2B7 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM gemfibrozil relative to control,Other,22028316.0,
5001,1213078,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM gemfibrozil relative to control,Other,22028316.0,
5002,1213079,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM gemfibrozil relative to control,Other,22028316.0,
5003,1213080,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured at 25 uM by LC-MS/MS analysis in presence of 10 uM hecogenin relative to control,Other,22028316.0,
5004,1213081,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured at 25 uM by LC-MS/MS analysis in presence of 10 uM niflumic acid relative to control,Other,22028316.0,
5005,1213082,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured at 25 uM by LC-MS/MS analysis in presence of 10 uM gemfibrozil relative to control,Other,22028316.0,
5006,1213083,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured at 100 uM by LC-MS/MS analysis in presence of 10 uM gemfibrozil relative to control,Other,22028316.0,
5007,1213084,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as O-glucuronide measured at 200 uM by LC-MS/MS analysis in presence of 10 uM gemfibrozil relative to control,Other,22028316.0,
5008,1213085,1,2,,103167216,3559,Unspecified,,,,,Drug excretion in human urine,Other,22028316.0,
5009,1213087,1,1,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as velocity of O-glucuronidation at 100 uM by LC-MS/MS analysis,Other,22028316.0,
5010,1213088,1,1,,103167216,3559,Unspecified,,,,,Drug metabolism assessed as human liver microsomes assessed as velocity of N-glucuronidation at 100 uM by LC-MS/MS analysis,Other,22028316.0,
5011,1213089,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
5012,1213090,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as N-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
5013,1213091,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation at 100 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
5014,1213092,1,2,,103167216,3559,Unspecified,29839451.0,54600.0,,,Drug metabolism assessed as recombinant human UGT1A9 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM niflumic acid relative to control,Other,22028316.0,
5015,1213093,1,2,,103167216,3559,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human UGT1A4 assessed as O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis in presence of 10 uM niflumic acid relative to control,Other,22028316.0,
5016,1215120,1,1,,103167216,3559,Active,,,1.56,Kd,Binding affinity to Wistar rat brain lipid by TRANSIL assay,Confirmatory,21071520.0,
5017,1215121,1,2,,103167216,3559,Unspecified,,,,,Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
5018,1215122,1,1,,103167216,3559,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
5019,1215123,1,2,,103167216,3559,Unspecified,124028612.0,24186.0,96.9,Kd,Binding affinity to Wistar rat serum albumin,Confirmatory,21071520.0,
5020,1215124,1,1,,103167216,3559,Unspecified,,,,,Binding affinity to Wistar rat brain lipid assessed as fraction unbound by TRANSIL assay,Other,21071520.0,
5021,1215125,1,1,,103167216,3559,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay,Other,21071520.0,
5022,1215127,1,2,,103167216,3559,Unspecified,,,,,Ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay to fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
5023,1215128,1,1,,103167216,3559,Unspecified,,,,,"Ratio, ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM dosed as discrete compounds after 5 hrs by TRANSIL assay to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay",Other,21071520.0,
5024,1215935,1,1,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human intestinal microsomes at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5025,1215936,1,2,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human liver microsomes at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5026,1215937,1,1,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human intestinal cytosol at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5027,1215938,1,1,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human liver cytosol at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5028,1215939,1,1,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5029,1215940,1,1,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human liver S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5030,1215943,1,1,,103167216,3559,Unspecified,,,,,Metabolic stability in human intestinal S9 fraction assessed as compound remaining at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5031,1215944,1,1,,103167216,3559,Unspecified,,,,,Intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis,Other,23444387.0,
5032,1215945,1,1,,103167216,3559,Unspecified,,,,,Metabolic stability in human intestinal S9 fraction assessed as compound remaining at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis in presence of NADH,Other,23444387.0,
5033,1215946,1,1,,103167216,3559,Unspecified,,,,,Intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis in presence of NADH,Other,23444387.0,
5034,1215948,1,1,,103167216,3559,Unspecified,,,,,Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis in presence of NADPH,Other,23444387.0,
5035,1215949,1,1,,103167216,3559,Active,,,,,Metabolic stability in human intestinal cytosol at 200 nM after 60 mins in presence of menadione,Other,23444387.0,
5036,1215951,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism in human intestinal cytosol at 200 nM after 60 mins in presence of flufenamic acid,Other,23444387.0,
5037,1215953,1,2,,103167216,3559,Unspecified,,,,,Drug metabolism in human intestinal cytosol at 200 nM after 60 mins in presence of ondansetron,Other,23444387.0,
5038,1215955,1,1,,103167216,3559,Unspecified,,,,,Apparent permeability of the compound at 50 uM at pH 7.4 after 240 mins by PAMPA,Other,23444387.0,
5039,1215962,1,2,,103167216,3559,Unspecified,118519.0,873.0,250.0,Km,Activity of carbonyl reductase in liver cytosol (unknown origin) assessed as enzyme-mediated drug metabolism,Confirmatory,23444387.0,
5040,1215963,1,2,,103167216,3559,Unspecified,118519.0,873.0,1200.0,Km,Activity of recombinant carbonyl reductase (unknown origin),Confirmatory,23444387.0,
5041,1221956,1,1,,103167216,3559,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
5042,1221957,1,1,,103167216,3559,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
5043,1221958,1,1,,103167216,3559,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
5044,1221960,1,1,,103167216,3559,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5045,1221961,1,1,,103167216,3559,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5046,1221962,1,1,,103167216,3559,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5047,1221963,1,1,,103167216,3559,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5048,1221964,1,1,,103167216,3559,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5049,1221965,1,1,,103167216,3559,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5050,1221982,1,1,,103167216,3559,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
5051,1222793,1,1,,103167216,3559,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
5052,1224817,1,1,,443245,3559,Inactive,,,,,Assays to identify small molecules inhibitory for eIF4E expression,Other,26144883.0,
5053,1224818,1,1,,312344708,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
5054,1224819,1,1,,312344708,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
5055,1224820,1,1,,312344708,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
5056,1224821,1,1,,312344708,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
5057,1224822,1,1,,312344708,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
5058,1224823,1,1,,312344708,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
5059,1224824,1,1,,104171168,3559,Inactive,,,1.6626,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
5060,1224825,1,1,,104171168,3559,Inactive,,,23.485,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
5061,1224834,3,1,,144210793,3559,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5062,1224834,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5063,1224835,1,1,,144210793,3559,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5064,1224835,1,1,,170464841,3559,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5065,1224836,1,1,,144210793,3559,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5066,1224836,1,1,,170464841,3559,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5067,1224837,1,1,,144210793,3559,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5068,1224837,1,1,,170464841,3559,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5069,1224838,1,1,,144210793,3559,Active,66775687.0,9970.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5070,1224838,1,1,,170464841,3559,Active,66775687.0,9970.0,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5071,1224839,1,1,,144210793,3559,Inactive,66775687.0,9970.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5072,1224839,1,1,,170464841,3559,Inactive,66775687.0,9970.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5073,1224840,3,1,,144210793,3559,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5074,1224840,3,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5075,1224841,3,1,,144210793,3559,Inactive,325495545.0,2101.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5076,1224841,3,1,,170464841,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5077,1224842,3,1,,144210793,3559,Inconclusive,325495545.0,2101.0,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5078,1224842,3,1,,170464841,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5079,1224843,1,1,,144210793,3559,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5080,1224843,1,1,,170464841,3559,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5081,1224844,1,1,,144210793,3559,Inconclusive,,,0.2754,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5082,1224844,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5083,1224845,1,1,,144210793,3559,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5084,1224845,1,1,,170464841,3559,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5085,1224846,1,1,,144210793,3559,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5086,1224846,1,1,,170464841,3559,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5087,1224847,1,1,,144210793,3559,Inconclusive,,,113.00399999999999,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5088,1224847,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5089,1224848,3,1,,144210793,3559,Active,325495545.0,2101.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5090,1224848,3,1,,170464841,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5091,1224849,3,1,,144210793,3559,Inactive,325495545.0,2101.0,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5092,1224849,3,1,,170464841,3559,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5093,1224857,2,1,,104171168,3559,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5094,1224857,2,1,,170464841,3559,Inactive,,,35.4813,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5095,1224857,2,1,,312344708,3559,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5096,1224859,2,1,,90341418,3559,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5097,1224859,2,1,,104171168,3559,Inactive,,,0.3317,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5098,1224859,2,1,,170464841,3559,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5099,1224863,1,1,,176483995,3559,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5100,1224863,1,1,,176484755,3559,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5101,1224863,1,1,,316920352,3559,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5102,1224864,1,2,,316933989,3559,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
5103,1224865,1,2,,56422397,3559,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
5104,1224867,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5105,1224867,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5106,1224868,1,1,,144210793,3559,Active,,,17.3739,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5107,1224868,1,1,,170464841,3559,Active,,,8.4852,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5108,1224869,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5109,1224869,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5110,1224870,1,1,,144210793,3559,Active,,,54.941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5111,1224870,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5112,1224871,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5113,1224871,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5114,1224872,1,1,,144210793,3559,Active,,,13.8006,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5115,1224872,1,1,,170464841,3559,Active,,,5.3538,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5116,1224873,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5117,1224873,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5118,1224874,1,1,,144210793,3559,Active,,,21.8724,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5119,1224874,1,1,,170464841,3559,Active,,,8.4852,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5120,1224875,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5121,1224875,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5122,1224876,1,1,,144210793,3559,Active,,,43.6412,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5123,1224876,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5124,1224877,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5125,1224877,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5126,1224878,1,1,,144210793,3559,Active,,,24.5412,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5127,1224878,1,1,,170464841,3559,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5128,1224879,1,1,,144210793,3559,Active,,,24.5412,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5129,1224879,1,1,,170464841,3559,Active,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5130,1224880,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5131,1224880,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5132,1224881,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5133,1224881,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5134,1224882,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5135,1224882,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5136,1224883,1,1,,144210793,3559,Active,,,21.8724,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5137,1224883,1,1,,170464841,3559,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5138,1224884,1,1,,144210793,3559,Inconclusive,,,54.941,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5139,1224884,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5140,1224885,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5141,1224885,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5142,1224886,1,1,,144210793,3559,Active,,,13.8006,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5143,1224886,1,1,,170464841,3559,Active,,,8.4852,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5144,1224887,1,1,,144210793,3559,Active,,,13.8006,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5145,1224887,1,1,,170464841,3559,Active,,,9.5205,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5146,1224888,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5147,1224888,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5148,1224889,1,1,,144210793,3559,Inconclusive,,,13.8006,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5149,1224889,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5150,1224890,1,1,,144210793,3559,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5151,1224890,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5152,1224892,1,1,,144210793,3559,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5153,1224892,1,1,,170464841,3559,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5154,1224893,1,1,,144210793,3559,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5155,1224893,1,1,,170464841,3559,Inconclusive,66775687.0,9970.0,18.8336,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5156,1224894,1,1,,144210793,3559,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5157,1224894,1,1,,170464841,3559,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5158,1224895,1,1,,144210793,3559,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5159,1224895,1,1,,170464841,3559,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5160,1224896,1,1,,144210793,3559,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5161,1224896,1,1,,170464841,3559,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5162,1224905,2,1,,92308931,3559,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5163,1224905,2,1,,92308931,3559,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5164,1224905,2,1,,121361232,3559,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5165,1224905,2,1,,121361232,3559,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5166,1232316,1,1,,103167216,3559,Unspecified,,,,,Volume of distribution at steady state in mouse,Other,25799158.0,
5167,1249734,1,1,,103167216,3559,Active,118206.0,1813.0,0.0009599999999999999,Ki,Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells,Confirmatory,26288260.0,
5168,1249735,1,1,,103167216,3559,Active,1169206.0,1814.0,0.0068,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,26288260.0,
5169,1256682,1,1,,103167216,3559,Unspecified,,,,,"Neurotoxicity in Chinese Kun Ming mouse assessed as locomotor activity by measuring total distance traveled at 0.1 mg/kg, po administered 1 hr before test measured for 10 mins (Rvb = 13415.6 +/- 9555.8 millimeter)",Other,26483200.0,
5170,1256683,1,1,,103167216,3559,Unspecified,,,,,"Neurotoxicity in Chinese Kun Ming mouse assessed as locomotor activity by measuring total distance traveled at 0.3 mg/kg, po administered 1 hr before test measured for 10 mins (Rvb = 13415.6 +/- 9555.8 millimeter)",Other,26483200.0,
5171,1256684,1,1,,103167216,3559,Unspecified,,,,,"Neurotoxicity in Chinese Kun Ming mouse assessed as locomotor activity by measuring total distance traveled at 1 mg/kg, po administered 1 hr before test measured for 10 mins (Rvb = 13415.6 +/- 9555.8 millimeter)",Other,26483200.0,
5172,1257655,1,1,,103167216,3559,Active,543727.0,3356.0,0.1,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, aA1, 5-HT2C and H1 Receptors.",Confirmatory,,
5173,1257656,1,1,,103167216,3559,Unspecified,400630.0,6532.0,1.0,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
5174,1257657,1,1,,103167216,3559,Active,112816.0,3358.0,3.949,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
5175,1257658,1,1,,103167216,3559,Active,,,0.78,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
5176,1257659,1,1,,103167216,3559,Active,118206.0,1813.0,0.0007,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
5177,1257660,1,1,,103167216,3559,Active,1168246.0,148.0,0.011000000000000001,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
5178,1259241,1,1,,144210793,3559,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5179,1259241,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5180,1259242,1,1,,144210793,3559,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5181,1259242,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5182,1259243,1,1,,144210793,3559,Active,124375976.0,367.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5183,1259243,1,1,,170464841,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5184,1259244,1,1,,144210793,3559,Active,348019627.0,2099.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5185,1259244,1,1,,170464841,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5186,1259247,1,1,,144210793,3559,Inconclusive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5187,1259247,1,1,,170464841,3559,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5188,1259248,1,1,,144210793,3559,Inconclusive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5189,1259248,1,1,,170464841,3559,Inconclusive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5190,1259252,1,1,,104171168,3559,Inconclusive,169655958.0,,29.5659,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
5191,1259253,1,1,,104171168,3559,Active,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
5192,1259255,1,1,,104171168,3559,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
5193,1259256,1,1,,104171168,3559,Active,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
5194,1259309,1,1,,178126026,3559,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
5195,1259310,1,1,,332877203,3559,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5196,1259310,1,1,,332877209,3559,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5197,1259310,1,1,,332877275,3559,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5198,1259311,1,1,,178126026,3559,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
5199,1259313,1,1,,56422397,3559,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
5200,1259318,1,1,,855969,3559,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
5201,1259325,1,2,,336954274,3559,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
5202,1259344,1,1,,144203713,3559,Inconclusive,,,7.9433,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
5203,1259354,1,1,,348412572,3559,Inconclusive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
5204,1259355,1,1,,26751574,3559,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
5205,1259356,1,1,,104171168,3559,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
5206,1259364,1,1,,144210793,3559,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5207,1259364,1,1,,170464841,3559,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5208,1259365,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5209,1259365,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5210,1259366,1,1,,144210793,3559,Active,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5211,1259366,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5212,1259367,1,1,,144210793,3559,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5213,1259367,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5214,1259368,1,1,,144210793,3559,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5215,1259368,1,1,,170464841,3559,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5216,1259369,1,1,,144210793,3559,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5217,1259369,1,1,,170464841,3559,Inconclusive,109731339.0,2737.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5218,1259370,2,2,,124633897,3559,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5219,1259370,2,2,,124633897,3559,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5220,1259370,2,2,,124633897,3559,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5221,1259377,1,1,,144210793,3559,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5222,1259377,1,1,,170464841,3559,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5223,1259378,1,1,,144210793,3559,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5224,1259378,1,1,,170464841,3559,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5225,1259379,1,1,,144210793,3559,Active,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5226,1259379,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5227,1259380,1,1,,144210793,3559,Active,,,21.6899,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5228,1259380,1,1,,170464841,3559,Active,,,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5229,1259381,1,1,,144210793,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5230,1259381,1,1,,170464841,3559,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5231,1259382,1,1,,144210793,3559,Inconclusive,,,38.5708,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5232,1259382,1,1,,170464841,3559,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5233,1259383,1,1,,144210793,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5234,1259383,1,1,,170464841,3559,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5235,1259384,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5236,1259384,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5237,1259385,1,1,,144210793,3559,Inconclusive,119601739.0,7253.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5238,1259385,1,1,,170464841,3559,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5239,1259386,1,1,,144210793,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5240,1259386,1,1,,170464841,3559,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5241,1259387,1,1,,144210793,3559,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5242,1259387,1,1,,170464841,3559,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5243,1259388,1,1,,144210793,3559,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5244,1259388,1,1,,170464841,3559,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5245,1259389,1,1,,124636953,3559,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
5246,1259390,1,1,,144210793,3559,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5247,1259390,1,1,,170464841,3559,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5248,1259391,1,1,,144210793,3559,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5249,1259391,1,1,,170464841,3559,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5250,1259392,1,1,,144210793,3559,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5251,1259392,1,1,,170464841,3559,Active,109731339.0,2737.0,10.5909,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5252,1259393,1,1,,144210793,3559,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5253,1259393,1,1,,170464841,3559,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5254,1259394,1,1,,144210793,3559,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5255,1259394,1,1,,170464841,3559,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5256,1259395,1,1,,144210793,3559,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5257,1259395,1,1,,170464841,3559,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5258,1259396,1,1,,144210793,3559,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5259,1259396,1,1,,170464841,3559,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5260,1259400,1,1,,170464841,3559,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
5261,1259401,1,1,,144210793,3559,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5262,1259401,1,1,,170464841,3559,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5263,1259402,1,1,,144210793,3559,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5264,1259402,1,1,,170464841,3559,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5265,1259403,1,1,,144210793,3559,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5266,1259403,1,1,,170464841,3559,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5267,1259404,1,1,,144210793,3559,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5268,1259404,1,1,,170464841,3559,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5269,1259407,1,1,,363899580,3559,Inactive,,,,,CCRIS mutagenicity studies,Other,,
5270,1259408,1,1,,363894800,3559,Active,,,,,GENE-TOX mutagenicity studies,Other,,
5271,1259409,1,1,,363899580,3559,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
5272,1259415,1,1,,855969,3559,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
5273,1259416,1,2,,855969,3559,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5274,1259416,1,2,,340080011,3559,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5275,1259416,1,2,,375174937,3559,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5276,1259419,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,8935801.0,
5277,1259419,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,9732398.0,
5278,1259419,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,12629531.0,
5279,1259419,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,15102927.0,
5280,1259419,1,1,,135650345,3559,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,18308814.0,
5281,1259421,1,1,,340080011,3559,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5282,1259421,1,1,,375174937,3559,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5283,1259423,1,2,,354787941,3559,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5284,1259423,1,2,,354813554,3559,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5285,1259423,1,2,,354935416,3559,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5286,1259423,1,2,,354965283,3559,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
